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excitement about the future. 
Abstract 
Lung cancer is the most common cause of cancer death in the UK. In suitable 
cases, the best chance of cure is surgical resection. Due to high levels of co-
morbidity seen in this population, lung resection is associated with high cardio-
respiratory complication rates. One such complication is the development of 
Acute Lung Injury / Acute Respiratory Distress Syndrome (ALI/ARDS). ALI/ARDS is 
reported to occur in four to 11% of patients undergoing lung resection and is the 
major cause of hospital mortality following lung resection.  
 ALI/ARDS occurring following lung resection is widely interpreted to be a variant 
of ALI/ARDS and follows an identical clinical and pathophysiological course to 
that seen in the wider critical care environment. The pathophysiology of lung 
injury following lung resection is complex and can be broadly conceptualised as 
occurring secondary to insults specific to both the ipsilateral (surgical) lung, the 
contralateral (anaesthetic) lung in addition to those insults common to both 
lungs. Increased recognition of the role of ventilator induced lung injury, and 
peri-operative fluid prescribing in the pathogenesis of lung injury in this 
population has brought the prevention of lung injury to the attention of the 
thoracic anaesthetist. Though high quality evidence is lacking, expert opinion 
widely favours the adoption of lung protective ventilatory strategies and 
restriction of peri-operative fluids in patients undergoing lung resection. 
This thesis presents the rationale, methodology and results of four discrete 
studies concerning the development of lung injury in the thoracic surgical 
population undergoing resection of primary lung cancer. 
Investigation I is a survey of contemporary UK thoracic anaesthetic practice 
when anaesthetising for thoracic surgery and lung resection, with specific 
reference to strategies designed to prevent lung injury. Though implementation 
of the techniques described is far from universal, the survey results suggest that 
aspects of lung protective ventilation are widespread within UK thoracic 
anaesthetic practice. 
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Investigation II seeks to examine the impact of increased adoption of such 
strategies over time. A random effects meta-analysis and meta-regression 
analysis was performed to examine the trends in the incidence of and mortality 
from ALI and/or ARDS over time. The main findings of this study are that whilst 
there is no evidence to suggest the incidence of ALI and/or ARDS post-lung 
resection is falling, mortality due to ARDS (but not ALI) does appear to be falling 
over time. 
Investigations III and IV examine the utility of two clinical monitoring 
methodologies which have potential to provide bedside clinical monitoring of 
lung injury development in the thoracic surgical population in order to guide 
clinical decision making, monitor patient progress and serve as a surrogate end 
point in future clinical studies.  
Investigation III examines the utility of a single lung injury biomarker (long chain 
Pentraxin 3 – PTX3) and a panel of multiple lung injury biomarkers in the early 
post-operative period following lung resection. The properties of the ‘ideal’ lung 
injury biomarker are defined, against which PTX3 and the multiple biomarker 
panel are compared. PTX3 compared favourably to properties of the ‘ideal’ lung 
injury biomarker and appeared to identify a population of patients with elevated 
post-operative Lung Injury Score with high sensitivity. Conversely there is no 
evidence from the results presented that a ‘risk of lung injury score’ derived 
from a panel of 7 candidate lung injury biomarkers (as previously defined in a 
cohort of critically ill patients with ALI/ARDS) has any utility in the lung 
resection population.  
Investigation IV tests the reproducibility and construct validity of 
transpulmonary thermodilution derived measurements of extravascular lung 
water and pulmonary vascular permeability index in patients undergoing lung 
resection. The study’s findings are largely supportive of the reproducibility and 
construct validity of extravascular lung water measurement and pulmonary 
vascular permeability measurements after lung resection.  
In combination, it is hoped that the studies presented provide greater insight 
into the syndrome of post lung resection lung injury. More accurate definition of 
standard anaesthetic practice and the incidence of and mortality from ALI/ARDS 
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following lung resection should serve to inform future clinical studies seeking to 
prevent, treat, or better understand this important clinical syndrome. The 
biomarker PTX3 and transpulmonary thermodilution derived measurement of 
extravascular lung water and pulmonary vascular permeability index are 
presented as surrogate endpoints suitable for use in such studies. 
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1 Introduction 
The work presented in this thesis concerns the occurrence of Acute Lung Injury / 
Acute Respiratory Distress Syndrome (ALI/ARDS) post-operatively in patients 
undergoing surgical resection of lung cancer. By way of introduction, the first 
section of this opening chapter describes the incidence and mortality of lung 
cancer, the expanding role of surgical resection in its treatment and goes on 
briefly to describe mortality and morbidity after lung resection. The remainder 
of this chapter reports the findings of a detailed literature review examining the 
pathophysiology of pulmonary oedema, the definition and pathophysiology of 
ALI/ARDS and the role of ventilator induced lung injury in ALI/ARDS. Finally the 
syndrome of post-lung resection acute lung injury (PLR-ALI) is comprehensively 
discussed in terms of its definition, pathophysiology, risk factors, management 
and potential preventative strategies. 
In the subsequent chapters, the methodology and results of four discrete 
‘investigations’ are presented and discussed: 
Investigation I is a survey of contemporary UK thoracic anaesthetic practice 
when anaesthetising for thoracic surgery and lung resection, with specific 
reference to the adoption of strategies to prevent PLR-ALI. 
Investigation II seeks to examine the impact of increased adoption of such 
strategies over time. A random effects meta-analysis and meta-regression 
analysis was performed to examine the trends in the incidence of and 
mortality from PLR-ALI over time. 
Investigations III and IV examine the utility of two clinical monitoring 
methodologies which have potential to provide bedside clinical monitoring of 
lung injury development in the thoracic surgical population in order to guide 
clinical decision making, monitor patient progress and serve as a surrogate end 
point in future clinical studies seeking to prevent, treat, or better understand 
this important clinical syndrome. 
Investigation III examines the utility of a single lung injury biomarker (long 
chain Pentraxin 3 – PTX3) and a panel of multiple lung injury biomarkers in 
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the early post-operative period following lung resection. In order to provide 
background, a targeted literature review is provided concerning the use of 
lung injury biomarkers. The properties of the ‘ideal’ lung injury biomarker 
are defined, against which Pentraxin 3 and the multiple biomarker panel 
are compared. 
Investigation IV tests the reproducibility and construct validity of trans-
pulmonary thermodilution derived measurements of extravascular lung 
water and pulmonary vascular permeability index in patients undergoing 
lung resection. Preceding this, a further targeted literature review details 
the concepts involved in establishing reproducibility and validity of a 
clinical monitor and provides an in depth exploration of the principles of 
transpulmonary thermodilution, and the potential impact of both lung 
resection and lung injury on the results obtained. 
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1.1 Lung cancer 
1.1.1 Incidence of and mortality from lung cancer 
In the words of W. Michael Alberts (then) immediate past president of the 
American College of Chest Physicians (ACCP) in his introduction to the ACCP 
Evidence-Based Clinical Practice Guidelines on the Diagnosis and Management of 
Lung Cancer:  
“The numbers are still staggering...”  
W. Michael Alberts (2007)1. 
This statement is nowhere more true than in Glasgow. In 2011, there were some 
43,463 new cases of lung cancer in the UK, making lung cancer the second most 
commonly diagnosed cancer after breast cancer2. Within the UK, lung cancer is 
especially common in Scotland, with a European age-standardised incidence rate 
of 66 per 100,000 population compared to 44 in England and 50 in Wales2. In 
Greater Glasgow, lung cancer incidence is almost a third higher than the 
Scotland wide average.  As an area traditionally associated with heavy industry 
and shipbuilding, and with particularly high levels of socio-economic deprivation, 
lung cancer rates in Greater Glasgow are amongst the highest worldwide2.  
Reflecting trends in cigarette smoking prevalence, male lung cancer incidence 
rates have decreased overall in the UK since the mid 1970s, but continue to rise 
in females (where the peak in smoking prevalence came later). As such, overall 
incidence rates are essentially static2.  
“Lung cancer has an enormous impact on national mortality” 
Cancer Research UK (2014)2 
Lung cancer is the most common cause of cancer death in the UK, accounting for 
6% of all deaths (including non-cancer deaths). One year survival following lung 
cancer diagnosis is approximately 30%, falling to less than 10% by five years2. 
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1.1.2 Surgical resection of lung cancer 
It is well established for early stage non-small cell cancer (NSCLC) that the best 
chance of cure is surgical resection3, 4. The National Institute for Health and Care 
Excellence (NICE) describe surgical resection by lobectomy as the “treatment of 
first choice” for patients with NSCLC “who are medically fit and suitable for 
treatment with curative intent”. 
 
Figure 1.1. Lung resections by year in the UK. 
From the Society for Cardiothoracic Surgery 2
nd
 National Thoracic Surgery Activity and Outcomes 
Report, 2011
5
. 
In 2010 (the most recent year for which data are available), over 8500 people 
underwent lung resection surgery in the UK, more than 5000 of which were for 
resection of primary lung cancer5. Since 2005 there has been a dramatic increase 
in surgery for lung cancer in the UK5 (Figure 1.1). Such an expansion probably 
reflects the effects of three major drivers. 
Firstly, it had been recognised for some time that lung cancer outcomes in the 
United Kingdom lagged behind those observed in other parts of Western Europe6. 
Whilst the explanation for this was likely to be multi-factorial (with influences 
from socio-economic to political), lung resection rates in the UK were half those 
seen elsewhere in Europe7, 8. Thoracic surgery in the UK was “in crisis”8; a joint 
working party of the Society of Cardiothoracic Surgeons and the British Thoracic 
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Society described the “critical under-provision of thoracic surgery in the UK” 
reporting that “fifty extra surgeons were required to come up to European 
average standards”7. In parallel, data was accumulating which demonstrated 
wide geographical variation in resection rates throughout the UK, mirrored by a 
corresponding variation in survival9, 10. It was becoming clear that “[there was] a 
large number of lung cancer deaths that could be postponed if more patients 
were resected”9. These observations triggered a response from central 
government,  beginning in 1998 with the Department of Health publishing 
guidance on commissioning services for lung cancer under the title ‘Improving 
Outcomes in Lung Cancer’, followed in 2000 by the ‘NHS Cancer Plan’ aiming to 
tackle inequalities in quality of care and treatment10. As a result thoracic 
surgery has seen increased investment, radical restructuring in the delivery of 
services and “a welcome expansion of the thoracic surgical workforce”5.  
Secondly, surgeons and anaesthetists are increasingly likely to offer surgery to 
patients previously considered unsuitable for resection due to co-morbidity. 
There is increased recognition that acceptable levels of peri-operative morbidity 
and mortality are achievable even in patients previously considered to be ‘very-
high risk’11. Reflecting this, recent clinical guidelines have undergone a shift of 
emphasis, moving the basis of assessment of suitability for resection from rigid 
criteria based on the results of physiological testing, to a more global 
assessment of functional ability11, 12. Clinicians are encouraged to “offer patients 
with [baseline pulmonary function] below the recommended limit[s]... the 
option of undergoing surgery if they accept the risks of dyspnoea and associated 
complications”13. 
Thirdly, current evidence supports an expansion in lung cancer surgery in 
patients with more advanced disease and a greater uptake in patients who are 
willing to accept higher risks14.  Though survival rates in patients with more 
advanced disease are lower, in patients with (regional lymph node) N1-N3 
disease (stage II & III - previously considered not to be suitable for resection), 
surgery confers an absolute 5-year survival benefit of 11% (8% no surgery vs 17% 
with surgery)15. 
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1.1.2.1 Morbidity and mortality following lung resection 
Since 1980, the Society for Cardiothoracic Surgery in Great Britain & Ireland has 
been auditing thoracic surgical activity in the UK. The most recent report, the 
Second National Thoracic Surgery Activity & Outcomes Report (2011), reports in-
hospital mortality from a cumulative series of over 100,000 lung resections and 
reveals that “combined operative mortality for all patients having lung cancer 
surgery has almost halved from 3.8% in 2001-2002  to 2.1% in 2009-2010”5. 
Whilst in-hospital mortality of 2% might represent ‘acceptable’ risk for what is a 
destructive, major operation, this is set against considerable morbidity. Almost 
all patients undergoing lung resection for lung cancer have been long-term 
smokers, many from low socio-economic backgrounds. As such, thoracic surgical 
patients exhibit high levels of pre-existing cardio-respiratory disease5, 16. Perhaps 
unsurprisingly therefore, cardio-respiratory complication rates following lung 
resection are high. Combined cardio-respiratory complication rates (including 
complications ranging from supra-ventricular tachy-arrhythmias, myocardial 
ischaemia / infarction, right ventricular dysfunction, cardiogenic pulmonary 
oedema and pulmonary thromboembolism to atelectasis, sputum retention, 
pneumonia, bronchospasm, respiratory failure and acute lung injury / acute 
respiratory distress syndrome), are reported to occur in 20-65% of cases17-21. 
Such complications are associated with increased mortality, costs and prolonged 
duration of both critical care unit and hospital stay17, 19. 
In conclusion, lung cancer is a devastating disease, which carries high mortality. 
Surgical resection offers the greatest potential for cure in the approximately 15% 
of patients suitable for treatment with curative intent. As advances in surgical 
techniques and adjuvant therapies confer survival benefits; more, older and 
sicker patients with more advanced disease are going to present for lung 
resection. It is incumbent therefore on all involved in the care of such patients, 
to embrace this increasing demand, and strive to better understand and combat 
the causes of mortality and morbidity in this patient group. The occurrence of 
acute lung injury / acute respiratory distress syndrome following lung resection 
(the subject of this thesis), though not the most commonly occurring 
complication, represents the major cause of early, non cancer related mortality 
in this patient group.  
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1.2 Pulmonary oedema  
Before exploring the pathophysiology of lung injury, I will first discuss the 
structure and physiology of the alveolar-capillary membrane, the mechanisms 
which serve to regulate microvascular fluid exchange and prevent pulmonary 
oedema formation, and the influence of pathology upon these mechanisms. In 
recent years, the increased recognition of the role played by the endothelial 
glycocalyx has challenged many long held beliefs.  
1.2.1 Structure and function of the lung 
The lung has evolved as a tremendously efficient unit to facilitate its primary 
function of gas exchange; uptake of oxygen and elimination of carbon dioxide. A 
copious network of capillaries are wrapped around approximately 300 million 
alveoli providing an effective surface area for gas exchange of 130 square 
meters, whilst occupying a volume of only approximately four litres22, 23. Much of 
this efficiency of gas exchange may be attributed to the extremely thin nature 
of the air-blood barrier; as little as 0.3 micrometres in some places. Pulmonary 
oedema occurs when the delicate physiological balance which maintains fluid 
within the capillaries and keeps the alveolar air spaces free of fluid 
accumulation becomes disrupted. 
1.2.1.1 Anatomy of the alveolar-capillary barrier 
The alveolar-capillary (or air-blood) barrier is described as having ‘thin’ and 
thick portions22, 24 (Figure 1.2). The alveolar side of the barrier is lined 
predominantly with type I epithelial cells, whilst on the capillary side, the 
capillary wall comprises a single layer of endothelial cells. 
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Figure 1.2. Electron micrograph of a single pulmonary capillary. 
The thick portion of the alveolar-capillary barrier lies on the right where the epithelial cell (EP) and 
endothelial cell (EC) are separated by an interstitial space (IS). In the thin portion (lying on the left), 
epithelial and endothelial cells lie on a fused basement membrane (BM). RBC, red blood cell; AS, 
alveolar space. Horizontal bar = 1μm. From Murray (2010)
22
. 
Gas exchange takes place predominantly across ‘thin’ portions of the alveolar-
capillary barrier where capillary blood and air space are separated by thin 
cytoplasmic extensions of both alveolar and endothelial cells with their 
basement membranes fused into a single layer. At the other side of the capillary 
(the right hand side in Figure 1.2), the alveolar space and capillary lumen are 
further apart, separated by the bulk of the endothelial cell nucleus, and an 
interstitial space containing connective tissue fibrils. This is the ‘thick’ portion 
of the alveolar-capillary barrier across which liquid and solute exchange occurs22-
24. Though the majority of the alveolar surface is lined by type I epithelial cells, 
the dominant cell type in the alveolar epithelium is in fact the smaller type II 
cell. Type II epithelial cells produce surfactant, a phospholipid molecule 
responsible for reducing surface tension and maintaining alveolar stability22, 23. 
1.2.2 Pathophysiology of pulmonary oedema 
1.2.2.1 Starling forces 
The regulation of fluid exchange across the alveolar-capillary barrier is 
classically described by the ‘Starling principle’ of microvascular fluid exchange. 
Following experiments in dogs, Starling proposed that the walls of the capillaries 
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are semi-permeable membranes25. From these observations, hydrostatic and 
oncotic pressure were identified as the primary determinants of microvascular 
fluid exchange26. The relationship between these forces is represented by the 
widely adopted ‘Starling’ equation:  
  
 
                 –        
Equation 1.1 
  
Where,        Jv is net filtration rate of fluid per unit area (A) of capillary wall, 
  K is the membrane permeability, 
  PC is the hydrostatic pressure in the capillary, 
  PI is the hydrostatic pressure in the interstitium, 
  Θ is the reflection coefficient to plasma protein, 
ΠP is the plasma protein oncotic pressure, 
and ΠI is the protein oncotic pressure in the interstitium. 
 
From Equation 1.1, it can be appreciated that the overall trans-vascular flow 
across a pulmonary capillary is determined by the balance between forces 
favouring outward flow (extravasation of fluid) - PC and ΠI, and forces favouring 
inward flow (reabsorption of fluid) - PI, and ΠP, and by the permeability of the 
endothelium to water (K) and protein (θ). Classical descriptions of the ‘Starling 
forces’ describe changes in the direction of microvascular fluid exchange at 
different sites in the capillary. At the arterial end Pc is high and so there is a net 
filtration of fluid, whilst at the venous end of the capillary Pc has fallen such 
that there is net absorption of fluid27.  
 
Figure 1.3. Schematic diagram showing the location and magnitude of the Starling forces in 
healthy human lung. 
Part, mean pulmonary artery pressue; Pven, mean pulmonary venous pressue; Pcap, hydrostatic 
pressure in the capillary; Pis, hydrostatic pressure in the interstitum, Πcap is the plasma protein 
oncotic pressure (referred to as ΠP above); Πis, protein oncotic pressure in the interstitum. From 
Murray (2011)
28
. 
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Figure 1.3 provides estimated values for P and Π in health, where it can be seen 
that balance of the outward hydrostatic force (10 — -2 = 12mmHg) exceeds the 
net inward oncotic force (25 — 19 = 6mmHg) such that a net filtration pressure 
of 6mmHg favours extravasation of fluid29. This pressure gradient results in a 
continuous transvascular flow of fluid from pulmonary capillary to interstitum. 
1.2.2.2 Pulmonary lymphatics 
Following formation by filtration across the pulmonary capillary endothelium 
into the interalveolar septum, filtrate is able to flow directly through the loose 
interstitial tissue surrounding arterioles, venules and bronchioles from where it 
may pass into the terminal branches of the pulmonary lymphatics. Such flow is 
maintained by a pressure gradient between the interalveolar interstitium (where 
pressure is approximately equivalent to alveolar pressure) and the 
peribronchovascular interstitium (where pressure is approximately equivalent to 
pleural pressure)28.  Though technically challenging to measure, extrapolation 
from animal data suggests that in health lung lymph flow is 8-9ml/h, though in 
pathological states lymph flow can increase 10-fold or more30.  
1.2.2.3 Evolution of pulmonary oedema formation 
From Equation 1.1 it can easily be appreciated that increased fluid extravasation 
may occur in any situation where either the net filtration pressure increases, or 
where membrane permeability increases. In clinical practice two discrete 
clinical syndromes are recognised; ‘hydrostatic’ pulmonary oedema where 
increased filtration pressure leads to increased fluid extravasation across an 
essentially normal capillary endothelium, and ‘permeability’ pulmonary oedema 
where increased filtration occurs as a result of pathological increases in capillary 
permeability. Classical examples are those of ‘hydrostatic’ pulmonary oedema 
occurring in left ventricular failure, and ‘permeability’ pulmonary oedema 
occurring in acute lung injury / acute respiratory distress syndrome. In 
hydrostatic oedema the filtrate is watery, where in ‘permeability’ oedema, 
increased capillary permeability permits extravasation of protein resulting in an 
oedema fluid rich in protein.  
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The histological appearances of pulmonary oedema formation have been well 
describedA. As net filtration across the endothelial barrier increases, lymph flow 
increases in parallel such that initially interalveolar interstitial volume is not 
increased, but peribronchovascular lymphatics become engorged; observable as 
fluid ‘cuffs’ around small vessels and bronchioles. Fluid filtration in excess of 
the capacity of the lymphatics leads to interstitial water accumulation; evident 
as increased width of alveolar septae. Further accumulation of interstitial 
oedema leads to increase interstitial pressure which (especially in the presence 
of endothelial injury) results in alveolar flooding24, 29. The degree of alveolar 
flooding depends on the extent of interstitial oedema, the integrity of the 
alveolar epithelium and the ability of the epithelium to actively remove alveolar 
oedema31.  
1.2.2.4 Alveolar fluid clearance 
Once oedema has progressed to the point of alveolar flooding, clearance of 
oedema from the alveolar spaces relies upon active transport of sodium across 
the alveolar epithelial barrier. Sodium crosses the apical membrane of alveolar 
type II pneumocytes via amiloride-sensitive sodium channels, and is then actively 
transported across the basolateral membrane into the interstitum by the Na+-K+-
ATPase ion transporter. Water is then able to follow sodium passively; in the 
lung osmotic permeability to water is high32, 33. Clinical studies have revealed 
that patients with increased permeability pulmonary oedema have impaired 
alveolar epithelial fluid transport32.  
1.2.3 The endothelial glycocalyx and the revised Starling equation 
In recent years, it has become evident that ‘conventional’ principles of 
microvascular fluid exchange (as represented by the Starling equation, Equation 
1.1) are inadequate to describe microvascular fluid exchange, with several 
observations combining to undermine the validity of the ‘Starling’ equation. 
Firstly, several researchers have failed to demonstrate reabsorption of 
interstitial fluid (as hypothesised to occur at the venous end of the capillary and 
                                         
A
This paragraph refers to the histological appearances of pulmonary oedema per se, rather than 
the appearances of diffuse alveolar damage, a pathognomic finding in ALI/ARDS. 
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in the venule by the Starling principle) as a consistent component of 
microvascular fluid homeostasis. In experimental models manipulating capillary 
pressure (Pc), when Pc falls transiently below oncotic pressure (ΠP) net 
absorption of fluid is observed, but at steady state (with Pc > ΠP), no absorption 
occurs27, 34, 35. Similarly, it has been observed that net absorption of fluid cannot 
play any significant role in microvascular fluid homeostasis in tissues greater 
than ~10cm below the heart as venous Pc exceeds ΠP in this situation
27, 34, 35.  
Secondly, if in the circumstances just described, reabsorption of interstitial fluid 
is unlikely to play any significant role in maintaining tissue fluid balance, then 
the lymphatic system becomes the principle method for returning filtrate to the 
circulation. Observed values of overall lymph flow are however an order of 
magnitude less than would be needed to account for levels of filtration 
suggested by the ‘Starling principle’. This observation has been described as the 
‘low filtration force paradox’; to account for observed levels of lymph flow, 
globally averaged net filtration force should be in the region of 1mmHg, rather 
than the 5-10mmHg predicted by the ‘Starling equation’34, 35.  
Thirdly, in a series of experiments involving direct manipulation of interstitial 
oncotic pressure (ΠI), several researchers have demonstrated that manipulations 
in ΠI, even to the extent that ΠI = ΠP, have minimal effect on filtration rate; a 
finding incompatible with the ‘Starling principle’34, 35. The latter observation, 
that filtration rate is independent of interstitial oncotic pressure intimates that 
microvascular fluid exchange is governed by principles other than the simple 
balance of capillary and interstitial hydrostatic and oncotic pressures.  
1.2.3.1 Structure and function of the endothelial glycocalyx 
In 1966, using electron microscopy with a ruthenium red stain, Luft identified 
the presence of a three dimensional network of fibrous chains adherent to the 
luminal surface of the capillary36. As early as 1979, Michel suggested that the 
“molecular sieving properties of the capillary wall” (the semi-permeable 
membrane across which filtration takes place and is regulated), may lie within 
this endocapillary layer rather than within or between endothelial cells forming 
the capillary wall37. It has not been until recently however, that the structure 
and function of endocapillary layer has been more fully appreciated. 
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The endothelial glycocalyx (as this layer has become known), is a meshwork 
membrane bound glycoproteins, proteoglycans and glycosaminoglycans found on 
the luminal side of endothelial cells (Figure 1.4)38, 39. 
 
Figure 1.4. Electron microscopic pictures showing an intact endothelial glycocalyx in 
coronary vessels of a guinea pig heart. 
From Brettner et al (2012)
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. 
In non-fenestrated capillaries such as those found within the lung, the 
endothelial glycocalyx (EGL) forms a continuous layer lining the endothelial cell 
walls and filling the inter-endothelial cell clefts38. The EGL is freely permeable 
to water, and behaves as a semipermeable membrane with respect to plasma 
protein molecules such as albumin. As a consequence, within the EGL lies a 
volume of fluid; intravascular, yet excluded from the circulating volume, devoid 
of red blood cells and low in protein concentration35.  
At the site of the endothelial inter-cellular junction (the primary fluid 
conducting pathway across the capillary endothelium), the sub-glyocalyceal 
space is in direct communication with the interstitial space via the intercellular 
cleft. Filtration of fluid at this site therefore is not driven by the interaction 
between hydrostatic pressure and interstitial colloid oncotic pressure, but by the 
sub-glyocalyceal colloid oncotic pressure (ΠG)
34, 35, 38 (Figure 1.5).  
Chapter 1  35 
 
Figure 1.5. The revised Starling principle: forces acting to govern microvascular fluid 
transport across the endothelial semipermeable membrane. 
PC, hydrostatic pressure in the capillary; Pi, hydrostatic pressure in the interstitum; ΠP, plasma 
protein oncotic pressure; Πg, protein oncotic pressure in the sub-glyocalyceal space. Modified from 
Levick and Michel (2010)
35
. 
Whilst protein molecules are able to reach the interstitial space by direct 
transport through endothelial cells, (maintaining interstitial colloid oncotic 
pressure) the EGL is protected from the accumulation of protein by two 
mechanisms35. Firstly, the reflection coefficient to plasma protein (Θ) of the EGL 
is high (in part due to the negatively charged glycosaminoglycans), preventing 
direct extravasation of plasma protein. Secondly, the retrograde passage of 
protein from the interstitum into the subglycocalyceal space is prevented by the 
long and tortuous path of the intercellular cleft, through which continuous and 
relatively high velocity flow of ultrafiltrate prevents upstream flow of protein. 
As such, ΠG is maintained at a considerably lower level than ΠIS, so low in fact, 
that the colloid oncotic pressure opposing fluid filtration is essentially ΠP, rather 
than ΠP-ΠIS as predicted by the Starling equation. Incorporating these principals 
into Equation 1.1 leads to the formation of a ‘revised Starling principle’34, 35: 
  
 
                 –       
Equation 1.2 
 
Where, ΠG is the sub-glycocalyceal oncotic pressure. 
Mathematical modelling based on this ‘revised Starling principle’ predicts 
reduced filtration rates to values in keeping with observed lymph flow, providing 
a solution to the ‘low filtration force paradox’35. 
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In addition to the regulation of microvascular flow as discussed, the EGL has 
several other important functions, notably the attenuation of vascular shear 
stress and regulation of leucocyte and platelet adhesion39, 41. Nitric oxide (NO) 
mediated vasodilation in response to increased endothelial shear stress is an 
essential regulatory mechanism within the capillary serving to couple vessel 
diameter to flow. Whilst the relevant mechanisms are not completely 
understood, it is now believed that interactions between plasma constituents 
and the EGL play an essential role in mechano-transduction39, 41. Endothelial cell 
adhesion molecules such as P-selectin, Intracelluar Adhesion Molecule 1 (ICAM-1) 
and Vascular Cell Adhesion Protein 1 (VCAM-1) are found on the endothelial cell 
wall, buried deep within the EGL. The presence of an intact EGL prevents 
interaction between leucocytes and platelets and these molecules, preventing 
adhesion of these cells to the endothelial wall39, 41.   
1.2.3.2 Pathophysiology of the endothelial glycocalyx 
The EGL plays a fundamental role in determining capillary permeability, 
regulating blood cell – endothelial cell interaction and mediating the sensing of 
shear stress. In a variety of pathological situations however, the EGL can become 
damaged (characteristically described as ‘shedding’), leading to loss of EGL 
constituents which can subsequently be found in plasma. Such glyocalyceal 
degradation, inhibits these key homeostatic roles of the glycocalyx and results in 
the development of capillary leak, oedema formation, accelerated 
inflammation, platelet hyper-aggregation and loss of vascular responsiveness41. 
Systemic inflammatory states such as ischaemia-reperfusion injury, sepsis, 
trauma, atherosclerosis and diabetes are all well recognised pathophysiological 
syndromes in which EGL damage has been documented38, 41. 
The endothelial glycocalyx and pulmonary oedema formation 
Greater understanding of the determinants of microvascular filtration and 
endothelial cell function suggest that the theoretical division of the mechanisms 
of pulmonary oedema formation into ‘hydrostatic’ (where capillary permeability 
is perceived to be normal) and ‘permeability’ (where hydrostatic pressure is 
normal and permeability is increased), is likely to be an over simplification. The 
classic ‘Starling principle’ suggests that increases in capillary hydrostatic 
pressure (as might be expected in true ‘hydrostatic’ pulmonary oedema), would 
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result in a linear increase in net filtration (Figure 1.6). Research conducted in 
isolated animal lung models however, reveals a non-linear relationship between 
capillary hydrostatic pressure and net filtration, such that as capillary 
hydrostatic pressure increases, capillary permeability is also increased (Figure 
1.6)42. 
 
Figure 1.6. Schematic representation of the relationship between capillary pressure and 
capillary filtration. 
Modified from Collins et al (2013)
42
. 
Located at the interface of the endothelium and vascular shear stresses, there is 
evidence to suggest heparan sulphate chains (the predominant glycoaminoglycan 
chain of the EGL) act as a mechano-transducer in this process; shear stresses 
applied to the capillary endothelium are ‘sensed’ by heparan resulting in 
increased capillary permeability via intracellular changes mediated though 
increased nitric oxide production42, 43. 
The endothelial glycocalyx and lung injury 
In laboratory and animal studies (of capillary endothelial cells in a variety of 
anatomic locations), damage to the glycocalyx has been linked to a myriad of 
pathogenic processes pertinent to the development of lung injury; adhesion of 
platelets and leucocytes to the capillary endothelial surface,  activation of 
coagulation pathways, leakage of fluid and protein into the interstitial space and 
the development of tissue oedema42, 44. It appears in fact that the theoretical 
evidence for a role for EGL injury in ALI/ARDS overwhelming yet to date there is 
a paucity of clinical data42. 
In 2012, Schmidt et al published a seminal paper cataloguing how in a series of 
animal (mice) and human studies “the pulmonary endothelial glycocalyx 
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regulates neutrophil adhesion and lung injury during experimental sepsis”45. 
The authors demonstrated that systemic sepsis led to glycocalyx degradation via 
TNF-α mediated activation of endothelial heparanase leading to loss of heparan 
sulphate. The resulting rapid thinning of the EGL facilitated neutrophil adhesion 
to endothelial adhesion molecules. Excitingly, inhibition of endothelial 
heparanase in animal models abolished degradation of the EGL, prevented 
neutrophil adhesion and attenuated sepsis induced ALI, highlighting the potential 
of the EGL as a target for therapeutic intervention41, 45. In humans, increased 
heparan sulphate degradation activity was observed in patients with respiratory 
failure secondary to non-pulmonary sepsis.  In a separate cohort of lung biopsy 
specimens with diffuse alveolar damage, heparanase immunofluorescense was 
eight-fold higher than in normal controls. This the authors conclude “suggest[s] 
that heparanase is active in human sepsis and contributes to inflammatory lung 
injury”45. Though inconclusive, these observations provide the strongest 
evidence to date for a role of EGL injury in ALI/ARDS. 
Endothelial glycocalyx injury after major surgery 
In 2007, Rehm et al measured plasma markers of EGL degradation (syndecan-1 
and heparan sulphate) in 14 patients undergoing infrarenal aortic aneurysm 
repair46. Infrarenal ischemia-reperfusion was followed by 15- and 3-fold 
increases, in syndecan-1 and heparan sulphate respectively (p<0.001 for both). 
In 2011, Steppan et al measured the same two markers of EGL degradation in a 
cohort of patients undergoing major abdominal surgery, in patients with severe 
sepsis and in healthy controls47. Though patients undergoing major abdominal 
surgery (primary site: pancreas 46%, colon 18%, liver 7%, genitourinary 11% and 
other 18%) exhibited less evidence of inflammation (lower interleukin-6 levels) 
than patients with severe sepsis, plasma levels of syndecan-1 and heparan 
sulphate were markedly elevated post-operatively when compared to controls. 
Whilst (unfortunately) neither of these studies provides any link between EGL 
degradation and clinical outcomes, it suggests a role of EGL degradation in the 
pathogenesis of pulmonary oedema formation in the peri-operative period. To 
date, there have been no studies examining EGL function in patients undergoing 
lung resection42, though a potential role of EGL damage in the pathogenesis of 
ALI/ARDS after lung resection has been postulated42, 48, 49.  
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1.3 Acute Lung Injury / Acute Respiratory Distress 
Syndrome 
Before discussing the specifics of Acute Lung Injury / Acute Respiratory Distress 
Syndrome (ALI/ARDS) occurring in the immediate post-operative period in 
patients undergoing lung resection, I shall first explore the derivation and 
definitions of the terms ALI/ARDS, before briefly reviewing their pathophysiology 
and specifically, the role of ventilator induced lung injury in their pathogenesis. 
1.3.1 What is ALI/ARDS? 
In 2011, the European Society of Intensive Care Medicine, endorsed by the 
American Thoracic Society and the (US) Society of Critical Care Medicine 
convened a consensus panel, “The ARDS Definition Taskforce” to revise the 
definition of Adult Respiratory Distress Syndrome. In the process of deriving an 
updated definition (which will be discussed below), the ‘ARDS Definition Task 
Force’ (an international expert panel of clinicians and researchers active in the 
field of ALI/ARDS) defined a ‘conceptual model’ of ARDS50:  
“The panel agreed that ARDS is a type of acute diffuse, inflammatory 
lung injury, leading to increased pulmonary vascular permeability, 
increased lung weight, and loss of aerated lung tissue. The clinical 
hallmarks are hypoxemia and bilateral radiographic opacities, associated 
with increased venous admixture, increased physiological dead space, and 
decreased lung compliance. The morphological hallmark of the acute 
phase is diffuse alveolar damage (i.e., oedema, inflammation, hyaline 
membrane, or haemorrhage)”. 
The ARDS Definition Task Force (2012)50 
 
This statement represents the most contemporary understanding of the 
syndrome of ALI/ARDS. 
1.3.1.1 Development of a definition of ALI/ARDS 
On Saturday 12th August 1967, David G Ashbaugh and colleagues from the 
University of Colorado Medical Center, published the first reported description 
of  what is now known as ALI/ARDS51. In a case series of 12 patients, with 
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pathologies as diverse as trauma, pancreatitis and viral pneumonia, Ashbaugh et 
al observed that “despite a variety of physical and possibly biochemical insults 
the response of the lung was similar in all 12 patients”51. Patients exhibited a 
syndrome of acute respiratory distress characterised by severe dyspnoea, 
tachypnoea, cyanosis refractory to oxygen therapy, loss of lung compliance and 
diffuse alveolar infiltrates on chest radiography51. 
Subsequently, in 1971, Petty and Ashbaugh went on to refine the description of a 
condition whose pathophysiology (they describe) “is basically a nonspecific 
response to a variety of pulmonary injuries”52. Petty and Ashbaugh describe the 
cardinal features of the syndrome as may be recognised today52: 
1. Direct or indirect mechanism of injury 
2. Diffuse alveolar infiltration on chest radiography 
3. Hypoxaemia secondary to a large right to left shunt  
4. Potential for resolution and recovery, or progressive pulmonary 
insufficiency leading to interstitial fibrosis and death 
 
For several decades, this description of ARDS stood (though at this time the ‘A’ 
stood for ‘adult’ rather than ‘acute’), but increasingly drew criticism as being 
open to subjective interpretation and not being sufficiently specific53. 
In 1988 Murray et al published “an expanded definition of the Adult Respiratory 
Distress Syndrome”54. This three part definition sought to differentiate the 
course of the syndrome (acute or chronic), characterise the severity of the 
pulmonary injury and identify the cause or risk factors associated with the 
injury53, 54. Calculation of the ‘lung injury score’ (LIS – Table 1.1) allowed the 
severity of lung injury to be defined where a score of 0 points defined ‘no lung 
injury’, 0.1-2.5 points signified mild to moderate lung injury and greater than 
2.5 points signified ‘severe lung injury’ or ‘ARDS’53, 54. 
Murray et al’s LIS has been widely used in clinical studies of patients with 
ALI/ARDS, providing a method of characterising the severity of ALI and ARDS on a 
numerical scale. As a definition of ARDS however, the three part definition 
adovated by Murray et al had one important shortfall; no formal criteria exist 
within the definition to distinguish cardiogenic from non-cardiogenic pulmonary 
oedema53. 
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Table 1.1. Calculation of the lung injury score. 
Component Score 
Chest radiograph 
- No alveolar consolidation 
- Alveolar consolidation confined to 1 quadrant 
- Alveolar consolidation confined to 2 quadrants 
- Alveolar consolidation confined to 3 quadrants 
- Alveolar consolidation confined to 4 quadrants 
 
 
0 
1 
2 
3 
4 
Hypoxaemia score 
- PaO2/FiO2  ≥300 mmHg 
- PaO2/FiO2  225-299 mmHg 
- PaO2/FiO2  175-224 mmHg 
- PaO2/FiO2  100-174 mmHg 
- PaO2/FiO2  <100 mmHg 
 
 
0 
1 
2 
3 
4 
PEEP score (when mechanically ventilated) 
- ≤5 cmH2O 
- 6-8 cmH2O 
- 9-11 cmH2O 
- 12-14 cmH2O 
- ≥ 15 cmH2O 
 
 
0 
1 
2 
3 
4 
Respiratory system compliance score (when available)  
- ≥80 ml/cmH2O 
- 60-79 ml/cmH2O 
- 40-59 ml/cmH2O 
- 20-39 ml/cmH2O 
- ≤19 ml/cmH2O 
 
0 
1 
2 
3 
4 
The lung injury score is calculated by dividing the cumulative scores for each component by the 
number of components scored in the derivation. PEEP, positive end-expiratory pressure. From 
Murray et al (1988)
54
. 
The American-European Consensus Conference definition of ALI/ARDS 
In 1992, the American Thoracic Society and the European Society of Intensive 
Care Medicine convened a series of meetings of the “American-European 
Consensus Committee on ARDS...in attempt to bring clarity and uniformity to 
the definition of ALI and ARDS”, largely motivated by a desire to facilitate 
increased trans-Atlantic co-operation in the conduct of clinical studies55.  
At this meeting it was recognised that ARDS represented a spectrum of disease 
severity characterised by a continuum of arterial blood gas and chest X-ray 
abnormalities; the term ‘Acute Lung Injury’ (ALI) was defined as representing 
the entirety of this spectrum, whilst the term ‘acute respiratory distress 
syndrome’ (ARDS) was to be reserved for the most severe cases. The American-
European Consensus Conference (AECC) criteria for ALI and ARDS were thus 
defined (Table 1.2)51. This definition of ALI/ARDS was subsequently widely 
adopted and has been utilised as recruitment criteria in a large number of 
international multicentre randomised controlled trials. It was not however 
without criticism: 
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Table 1.2. The ‘American-European Consensus Conference’ and ‘Berlin’ definitions of ALI 
and ARDS. 
 
AECC definition Berlin definition 
Timing Acute onset Within one week of a known clinical 
insult or new/worsening respiratory 
symptoms 
 
Oxygenation 
impairment 
ALI: PaO2/FiO2 <300  
ARDS: PaO2/FiO2 <200  
Mild: PaO2/FiO2 200-300 with PEEP or 
CPAP>5cmH2O 
Moderate: PaO2/FiO2 100-200 with 
PEEP ≥ 5cmH2O 
Severe: PaO2/FiO2 ≤ 100 with PEEP ≥ 
5cmH2O 
ALI abolished 
 
Chest 
imaging 
Bilateral infiltrates consistent with 
pulmonary oedema (on CXR) 
Bilateral opacities – not fully explained 
by effusions, lobar/lung collapse or 
nodules (on CXR or CT scan) 
 
Origin of 
oedema 
Pulmonary artery occlusion pressure 
≤18mmHg or no clinical suspicion of 
left atrial hypertension 
Respiratory failure not fully explained 
by cardiac failure or fluid overload; 
Need objective assessment (e.g., 
echocardiography) to exclude 
hydrostatic oedema if no risk factor 
present 
 
PEEP, positive end-expiratory pressure; CPAP, continuous positive airway pressure. PaO2/FiO2 in 
mmHg. ased on The ARDS Definition Task Force, (2012)
50
. 
Time frame 
The AECC definition requires that the respiratory failure be of ‘acute onset’, but 
provides no guidance as to what timeframe this represents (e.g. hours, days, 
weeks?). 
Hypoxaemia criterion 
The AECC classifies hypoxaemia by the ratio of partial pressure of oxygen in 
arterial blood (PaO2) to the fraction of inspired oxygen (FiO2) - the ‘PaO2/FiO2 
ratio’. Whilst PaO2/FiO2 performs the essential function of normalising arterial 
oxygenation for the level of inspired oxygen administered, its performance in 
such a function has limitations. Firstly, the relationship between PaO2 and FiO2 is 
non-linear such that PaO2/FiO2 varies substantially as FiO2 is altered
56. Secondly, 
the relationship between PaO2 and FiO2 is dependent on the degree of 
pulmonary shunt56 and it stands to reason therefore, that manipulation of 
positive end-expiratory pressure may alter PaO2/FiO2 without any immediate 
effect on the severity of lung injury. Ferguson at al described the effect of 
standardising ventilator settings on the eligibility of patients for recruitment to a 
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clinical trial57. Forty two patients with PaO2/FiO2 less than 200 (assessed prior to 
intervention), were subjected to a standardised ventilatory protocol (tidal 
volume (VT) 6-8ml/Kg, positive end-expiratory pressure (PEEP) 10cmH2O and FiO2 
1.0) and PaO2/FiO2 was reassessed 30 minutes later. In 58.5% of patients, on re-
assessment PaO2/FiO2 was greater than 200
57.  
Chest X-ray scoring  
Rubenfeld et al took the opportunity to study the interobserver variability of the 
chest X-ray (CXR) criteria of the AECC definition in 21 ‘experts’ recruited from 
those attending a mechanical ventilation workshop (in Toronto, Canada in 1997) 
and from members of the National Institutes of Health ARDS Network58. 
Participants were shown CXRs from hypoxaemic critically ill patients and asked 
to decide whether they “fulfill the AECC definition for ALI and ALI-ARDS, 
‘bilateral infiltrates consistent with pulmonary edema’? Note that the 
American-European Consensus Conference definition specifically included mild 
and patchy infiltrates”. The authors report only ‘moderate agreement’ between 
observers with a K-statistic value of 0.55. Infiltrates limited to lower lung zones, 
atelectasis, small lung volumes, mild involvement, pleural effusions, and 
overlying monitoring devices were identified as contributing factors for high 
variability of radiograph interpretations.  
Meade et al, performed a large study comparing the interobserver agreement 
between clinicians assessing CXRs at the time they were performed, and a pair 
of study investigators (one a radiologist, one a critical care physician) who 
assessed the CXRs independently, but had previously taken part in a ‘consensus 
process’. The ‘consensus process’ involved the investigators independently then 
simultaneously reviewing a training set of 63 films, allowing discussion of the 
reason for disagreement and development of standards and rules that would be 
applied when CXR interpretation was difficult.  One of eight different clinicians 
and both study investigators reviewed 778 CXRs from 99 critically ill patients, 
asking “Is this chest radiograph consistent with ARDS?” In keeping with the 
findings of Rubenfeld et al, for rater pairings who had not jointly participated in 
the consensus process (i.e. any of the clinicians and either of the study 
investigators) interobserver variability was only moderate (K-statistic of 0.38-
0.55). Inter-observer variability between the two study investigators (who had 
participated in the consensus process) was better with K=0.72-0.88. 
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Pulmonary artery catheterisation 
As described in the ARDS conceptual model50, ALI/ARDS concerns the presence of 
non-cardiogenic pulmonary oedema; ‘permeability’ pulmonary oedema not 
caused by heart failure. Establishing the ‘absence’ of cardiogenic pulmonary 
oedema can however be challenging. Provision for such a distinction is made in 
the AECC definition as a pulmonary artery wedge pressure (PAWP) ≤18mmHg 
(when measured), or “no clinical evidence of left atrial hypertension”55. Though 
the committee concluded that “pulmonary artery wedge [pressure] 
measurement was not considered essential for diagnosis in all cases”, its use 
“was recognized as clearly useful in some cases, especially in which cardiac 
pulmonary edema is a distinct clinical possibility”55. 
The practice of intensive care medicine has changed significantly since the 1994 
AECC was convened. Whilst pulmonary artery catheterisation was a common 
technique in the early 1990s, in the intervening years as a result of reports 
suggesting at best no difference59 and at worst increased harm60 resulting from 
pulmonary artery catheterisation, the technique is currently in decline61. 
Furthermore increased understanding of the complex pathophysiology of the 
critically ill patient has led to the understanding that ARDS and cardiac failure 
can co-exist, or that patients with ARDS often have elevated PAWP due to 
elevated pleural pressures or vigorous fluid resuscitation60, 62.   
Lack of validity verses histological findings of diffuse alveolar damage 
Unlike many disease processes, (and reflecting the nature of ALI/ARDS as a 
syndrome rather than specific disease), there is no reference standard for the 
diagnosis of ALI/ARDS. Arguably, the closest available criterion to such a 
standard is the morphological finding of diffuse alveolar damage (DAD). Though 
obtaining specimens for morphological analysis is invasive (and so rarely 
appropriate), there have been several studies comparing patients identified as 
having ALI/ARDS by clinical criteria to the pathological findings of diffuse 
alveolar damage, either in lung biopsy specimens or at autopsy63, 64. The findings 
from such studies have been consistently poor; as Frohlich et al describe, “up to 
half of the patients captured by the definitions do not have the disease”65.  
For many of these reasons, “and because all definitions should be reviewed and 
adjusted periodically to reflect new information and experience”50, the ‘ARDS 
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Definition Task Force’ was convened to “address the limitations of the previous 
AECC definition and propose revisions” 66. 
The Berlin definition of ARDS 
The ‘Berlin definition’ of ARDS as proposed by the ‘ARDS Definition Task Force’ 
is summarised alongside the AECC definition in Table 1.2. At first glance there 
seems to be little difference between the two definitions, with both 
fundamentally being based on the co-existence of hypoxaemia and pulmonary 
infiltrates on chest radiography in patients not perceived to be suffering 
cardiogenic pulmonary oedema. The Task Force have however made significant 
attempts to address many of the criticisms of the AECC definition. These can be 
summarised as follows: 
1. A time frame of one week from a known insult or clinical deterioration 
has been provided as a definition of ‘acute onset’. 
2. The term ALI has been abolished and oxygenation criteria defined as 
‘mild’, ‘moderate’ or ‘severe’ on the basis of PaO2/FiO2  estimates 
made using a standardised level of PEEP of ≥ 5cmH2O. 
3. The chest radiography criteria have been subtly re-defined to exclude 
the existence of bilateral infiltrates in situations where an alternative 
explanation exists. In addition, with the aim of improving inter-
observer variability, the panel provided a training set of CXRs “judged 
by the panel to be illustrative of the spectrum of images that are 
consistent, inconsistent, or equivocal for the diagnosis of ARDS”66. 
4. The need for pulmonary artery wedge pressure measurement has been 
removed. The potential co-existence of hydrostatic and permeability 
oedema has been recognised; ARDS is diagnosed when respiratory 
failure cannot “be fully explained by cardiac failure or fluid 
overload”50. In cases where no risk factor for the development of ARDS 
can be identified, hydrostatic oedema must be objectively ruled out. 
The underlying question of whether the revised ‘Berlin definition’ is superior to 
the ‘AECC definition’ is yet to be resolved. The initial description of the Berlin 
definition included a retrospective ‘empirical evaluation’ against data from 
nearly 5000 patients included in multi- and single-center clinical data sets. 
Whilst the definition appeared to behave appropriately in so much as mortality, 
ventilator free days and duration of mechanical ventilation differed as 
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anticipated between patients with mild, moderate and severe ARDS, the 
predictive values for mortality of both the AECC definition and Berlin definition 
were relatively poor (AUROC of 0.577 vs 0.536 respectively). It is hard to 
conceive that the “better predictive validity for mortality” observed of the 
Berlin definition is of any clinical significance (AUROC of 0.041, 95% CI 0.030-
0.050)50. Hernu et al attempted to perform a prospective validation of the Berlin 
definition and could find no relationship between severity of ARDS as defined by 
the Berlin definition and mortality, concluding that their study “did not validate 
the Berlin definition of ARDS”67. 
A recent study by Thille et al compared the Berlin definition of ARDS with 
autopsy findings of diffuse alveolar damage68. Whilst no direct comparison was 
made with the AECC definition, the findings were similar to previous studies; 
diffuse alveolar damage was found in just 45% of patients with clinical criteria 
for ARDS as defined by the Berlin definition68. Frohlich et al have been damning 
in their interpretation, suggesting the Berlin definition “to be no superior to its 
predecessor”65. Without a “biological definition” capable of distinguishing 
“hypoxemic respiratory failure as a result of alveolar inflammation (ARDS) from 
other pulmonary conditions”, they argue, significant progress in the treatment 
of ARDS is unlikely65.  
1.3.1.2 Alternative diagnostic techniques 
Frohlich et al have not been alone in their criticism of the Berlin definition of 
ARDS, with many authors concluding both that reform was needed, and that the 
Berlin definition ‘does not go far enough’65, 69-72. 
For many years the late Daniel Schuster (formerly Chair in Respiratory Intensive 
Care Medicine and a professor of medicine, University of Washington)B made a 
consistent and vocal argument for the inclusion of some objective measurement 
of pulmonary oedema and increased vascular permeability in the diagnostic 
criteria for ALI/ARDS73-76. ARDS he describes “should not be a diagnosis of 
exclusion but should instead depend on some direct measure of lung injury”73. In 
                                         
B
 Much is made in this section of the opinions of the late Daniel Schuster; it must be emphasised, 
that his work was widely cited, and his opinions shared by a significant number of the wider critical 
care community. 
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a patient with acute bilateral radiographic infiltrates, the diagnosis of ARDS 
could then be made based on the (objective) presence of both pulmonary 
oedema and increased pulmonary vascular permeability.  
It is inherent, that both at the clinical bedside and in the conduct of clinical 
research, in addition to the ability to diagnose ALI/ARDS, the ability to 
characterise the severity would be advantageous. The AECC definition 
categorises patients into ALI or ARDS, whilst the new Berlin definition makes 
provision for mild, moderate and severe categories of ARDS. Clinicians / 
researchers wishing to quantify severity beyond these broad categories, or 
indeed to monitor change over time, will often do so on the basis of oxygenation 
(PaO2/FiO2) or Lung Injury Score (LIS). As Schuster describes: 
“It seems reasonable to assume that as an injury becomes more severe, 
recovery becomes less likely. Thus, implied in any attempt to quantify injury is 
really an attempt to determine prognosis.” 
Schuster D.P. (1998)75 
 
Yet neither the PaO2/FiO2 nor the LIS are good predictors of mortality
77, 78. It is 
arguable that in addition to the need for a ‘biological definition’ and 
appropriate and objective ‘diagnostic criteria’, what is also required is a novel 
‘measurement of severity of lung injury’. Though emphasising the important 
distinctions between ‘definition’, ‘diagnostic criteria’ and ‘severity of injury’, in 
the case of ALI/ARDS Schuster further agues; 
“It seems natural, in the case of lung injury, to assume that measures of 
pulmonary edema and increased vascular permeability could be used for this 
purpose as well as for diagnosis”.  
Schuster From, Schuster D.P., (1998)75 
 
To date, two broad streams of research have come closest to offering a 
quantifiable, ‘biological’ measure of lung injury. Though both were considered 
by the ARDS Definition Task Force but discounted “because of current feasibility 
and lack of data on operational characteristics”50, 66, the measurement of 
extravascular lung water and pulmonary vascular permeability index by 
transpulmonary thermodilution69, 70, 73, 74, 79, and the measurement of plasma  
biomarkers of lung injury80-83 have been advocated by many commentators as 
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potential candidates for addition to the diagnostic criteria of ALI/ARDS. 
Investigations III and IV concern the application of these technologies in the 
post-operative period following lung resection. A detailed literature review 
concerning each topic is provided alongside. 
1.3.2 Pathophysiology of ALI/ARDS 
It is outwith the scope of this work to provide a detailed examination of the 
pathogenesis of ALI/ARDS. In this section, I shall discuss the patho-physiology of 
ALI/ARDS with specific reference to the contribution of ventilator induced lung 
injury (VILI), and the development of peri-operative lung injury. 
The pathophysiological hallmark of ALI/ARDS is increased permeability at the 
alveolar-capillary interface, which is manifest morphologically as diffuse 
alveolar damage. Histological examination in established ARDS reveals 
neutrophil, macrophage and erythrocyte infiltration of the alveolar space, 
hyaline membrane formation, the presence of protein rich oedema fluid and 
disruption of the alveolar epithelium84. Many years of experimental studies have 
defined the contribution of neutrophils, cytokines, reactive oxygen and nitrogen 
species and dysregulation of the coagulation cascade to the pulmonary 
inflammatory injury sustained in ALI/ARDS. As can be observed in the now iconic 
figure from Ware and Matthay, lung injury results from a complex cascade of 
simultaneously occurring pathological processes (Figure 1.7) occurring both at 
the endothelial and epithelial sides of the alveolar-capillary barrier. 
Pulmonary endothelial injury leads to formation of intracellular gaps between 
endothelial cells and necrosis, fragmentation and sloughing of the pulmonary 
endothelium. It is (as Ware describes) “this focal and reversible gap formation 
that is accepted as the ultra-structural basis for increased microvascular 
permeability”85. Whilst endothelial injury has long been recognised as a 
mechanism of increased permeability and consequent pulmonary oedema 
formation, in ALI/ARDS, the role of epithelial injury has more recently been 
described. In addition to contributing to the development of increased 
permeability of the alveolar-capillary barrier, epithelial injury further 
compromises alveolar epithelial fluid transport, preventing reabsorption alveolar 
fluid and increasing the severity and duration of the oedema32, 84, 85. In  
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Figure 1.7. The normal and injured alveolus in the acute phase of acute lung injury / acute 
respiratory distress syndrome. 
Simultaneous neutrophil, cytokine and oxidative mediated injuries to both the pulmonary 
endothelial and epithelial cells leads to formation of intracellular spaces between pulmonary 
endothelial cells, denudement of the basement membrane, sloughing of bronchial epithelium and 
necrosis and apoptosis of epithelial cells resulting in accumulation of protein rich oedema fluid and 
development of hyaline membranes. From Ware and Matthay (2000)
84
. 
addition, reduced surfactant production by type II pneumocytes contributes to 
the altered lung mechanics and gas exchange abnormalities observed. 20, 21.  
1.3.3 Ventilator induced lung injury in the pathogenesis of 
ALI/ARDS 
Since its introduction to critical care medicine, born of necessity during the 1952 
polio epidemic, mechanical ventilation has long since been recognised as the 
main stay of supportive therapy in patients with ALI/ARDS; 7 of 12 patients in 
Ashbaugh’s initial description of the syndrome received ‘respirator’ support51. 
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Whilst undoubtedly a life saving supportive therapy, in the years since its 
introduction the potentially harmful effects of mechanical ventilation have 
increasingly been recognised. 
1.3.3.1 Barotrauma in the pathogenesis of ventilator induced lung injury 
As early as the 1950’s, clinicians were recognising the potential for mechanical 
ventilation to cause injury to the lung85, and by the 1970’s, the term 
‘barotrauma’ was in recognised use86. Gross barotruama refers to the 
appearance of air leaks manifest as pneumothoraces, pneumomediastinum, 
surgical emphysema and gas embolism. Whilst such macroscopic trauma is easily 
recognisable, it became clear to researchers that a more subtle physiological 
and morphological syndrome can result from mechanical ventilation with 
“alterations of lung fluid balance, increases in endothelial and epithelial 
permeability and severe ultrastructural  damage”87. 
Webb and Tierney were in 1974 the first to demonstrate that mechanical 
ventilation could induce lung injury in otherwise normal lungs88. By ventilating 
rats for one hour with increasing levels of peak airwary pressure (Ppeak) the 
authors observed that at a Ppeak of 14 cmH2O there was no histological evidence 
of lung injury, at Ppeak of 30cmH2O there was evidence of perivascular oedema 
whilst at 45cmH2O all the rats ventilated developed severe pulmonary oedema, 
with histological evidence of marked perivascular and alveolar oedema; all of 
the animals died before the end of the hour. Similar findings were demonstrated 
by others both in rats and a variety of other animal species88. 
1.3.3.2 Volutrauma in the pathogenesis of ventilator induced lung injury 
In the late 1980’s, Dreyfuss et al suggested that it was the effects of high tidal 
volumes, rather than pressures that was responsible for causing lung injury and 
coined the term ‘volutrauma’89. To discriminate between the effects of pressure 
and volume, Dreyfuss et al ventilated rats at high inflation pressures and varied 
the resulting tidal volume by limiting chest expansion by application of 
thoracoabdominal strapping. Rats exposed to high-pressure, high-volume 
ventilation rapidly developed pulmonary oedema whilst those in which tidal 
volume was limited did not (Figure 1.8). Adding further weight to this 
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hypothesis, Dreyfuss et al included another group of animals in which high tidal 
volumes were achieved, but following application of negative pressures in an 
iron lung. Similar levels of oedema were observed in both high-pressure, high-
volume and low-pressure, high-volume groups (Figure 1.8)89.  
 
Figure 1.8. Comparison of the effects of high-pressure, and high volume ventilation on the 
development of lung injury. 
Lung injury is assessed by determination of extravascular water content (Qwl/BW) and permeability 
alterations by bloodless dry-lung weight (DLW/BW). HiP, high-pressure; HiV, high volume; LoP, 
low-pressure (iron lung ventilation); LoV, low volume (thoracoabdominal strapping). Dotted lines 
represent the upper 95% confidence limit for control values. From Dreyfuss et al (1988)
89
, as 
reproduced by de Prost et al (2011)
90
. 
1.3.3.1 Biotrauma in the pathogenesis of ventilator induced lung injury 
To this point, the mechanism of barotrauma and volutrauma in the causation of 
lung injury has been assumed to be purely mechanical. Where the mechanical 
effects of high pressure and overdistention at high volumes are extreme enough 
to ‘break’ the lung structure, there is little doubt that lung injury by such a 
mechanism can occur. Since the early 1990s however, the potential for the 
mechanical forces described to lead to release of inflammatory mediators has 
been understood. Such an effect may occur ‘directly’ by injury to pulmonary 
epithelial and endothelial cells or ‘indirectly’ by transduction of these forces 
leading to activation of cell-signalling pathways in epithelial, endothelial and 
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inflammatory cells91. Evidence for such ‘biotrauma’ has been provided by the 
observation of neutrophil infiltration in animals ventilated with high peak 
pressures, and the recognition of a systemically deleterious effect of mechanical 
ventilation90. In addition there have been countless animal and human studies 
reporting increased levels of both pulmonary and systemic cytokine levels in 
proportion to the intensity of the mechanical ventilation. To cite one such 
example, Tremblay et al demonstrated increased levels of tumour necrosis 
factor-α, interleukin-1β (IL-1β), IL-6 and macrophage inflammatory protein-2 in 
unperfused rat lungs subjected to high tidal volume ventilation when compared 
to controls92. 
1.3.3.2 Atelectotrauma in the pathogenesis of ventilator induced lung injury 
In addition to the injurious effects of high lung volumes, it is also evident that 
lung injury occurs at low lung volumes90, 91. Application of positive end-
expiratory pressure (PEEP) has been demonstrated by many to protect against 
lung injury. In Webb and Tierney’s seminal paper discussed above, application of 
10cmH2O PEEP resulted in a less severe lung injury and indeed survival of all of 
the animals subjected to ventilation at Ppeak of 45 cmH2O
88. Prevention of 
cyclical recruitment / de-recruitment of distal lung units has become accepted 
as a mechanism by which PEEP prevents lung injury90, 93. Rather than absolute 
lung volume or pressure, it appears that large cyclical changes in lung volume / 
pressure may lead to the development of lung injury90. This is supported by the 
findings of Cobridge et al, who demonstrated in hydrochloric acid injured dog 
lungs that at equivalent peak inspiratory pressure, low tidal volume and high 
PEEP resulted in reduced lung injury in comparison to high tidal volume and low 
PEEP94.  Similar effects have been demonstrated by others in a variety of 
models. 
In addition to the effects of cyclical recruitment / de-recruitment the presence 
of atelectatic lung regions has been demonstrated to contribute to the 
pathogenesis of lung injury by a number of other mechanisms95: Localised 
alveolar hypoxia in atelectatic regions has been shown to induce lung 
inflammation through macrophage recruitment96, whilst the presence of 
ateletatic lung regions which do not undergo tidal recruitment leads to 
increased mechanical strain on adjacent ventilated lung units. Mead et al 
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calculated that at an airway pressure of 30 cmH2O, a pressure as high as 140 
cmH2O may be exerted locally at the interface between closed and open lung 
units97. 
1.3.3.3 Lung protective mechanical ventilation in the prevention of ventilator 
induced lung injury 
Gattinoni has described the lung in established ARDS as resembling that of a 
baby98. In studies using computed tomography in patients with lung injury, the 
volume of normally aerated lung tissue he reports, has the dimensions of that of 
a 5-6 year-old child (300-500g aerated lung tissue). Furthermore, Gattinoni 
demonstrated that the intrinsic elasticity of the aerated lung units was normal, 
suggesting that in ARDS the lung should be thought of as ‘small’ rather than 
‘stiff’98. From these observations and those discussed above under the headings 
baro-, volu-, bio- and atelecto- trauma it becomes easy to understand what 
needs to be done in order to provide safe, ‘lung protective’ mechanical 
ventilation. Reducing tidal volume to the dimensions of the hypothesised baby 
lung and limiting peak inspiratory pressures should prevent baro- and volu- 
trauma, whilst institution of appropriate levels of PEEP should serve to maximise 
the functional volume of the ‘baby lung’ whilst preventing harmful recruitment / 
de-recruitment. Clearly avoidance of baro-, volu- and atelecto- trauma should in 
turn limit bio-trauma. 
In 2000, a large body of pre-clinical and early phase clinical study data 
culminated in the publication of the US ARDS Network’s multicentre randomised 
clinical trial on “Ventilation with Lower Tidal Volumes as Compared with 
Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory 
Distress Syndrome”99. In this study of 861 patients with ARDS (defined according 
to the AECC definition), the authors compared the effects of ‘traditional’ tidal 
volumes (VT=12ml/kg) verses ‘lower’ tidal volumes (VT=6ml/kg) alongside a 
standardised approach to setting PEEP. The number of ventilator free days and 
mortality was lower in the group treated with lower tidal volumes than in the 
group treated with traditional tidal volumes (31.0 vs. 39.8% mortality 
respectively, P=0.007, Figure 1.9)99. 
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Figure 1.9. Probability of survival and hospital discharge in the US ARDS Network's 'lower 
tidal volume ventilation' trial. 
‘Lower’ tidal volume = 6ml/kg, ‘traditional’ tidal volume = 12ml/kg. ‘Discharge’ reflects being 
discharged home and breathing without assistance, during the first 180 days after randomization. 
From the US ARDS Network, (2000)
99
. 
At the time of writing (13th October 2014), this study has been cited 3128 times 
(source: http://www.nejm.org/doi/full/10.1056/NEJM200005043421801), and it 
is no exaggeration to suggest that no other study has had greater influence on 
the practice of critical care medicine. Indeed the study’s effects have been 
wider reaching, triggering alterations in the practice of mechanical ventilation in 
the operating theatre environment. 
1.3.3.4 Ventilator induced lung injury and the ‘multiple-hit’ hypothesis of 
ALI/ARDS pathogenesis 
Many of the animal studies discussed in this section have so far, have been 
concerned with the deleterious effects of mechanical ventilation at extremes of 
pressure or volume on the development of lung injury in normal lungs. It is 
important to discuss however a parallel body of work suggesting that pre-existing 
injury may sensitise the lungs to the deleterious effects of mechanical 
ventilation90. For example, Hernandez et al studied an ex-vivo rabbit model of 
oleic acid induced injury100.  Whilst neither low doses of inhaled oleic acid nor 
mechanical  ventilation (Ppeak 25cmH2O) alone were sufficient to cause lung 
injury, the combination of oleic acid inhalation and mechanical ventilation led 
to increased pulmonary capillary permeability100.  
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Such a concept has become embodied in the ‘multiple-hit’ hypothesis of 
ALI/ARDS. It has been hypothesised that mechanical ventilation may serve as a 
‘second-hit’, increasing the risk of lung injury development in mechanically 
ventilated patients who at the time of ventilation, do not have ALI/ARDS, but 
whose lungs have been primed for injury by a physiologic insult such as 
pneumonia, aspiration or sepsis101-103. Given the great success of instituting lung 
protective ventilation in patients with established ALI/ARDS99, it seems a logical 
step therefore to apply the principles of lung protective ventilation to patients 
‘at risk’ of ALI104.  
1.3.3.5 Peri-operative lung injury 
Two large retrospective cohort studies have reported a 2.6-7% incidence of 
ALI/ARDS in the post-operative period105, 106.   Patients with pre-existing sepsis,  
undergoing emergency procedures or those involving aortic-cross clamping, 
cardiopulmonary bypass and one-lung ventilation have been identified as being 
at particularly increased risk105, 106. It is intuitive therefore to suggest that peri-
operative lung injury may also be the consequence of a similar ‘multiple-hit’ 
model where the deleterious effects of mechanical ventilation may be sufficient 
to induce lung injury in patients already at increased risk due to the specifics of 
the type of surgery, or their pre-existing condition. From here, it appears a 
further logical step, to apply the principles of lung protective ventilation to 
patients at increased risk of ALI/ARDS in the peri-operative period. Indeed, data 
from a meta-analysis (incorporating many patients undergoing lung resection 
surgery) has demonstrated a reduction in the incidence of post-operative 
ALI/ARDS in patients ventilated to a lower tidal volume / higher PEEP protocol 
(risk ratio 0.40 (95% CI 0.22-0.70) for lower VT, 0.29 (0.14-0.60) for PEEP)107.  
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1.4 Post-lung resection acute lung injury 
The occurrence of pulmonary oedema in the early post-operative period 
following lung resection was first reported by Gibbon and Gibbon in 1942108. In 
this publication, the authors report the case histories of two young patients 
(aged 19 and 24) undergoing pulmonary lobectomy for bronchiectasis. The 
patients died in the early post-operative period and in both cases the only 
significant finding on autopsy was of oedema of the remaining lobes. The most 
frequently cited case series of patients with oedema following lung resection 
was published in 1984 by Zeldin et al 109. The authors reported a case series of 
10 patients who developed oedema following “otherwise uncomplicated 
pneumonectomies”; “Post-pneumonectomy pulmonary oedema [also the title of 
the paper] has become a worldwide problem” they report. Though the term 
‘post-pneumonectomy pulmonary oedema’ was in widespread use in 1984, it is 
evident from others (including Gibbon et al who first reported the syndrome 108), 
that the syndrome of pulmonary oedema after lung resection is not restricted to 
pneumonectomy, but also occurs after lesser resections 110, 111.  
1.4.1 Nomenclature and definitions 
Variably known as ‘post-pneumonectomy pulmonary oedema’109, 112-114,  ‘post-
thoracotomy acute lung injury’115, ‘permeability pulmonary oedema’116, ‘acute 
lung injury after thoracic surgery’117 and ‘low pressure oedema’118, the clinical 
syndrome of pulmonary oedema formation following thoracic surgery for lung 
resection has been well documented. To date, however, there is no established 
definition nor nomenclature for what will be discussed from here on in this 
thesis as ‘post-lung resection acute lung injury’ (PLR-ALI). A number of 
definitions have been reported: 
“Oedema formation following pneumonectomy characterized by normal 
cardiac filling pressures, high pulmonary artery pressures and high 
cardiac output”.  
Peters et al (1989)112 
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“Respiratory distress in a patient with pulmonary infiltrates on chest 
radiography but in the absence of evidence of cardiac failure, 
pneumonia, sepsis or aspiration”.  
Turnage et al (1993)119 
 
“Severe and often lethal respiratory failure secondary to non cardiac 
pulmonary edema shortly after resection of the lung”.  
Shapira et al (1993)120 
 
“Pulmonary oedema and hypoxaemia developing after lung resection”.  
Jordan et al (2000)121 
 
Following the adoption of the 1994 American-European consensus conference 
(AECC) definition for ALI/ARDS, and the recognition that the pulmonary oedema 
occurring following lung resection “follows a clinical and histopathological 
course indistinguishable from ARDS” (discussed below)121, in recent years many 
authors have used the AECC definition to define PLR-ALI 115, 122. 
1.4.2 What is post-lung resection ALI? 
A large number of authors have used the AECC definition of ARDS55 to identify a 
population of patients with ALI/ARDS post-operatively following lung resection. 
By definition therefore, evidence of hypoxaemia with radiological evidence of 
bilateralC  radiographic opacities is evident in a cohort of patients following lung 
resection. The question which remains however is whether these clinical 
appearances reflect the same underlying pathophysiological processes which are 
seen in ALI/ARDS? 
Jordan et al suggest  that “In its extreme form, [post-pneumonectomy 
pulmonary oedema] follows a clinical and histopathological course 
indistinguishable from acute respiratory distress syndrome”121. In agreement 
with these authors, post-lung resection ALI (PLR-ALI) is widely interpreted to be 
a variant of ALI/ARDS following an identical clinical and pathophysiological 
course 115, 117, 118, 122-124. As discussed previously, the ARDS definition task force 
describe ARDS as a syndrome of: 
                                         
C
 Though strictly the AECC definition describes bilateral opacities, this definition is also widely 
applied to patients who have undergone pneumonectomy. 
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“acute diffuse inflammatory lung injury... [characterised by] increased 
pulmonary vascular permeability [and the] morphological hallmark... 
diffuse alveolar damage. [Furthermore] patients may qualify as having 
ARDS as long as they have respiratory failure not fully explained by 
cardiac failure or fluid overload”50.  
‘ARDS Definition Task Force’ (2012)50 
 
To support Jordan et al’s hypothesis therefore, evidence is required of 
pulmonary oedema formation following lung resection, in the absence of cardiac 
failure, with increased pulmonary vascular permeability and diffuse alveolar 
damage. The evidence for each is presented in turn. 
1.4.2.1 Evidence of non-cardiogenic pulmonary oedema following lung 
resection 
In addition to the presence of hypoxia and pulmonary infiltrates on chest 
radiography, diagnosis of acute lung injury according to the American-European 
consensus conference (AECC) definition of ARDS55 requires the absence of 
cardiac failure. Whilst by strict (AECC) definition this requires documentation of 
pulmonary artery wedge pressure of less than ≤18mmHg, this is generally 
interpreted to reflect the absence of clinical evidence of left atrial 
hypertension50.  By definition therefore, all of the reports of PLR-ALI made using 
the AECC definition as diagnostic criteria are reporting the presence of oedema 
without evidence of cardiac failure. 
Several authors have gone further to confirm the non-cardiogenic nature of the 
oedema. In Zeldin et al’s, cohort of 10 patients with post-pneumonectomy 
pulmonary oedema discussed above, the authors report that central pressure 
measurements (pulmonary artery wedge pressure) revealed no evidence of left 
ventricular failure or cardiogenic pulmonary oedema109. Mathru et al, reported 
five cases of non-cardiogenic pulmonary oedema occurring after lung resection. 
They reported that the “non-cardiac origin of the oedema is suggested by the 
presence of normal filling pressure, [and] normal or high cardiac output”116. 
Turnage et al, report pulmonary artery catheter data from 21 patients with PLR-
ALI; mean pulmonary artery occlusion pressure was in the region of 10-14mmHg 
for the duration of the monitored period119. 
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1.4.2.2 Evidence of increased pulmonary vascular permeability following 
lung resection 
Waller et al, performed lung scintigraphy in 21 men following lung resection125. 
By use of a radio-labelled albumin technique to observe a statistically significant 
accumulation of pulmonary albumin in the first six hours post-operatively, 
Waller et al demonstrated evidence of increased pulmonary vascular 
permeability post-operatively in 9 out of 10 patients who had undergone 
pneumonectomy. In a further 11 patients who had undergone lobectomy, 6 
patients demonstrated increased permeability but this was not statistically 
significant. No changes in either pulmonary artery wedge pressure nor 
pulmonary capillary pressure were observed peri-operatively, mitigating against 
a hydrostatic component to the protein extravasation. Only one patient 
displayed clinical evidence of PLR-ALI in this case series suggesting that 
subclinical changes in pulmonary vascular permeability are occurring in the 
majority of patients.  
Mathru et al investigated the aetiology of pulmonary oedema in five patients 
suffering “severe respiratory distress and.. [demonstrating] x-ray evidence of 
diffuse interstitial pulmonary oedema within 12 hours” of lung resection (4 
following pneumonectomy, 1 following lobectomy). They report that the mean 
ratio of oedema fluid protein to serum protein was 0.6 or greater suggesting an 
oedema caused by increased permeability rather than transudation116.  
1.4.2.3 Morphological evidence of diffuse alveolar damage following lung 
resection 
Kozian et al studied a porcine model of one lung ventilation and thoracic 
surgery. Animals were subject to one-lung ventilation, left lateral thoracotomy 
and repeated handling of lung tissue. Following euthanasia and tissue harvesting, 
the authors observed histologic evidence of alveolar oedema, interstitial 
oedema, microatelectasis, microhaemorrhage, neutrophil infiltration and 
alveolar overdistention; the “pathomorphologic” features of diffuse alveolar 
damage (DAD) in both lungs126.  
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Turnage et al reported autopsy findings from 17 patients who died from ‘post-
pneumonectomy pulmonary oedema’.119 Post-pneumonectomy pulmonary 
oedema was defined in this study (which precedes the AECC) as respiratory 
distress in a patient with pulmonary infiltrates on chest radiography but in the 
absence of evidence of cardiac failure, pneumonia, sepsis or aspiration. Of the 
21 patients with PPE by these criteria, Turnage et al observed characteristic 
histological findings of ARDS (no definition provided) in 15 of 17 cases. 
In summary, there appears to be good evidence to suggest that a syndrome 
exists following lung resection of hypoxia, radiological findings of pulmonary 
oedema, where the oedema appears to be one of non-cardiogenic origin with 
evidence of increased pulmonary permeability and with histological findings in 
both animal models and autopsy specimens of DAD. It seems reasonable 
therefore to conclude that PLR-ALI is a variant of ALI/ARDS and that lung 
resection simply serves to trigger the same pathophysiological and clinical 
syndrome in the susceptible individual. 
1.4.3 Incidence and mortality of post-lung resection ALI 
Investigation II of this thesis is a meta-regression analysis of the incidence and 
mortality of PLR-ALI. More extensive discussion of the incidence and mortality is 
therefore provided in that section (chapter 3). 
The incidence of PLR-ALI is variously quoted as being between 2 and 11%127-130. 
The overall (all cause) mortality following lung resection in the UK has been 
falling over time. Mortality following lobectomy for primary lung cancer has 
fallen from in excess of 4% in the 1980s to current levels of just under 2%5.  It is 
interesting however to note a changing trend in the causes of mortality following 
lung resection. Historically, surgical complications (for example broncho-pleural 
fistula and empyema) were the leading cause of post-operative death in patients 
undergoing lung resection. As improvements in surgical technique have led to a 
reduction in surgical complications, in recent years respiratory complications 
have been reported to be the major cause of mortality131. 
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Though the incidence of PLR-ALI may be low, the mortality of PLR-ALI is high. 
The mortality from PLR-ALI is generally quoted as being in the region of 40 to 
60% 110, 111, 129, 130, 132. In some series mortality in excess of 80% has been 
reported133-135. As with the incidence of PLR-ALI, mortality appears to be related 
to size of resection; in a study of 50 patients developing PLR-ALI and requiring 
post-operative mechanical ventilation, Dulu et al reported a 50% mortality 
following pneumonectomy, 42% following lobectomy and 22% following sub-lobar 
resections111. Though no direct comparisons have been made, the mortality from 
PLR-ALI appears to be higher than the 44% mortality reported for ALI/ARDS in 
the general intensive care population (outwith clinical trials)136. 
Ruffini et al report the incidence and mortality of PLR-ALI in a case series of 
1221 patients undergoing lung resection in the 1990s. PLR-ALR developed in 2.2% 
of cases and carried a 52% mortality. This meant that PLR-ALI accounted for 41% 
of the overall  hospital mortality of 1.2% and that PLR-ALI was the major cause 
of mortality following lung resection 129. Kutlu et al 130 reached the same 
conclusion: 
“ALI and ARDS are the major causes of mortality after lung resection”. 
1.4.4 Pathophysiology of post-lung resection lung injury 
1.4.4.1 PLR-ALI as a single disease process? 
In 2003 Licker et al published one of the seminal papers exploring the risk 
factors for PLR-ALI128. In a cohort of 879 consecutive patients from a single 
institution undergoing thoracic surgery for lung cancer, Licker et al prospectively 
collected clinical, anaesthetic, surgical, radiological, biochemical and 
histopathologic data. The overall incidence of PLR-ALI was 4.2% (n=37). The 
authors reported a bimodal distribution of PLR-ALI (Figure 1.10). 
In the majority of cases (n=27), PLR-ALI developed within the first three days 
post-operatively, whilst a lesser proportion (n=10) developed ALI after the third 
post operative day. Licker et al defined the early cases of PLR-ALI as ‘primary 
ALI’, attributing them to the pathophysiological processes discussed below, 
whilst the latter cases, defined as ‘secondary ALI’ appeared to occur following 
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Figure 1.10. Time-related distribution of ALI after lung resection. 
 The biomodal distribution is clearly evident. From Licker at al, 2003
128
. 
the development of other complications (e.g. bronchopneumonia, gastric 
aspiration or broncho-pleural fistula)128. 
The remainder of this discussion concerning the pathophysiology of PLR-ALI (and 
to a great extent the rest of thesis), concerns the development of primary PLR-
ALI. 
1.4.4.2 Pathophysiology of primary PLR-ALI 
Given the discussions above, it is inherent that the cellular pathology resulting in 
pulmonary oedema formation in PLR-ALI is the same as in any other form of ALI; 
endothelial barrier function is disrupted and there is extravasation of plasma. 
Gothard succinctly describes that PLR-ALI “probably represents the pulmonary 
manifestations of a panendothelial inflammatory vascular injury”121, 122. Copious 
evidence has been presented documenting increases in both pro- and anti-
inflammatory cytokine levels and the generation of reactive oxygen and  
nitrogen species (ROS & RNS) both systemically and in the lung in patients 
undergoing lung resection. As with ALI/ARDS in the non-lung resection 
population, it is unlikely that PLR-ALI occurs as a result of any single aetiological 
factor, but rather as the result of a ‘multiple-hit’ sequence of deleterious 
events115, 117, 118, 123, 126, 137. In the following discussion a number of potential 
triggers are examined. 
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As the thoracic anaesthetist is forced to separate the lungs and ventilate one 
independently of the other, when considering the pathophysiology of PLR-ALI the 
lungs must similarly be thought of separately. The dependent, ventilated, 
‘anaesthetic’ lung and the non-dependent, non-ventilated, ‘surgical’ lung are 
subject to parallel insults, each potentially resulting in, or contributing to the 
development of lung injury.  
Pathophysiology of injury to the dependant, ventilated lung  
In 2002, Padley et al reported the results of a retrospective review of intensive 
care admissions of patients with ALI after lung surgery138. Nine of the 17 patients 
subsequently identified as having sustained post-operative ARDS following 
lobectomy or sub-lobar resection had both pre-operative and post-operative CT 
scans available for analysis. In 8 of these 9 patients the authors observed lung 
density to increase more in the non-operated lung than in the operated lung, 
causing the authors to conclude that “following lobectomy, there appears to be 
a truly asymmetric form of ARDS”, with “relative sparing of the lung that 
underwent lobectomy” (Figure 1.11)138. 
 
Figure 1.11. Transverse computed tomography image obtained post-operatively following 
lung resection. 
Following right sided resection (left side of the image, evidenced by presence of chest drains), 
there is marked asymmetry of parenchymal opacity, with relative sparing of the operative lung. 
Ground glass parenchymal opacification, increased prominence of interlobular septa and an 
anteriorposterior opacity gradient are evident in the non-operative lung consistent with 
development of lung injury. From Padley et al (2002)
138
. 
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Factors implicated in the development of lung injury in the ventilated, 
dependant lung are ventilator induced lung injury, oxygen toxicity and  
hyperperfusion. Each will be considered in turn. 
Ventilator Induced Lung Injury 
The concept and pathophysiology of ventilator induced lung injury (VILI) has 
been discussed in detail (section 1.3.3). It is reasonable to expect that VILI may 
equally be a problem during one lung ventilation as during two; indeed if during 
OLV the ventilated lung is exposed to increased pressures, tidal volumes or 
fraction of inspired oxygen then the potential for VILI during OLV may be 
increased. 
Traditional teaching of thoracic anaesthesia has described OLV with a target 
tidal volume of 10 mL/kg, an FiO2 of 1.0, zero positive end expiratory pressure 
(ZEEP) and an intention to maintain normocapnia124, 139-141. Such advice was 
provided primarily to guard against hypoxaemia, with the belief that “relatively 
large tidal volumes are needed to recruit alveoli in the dependent ventilated 
lung”140. Katz et al had previously demonstrated that higher tidal volumes and 
ZEEP were associated with improved oxygenation during OLV142. 
In recent years however, in parallel with the greater understanding of the role of 
ventilator associated lung injury in the general intensive care population, and 
the recognition of the striking similarities between the single ventilated lung and 
the baby lung concept described by Gattioni in ARDS98 (a smaller total lung 
volume, with decreased oxygenation and V/Q mismatch from increased shunt 
and atelectasis124, 143), it became apparent use of high tidal volumes during OLV 
may be harmful 122, 124, 141.  
Whilst ventilating one lung with the same tidal volume as two intuitively 
provides the potential for volutrauma, applying such a large tidal volume to a 
single lung also holds the potential for development of barotrauma. Szegedi et al 
reported that with a fixed tidal volume of 10ml/kg, peak airway pressure 
increased (Ppeak) by 55% and plateau pressure by 42% (Pplateau) when switching 
from two- to one-lung ventilation144. Whilst Szegedi et al’s observations were 
made in the supine position144, the potential for barotrauma is increased further 
as a result of reduced compliance of the dependant ventilated lung intra-
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operatively. Larsson et al report a fall in compliance from 29 to 23 ml/cmH20 
(p<0.05; n=8) on turning from supine to the lateral decubitus position145. 
Evidence from animal models of one-lung ventilation 
Gama de Abreu et al used an isolated, perfused rabbit lung model to examine 
the effects of tidal volume (VT) on the development of lung injury during OLV
146.  
Animals were randomised to non-protective OLV (no VT reduction on institution 
of OLV (~8ml/kg), and zero positive end-expiratory pressure (ZEEP)), or to 
protective OLV (VT 50% of pre-OLV values (~4ml/kg), with PEEP) and controls 
(two-lung ventilation). Non-protective OLV resulted in significantly increased 
Ppeak (13.5 vs 5.1 cmH20; p<0.001) compared to protective OLV. After ninety 
minutes of OLV, preparations exposed to non-protective OLV demonstrated 
increased lung injury as evidenced by significantly greater lung weight gain and 
thromboxane B2 concentration in perfusate compared to protective OLV and 
controls146. 
Kuzkov et al reported significantly reduced extravascular lung water post-
operatively following pneumonectomy in sheep that were ventilated with 
protective ventilation (VT 6ml/kg, PEEP 2cmH2O) compared with controls (VT 
12ml/kg, ZEEP147)D. 
Evidence from human studies of one-lung ventilation 
Due to the relative infrequency of ALI development, several human studies have 
examined pulmonary and systemic cytokine levels as a surrogate marker for lung 
injury. Schilling et al reported increased numbers of intra-alveolar cells, and 
protein, albumin, interleukin-8 (IL-8), elastase, IL-10, tumour necrosis factor 
alpha (TNF-α), soluble intracellular adhesion molecule (sICAM) concentrations in 
(dependant lung) broncho-alveolar lavage (BAL) specimens after one-lung 
ventilation with VT of 10ml/kg in humans
148. BAL concentrations of TNF-α and 
sICAM were significantly lower in a second group randomised to receive OLV with 
a VT of 5ml/kg
148. In a similar study, Michelet et al randomised patients 
undergoing oesophagectomy with OLV to protective ventilation (VT 5ml/kg, PEEP 
5cmH2O) during OLV or ‘conventional ventilation’ (VT 9ml/kg, ZEEP)
149. Plasma 
levels of IL-1β, IL-6, and IL-8 were lower at the end of the period of OLV  and 18 
                                         
D
 The role of extravascular lung water measurement in the diagnosis of ALI/ARDS is discussed in 
detail in chapter 5. 
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hours later in the lung protective ventilation group (mean duration 85 and 89 
minutes in the protective and conventional ventilation group respectively)149. 
Together the studies of Gama de Abreu146, Kuzkov147, Schilling150 and Michelet149 
and colleagues provide evidence of pulmonary and systemic inflammation 
(presumed surrogate markers of lung injury) secondary to OLV which can to an 
extent be ameliorated by reduced tidal volumes. In order to establish a link 
between ventilation and the development of ALI in human patient populations 
however, evidence from much larger cohorts is required. Such evidence has been 
provided in a number of observational studies (Table 1.3), which have reported 
association between ventilatory variables and the development of PLR-ALI. Both 
increased peak airway pressure (Ppeak) intra-operatively or during the period of 
OLV 151, 152, and tidal volume during the period of OLV152 have been shown to be 
independent risk factors for the development of PLR-ALI (Table 1.3).  
Duration of one-lung ventilation 
Intuitively, the duration of OLV is also likely to be important in determining the 
degree of VILI to which the lung is exposed. In Licker et al’s 2003 case series, in 
order to represent the cumulative effect of baro-trauma throughout the duration 
of the period of OLV, the authors constructed a ‘ventilatory hyperpressure 
index’, defined as the “product of inspiratory pressure >10cmH2O and the 
duration of OLV”. In multivariate logistic regression analysis, ventilatory 
hyperpressure index represented the strongest risk factor for the development 
of PLR-ALI observed in this cohort (851 patients with a complete data set), with 
an odds ratio of 3.53 (95% CI 1.71-8.45; p<0.001); representing an approximately 
three-fold increased risk of PLR-ALI if peak inspiratory pressure is ≥25cmH2O 
versus 15cmH2O
128. The importance of OLV duration on the development of PLR-
ALI is supported by an animal study in which rats were exposed to OLV for 
between one and three hours; biochemical and histological evidence of 
pulmonary tissue damage increased with the duration of OLV156. In humans, 
Misthos et al have demonstrated higher plasma malondialdehyde level (a marker 
of oxidative stress) intra- and post-operatively as the duration of OLV 
increases157. 
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Table 1.3. Risk factors for development of post-lung resection acute lung injury identified 
following multivariate analysis. 
Study N Popn. Risk factor Magnitude 
Patient factors 
Parquin et al. 
1996
153
 
146 P Perfusion fraction of remaining 
lung (<55%) 
Not given 
 
Licker et al. 
2003
128,C 
 
851 P, L, 
SL 
Chronic alcohol consumption 
(≥60g ethanol per day) 
OR = 1.87 (CI 1.09-
4.56) 
Alam et al. 
2007
154
 
1428 P, L, 
SL 
ppo-FEV1 OR = 1.10 (CI 1.01-1.2) 
Sen et al. 
2010
127
 
 
143 P, L, 
SL  
ASA score 
 
Alcohol abuse 
OR = 1257 (CI 17.8-
88604) 
OR 39.6 (CI 6.4-645.2) 
Kim et al. 
2010
134
 
 
425 P Perfusion fraction of resected 
lung 
ppo-FEV1 
RR = 1.1 ( CI 1.03-
1.17) 
RR = 0.93 (CI 0.90-
0.99) 
Ventilatory parameters 
van der Werrf et 
al. 1997
151
  
197 P Highest ventilation pressure 
(≤40 vs ≥ 40cmH2O) 
OR = 3.0 (CI 1.2-7.4) 
Licker et al. 
2003
128,C 
851 P, L, 
SL 
Ventilator hyperpressure index 
(PIP>10cmH2O x duration of 
OLV) 
OR = 3.53 (CI 1.71-
8.45); p<0.001 
Jeon et al. 
2009
152
  
146 P VT – OLV 
 
Ppeak - OLV 
OR 3.37 per ml/kg  
CI (1.65-6.86)  
OR 2.32 (CI 1.46-3.67) 
per 1cmH2O increase 
Peri-operative fluid administration 
Parquin et al. 
1996
153,C 
146 P Total fluid load > 2L Not provided 
Licker et al. 
2003
128
 
851 P, L, 
SL 
Fluid infused intra-op and in 
first 24h (<4L vs >4L) 
OR = 2.91 (CI 1.87-
7.38) 
Alam et al. 
2007
154
  
1428 P, L, 
SL 
Peri-operative fluid 
administration 
OR = 1.2 per 500ml 
increase  
Licker et al 
2009
155,C 
1091 P,L,S
L 
Cumulative peri-op. fluid 
infused  
OR = 1.42 (CI 1.09-
4.32) per ml/kg/hr 
Blood product administration 
van der Werff et 
al. 1997
151
  
197 P Receipt of FFP;( yes / no) OR 4.7 (CI 1.4-16.3) 
Sen et al. 
2010
127
 
143 P, L, 
SL  
Receipt of FFP;  OR 28.6 (CI 1.2-1.9) 
Side of resection 
Kim et al. 
2010
134
 
425 P Right sided resection; yes /no RR 4.8 (CI 1.6-14.4) 
Size of resection 
Licker et al. 
2003
128,E
 
851 P, L, 
SL 
Pneumonectomy; yes/no OR 2.78 (CI 1.5-6.3) 
Sen et al. 
2010
127
 
143 P, L, 
SL  
‘Pulmonary resection type’ OR 1.4 (CI 1.2-1.9) 
N, number of patients; ppo-FEV1 – predicted post-operative FEV1; ASA – American Society of 
Anaesthetists; FFP, fresh frozen plasma; P, pneumonectomy; L, lobectomy; SL, sub-lobar 
resection; VT, tidal volume; OLV, one lung ventilation; PIP, peak inspiratory pressure.  
                                         
E
 It is likely that some patients in the ‘historical group’ (n=533) in Licker et al’s 2009 publication are 
common to their 2003 publication. 
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Post-operative hyperinflation 
The injurious effects of hyperinflation may not be restricted to the period of 
one-lung ventilation114, 122, 147, 158, 159. Following lung resection, residual lung 
tissue inflates and there is mediastinal shift towards the resected side. Larsson 
et al documented functional residual capacity (FRC) to be 10% greater in the 
non-operative lung following (lobar / sub-lobar) lung resection, (though this 
finding was not statistically significant in this small sample; n=8) and 35% greater 
following pneumonectomy (no statistical comparison; n=2)145. Slinger suggests 
that hyperinflation leads to widening of intracellular junctions; a 
pathophysiological process similar to the pulmonary capillary stress failure seen 
with high intravascular pressures114. Such hyperinflation could therefore 
contribute to the pathogenesis of PLR-ALI, a hypothesis which is supported by 
the findings of Alvarez et al158. These authors performed a retrospective review, 
examining two cohorts of patients undergoing pneumonectomy before and after 
the introduction of a novel ‘balanced’ chest drainage system. In comparison to a 
conventional under-water seal, the balanced systems seek to limit the extremes 
of positive and negative pressure that can be generated within the operative 
hemithorax, so preventing post-operative mediastinal shift and hyperinflation.  
With close to 30 patients in each group, the authors observed that the rate of 
PLR-ALI fell from 4 cases (14.3% incidence) in the conventional under-water seal 
group to zero in the balanced drainage group (p<0.001)158. 
Oxygen toxicity 
In response to inflammatory stimuli, lung endothelial cells, alveolar cells, and 
airway epithelial cells, as well as activated alveolar macrophages produce 
reactive oxygen and reactive nitrogen species (ROS & RNS)160. In toxic levels 
these reactive species can cause molecular and cellular damage by oxidation and 
nitration of proteins, lipids and DNA161. The generation of ROS following lung 
resection has been demonstrated by a number of authors; oxidative injury has 
been demonstrated in humans undergoing lung resection and OLV as reduced 
plasma thiol levels / increased plasma carbonyl levels162 and increased levels of 
exhaled hydrogen peroxide 163, 164 and malondialdehyde (MDA) in both plasma 157, 
165, 166 and urine163. 
The toxic effects of high fractions of inspired oxygen (FiO2) resulting in the 
development of ROS and subsequent lung injury have been well described, both 
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in animal models and in humans. Exposure to high FiO2 causes histopatholgical 
changes similar to those seen in ARDS167, 168; in addition, evidence from animal 
models suggests hyperoxia can exacerbate, or predispose to lung injury from 
another aetiology167, 168. 
In light of increased understanding of the potentially harmful effects of high FiO2 
and the demonstration of oxidative stress following lung resection, it has been 
widely suggested that exposure of the lung to high FiO2 during OLV (as per 
‘conventional practice’ described above), may contribute to the development of 
PLR-ALI169-172. The evidence for such an assertion is limited however; the 
majority of studies reporting generation of ROS after lung resection are small 
and there is little if any hard evidence to link ROS generation with development 
of PLR-ALI. In the study of Lases et al, one of 28 patients undergoing lung 
resection developed PLR-ALI; in this patient exhaled hydrogen peroxide and 
urinary MDA were ‘significantly elevated’ compared to others163. Misthos et al 
studied a cohort of 132 patients undergoing lung resection for non-small cell 
lung cancer165. The authors reported highest plasma MDA levels in the subgroup 
of patients exposed to OLV for the longest duration (120 minutes); in this group 
the incidence of respiratory failure, cardiac arrthymias and pulmonary 
hypertension was significantly greater than in patients subjected to shorter 
durations of OLV. The authors go on to perform a multivariate analysis seeking 
risk factors for post-operative complications, but unfortunately make no attempt 
to assess the role of oxidative stress in the causation of post-operative 
complications independently of OLV duration165. 
Though hard evidence against the detrimental effects of high FiO2 is lacking, 
several commentators make the point that in the absence of good evidence for 
the need to ventilate with high FiO2 during OLV, the practice of ventilation with 
FiO2=1.0 in a population undoubtedly at significant risk of lung injury should be 
questioned169, 170. 
Hyperperfusion 
During OLV, the combined effects of gravity, collapse of the non-dependent 
lung, and hypoxic pulmonary vasconstriction (HPV) within the non-dependent 
lung vascular bed serve to divert blood flow towards the dependent lung, 
minimising shunt and maintaining oxygenation. In a porcine model of OLV / ALI, 
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Kozian et al determined the distribution of pulmonary perfusion during OLV by 
performing single-photon emission computed tomography (SPECT) following the 
administration of 99mTechnetium labelled macro-aggregated albumin173. During 
two lung ventilation (TLV) perfusion was split 48% to the non-dependent lung 
and 52% to the dependent lung. During OLV, perfusion of the non-dependent 
lung was described as falling to “only a minimal percentage of whole 
perfusion”. Histopathological examination after 90 minutes of OLV and 
simulated surgical manipulation, followed by a further 90 minutes of TLV 
revealed diffuse alveolar damage bilaterally, but more pronounced in the 
dependent ventilated lung; reflecting (according to the authors) the combined 
insults of hyperperfusion and hyperinflation173. 
Though non-dependent lung collapse and HPV reduce shunt and improve 
oxygenation, the preferential perfusion of the single dependent lung appears not 
to be without cost. Pulmonary artery pressure and pulmonary vascular resistance 
are increased during the period of OLV and in the immediate post-operative 
period (observed in Kozian et al’s porcine model173 but also reported in 
humans125, 174). Several authors have suggested that increased blood flow and 
increased pulmonary artery pressure in the dependent lung during the period of 
OLV (and indeed the remaining lung immediately post-operatively) may promote 
disruption of the capillary endothelial cell barrier114, 116, 119, 169. Such alveolar-
capillary barrier disruption may occur due to a number of mechanisms. 
Firstly, as originally described by West et al in a series of studies examining the 
pathophysiology of high altitude pulmonary oedema175, pulmonary capillary 
stress failure refers to mechanical failure of the pulmonary alveolar-capillary 
barrier in response to increased transmural capillary pressure. West reports 
disruption of the alveolar-capillary barrier occurring at transmural pressures as 
low as 24mmHg175. It is not known whether capillary transmural pressure 
increases to beyond 24mmHg during OLV; several authors have reported 
unchanged pulmonary artery wedge pressures (PAWP - of the order of 10-
12mmHg) during OLV174, 176, yet rises in pulmonary artery pressure (PAP) have 
been well documented125, 174. Waller et al determined pulmonary capillary 
pressure (Pc - NB. representing hydrostatic pressure within the capillary, not 
transmural pressure) from the equation Pc = PAOP + 0.4(meanPAP-PCWP), 
reporting no increase in Pc during OLV nor the immediate post-operative 
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period125. It might be hypothesised however that local capillary transmural 
pressures in dependent areas, and areas of alveolar hypoxia may will increase to 
injurious levels. Interestingly, and of undoubted relevance to one-lung 
ventilation, West et al describe the combined effects of increased capillary 
transmural pressure, lung hyperinflation and alveolar hypoxia as being 
circumstances particularly conducive to stress failure175. 
Secondly, injury to endothelial cells may not occur secondarily to increased 
pressures, but as a result of increased linear velocity of blood flow114, 123 
(hypothesised, but not proven to occur as the same or greater cardiac output is 
required to pass through a lower volume vascular bed). Staub describes the 
potential for inertial injury (direct impact of blood against endothelium), and 
frictional injury (increased wall shear stress) occurring at vulnerable places 
within the pulmonary microcirculation (such as capillary junctions)177. Staub’s 
group subsequently demonstrated increased pulmonary lymph flow in an ovine 
model of hyperperfusion, where conditions of hyperperfusion of the left lower 
lobe were created by resection of right lung and left upper lobe whilst 
maintaining cardiac output. In this experiment however, increased oedema was 
hydrostatic in origin, as evidenced by reduced lymph:plasma protein 
concentration. Whilst increased linear velocity of blood flow in the residual 
vascular bed could potentially be a contributory factor, it seems that PLR-ALI 
may not purely be a syndrome of increased capillary permeability as 
conventionally described. 
Finally, in laboratory experiments in a perfused rat lung model, pressure 
elevation in the lung venular capillary has been shown to have a pro-
inflammatory effect. Kuebler et al demonstrated pressure induced increases in 
endothelial cell intracellular calcium concentration associated with enhanced 
luminal expression of P-selectin (a key mediator of neutrophil adhesion in 
inflammatory lung injury)178. In seems plausible that in addition to the direct 
pro-inflammatory effect of mechanical ventilation during OLV, increased 
capillary pressures may constitute a further pathway by which endothelial 
inflammation might be triggered. 
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Pathophysiology of injury to the non-dependent, non-ventilated lung  
Yin et al performed lung biopsies of the non-dependent, non-ventilated lung in a 
series of pigs undergoing 60 minutes of OLV, before resumption of TLV179. 
Histological analysis of biopsy specimens revealed the presence of ‘vascular 
congestion’, with ‘cuffing of the blood vessels’ and ‘alveolar wall thickening’ in 
specimens obtained 30- and 60-minutes after return to TLV, changes the authors 
interpret as providing evidence of injury to the non-dependant, non-ventilated 
lung179. In a porcine model of OLV and ALI, Kozian et al also reported evidence 
of lung injury in the non-dependent lung, but to a lesser extent than in the 
dependent lung173. 
Direct injury due to surgical manipulation and ischaemia-reperfusion injury due 
to collapse and re-inflation of the operative lung are proposed mechanisms by 
which the non-dependent, non-ventilated lung may become injured during lung 
resection.  
Surgical manipulation 
It is widely suggested that intra-operative surgical manipulation of lung tissue 
leads to a degree of localised parenchymal injury, potentially triggering an 
inflammatory reaction117, 121, 143. Such is the perceived importance of the surgery 
in the pathogenesis of PLR-ALI, researchers constructing animal models of OLV 
have simulated surgical manipulation of the lung in order to adequately mimic 
the clinical situation173.  There have however, been no studies examining the 
influence of surgical technique on PLR-ALI, with the possible exception of video 
assisted thoracoscopic surgery (VATS).  
VATS surgery has been demonstrated to lessen the systemic inflammatory 
response following lung resection, as evidenced by reduced C-reactive protein 
and IL-6 levels in plasma when compared to open resection180. In addition, 
neutrophil and monocyte reactive oxygen species generation was reduced 
following VATS surgery180. Is uncertain however to what degree the observed 
changes in systemic inflammation and oxidative stress influence the pulmonary 
inflammatory response.  Studies directly comparing patient outcome after lung 
resection via VATS versus open thoracotomy, have not shown any reduction in 
the incidence of PLR-ALI, though overall complication rate appears to be 
reduced and these studies have not been powered to study the incidence of PLR-
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ALI181-183. In one case series of 1100 VATS lobectomies, the post-operative 
incidence of ‘ARDS’ was less than one percent which compares favourably with 
reported rates of PLR-ALI after open resection184. 
Ischaemia-reperfusion injury 
Ischaemia-reperfusion injury of the non-dependent surgical lung constitutes a 
further mechanism by which the lung may become susceptible to oxidative 
injury, and is widely described as a cause of PLR-ALI121, 143, 147, 169. Ischaemia 
occurs once oxygen delivery to a tissue falls below a threshold concentration. 
The lung (uniquely) has three potential sources of oxygenation; pulmonary 
arteries,  bronchial arteries and alveolar ventilation. Experimental models 
suggest that interruption of any one of these supplies is sufficient to cause 
ischaemia185.  Whilst ischaemia in itself leads to inflammatory cell activation and 
subsequent lung injury, there is evidence to suggest that reperfusion plays a 
significantly more important role in the causation of lung injury. Reperfusion 
leads to further inflammatory cell activation and neutrophil infiltration. In 
addition, it appears that ischaemia ‘primes’ lung tissue (possibly by activation of 
xanthine oxidase) such that re-oxygenation leads to generation of further ROS185.   
Williams et al examined the role of ROS in the pathogenesis of lung injury in an 
isolated, blood perfused rodent lung model of pulmonary resection186. Animals 
were divided into three groups; control, OLV followed by pneumonectomy and 
OLV followed by reinflation of the collapsed lung. Lung injury was quantified by 
estimation of extravascular albumin accumulation (EAA) and ROS production was 
quantified by measurement of hydroxylation of phenylalanine by hydroxyl radical 
in plasma. Increased EAA was observed bilaterally both following collapse and 
resection and after collapse and reinflation, though EAA was greater in the 
collapse-reinflation group. In addition, EAA was greater in the right (collapsed) 
lung in the collapse and reinflation group than in either the ventilated lung or 
the resected lung in the pneumonectomy group. These finding suggest that not 
only is ischaemia / hypoperfusion detrimental to pulmonary vasculature, but 
that reperfusion appears to provide an additional insult. This is supported by the 
finding of increased ROS production in the collapse-reinflation group and the 
observation that ROS production could be attenuated (and lung injury 
ameliorated) by co-administration of ROS scavenger (superoxide dismutase or 
nitric oxide synthase inhibition)186. 
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Misthos et al determined ROS activity during and after lung resection by 
measurement of plasma malondialdehyde (MDA) in 212 patients undergoing lung 
resection for non small cell lung cancer. MDA levels were significantly elevated 
in all patients subjected to one lung ventilation, with peak MDA levels evident at 
the time of reventilation of the operative lung. Patients undergoing 
pneumonectomy by comparison exhibited no such evidence of ROS activity. Ahn 
et al observed a similar peak in plasma MDA on resumption of TLV166. 
The effect of FiO2 during reperfusion has not been examined in the context of 
OLV. Hypoxaemic reperfusion has been shown to attenuate the histopathological 
and inflammatory consequences of intestinal injury187; perhaps providing further 
incentive to use lower FiO2 during thoracic surgery
143. 
Risk factors for lung injury common to both lungs 
Patient factors, peri-operative fluid administration, impaired lymphatic drainage 
and blood product transfusion are all risk factors common to both lungs which 
may influence the development of PLR-ALI. 
Patient factors 
A number of patient factors have been identified as independent risk factors for 
the development of PLR-ALI. These include alcohol consumption, American 
Society of Anaesthetists (ASA) physical status classification and pre-operative 
lung function (Table 1.3).  
Alcohol consumption 
Both Licker et al 128 and Sen et al 127 identified alcohol consumption to be a risk 
factor for the development of PLR-ALI. Whilst alcohol is well understood to be 
associated with a two to five fold increase in post-operative complications 
(including increased need for high dependency / intensive care unit admission 
and prolonged hospital stay) following major surgery188, there are further 
reasons why chronic alcohol abuse may be a risk factor for PLR-ALI. 
In the general intensive care environment, chronic alcohol abuse is an 
independent risk factor for development of ARDS in at risk patients (relative risk 
1.96; 95% CI 1.32-2.85). In addition in patients that develop ARDS, chronic 
alcoholics are more likely to die than non alcoholics (p=0.003)189. In order to 
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study this increased susceptibility to ALI/ARDS in chronic alcohol abusers, Guidot 
and Roman developed a rat model of ethanol mediated susceptibility to ALI190. 
As in humans, Guidot and Roman observed that chronic ethanol ingestion 
increased the susceptibility to endotoxin mediated lung injury in isolated 
perfused rat lungs ex-vivo. Furthermore, these authors were able to 
demonstrate that deficiencies in glutathione (a key antioxidant molecule) in 
alveolar lining fluid and type-II pulmonary epithelial cells, occurring secondary 
to chronic ethanol ingestion led to altered surfactant synthesis and secretion, 
altered epithelial cell permeability and reduced cell viability. This evidence 
implicating oxidative stress in the increased susceptibility of alcoholics to ALI 
was further strengthened by the finding that glutathione supplementation could 
reduce lung injury190. It is plausible that the increased susceptibility of alcohol 
abusers to PLR-ALI is mediated in exactly the same way, with glutathione 
deficiency rendering patients increasingly susceptible to oxidative stress during 
the period of OLV. 
Pre-operative lung function 
Assessment of predicted post-operative pulmonary function (derived from pre-
operative function and adjusted based on the size of the proposed lung 
resection) forms the basis of risk assessment for patients undergoing lung 
resection in all major clinical guidelines currently available12, 191, 192. Low pre-
operative or predicted post-operative forced expiratory volume in one second 
((ppo)FEV1) and diffusing capacity for carbon monoxide ((ppo)DLCO) have been 
associated with development of cardio-respiratory complications and mortality 
following lung resection in a large number of studies16, 132, 193-197. It is perhaps 
unsurprising therefore that several studies have found ppo-FEV1 to be an 
independent risk factor for ALI development (Table 1.3). What is surprising 
perhaps is the relatively modest association observed (with odds ratios / relative 
risk confidence intervals falling only just on the side of significance (Table 
1.3)134, 154, and the finding that several studies (some of them large) found no 
evidence of respiratory function being a risk factor for PLR-ALI115, 129, 198. Though 
pre-operative respiratory function is a well accepted predictor of cardio-
pulmonary complications following lung resection, it appears to be only weakly 
predictive of PLR-ALI. 
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The pre-operative distribution of pulmonary perfusion was identified to be a risk 
factor for PLR-ALI after pneumonectomy by two studies (Table 1.3). Where the 
resected lung was in receipt of a high proportion of total pulmonary perfusion 
this increased the risk of lung injury134, 153. It is likely that injury secondary to 
hyperperfusion would be magnified in such circumstances where the residual 
lung tissue is less accustomed to high perfusion. 
Peri-operative fluid administration 
In their case series of 10 patients with PLR-ALI, Zeldin et al reported that large 
peri-operative fluid load, and high intra-operative and post-operative urine 
outputs were risk factors for the condition109. By comparing the fluid intake and 
output data for just four patients who developed pulmonary oedema following 
right pneumonectomy with that from six patients who underwent uncomplicated 
right pneumonectomy, Zeldin et al reported that the four patients with 
pulmonary oedema  had significantly higher mean absolute fluid inputs and urine 
outputs and a higher ratio of input and urine output to body weight than the six 
uncomplicated cases. Interestingly, the net 24 hour fluid balances were not 
significantly different. 
Zeldin et al went on to construct an animal model of PPPE. Right 
pneumonectomy was performed on a population of 13 dogs, randomised to 
receive pre-operative infusion of Ringer’s lactate solution at either 50 or 
100ml/kg. Five of eight dogs receiving the high volume fluid regimen suffered 
post-operative pulmonary oedema compared to one of five dogs in the low 
volume group (p=0.08 (Fishers exact test performed by the author (B Shelley), no 
statistical comparison offered by the authors)). Contrary to the observations 
seen in humans, it appeared that the ability of dogs to clear the high fluid load 
was important to the development of oedema; dogs able to maintain a net fluid 
load of less than 100ml/kg appeared to be less likely to develop oedema. Based 
on this laboratory data from 13 dogs, and the results of fluid balance data from 
just 4 patients, Zeldin et al boldly conclude that “post-pneumonectomy 
pulmonary oedema appears to result from infusion of excessive volumes of 
fluid”109.  
Whilst it is questionable that Zeldin et al had the evidence to make such a 
conclusion, subsequent reports have supported their assertions; the volume of 
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intravenous fluid administration has been implicated in the development of PLR-
ALI in both univariate and multivariate analyses (Tables 1.4 and 1.3 
respectively). The incidence of PLI-ALI has been linked to both the total volume 
of fluid infused intra- or peri-operatively and to 24 hour fluid balance in the 
peri-operative period. 
As Slinger writes in his 1995 review article entitled “the puzzle of post-
pneumonectomy pulmonary oedema”, whilst there appears to be a wealth of 
(predominantly) retrospective and anecdotal evidence suggesting some 
association between PLR-ALI and fluid overload,  a clear cause-effect 
relationship has not been demonstrated114. Indeed, there appear to several 
factors which question the nature of this relationship: 
Firstly, the finding of such association between fluid administration and the 
development of PLR-ALI is not universal. Both Turnage and Lunn (24 cases of 
PLR-ALI in 806 patients undergoing pneumonectomy119), and Waller et al (11 
cases in 402 resections201) were unable to show any such association. It would 
appear that the influence of fluid balance on the development of PLR-ALI is lost 
when fluid input is limited; in the series reported by Turnage and Lunn, mean 24 
hour fluid balance was restricted to approximately one litre (yet PLR-ALI still 
occurred with an incidence of 2.6%)119. 
This is the second factor arguing against the cause-effect relationship between 
fluid administration and PLR-ALI; the observation that PLR-ALI still occurs even 
in profoundly fluid restricted  patients. In keeping with the findings of Turnage 
and Lunn119, in 1991 Mathisen and Grillo reported that they “scrupulously 
restrict intra-operative and post-operative fluids but still see the problem” [of 
PLR-ALI]202.  
On this subject, Margolis et al succinctly conclude that: 
“Perhaps individual variations in pre-operative hydration, cardiac 
reserve, residual pulmonary lymphatic capacity, and pulmonary 
endothelial permeability affect the fluid volume that may be safely 
given”.  
Margolis et al (1990)200. 
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Table 1.4. Univariate analyses reporting association between intra- and peri-operative fluid balance and the incidence of PLR-ALI. 
Study, year Pop. N Incidence 
ALI 
Comparator ALI group No ALI 
group 
p-
value 
Findings robust to multivariate 
analysis? 
Zeldin et al, 1984
109
.  P 10 N/A 24h input 
24h balance 
67ml/kg 
37ml/kg 
46ml/kg 
27ml/kg 
0.10 
NS 
 
Not performed 
Verheijen-Breemhaar et al, 
1988
199
. 
P 243 4.5% 24h balance R: 
1800ml
F
 
L: 2600ml
F
  
R: 1050ml
F
 
L:1100ml
F
 
 
0.01 
0.001 
Not performed 
Margolis et al, 1990
200
.  
 
P 13 23% 24h balance 86.4ml/kg 47ml/kg 0.008 Not performed 
Parquin et al, 1996
153
. 
 
P 146 15% Total fluid load>2L 45% 20% <0.01 Yes 
Licker et al, 2003
128
. P,L,SL 879 4.2% Input intra-op 
24h input 
24h balance 
Cumulative input intra & 
post-op 
9.1ml/kg/h 
2.1L 
2.0L 
2.6L 
 
7.2ml/kg/h 
1.85L 
1.52L 
2.0L 
0.023 
0.075 
0.026 
0.003 
Yes 
Alam et al, 2007
154
. P,L,SL 152 N/A Peri-operative fluids 2775ml 2500ml 0.05 Yes 
Pop., study population; P, pneumonectomy; L, lobectomy; SL, sub-lobar resection. In Verheijen-Breemhaar et al, 1988
199
, figures are provided for right (R) and left (L) 
sided resections separately. 
 
 
                                         
F
 Approximate values, extrapolated from a figure in the text. 
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Impaired lymphatic drainage 
The essential role of the pulmonary lymphatic system in preventing the 
accumulation of pulmonary oedema has been discussed in Section 1.2.2. 
Impaired lymphatic drainage has been reported as a contributory factor to the 
development of PLR-ALI by a number of authors121. Ipsilateral lymph drainage is 
inevitably compromised during lobectomy or pneumonectomy121, especially when 
(as current guidelines dictate) surgical resection for malignancy routinely 
includes systematic lymph node sampling in order to provide accurate 
pathological staging13. 
Several authors have reported that PLR-ALI occurs more commonly following 
right sided lung resection than left109, 119, 134, 199, an observation which remained 
significant following multivariate analyses in one large series of patients 
undergoing pneumonectomy134 (Table 1.3). In the opinion of many 
commentators, this can be explained anatomically by the observation that a 
significant proportion of the lymphatic drainage of the left lung is via the right, 
whilst the right lung relies very little on left sided lymphatics114, 121. Nohl-Oser  
examined mediastinoscopy and scalene node biopsy specimens in a series of 749 
patients with bronchogenic carcinoma203. By charting the pattern of mediastinal 
spread of carcinoma, Nohl-Oser concluded that whilst the lymphatic drainage of 
the right lung to the superior mediastinum is ipsilateral, that of the left lung “is 
as frequently contralateral as ispsilateral”203. Contralateral spread 
predominantly originated from the left lower lobe. 
Allen et al reported the results of a large multicentre study examining the 
effects of two different lymph node sampling strategies in patients undergoing 
lung resection204. There was no difference in the incidence of PLR-ALI between 
patients randomised to complete mediastinal lymph node dissection versus a 
more conservative lymph node sampling, (n=1023; p=0.28; Fishers exact test 
performed by the author (B Shelley), no statistical comparison offered by the 
study authors)204. 
Blood product transfusion 
Blood product transfusion has long been understood to be a risk factor for 
ALI/ARDS205, 207; it is plausible therefore that peri-operative transfusion in 
patients undergoing lung resection could contribute to the development of PLR-
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ALI117, 118, 121. Gibbon and Gibbon’s first descriptions of PLR-ALI were in two 
patients who had undergone blood transfusion108. These authors went on to  
demonstrate in cats that whilst residual lung became congested (increased lung 
weight compared to controls) following (extensive) lung resection, following 
lobectomy and blood or plasma transfusion, frank pulmonary oedema was almost 
universally observed108, 208. Both van der Werff et all151 and Sen et al 127 have 
more recently demonstrated fresh frozen plasma transfusion to be an 
independent risk factor for the development of PLR-ALI (Table 1.3). 
Size of resection 
The observation of increased incidence of PLR-ALI in patients undergoing 
pneumonectomy in comparison to lobectomy and in turn sub-lobar resection is a 
near universal finding110, 111, 127, 129, 130, 198. Such an observation potentially 
provides some further insight into what are the most important causative 
mechanisms for PLR-ALI. Ischaemia-reperfusion injury is not a feature of 
pneumonectomy, and though it may play a role in the development of PLR-ALI in 
lesser resection, it cannot in pneumonectomy. The duration of positive pressure 
OLV, will be marginally longer for pneumonectomy than in lesser resections, but 
the tidal volumes and airway pressures involved should be no greater. Patients 
undergoing pneumonectomy however are potentially subject to greater post-
operative hyperinflation, whilst the residual lung is subsequently hyperperfused 
to a greater extent. It is perhaps reasonable to hypothesise therefore that these 
factors may be some of the more important in the aetiology of PLR-ALI. 
1.4.5 Management of post-lung resection lung injury 
As with ALI/ARDS in the general critical care environment, there is no specific 
therapy for PLR-ALI and management is largely supportive. Oxygen, chest 
physiotherapy, inhaled bronchodilators and close attention to fluid balance with 
consideration of induced diuresis are the mainstay209. Positive pressure 
ventilation in the early post-operative period following lung resection carries 
increased risk of pneumothorax, bronchial stump disruption and bronchopleural 
fistula formation and as such, avoidance of mechanical ventilation is an early 
goal. To this end there is some evidence to suggest that early institution of non-
invasive ventilation may prevent progression to invasive ventilation and reduce 
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mortality210. A study examining the utility of high-flow nasal oxygen in patients 
undergoing lung resection is in progress211. 
The roles of corticosteroid therapy212 and nitric oxide administration213 in the 
treatment of ALI/ARDS are controversial; use of both has been reported in PLR-
ALI. Mathisen et al report the use of nitric oxide in ten patients receiving 
mechanical ventilation for PLR-ALI135. Nitric oxide administration led to an 
immediate improvement in oxygenation, a reduction in peak inspiratory pressure 
and an improvement in chest radiography appearances within 24 hours. Though 
this study lacked a contemporaneous control group, the authors report a 70% 
survival which was favourable to a historical control group (n=7) in which 
survival was only 14%135.  Lee et al similarly investigated the efficacy of low-dose 
steroid therapy in 12 patients with PLR-ALI making comparison to a historical 
control group214. The authors concluded that early low-dose steroid therapy 
significantly reduced in-hospital post-operative mortality (88% vs 8%; p<0.001).  
The use of extracorporeal carbon dioxide removal has been described in patients 
who have undergone broncho-pleural fistula repair following lung resection. 
Extracorporeal lung assist allowed airway pressures to be reduced, potentially 
contributing to the healing of the bronchial repair215. Use of extracorporeal 
membrane oxygenation has also been described in ARDS after post-traumatic 
pneumonectomy216. 
1.4.6 Prevention of post-lung resection lung injury 
With recognition of the poor prognosis of patients suffering PLR-ALI and the 
limited treatment options available, alongside increased understanding of the 
pathogenesis of the condition, in recent years there has been an increasing 
interest in methods of preventing PLR-ALI.  Peri-operative fluid management, 
the conduct of OLV, and mode of anaesthesia are arguably the most easily 
modifiable risk factors that can be targeted in the prevention of PLR-ALI. 
Investigation I of this thesis explores the extent to which these preventative 
strategies have been adopted into contemporary thoracic anaesthetic practice 
(Chapter 2). 
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1.4.6.1 Conduct of one-lung ventilation 
Lung protective (one-lung) ventilation 
Lung protective ventilation with low tidal volume, limitation of peak airway 
pressures and increased levels of positive end-expiratory pressure has been the 
single most effective intervention in reducing the incidence and mortality of 
ALI/ARDS in the general intensive care population99. Though expert opinion can 
be described as strongly being in favour of lung protective / low tidal volume 
ventilation in order to prevent PLR-ALI in the lung resection population115, 122, 124, 
141, the evidence for the efficacy of such a strategy is limited to observational 
studies110, 155, 217 and a single randomised controlled trial examining the efficacy 
of protective ventilation in preventing pulmonary complications (a composite 
primary endpoint of which ALI was a part)218.  
In 2008, Tang et al reported a retrospective review examining the incidence and 
mortality of ARDS in patients undergoing lung resection in a single centre. 
Comparison was made between two cohorts of patients; 1139 patients 
undergoing lung resection between 1991 and 1997, and 1376 undergoing 
resection between 2000 and 2005. The incidence and mortality from ARDS were 
observed to fall between the two cohorts from 3.2% and 72% to 1.6% and 45% 
(incidence and mortality respectively). This the authors attributed to “more 
aggressive strategies to avoid pneumonectomy, greater attention to protective 
ventilation strategies and to the improved ICU management of ARDS”110. 
Unfortunately ventilatory parameters during OLV were not recorded though the 
authors describe that “ventilatory strategies at this institution have become 
more protective over the last 5 years”110. 
Licker et al performed a similar observational analysis examining the incidence 
of PLR-ALI before and after implementation of a ‘protective lung ventilation’ 
protocol; 558 patients undergoing lung resection from 2003 to 2008 were 
compared to 553 historical controls undergoing resection from 1998 to 2003155. 
The ‘protective lung ventilation’ protocol consisted of small tidal volume, PEEP 
and recruitment manoeuvres; mean tidal volume was 6.5 ml/kg in the 
intervention group versus 9.2ml/kg in controls (p<0.05), with a correspondingly 
lower mean inspiratory plateau pressure in the intervention group (12 versus 
16cmH2O; p<0.05). Overall the incidence of PLR-ALI was reduced from 3.7 to 
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0.9% (p<0.01). Importantly, and adding strength to the findings, this difference 
was maintained after adjustment for baseline characteristics and non-ventilatory 
peri-operative management (including fluid administration) with the finding that 
the ‘protective lung ventilation’ protocol decreased the incidence of ALI, (odds 
ratio=0.34 (95% CI 0.23-0.75)). 
In 2011 Yang et al published the only randomised controlled trial examining the 
effect of lung protective ventilation on the incidence of post-operative 
pulmonary complications in the thoracic surgical population218. Yang et al 
compared ‘conventional ventilation’ (FiO2=1, VT=10ml/kg, ZEEP, volume 
controlled ventilation) to a ‘protective strategy’ (FiO2=0.5, VT=6ml/kg, 5cmH2O 
PEEP, pressure controlled ventilation) during OLV in 100 patients undergoing 
lung resection, examining the incidence of the composite endpoint of 
PaO2/FiO2<300mmHg and / or lung infiltration or atelectasis within 72 hours. In 
the intervention group the incidence of this composite primary outcome was 4% 
compared to 22% in the conventional ventilation group (p<0.05)218. This study 
also demonstrated a statistically non-significant trend towards a reduced 
incidence of PLR-ALI (4 cases, 8% incidence in control group, 1 case, 0.5% 
incidence in the treatment group; P=0.36). The remarkable reduction in the 
incidence of pulmonary complications in the intervention group is striking, but 
must be interpreted with caution. Firstly, it is worth remembering that studies 
with small sample sizes commonly overestimate treatment effects219, 220. 
Secondly, the study design and randomisation techniques utilised in this study 
have been subject to a multitude of criticisms221. Furthermore, it is noteworthy 
that the primary endpoint in the final published manuscript of this study218  
differed from that published initially on the Australian New Zealand Clinical 
Trials Registry website (ACTRN12609000861257; www.anzctr.org.au; accessed 
22nd March 2014). The published manuscript reported the occurrence of 
PaO2/FiO2<300mmHg and / or lung infiltration or atelectasis within 72 hours 
post-operatively, whilst the published protocol considered the same outcomes 
but occurring within the first post-operative week. 
As Lohser points out, these studies of ‘lung protective ventilation’ study the 
composite effect of low VT ventilation, PEEP and recruitment manoeuvres as a 
whole, but fail to answer the question of which of VT reduction, application of 
PEEP or recruitment manoeuvres are the beneficial intervention143. Much of the 
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purpose of maintaining high VT during OLV (as historically advocated) was to 
promote recruitment / prevent development of atelectasis in the dependent, 
ventilated lung140. As tidal volumes reduce, the potential for atelectasis 
increases143 and as such, in many protective ventilatory strategies recruitment 
manoeuvres and the judicious use of PEEP are advocated alongside VT reduction 
in order to prevent atelectasis124, 128, 143, 222. It is worthwhile briefly considering 
the effect of recruitment manoeuvres and PEEP application. 
Recruitment manoeuvres during one-lung ventilation 
Recruitment manoeuvres have been shown to reduce alveolar dead space and 
improve arterial oxygenation during OLV223, 224. In this context however it is 
worth noting the findings of some animal studies conducted in a rat models225, 
226. Farias et al demonstrated that a single recruitment manoeuvre of 40cmH2O 
for 40 seconds leads to elevation of biomarkers of lung injury in animals with 
normal lungs225. Silva et al randomised mechanically ventilated animals (TLV) 
with ALI into five groups; recruitment by four different protocols and a control 
group. Whilst all recruitment manoeuvre protocols resulted in improved 
oxygenation and lung compliance, two of the protocols (those associated with 
the most rapid increase to maximum airway pressure) resulted in increased 
mRNA expression in lung tissue of inflammatory, fibrogenetic and apoptotic 
biomarkers compared to controls ventilated without recruitment226. Together 
these studies suggest that firstly, recruitment manoeuvres may not be as benign 
as first thought and may in themselves cause harm, and secondly that all 
methods of recruitment may not be equal.  
Positive end-expiratory pressure during one-lung ventilation 
Application of appropriate levels of PEEP leads to improved oxygenation during 
OLV227. In addition there is little doubt that application of PEEP as part of a 
protective lung ventilation protocol has proved efficacious in decreasing 
surrogate markers of lung injury in both animal models and human studies146, 147, 
228. The effect of PEEP on the development of lung injury during OLV has not 
however been studied in isolation. In contrast, Schilling et al’s  comparison of 
5ml/kg TV with 10ml/kg and ZEEP in humans demonstrated the independently 
beneficial effect of low VT
148. The effects of PEEP appear to be rather more 
subtle. Firstly, setting the appropriate level of PEEP during OLV requires careful 
consideration of the patient’s position on the static pulmonary compliance curve 
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and the cumulative effect of extrinsically applied PEEP and intrinsic ‘auto-PEEP’ 
(extrinsic-PEEP + intrinsic-PEEP = total-PEEP).  Application of PEEP to patients 
with high levels of auto-PEEP is likely to worsen oxygenation143, 227.  
Kozian et al report an elegant study demonstrating the combined effects of low 
tidal volume ventilation, recruitment manoeuvres and PEEP application during 
OLV229. In a porcine model of OLV, the authors used computerised tomography 
scanning (CT) to determine lung aeration during OLV in animals randomised to a 
high (10ml/kg) or low (5ml/kg) tidal volume protocol. Use of a recruitment 
manoeuvre prior to OLV increased the fraction of normally aerated dependent 
lung, reducing the volume of poorly aerated and atelectatic regions, an effect 
which (with the addition of 5cmH2O PEEP) persisted for the duration of OLV. 
Whilst high TVs lead to marginal further increases in the volume of aerated lung, 
this only occurred at end-inspiration; at end expiration the volume of aerated 
lung was equivalent suggesting that during high VT ventilation the lung was 
exposed to cyclical recruitment / derecruitment, increasing mechanical stress 
on the lung229. 
Attempting to ‘unpick’ the impact of the individual components of a lung 
protective ventilatory strategy is likely to be a futile exercise – low VT, 
recruitment manoeuvres, and PEEP application work together to allow reduced 
airway pressures whilst maintaining oxygenation and preventing harmful 
atelectotrauma. 
1.4.6.2 Peri-operative fluid management 
Though numerous studies have implicated the volume of intra-venous fluid 
administered in the development of PLR-ALI (Tables 1.3 and 1.4), there have 
been no randomised trials of a fluid restrictive strategy in patients undergoing 
lung resection. As early as 1984 Zeldin concluded that in order to prevent PLR-
ALI, “the anaesthesiologists must not boldly load the patient up with fluids 
prior to induction”109. It is widely believed in the thoracic anaesthetic and 
surgical communities that fluid restriction is mandatory in patients undergoing 
lung resection114-116, 200, 230-232.  
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Until recently therefore it seemed equipoise did not exist, and that a study of a 
restrictive versus a liberal fluid strategy would be unlikely, if not ethically 
unjustifiable. In recent years however, increased attention has been drawn to 
the potential for renal dysfunction after lung resection; it has been suggested by 
some that fluid restriction has gone ‘too far’ and that some patients are being 
subjected to unnecessary risk of renal dysfunction49, 233. As such, studies of 
alternative fluid management strategies (involving goal directed fluid therapy) 
have begun234, 235. Unfortunately to date, these studies have been too small to 
provide any insight into the incidence of PLR-ALI, and have concentrated on 
extravascular lung water measurement as a surrogate234. (A detailed review of 
the application of extravascular lung water measurement in patients undergoing 
lung resection is provided in Chapter 5). 
1.4.6.3 Volatile anaesthesia and lung protection 
The question of which mode of anaesthetic delivery (total intravenous 
anaesthesia (TIVA) with propofol or volatile anaesthesia) for thoracic surgical 
procedures has been the subject of much debate. A recent update to a 2008 
Cochrane review concluded “that no evidence indicated that the drug used to 
maintain anaesthesia during one-lung ventilation affected participant 
outcomes” and reported that there was a lack of data from randomized 
controlled trials examining participant outcomes rather than changes in 
physiological (or immunological) endpoints236. 
Volatile anaesthetic agents undoubtedly have immunomodulatory effects. There 
has been a great deal of interest in the potential that volatile anaesthetic agents 
may have a cardioprotective effect222, 237. Laboratory and clinical evidence 
suggests that volatile anaesthesia during cardiac surgery can lower post-
operative Troponin I and Brain Natriuretic Peptide levels, improve left 
ventricular function, reduce inotrope requirements and shorten critical care and 
hospital stay. Evidence from studies adequately powered to assess the incidence 
of major cardiac events and mortality however is still awaited237, 238. More 
recently, it has been understood that anaesthetic agents can have protective 
effects on other organs. Several studies in animal models of lung injury have 
demonstrated both pre- and post-conditioning effects of volatile anaesthetic 
agents239, 240. The mechanisms of anaesthetic pre- / post-conditioning in the lung 
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are not completely understood; it appears volatile anaesthetic agents reduce the 
expression of cytokines and adhesion molecules in alveolar epithelial cells by a 
number of complex pathways including activation of adenosine, α- and β-
adrenergic receptors and increased nitric oxide production239, 241.  
There have been several studies directly comparing the pulmonary immune 
effects of propofol and volatile anaesthesia in patients undergoing thoracic 
surgery with OLV241-243. Both Schilling et al148, 241 and de Conno et al242 
randomised patients to either propofol or volatile anaesthesia and examined 
cytokine levels in bronchoalveolar lavage fluid; Schilling et al in BAL from the 
dependent, ventilated lung241, 243, de Conno et al from the non-dependent, non-
ventilated lung242. In all three studies, BAL cytokine levels were significantly 
lower in patients receiving volatile anaesthesia. In their 2011 study, Schilling et 
al compared propofol to both sevoflurane and desflurane finding both volatile 
anaesthetic agents ‘suppressed the alveolar inflammatory response’ to a similar 
extent; in keeping with suggestions that immunomodulation is a class effect241. 
Neither of the studies by Schilling et al sought to make any comparison regarding 
clinical outcomes, though both were of insufficient size to be powered for this 
purpose (30243 and 42241 patients respectively). In the study of De Conno et al 
(sample size 54, 27 patients per group), the incidence of adverse events in the 
propofol group was significantly higher than in the volatile group (40 vs. 18; p≤ 
0.05), though there were no patients in either group who developed ARDS as 
part of this composite end point. In addition, patients in the propofol group had 
significantly prolonged intensive care unit stay (1.52 vs. 0.87 days; p≤0.05)242. 
  
Chapter 1  88 
1.5 Aims and hypotheses 
This thesis presents the rationale, methodology and results of four discrete 
studies concerning the development of lung injury in the thoracic surgical 
population undergoing resection of primary lung cancer. 
From the literature review presented in this chapter, the author (B.Shelley) 
offers the following observations: 
 ALI/ARDS is reported to occur in four to 11% of patients undergoing lung 
resection and is the major cause of hospital mortality following lung 
resection.  
 The pathophysiology of lung injury following lung resection is complex and 
can be broadly conceptualised as occurring secondarily to insults specific to 
both the ipsilateral (surgical) lung and the contralateral (anaesthetic) lung in 
addition to those insults common to both lungs. 
 Increased recognition of the role of ventilator induced lung injury, and peri-
operative fluid prescribing in the pathogenesis of lung injury in this 
population has brought the prevention of lung injury to the attention of the 
thoracic anaesthetist. Though high quality evidence is lacking, expert opinion 
widely favours the adoption of lung protective ventilatory strategies and 
restriction of peri-operative fluids in patients undergoing lung resection. 
From these observations the author (B. Shelley) offers the following two 
hypotheses examined in Investigations I and II: 
Hypothesis I: The use of lung protective ventilatory strategies and restriction of 
peri-operative fluids is widespread within contemporary UK thoracic anaesthetic 
practice. 
 - This is examined in investigation I by conducting an online survey of UK 
thoracic anaesthetic practice, disseminated by the Association of Cardiothoracic 
Anaesthetists. 
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Hypothesis II: Such widespread adoption of strategies aimed at preventing the 
development of lung injury should result in an overall reduction in both 
incidence of and mortality from lung injury in patients undergoing thoracic 
surgery. 
 - This is examined in investigation II which is a random effects meta-
analysis and meta-regression analysis of all published literature since 1994, 
seeking to define pooled incidence and mortality estimates, and to examine the 
trends in the incidence of and mortality from PLR-ALI over time. 
In the author’s reading, and from the studies described in the preceding 
chapter, it is clear that though the major cause of mortality following lung 
resection, PLR-ALI remains a rare diagnosis. As such, surrogate end-points are 
increasingly being used in both laboratory and clinical studies seeking to 
evaluate the efficacy of preventative strategies. Of these, the use of plasma 
biomarkers of lung injury, and the trans-pulmonary thermodilution derived 
measurement of extra-vascular lung water (EVLW) and pulmonary vascular 
permeability index (PVPI) are prominent. Both measurement of plasma 
biomarkers and thermodilution measurement of EVLW and PVPI have the 
potential to provide bedside clinical monitoring of lung injury development in 
the thoracic surgical population in order to guide clinical decision making, 
monitor patient progress and serve as a surrogate end points in future clinical 
studies seeking to prevent, treat, or better understand this important clinical 
syndrome. 
Based on detailed review of the relevant literature (presented in the opening 
sections of Chapters 4 and 5), the author (B. Shelley) offers the following further 
observations and hypotheses: 
 There is a sound biological plausibility (discussed in detail in Section 4.1), to 
support the use of Pentraxin 3 as a lung injury biomarker in both the wider 
critical care environment and in the early post-operative period following 
lung resection.  
Hypothesis III: Pentraxin 3 is a suitable candidate plasma biomarker of lung 
injury following lung resection. 
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 - This is examined in investigation III. Firstly the properties of the ‘ideal’ 
lung injury biomarker are defined, against which Pentraxin 3 is compared in an 
observational cohort of thirty five patients undergoing lung resection for lung 
cancer. 
 Combination of multiple biomarkers (each reflecting different facets of the 
complex pathophysiology of ALI/ARDS) into panels in order to improve 
validity has become an increasing focus of biomarker research 244. 
Hypothesis IV: A panel of lung injury biomarkers reported in the literature by 
Freemont et al 83, may be suitable for use in the post-opertaive thoracic surgical 
population. 
 - This is examined in a subset of patients in Investigation III. A total ‘risk 
of lung injury score’, derived from the simultaneous measurement of 7 
biomarkers is compared to the same, pre-defined properties of the ‘ideal’ lung 
injury biomarker. 
 Trans-pulmonary thermodilution measurement of EVLW and PVPI are well 
validated in the general intensive care population, and are increasingly being 
used as study endpoints in patients undergoing thoracic surgery235, 245-247.  
 Due to methodological assumptions made in currently clinically available 
TPTD monitors, there is however significant reason to question the validity of 
these monitors in the lung resection population.  
 Despite increasing use, no such validation has been made. Furthermore, it 
has been suggested by some, that the methodology of TPTD be amended for 
use following lung resection 248. 
Hypothesis V: Transpulmonary-thermodilution monitoring of EVLW and PVPI are 
of questionable reliability and validity in the thoracic surgical population. 
Secondly, adjustment of TPTD methodology to reflect surgical resection of lung 
tissue will improve reliability and validity following lung resection. 
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- This is examined in Investigation IV, where the reliability and construct 
validity of TPTD derived EVLW and PVPI are pursued in an observational cohort 
of patients undergoing lung resection. Post-operative oxygenation, chest X-ray 
score and fluid balance are defined as ‘constructs’ with which association 
between construct and EVLW / PVPI would be expected. 
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2 Investigation I: Anaesthesia for lung resection – 
a survey of UK practice 
2.1 Introduction 
In recognition of the poor prognosis of patients suffering PLR-ALI and the limited 
treatment options available, alongside increased understanding of the 
pathogenesis of the condition, in recent years there has been an increasing 
interest in methods of preventing PLR-ALI.  The conduct of one-lung ventilation 
(OLV), peri-operative fluid management and mode of anaesthesia are arguably 
the most easily modifiable risk factors that can be targeted in the prevention of 
PLR-ALI.  
Traditional teaching of thoracic anaesthesia had described one lung ventilation 
with a target tidal volume of 10 mL/kg, an FiO2 of 1.0, zero positive end 
expiratory pressure (ZEEP) and an intention to maintain normocapnia124, 139-141. 
With increasing understanding of the contribution of ventilator induced lung 
injury (VILI) to the pathogenesis of PLR-ALI, expert opinion is calling for a 
revised approach to ventilation during OLV with many advocating the 
introduction of a ‘lung protective ventilatory strategy’115, 122, 124, 141. The role of 
VILI in the pathogenesis of PLR-ALI, and the potential role of ‘lung protective 
ventilation’ in its prevention was reviewed in detail in Chapter 1.  
Anecdotally, and with experience limited to West of Scotland practice, in the 
opinion of the author (Ben Shelley), lung protective ventilation during the period 
of OLV and a restrictive approach to fluid management are widely practiced. 
The aim of this investigation was to provide a snapshot of contemporary thoracic 
anaesthetic practice in the United Kingdom and Ireland, exploring the 
prevalence of lung protective ventilation, patterns of fluid prescribing and mode 
of anaesthesia used during lung resection. Facets of lung protective ventilation 
were defined as use of reduced tidal volume, use of positive end-expiratory 
pressure and fraction of inspired oxygen administered.  
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2.2 Methods 
An invitation to participate in the survey was e-mailed to all members of the 
(United Kingdom) Association of Cardiothoracic Anaesthetists (ACTA). 
Respondents completed an online survey with data collected via the 
commercially available ‘SurveyMonkey’ web platform (www.surveymonkey.com) 
during the months of July to September 2009. Participants were requested to 
complete questions in the context of their “current routine 'first choice' practice 
when anaesthetising for thoracotomy for lobectomy / pneumonectomy with 
one-lung ventilation... in the absence of any contra-indications or special 
(patient) considerations... [and where applicable] assuming oxygenation is not a 
problem... and blood loss is not exceptional”. Questions concerned anaesthetic 
technique, mode of ventilation during the period of one-lung ventilation, 
regional analgesic technique (if any), adjunctive analgesia, peri-operative fluid 
management, management of peri-operative hypotension and choice of lung 
separation technique.  
The survey itself was the product of an iterative design process. Firstly following 
a review of the relevant literature, a draft survey was prepared by the author 
(B. Shelley). This was subsequently reviewed, and comment provided, by 
Professor Stefan Schraag and Dr Alistair Macfie, consultant cardiothoracic 
anaesthetists at Golden Jubilee National Hospital, Clydebank. The subsequently 
revised survey was then piloted via the SurveyMonkey online platform by ten 
thoracic anaesthetists within the Department of Cardiothoracic Anaesthesia at 
the Golden Jubilee National Hospital; this allowed readability and survey 
navigation to be checked in addition to providing opportunity for further 
constructive comment. The further revised survey was then submitted for 
comment and approval to the committee of the Association of Cardiothoracic 
Anaesthetists (an elected panel of five consultant cardiothoracic surgeons from 
throughout the UK). Following further refinement the final survey transcript 
(reproduced in Appendix One) was resolved. 
For this thesis, only the results from questions concerning the practice of one-
lung ventilation, peri-operative fluid prescribing and mode of anaesthesia are 
presented (the published manuscript is provided in Appendix Two).  
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2.3 Results 
2.3.1 Responses received 
A total of 132 responses were received; two were excluded as they originated 
from outwith the UK. This represents at least one reply from 39 of 42 (93%) 
identified centres performing thoracic surgery in the UK and Ireland with a 
median response rate of 3 (range 0 - 8) per centre.  
2.3.2 Lung protective ventilation 
2.3.2.1 Tidal volume during one-lung ventilation 
Survey participants were asked – “during the period of one lung ventilation do 
you... ventilate with a target tidal volume?” 
Of the 129 respondents to this question, 53 (41%) respondents report ventilating 
to a target tidal volume. Of these, 44 (83%) answered the follow-up question “if 
yes, what target?”  The mean (SD) reported ‘target’ tidal volume during the 
period of one lung ventilation was 6.1 (±1.5) ml/kg (Figure 2.1). 
 
Figure 2.1. Target tidal volume during one-lung ventilation. 
(N=44) 
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2.3.2.2 Use of positive end-expiratory pressure during OLV 
Survey participants were asked – “during the period of one lung ventilation do 
you... routinely use positive end expiratory pressure (PEEP)?”  
Of the 128 respondents to this question, just under half (57, 45%) report the 
routine use of positive end expiratory pressure at a median (IQR) level of 5 (4-5) 
cmH2O. The distribution of PEEP values reported is demonstrated in Figure 2.2; 
it should be noted that users of PEEP are relatively underrepresented in Figure 
2.2 as 12 of the 57 respondents reporting use of PEEP did not answer the follow 
up question - “If yes, how much?” Nonetheless it is evident that the distribution 
of PEEP utilised by UK thoracic anaesthetists is bimodal, with a larger cohort 
(comprising over half of respondents) not using any PEEP, and another smaller 
cohort using 4-6 cmH2O PEEP. 
 
Figure 2.2. Positive end-expiratory pressure values utilised during one-lung 
ventilation.  
(N=116). 
2.3.2.3 Fraction of inspired oxygen during OLV 
Survey participants were asked – “during the period of one lung ventilation do 
you...routinely ventilate with a FiO2=1?”  
Of the 128 respondents to this question, the majority (114, 89%) of respondents 
report routinely ventilating with an FiO2 less than 1.0 with median FiO2 of 0.5 
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(0.5-0.7). The distribution of FiO2 levels reported is demonstrated in Figure 2.3. 
It is evident from the figure that the distribution of FiO2 levels administered by 
UK thoracic anaesthetists is bimodal, with the majority ventilating with an FiO2 
of between 0.4 and 0.7, whilst a smaller though significant cohort ventilate with 
FiO2=1.0. 
 
Figure 2.3.  Fraction of inspired oxygen administered during one-lung ventilation. 
(N=113). 
2.3.3 Peri-operative fluid management 
2.3.3.1 Routine intra-operative fluid administration 
Survey participants were asked – “What is the average volume of fluids you 
administer intra-operatively?  (Assuming blood loss is not exceptional)”. 
In the 117 respondents who answered this question, the mean (SD) volume of 
fluid administered intra-operatively was 1200 (±500) ml or 2.7 (±1.1) ml/kgG 
(Figure 2.4). 
                                         
G
 Calculated based on a 2.5 hour operation in a 70kg patient. In fact, the mean duration of surgery 
in the 34 patients recruited to Investigation III was 2.8 hours. 
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Figure 2.4. Typical intra-operative fluid administration.  
(N=118). 
2.3.3.2 Routine post-operative fluid prescribing 
Survey participants were asked – “What is your standard fluid prescription?  (For 
the immediate post-operative period / night of surgery - assuming intra-
operative losses were not exceptional - in an 'average' 70kg patient)”. 
In the 81 respondents who answered this question, the mean (SD) post-operative 
fluid prescription was 77 (±19) mls/hr or 1.1 (±0.3) mls/kg/hr Figure 2.5). 
 
Figure 2.5. Typical post-operative fluid prescribing. 
(N=81). 
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2.3.3.3 Attitudes to fluid restriction  
Survey participants were asked to select one of two possible responses: 
1. “I believe it is important to adopt a 'restrictive' approach to post-
operative fluids in this patient group [undergoing lung resection]. 
2. I do NOT restrict post-operative fluids in this patient group”. 
Of the 74 respondents to the question, 61 (82%) respondents selected option 
one, suggesting the majority of UK thoracic anaesthetist do believe it is 
important to adopt a restrictive approach to post-operative fluid prescribing. 
2.3.4 Choice of anaesthetic technique 
Survey participants were asked – “Concerning your typical 'first choice' 
anaesthetic technique for thoracotomy and one-lung ventilation do you:  
1. Use target controlled (TCI) Propofol / TIVA?  
2. Use inhalational anaesthetic agents?” 
Of the 129 respondents answering this question, 109 (84%) respondents indicated 
that they routinely use inhalational anaesthetic agents for maintenance of 
anaesthesia during thoracotomy. 
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2.4 Discussion 
The results of the survey reported above suggest that the contemporary practice 
of one-lung ventilation in the UK has evolved some distance from the classical 
‘textbook’ descriptions. This survey demonstrates that aspects of lung protective 
ventilation are widespread within UK thoracic anaesthetic practice; nearly half 
(47%) of UK thoracic anaesthetists report routine use of PEEP during OLV, 40% 
report ventilating to a target tidal volume (of which the mean observed was 
6.1ml/kg) and 89% routinely ventilate with an FiO2 less than 1.0.  
2.4.1 Limitations 
Whilst the survey reflects the practice of a large number (130) of thoracic 
anaesthetists in the United Kingdom and Ireland, unfortunately establishing a 
denominator for this response rate was impractical because it is unknown what 
fraction of the 458 Association of Cardiothoracic Anaesthetists (ACTA) members 
(at the time of survey release, personal communication, ACTA administrator) 
actively practice thoracic anaesthesia. In addition, by circulating the survey 
within the membership of ACTA, all thoracic anaesthetists who are not members 
of ACTA are effectively excluded from participation. Nonetheless, the responses 
received represent at least one reply from 39 of 42 (93%) identified centres 
performing thoracic surgery in the UK and Ireland with a median response rate of 
3 (range 0 - 8) per centre, suggesting the survey is likely to be broadly 
representative of practice throughout the UK.  
This survey is subject to several potential sources of bias inherent to all survey 
research. Firstly, distribution of the survey via ACTA results in the risk of 
introducing selection bias; by definition all UK thoracic anaesthetists who are 
not members of ACTA were excluded from the study sample. It is plausible to 
suggest that the two groups of anaesthetists distinguished by ACTA membership 
may differ systematically in their attitudes and / or practices. Members of ACTA 
for example, are engaged in the activities of the specialist society, are likely to 
have more recently attended an ACTA meeting and as such could be 
hypothesised to have more up to date opinions / practices. Secondly, though 
difficult to quantify in lieu of the unknown response rate, this survey is also at 
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risk of non-responder bias. Practitioners with more passionately held opinions 
concerning their clinical practice are more likely to respond to such a survey; 
survey results might be more likely therefore to be representative of the 
extremes of practice, than the practice of the ‘average’ UK anaesthetist. 
Similarly, by not mandating an answer to every question in the survey (a 
conscious decision aimed at improving overall response rate), participants could 
elect to not answer specific questions. Postulated reasons of not answering 
include the belief that a questions topic is less ‘interesting’ or ‘important’, or 
the perception that the participants response is the ‘wrong answer’ for example, 
where the respondent recognises their practice to be in some way ‘unusual’ or 
‘old fashioned’. 
A further limitation of the survey is that no attempt was made to establish the 
respondent’s level of experience or the frequency of his/her thoracic 
anaesthetic practice and as such no assessment can be made concerning the 
effect experience makes on practice. 
2.4.2 UK practice of OLV in comparison to worldwide practice 
The findings of the survey were published in 2011 in a manuscript entitled 
“Anesthesia for thoracic surgery: a survey of practice” (Appendix one)230. 
Following its publication, the author (Ben Shelley), was invited to collaborate 
with several authors from King Saud University, Riyadh, Saudi Arabia, in 
performing the same survey in the Middle East. Now published as “Anesthesia for 
thoracic surgery: A survey of middle eastern practice”249, this survey reported 
similar practices in the Middle East as are seen in the UK. As in the UK, aspects 
of lung-protective ventilation are practiced by a substantial cohort, though it 
appears that in general, Middle Eastern practice (with specific reference to 
conduct of OLV) is more traditional than that seen in the UK. In 2013 Della Rocca 
et al published a similar survey examining Italian practice; again reduced tidal 
volume ventilation is common place (with nearly 90% of hospitals reporting tidal 
volumes of less than 8ml/Kg) and the majority (~80%) routinely applying PEEP250. 
Whilst there are several other published surveys examining thoracic anaesthetic 
practice, these largely concern analgesic techniques and make no assessment of 
the conduct of one-lung ventilation.  
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2.4.3 Interpretation of the survey’s findings 
Since its publication, the published manuscript reporting the results of this 
survey has received 11 citations (source: Google Scholar available at 
http://scholar.google.co.uk/citations?view_op=view_citation&hl=en&user=yfNVn
TUAAAAJ&citation_for_view=yfNVnTUAAAAJ:u5HHmVD_uO8C, accessed 
05/10/14). Whilst several of these citations concern analgesic technique or 
techniques of lung isolation (other topics covered in the manuscript but not 
reported in this thesis), several have concerned the practice of one-lung 
ventilation, with differences in opinion regarding whether the findings reflect 
positively or negatively on current practice: 
Qutub et al interpret the survey’s findings positively, commenting: 
“There is an increasing use of lower VT of 6ml kg-1 or less during OLV 
among Middle Eastern and British thoracic anaesthesiologists.” 
Qutub et al (2014)247 
 
Whilst Licker concludes that despite showing evidence of the adoption of lung 
protective ventilatory techniques, the survey demonstrates such techniques are 
not used enough: 
“A survey among members of the Association of Cardiothoracic Anaesthetists 
in the UK revealed that, only 40% of 132 respondents were selecting “low” 
VT (median 6 ml/kg, interquartile range 5-7 ml/kg), [and] 15% used FiO2 > 
0.8”. 
Licker et al (2012)251 
 
From the available evidence, it would appear that lung protective ventilatory 
techniques are part of contemporary thoracic anaesthetic practice worldwide. 
Without earlier reports with which to make a comparison however, it is 
impossible to conclude that this represents a shift away from traditional 
practice, though there is a long and consistent narrative throughout the 
literature to suggest that such an evolution has taken place110, 115, 122, 124.  
The mean target tidal volume reported during OLV was 6.1ml/kg. One remaining 
question is ‘whether this is low enough?’ Whilst 6ml/kg  is substantially less than 
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traditional recommendations which advocate tidal volumes of 10ml/kg during 
the period of one-lung ventilation124, 139-141, it must be acknowledged that 6ml/kg 
is the tidal volume advocated by the US ARDS Network for ventilation of both 
lungs in critically ill patients with ALI/ARDS. It is possible therefore that 6ml/kg 
whilst an improvement over 10ml/kg, may still represent an excessive tidal 
volume to apply to one lung. On inspection of Figure 2.1 it can be seen that a 
substantial proportion of UK thoracic anaesthetists are limiting tidal volume 
further (to 3-5ml/kg). There are no randomised clinical trials comparing for 
example ‘low’ (6ml/kg) to ‘very low’ (4ml/kg) tidal volume during one lung 
ventilation, however observational data subjected to multivariate regression by 
Jeon et al  (Table 1.3) suggests that during pneumonectomy, the odds-ratio for 
development of lung injury increases by 3.37 (CI 1.65-6.86) per ml/kg increase in 
tidal volume152. As such, providing tidal volume can be decreased below 6ml/kg 
safely and without complication, it may be reasonable to do so. 
Within the wider critical care environment (where the benefits of lung 
protective ventilation have been emphatically described), there is some limited 
evidence to suggest a direct impact of the US ARDS Network’s ‘lower tidal 
volume ventilation’ study99, on the subsequent practice of ventilation, where 
two before and after studies have demonstrated a fall in tidal volume252, 253. 
Some years later however, it is clear from several large observational studies 
that tidal volume reduction to the extent advocated by the ARDS Network study 
has not been universally adopted252, 254. Rubenfeld et al studied ‘barriers’ to the 
provision of lung-protective ventilation in patients with ALI in the intensive care 
setting identifying: 
“physician willingness to relinquish control of ventilator, physician 
recognition of ALI/ARDS, and physician perceptions of patient contra-
indications to low tidal volumes as important barriers to initiating lung-
protective ventilation. [whilst] Important barriers to continuing patients 
on lung protective ventilation were concerns over patient discomfort and 
tachypnea and concerns over hypercapnia, acidosis, and hypoxemia”  
Rubenfeld et al (2004)255 
 
 
In the setting of thoracic anaesthesia, (where arguably the benefits of lung-
protective ventilation have been less well established), it is interesting to 
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speculate that many of the same barriers may be preventing more widespread 
adoption of lung protective ventilation. In particular, given avoidance of 
hypoxaemia was the rationale behind the ‘traditional’ recommendations140, 142, it 
seems likely that concerns regarding hypoxaemia during the finite period of one-
lung ventilation may be preventing greater adoption of these techniques. It 
would be of value to repeat the original survey to firstly observe any trend in the 
practice of one-lung ventilation, and secondly to identify any barriers to the 
adoption of lung protective ventilatory techniques. 
2.4.4 Peri-operative fluid prescribing 
Whilst it is clear from the results of the survey that the majority of UK thoracic 
anaesthetists believe it is important to adopt a restrictive approach to peri-
operative fluid prescribing, what is less clear is what constitutes a restrictive 
approach? As highlighted by Doherty and Buggy: 
“..no common definition of ‘liberal’ or ‘restrictive’ [fluid management] 
protocols exists in clinical practice. A restrictive regime in one centre 
may actually be liberal in another”. 
 Doherty and Buggy (2012)256 
 
This is emphasised by comparison of the following three studies conducted in the 
lung resection population. Matot et al conducted a randomised controlled trial 
comparing the effects of  ‘high’ volume intra-operative fluid prescribing 
(8ml/kg/hr) versus ‘low’ volume (2ml/kg/hr) in patients undergoing video-
assisted thoracoscopic surgery for lung resection257. Haas et al, studied the 
effects of  goal directed fluid management in patients undergoing lung resection 
and chose an intentionally “rather fluid aggressive” intra-operative protocol, 
where intra-operative fluids were administered at 9ml/kg/hr235; a figure in 
keeping with the ‘high’ volume group of Matot et al257. Assad et al however, 
were studying the effects of  “liberalized fluid management” and administered 
intra-operative fluids at 2.5ml/kg/hr234; a value more in keeping with the ‘low’ 
volume prescription of Matot et al257.  
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Whilst many have discussed the topic of restrictive fluid management in thoracic 
surgery, few have committed themselves to make definable recommendations. 
Chau and Slinger recommend: 
“Crystalloid administration should be limited to <2L intra-operatively 
[~11ml/kg/hr] and <3 L [125ml/hr / ~1.8ml/kg/hr] in the first 24 hours 
post-operatively”.  
Chau and Slinger (2014)48 
 
Evans and Naidu conducted a structured ‘best evidence’ literature review asking 
the question “Does a conservative fluid management strategy in the peri-
operative management of lung resection patients reduce the risk of acute lung 
injury?”232 They concluded: 
“On this best evidence presented, we recommend a conservative strategy 
of administration of maintenance fluids at 1–2 ml/kg/h in the intra- and 
post-operative periods”. 
Evans and Naidu (2012)232 
 
Examined in the context of these recommendations, it can be concluded that 
peri-operative fluid prescribing by UK thoracic anaesthetists (where typical 
mean intra-and post-operative infusion rates are 2.7 and 1.1 ml/kg/hr 
respectively) is well within what may be considered ‘conservative’. It may 
however be unnecessary to seek a definition for ‘restrictive’ fluid prescribing. In 
a dynamic situation where an individual’s fluid requirements will depend on a 
combination of pre-operative deficit, maintenance requirements and ongoing 
losses, arguably the important factor is that thought is being applied to the issue 
of peri-operative fluid prescribing, and that there is a general consensus 
regarding the need to err on the side of restriction. 
2.4.5 Maintenance of anaesthesia 
The overwhelming majority of UK thoracic anaesthetists use volatile anaesthetic 
agents for the maintenance of anaesthesia during thoracotomy. Whilst (as 
discussed in detail in Chapter one (Section  1.4.6.3) there is some evidence to 
suggest a lung protective immunomodulatory effect of volatile anaesthetic 
agents, total intravenous anaesthesia (TIVA) with propofol has other theoretical 
benefits in the thoracic population in terms of maintenance of hypoxic 
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pulmonary vasoconstriction and separating anaesthesia provision from 
maintenance of the airway258.  
Data from the Royal College of Anaesthetists’ Fifth National Audit Project 
surveying the practice of anaesthesia during a one week period in September 
2013 (collecting data from over 20,000 anaesthetics) reports that in 92% of 
cases, provision of general anaesthesia is via inhalation of volatile anaesthetic 
agent259. It would appear therefore that TIVA is marginally over-represented in 
thoracic anaesthetic practice. What this survey unfortunately is unequipped to 
do is explore the rationale for the anaesthetic choice reported. 
2.4.6 Conclusion 
In conclusion, UK thoracic anaesthetists appear to be addressing the defined 
modifiable risk factors for the development of PLR-ALI; aspects of lung 
protective ventilation are being incorporated into contemporary practice whilst 
restrictive fluid prescribing and maintenance of anaesthesia using volatile 
anaesthetic agents is commonplace. It may be reasonable to hypothesise 
therefore that the incidence of PLR-ALI should be falling as a result. 
Investigation II of this thesis concerns this question: 
 “Is the incidence of, and mortality from PLR-ALI falling with time?”
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3 Investigation II: Trends in the incidence and 
mortality of post-lung resection lung injury over 
time: A meta-regression analysis  
3.1 Introduction 
Post-lung resection ALI/ARDS is the major cause of early mortality in patients 
undergoing lung resection129, 130.  As described in investigation one, a 
‘restrictive’ approach to peri-operative fluid management and aspects of ‘lung 
protective ventilation’ have been widely incorporated into thoracic anaesthetic 
practice in the belief they will prevent lung injury.  
Reports from single institutions suggest that the incidence of ALI/ARDS following 
lung resection has fallen over time, with much of this reduction being attributed 
by the authors to changes in ventilatory practice110, 260. Tang et al reported on ‘a 
10-year single institutional experience’ in the Royal Brompton Hospital, 
London110. By retrospectively comparing a cohort of patients undergoing lung 
resection between 2000-2005, to a cohort from 1991-1997, Tang et al concluded 
that “the incidence and mortality from ARDS has fallen significantly over the 
study period” (incidence from 3.2% to 1.6%, p=0.01; mortality from 72% to 45%, 
p=0.05). Though lacking data to make statistical comparison, the authors 
attributed much of the reduction to the adoption of lung protective ventilatory 
strategies, reporting that “although the ventilatory parameters on one lung 
ventilation are not recorded, the ventilatory strategies at this institution have 
become more protective over the past 5 years”110. In a large observational 
cohort, Licker et al assessed the impact of the introduction of a “protective lung 
ventilation protocol”155 in two affiliated Swiss hospitals. By comparing an 
‘historical cohort’ who underwent resection from 1998-2003 (before introduction 
of the protocol), to a ‘protocol group’ who underwent resection from 2003-2008, 
Licker et al demonstrated a reduction in the incidence of ALI from 3.8% to 0.9%. 
Whilst the two groups were relatively evenly matched in terms of baseline 
patient demographics, the ‘protocol group’ were exposed to significantly lower, 
tidal volume and inspiratory plateau pressures during one-lung ventilation155. 
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In the wider critical care setting, reports concerning trends in ALI/ARDS 
mortality are conflicting; clinical trialists report mortality is falling261, 262, whilst 
a larger meta-regression analysis including both randomised and observational 
studies suggests  mortality is stable136. 
Whilst the two institutional reports cited are encouraging, the potential for 
confounding is significant, and ultimately they reflect the activity of just three 
hospitals. The aim of investigation II therefore, is to attempt to extend the 
evidence base beyond single centre reports and further investigate trends in 
PLR-ALI incidence and mortality with time. This study is a meta-analysis and 
meta-regression analysis seeking to answer the following questions from 
published data: 
 Is the incidence of PLR-ALI falling with time? 
 Is mortality from PLR-ALI falling with time? 
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3.2 Methods 
3.2.1 Search strategy 
MEDLINE and EMBASE databases were searched for studies reporting the 
incidence of ALI and/or ARDS in patients undergoing lung resection according to 
the following search strategy. This search was last updated on 18th March 2013. 
1. pneumonectomy.mp. or exp Pneumonectomy/ 
2. (lung adj resection).tw. 
3. (pulmonary adj resection).tw. 
4. (thoracic adj surgery).tw. 
5. Thoracotomy.mp. or exp Thoracotomy/ 
6. 1 or 2 or 3 or 4 or 5 
7. acute lung injury.mp. or exp Acute Lung Injury/ 
8. respiratory distress syndrome, adult.mp or exp Respiratory Distress 
Syndrome, Adult/ 
9. pulmonary edema.mp. or exp Pulmonary Edema/ 
10. ALI.mp. or ARDS.tw. 
11. 7 or 8 or 9 or 10 
12. 6 and 11 
13. limit to English language 
14. limit 13 to yr=”1994-Current” 
 
3.2.2 Inclusion and screening 
Studies were included if the incidence of ALI, ARDS or ALI/ARDS (ALI or ARDS) in 
patients undergoing lung resection surgery was reported, and the time period of 
study recruitment could be derived from the paper. Inclusion was restricted to 
studies using the 1994 American-European consensus definition for ALI/ARDS. 
Titles and abstracts were screened and review articles, educational pieces, 
letters and conference proceedings, abstracts or studies not concerning PLR-ALI 
were excluded. The reference lists of all included articles and all excluded 
review articles were screened for further relevant studies. The remaining 127 
papers were subject to full text review. Papers were subsequently excluded if 
they concerned pulmonary complications but not PLR-ALI, PLR-ALI was not 
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defined according to the American-European consensus definition, data was 
duplicated in another publication or the study concerned a case series of 
patients with PLR-ALI for which no denominator was provided. Where possible, 
in situations where PLR-ALI was part of a composite endpoint or no definition 
was provided authors were contacted for clarification.  
3.2.3 Data extraction 
Due to inconsistency in reported endpoints, data was extracted on the incidence 
of, and mortality from ALI, ARDS and ALI/ARDS individually. Where a paper 
contained a historical control group, these groups were treated as separate 
patient cohorts within the analysis. Similarly, where data (for example patient 
demographics) was only provided by study sub-group (e.g. arms of a randomised 
controlled trial), these study sub-groups were treated as separate cohorts in the 
meta-regression. Thus, patient ‘cohort’ rather than ‘study’ became the unit of 
analysis. In addition to the incidence of PLR-ALI and the year of study 
recruitment, data was extracted on the following covariates defined a-priori as 
being known to influence the incidence of PLR-ALI: age and sex of study 
subjects, lung resected (pneumonectomy, lobectomy, sub-lobar resection) and 
laterality of resection, baseline pulmonary function (forced expiratory volume in 
1 second (FEV1) and diffusing capacity for carbon monoxide (DLCO)), prevalence 
of pre-operative induction chemo- and radio-therapy, duration of one-lung 
ventilation, intra-operative fluid administration, open or video assisted 
thoracoscopic technique and analgesic technique. 
3.2.4 Meta-analysis 
Random effects meta-analysis was performed to generate pooled incidence and 
mortality estimates along with 95% confidence intervals. Individual analyses 
were performed for the end points ALI, ARDS and ALI/ARDS for all patients, and 
where data was available, for subgroups of patients undergoing pneumonectomy 
or lobectomy. Meta-analysis and meta-regression was performed using 
‘Comprehensive Meta-Analysis’ software (ver. 2.2.064), BioStat, Englewood, New 
Jersey (www.meta-analysis.com). 
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3.2.4.1 Effect measure 
Incidence and mortality data were extracted as number of events and cohort 
sample size. The ‘effect measure’ for the purposes of meta-analysis was 
therefore defined as the logit function of the event rate (Equations 3.1 and 3.2) 
                
      
           
 
Equation 3.1 
 
                      
 
   
  
Equation 3.2 
 
3.2.4.2 Weighting 
In order to yield a random effects meta-analysis (and meta-regression), cohorts 
were weighted according to the sum of the within-cohort variance and the 
residual between-cohort variance263. Thus the weight assigned to each cohort 
(Wi
* for the ith cohort, where W* represent weight under random effects and W 
represents weight under fixed effects) is computed as: 
  
   
 
  
  
Equation 3.3 
 
Where, Vi
* is the within-cohort variance of cohort i plus the between-cohort 
variance, T2: 
   
         
  
Equation 3.4 
 
Where Tau-squared (T2) is defined as the variance of the true effect sizes, i.e. 
the between-cohorts variance independent of within-cohorts variance. As 
variance of the true effect size cannot be measured (without studies with 
infinitely large sample sizes, such that the observed variance is in fact the true 
variance), T2 was estimated from the observed effects according to the ‘method 
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of moments’ described by DerSimonian and Laird264, 265. Where T2 is computed 
as: 
   
    
 
 
Equation 3.5 
Where, 
      
   
 
   
 
Equation 3.6 
 
Where, as before, Wi is the weight assigned under fixed effects to the i
th cohort. 
3.2.4.3 Identification of outliers 
Screening for potential outliers was performed by visual inspection of forest 
plots, and examination of standardized residuals266. Standardized residuals (also 
known as internally studentized residuals) were calculated by the 
Comprehensive Meta-analysis software as the quotient of the raw residual and 
the sampling variance of the raw residual. A standardized residual of 2.0 or 
greater was defined as a level at which cohorts would be considered potential 
outliers and subject to further scrutiny. 
3.2.4.4 Heterogeneity 
Heterogeneity was explored using Q and I2 statistics. 
The Q statistic 
The ‘Q-statistic’ or ‘Q’, is derived by determining the deviation of each effect 
size from its mean, squaring it, weighting this by the inverse of the variance for 
the given cohort and then summing the values of all of the studies in the analysis 
to yield the weighted sum of squares or Q: 265. 
           
 
 
   
 
Equation 3.7 
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Where, Wi is the cohort weight (under fixed effects), Yi is the cohort effect size, 
M is the summary effect and k is the number of cohorts. 
The Q-statistic is then compared with the expected value of Q (were all studies 
assumed to share a common effect size). This is calculated simply as the degrees 
of freedom (df): 
       
Equation 3.8 
 
Where k is the number of cohorts. 
The difference between the observed weighted sum of squares (Q) and the 
expected (df) reflects the excess variation between cohorts. That is the 
variation that can be attributed to the difference in true effect between- 
cohorts, rather than within-cohorts. Comparing Q with a central chi-squared 
distribution (with df=k-1) allows formal statistical testing of heterogeneity 
yielding a p-value examining the null hypothesis that all cohorts share a common 
effect size. As the chi-squared test in this context inherently has low power, a p-
value of ≤0.10 was used to determine statistical significance267. 
I-squared 
The I-squared (I2) statistic describes the percentage of total variance across 
cohorts that is due to heterogeneity rather than chance268, or “what proportion 
of the observed variance reflects real differences in effect size?”269. I2 was 
determined as in Equation 3.9: 
    
    
 
            
Equation 3.9 
 
Whilst use of specific thresholds for the interpretation of I2 can be misleading, a 
rough guide is provided by the Cochrane Collaboration267: 
Chapter 3  113 
Table 3.1. Interpretation of I
2
. 
 
From the Cochrane Collaboration (2011)
267
.  
3.2.4.5 Subgroup analysis 
Where available, data was extracted from each cohort into subgroups of patients 
undergoing pneumonectomy or lobectomy (including bi-lobectomy). Data was 
combined within-cohorts according to a random-effects model. In view of the 
small number of cohorts in each subgroup (less than five on some occasions), 
within-group estimates of Tau-squared were pooled as advocated by Borenstein 
et al269. Event rate was compared across subgroups using a Q-test. The 
proportion of trueH variance explained (R2) by differences between subgroups 
was subsequently calculated according to Equation 3.10: 
       
       
 
      
 
  
Equation 3.10 
 
Where        
  is the between-cohorts variance within-subgroups, and       
  is the 
total between-cohorts variance (within-subgroups and between-subgroups). 
3.2.4.6 Detection of publication bias 
Presence of publication bias was assessed by visual inspection of funnel plots of 
Logit event rate by standard error. The impact of publication bias on pooled 
incidence and mortality estimates was assessed by Duval and Tweedie’s ‘trim 
and fill’ procedure270, 271. This procedure uses an ‘iterative’ approach, 
                                         
H
 This statistic reflects the proportion of true variance explained by the subgroup effect distinct from 
the within-cohort variance. The sum of true variance and within-cohort variance is the total 
variance observed. 
I2 Interpretation 
0% to 40% ‘might not be important’ 
30% to 60% ‘may represent moderate heterogeneity’ 
50% to 90% ‘may represent substantial heterogeneity’ 
75% to 100% ‘considerable heterogeneity’ 
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sequentially removing the most extreme small studies from the ‘positive’ side of 
the funnel plot and re-computing the effect size at each iteration. ‘Trimming’ 
continues until the funnel plot is symmetrical, providing an ‘adjusted’ effect 
size estimate. Such an procedure in isolation however would underestimate 
variability. The ‘fill’ procedure therefore returns the ‘trimmed’ study to the 
analysis, balanced by an imputed ‘mirror image’ for each, hence maintaining the 
‘trimmed’ effect size, but providing a more realistic estimate of variability265.  
3.2.5 Meta- regression 
Univariate logistic random effects meta-regression analysis was used to explore 
the association between incidence and mortality of ALI, ARDS and ALI/ARDS and 
median year of cohort recruitment in addition to other covariates. Between-
cohorts variance within the random effects model was computed according to 
the ‘method of moments’ of DerSimonian and Laird264, 265 as described 
previously.  
3.2.5.1 Multivariate meta-regression 
One of the initial goals of this investigation was to construct a multivariate 
logistic meta-regression model to describe the effect of covariates (including 
median year of study recruitment) on the incidence and mortality of PLR-ALI, 
and so distil the effect of median year of study conduct from other cofounders. 
Analogously to recommendations that 10 data points are required per covariate 
entered into a conventional multivariate regression model272, it is advised that 
10 studies are required per covariate entered into a multivariate meta-
regression model267, 273. As insufficient studies were available, no multivariate 
model could be constructed.  
3.2.6 Presentation and interpretation 
Meta-analyses are presented as ‘forest plots’ of event rate and 95% confidence 
interval, where the size of the effect size marker is proportional to the weight 
assigned to that cohort in the random-effects analysis. 
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Meta-regression analyses are presented as ‘bubble-plots’ where the logit 
function of the ‘event rate’ (either incidence or mortality) are plotted against 
the explanatory variable (median year of cohort recruitment or other covariate). 
The size of the ‘bubble’ reflects any given cohort’s weighting in the analysis 
(weighted (as with the meta-analysis) according to the sum of the within-trial 
variance and the residual between-trial variance263). The exponent of the slope 
of the regression line yields the odds-ratio for the relationship between event 
rate and covariate. This is provided as a point estimate and 95% confidence 
interval. The proportion of true variance explained (R2) by the addition of a 
moderator variable (covariate) to the initial meta-analysis was then calculated 
as below. 
       
            
 
      
   
Equation 3.11 
 
Where             
  is the residual between-cohorts variance after addition of the 
moderator and       
  is the total between-cohorts variance. 
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3.3 Results 
3.3.1 Studies  
Literature searching returned 127 relevant titles of which 35 studies were 
selected for data extraction (Figure 3.1 documents the flow of studies through 
the study). After exclusion of duplicated data (resulting from multiple 
publications from the same centre, or registry reports), data was finally 
extracted from 21 studies. Data was extracted from several studies in subgroups 
(either due to the presentation of a historical cohort group or the method by 
which demographic data was presented); this resulted in 27 patient ‘cohorts’ 
being available for analysis - 12, 16 and 7 in the ALI, ARDS and ALI/ARDS groups 
respectively. Of these, the mortality from ALI, ARDS and ALI/ARDS could be 
determined in 9, 13 and four cohorts respectively. The studies included in the 
analysis are summarised in Table 3.2. Whilst the median year of cohort 
recruitment was available for all studies (in lieu of this being an inclusion 
criterion), data concerning other covariates was not available in a considerable 
number of studies. Studies with missing data were not included in the respective 
analyses. 
3.3.2 Patient and study demographics 
The 27 patient cohorts included in the analysis represent data from 10,647 
patients (median 170 (IQR 65-546) patients per cohort), and report incidence 
and mortality of ALI, ARDS and ALI/ARDS between 1989 and 2009 (median year 
of cohort recruitment). For the cohorts from which age and sex data could be 
extracted, median patient age was 62 years, with more males (76%) than 
females included in the analysis (Table 3.2).  
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811 – Titles screened
151 – Abstracts screened
660 Excluded:
- not concerning ALI/ARDS or lung resection
- review / CME articles / letters
- conference proceedings
117 – Full text reviews
34 Excluded:
- not concerning ALI/ARDS or lung resection,
- review / CME articles / letters
- conference proceedings
127 – Full text reviews
10 Additional papers included:
- Searching review arts / reference lists / known 
resources
92 Excluded:
- PLR-ALI/ALI/ARDS but not AECC defn. (41)
- Pulmonary complications not ALI/ARDS (27)
- ALI/ARDS as part of composite endpoint (9)
- Duplication of data (5)
- Cohort of ALI/ARDS, no denominator (4)
- Miscellaneous (6)
35 – Final selection for data extraction
21 (studies) – Final selection for data analysis
[= 27 patient cohorts]
14 Excluded: Duplication of data
12 (cohorts) –
ALI
16 (cohorts) – ARDS 7 (cohorts) – ALI or 
ARDS
 
Figure 3.1. Flow diagram depicting study selection.  
CME, continuing medical education; AECC defn., American European Consensus Conference 
definition.
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Table 3.2. Summary of included studies. 
First author 
(reference) 
Year of 
publication 
Country of 
origin 
Study 
design 
Centres Cohort Age 
Sex 
(%male) 
Median year 
of cohort 
recruitment 
N 
Nos. of Endpoints extracted
A
 Follow up 
P L SL Incidence Mortality Incidence Mortality 
Ahn
166
 2012 South Korea RCT Single 
a 56.0 NA 2009 25 0 25 0 ALI NA 
NS NA 
b 59.0 NA 2009 25 0 25 0 ALI NA 
Blank
274
 2011 USA 
Retro. 
obs. 
Single - NA 90 2002 129 129 0 0 ALIorARDS NA NS NA 
Brunelli
132
 2009 Italy 
Pro. 
obs. 
Single - 66.5 NA 2007 204 27 177 0 ARDS ARDS 
30day or 
hosp. if 
longer 
30day or 
hosp. if 
longer 
Dulu
111
 2006 USA 
Retro. 
obs. 
Single - NA 45.4 2003 2192 126 1047 1019 ALIorARDS ALIorARDS NS Hospital 
Fernandez-
Perez
275
 
2006 USA 
Retro. 
obs. 
Single - NA 62.9 2000 170 170 0 0 ALI ALI 60 days 60 days 
Gomez-
Caro
133
 
2012 Spain 
Pro. 
obs. 
Single 
a 63.7 90.5 2008 53 0 53 0 ARDS ARDS NS 30 days 
b 64.5 84.6 2008 26 0 26 0 ARDS ARDS NS 30 days 
Kim
134
 2010 South Korea 
Retro. 
obs. 
Single - 63.5 90.9 2001 164 164 0 0 ARDS ARDS 30 days 30 days 
Kutlu
130
 2000 UK 
Retro. 
obs. 
Single - 51.7 57 1994 1139 198 612 329 
ALI, ARDS, 
ALIorARDS 
ALI, ARDS, 
ALIorARDS 
NS Hospital 
Langenfeld
276
 2012 USA 
Retro. 
obs. 
Single - NA NA 2004 625 0 625 0 
ALI, ARDS, 
ALIorARDS 
ALI, ARDS, 
ALIorARDS 
NS 
Hospital 
and/or 30 
day 
Leo
194
 2006 Italy 
Retro. 
obs. 
Single - 62 72.3 2001 202 202 0 0 ARDS ARDS NS 90 day 
Licker
155
 2009 Switzerland 
Retro. 
obs. 
Multi 
a 
 
62 64.4 2000 533 114 290 129 ALI ALI 
Resp. 
distress in 
first 48h 
Hospital 
b 63 63.1 2005 558 98 313 147 ALI ALI 
Resp. 
distress in 
first 48h 
Hospital 
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First author 
(reference) 
Year of 
publication 
Country of 
origin 
Study 
design 
Centres Cohort Age 
Sex 
(%male) 
Median year 
of cohort 
recruitment 
N 
Nos. of Endpoints extracted
A
 Follow up 
P L SL Incidence Mortality Incidence Mortality 
Marret
217
 2010 France 
Retro. 
obs. 
Single - 62 86.8 2002 129 129 0 0 ALI ALI Hospital Hospital 
Mathisen
135
 1998 USA 
Retro. 
obs. 
Single 
a NA NA 1989 175 175 0 0 ARDS ARDS NS NS 
b 58.4 NA 1995 412 83 329 0 ARDS ARDS NS Hospital 
Ruffini
129
 2001 Italy 
Retro. 
obs. 
Single - 63 85.0 1996 1142 188 861 93 
ALI, ARDS, 
ALIorARDS 
ALI, ARDS, 
ALIorARDS 
NS Hospital 
Song
277
 2006 Korea 
Retro. 
obs 
Single - 61.3 79.3 2002 635 101 505 29 
ALI, ARDS, 
ALIorARDS 
NA 30 days NA 
Steger
278
 2012 Germany 
Retro. 
obs. 
Single - NA 80.8 1997 146 78 68 0 
ALI, ARDS, 
ALIorARDS 
NA NS NA 
Stephan
279
 2000 France 
Retro. 
obs. 
Single - 59.0 77.0 1995 266 87 142 37 ARDS NA 30 days NA 
Tang
110
 2008 UK 
Retro. 
obs. 
Single - NA NA 2002 1376 88 601 687 ARDS ARDS NS NS 
Tisdale
280
 2009 USA RCT Multi 
a 61 52.3 2006 65 17 48 0 ARDS ARDS 
NS NS 
b 63 47.7 2006 65 15 50 0 ARDS ARDS 
Veen
281
 2009 Netherlands 
Retro. 
obs. 
Multi - 64 76 2002 91 91 0 0 ARDS NA 
Up to 30 
days post 
discharge 
NA 
Yang
218
 2011 Korea RCT Single 
a 60.0 62 2009 50 0 50 0 ALI ALI, ARDS 
NS NS 
b 58.0 62 2009 50 0 50 0 ALI ALI, ARDS 
A
Concerns whether incidence or mortality data was extracted for ‘ALI’, ‘ARDS’ or the combined endpoint ‘ALI or ARDS’. NS, definition not specified in the paper.NA, 
result not available from the paper. 
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3.3.3 Incidence of post-lung resection lung injury 
3.3.3.1 Detection of outliers 
Screening for potential outliers was performed by visual inspection of forest 
plots, and examination of standardized residuals (Figures 3.2 and 3.3). 
Outlier analysis - ALI incidence 
Two potential outliers (PO) were identified (Figure 3.2). PO1 was identified as a 
potential outlier from the appearance of the forest plot (Figure 3.2a). The 
standardized residual for this cohort was less than 2.0 (1.47, Figure 3.2b). 
Further scrutiny of this cohort revealed no reason to suggest that the study 
population was not generalizable; as such this study was retained in the analysis. 
PO2 was identified as having a standardized residual greater than -2.0 (-2.1, 
Figure 3.2b). Inspection of the forest plot suggests this result to be in keeping 
with several others (for example Kutlu et al and Licker et al (b), Figure 3.2a). 
Further scrutiny of this cohort revealed no reason to suggest the study 
population was not generalizable; as such this cohort was retained in the 
analysis. 
Outlier analysis - ARDS incidence 
One potential outlier was identified (Figure 3.3). This cohort from Kim et al, 
2010134, was identified as a potential outlier both from the appearances of the 
forest plot where it appeared to stand alone (Figure 3.3a), and as having a 
standardized residual greater than 2.0 (2.37, Figure 3.3b). Further scrutiny of 
this study revealed the following statement: 
“...the patients included in the current study showed higher risk 
features than those who underwent simple pneumonectomy without 
lung perfusion scanning, as evidenced by older age, more frequent 
smoking and poorer pulmonary function test results”. 
Kim et al (2010)134 
 
As it appears that this study comprised a ‘higher risk’ patient cohort, this study 
was removed from the analysis. Sensitivity analysis (including this outlying study) 
was performed throughout. 
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Figure 3.2. Outlier analysis - incidence of ALI following lung resection.  
a) forest plot, b) standardized residual plot. Potential outliers (PO) are identified and labelled; labels 
reflect corresponding cohorts in figures a) and b). 
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Figure 3.3. Outlier analysis for the incidence of ARDS following lung resection.  
a) forest plot, b) standardized residual plot. Potential outliers (PO) are identified and labelled; labels 
reflect corresponding cohorts in figures a) and b). 
 
Outlier analysis - ALI/ARDS incidence 
No potential outliers were identified (not shown). 
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3.3.3.2 Meta-analysis 
The pooled incidence estimates for ALI, ARDS and ALI/ARDS were 2.8% (1.6-4.9), 
2.5% (1.8-3.3) and 3.0% (2.1-4.3) respectively. There was evidence of 
‘substantial’ to ‘considerable’ heterogeneity in all groups (I2=82.7%, 54.3% and 
78.3% for ALI, ARDS, ALI/ARDS respectively (p<0.01 for all, Figures 3.4-6). 
 
Figure 3.4. Random effects meta-analysis of ALI incidence following lung resection. 
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Figure 3.5. Random effects meta-analysis of ARDS incidence following lung resection 
(outlier excluded). 
 
 
Figure 3.6. Random effects meta-analysis of ALI/ARDS incidence following lung resection. 
 
Sensitivity analysis: Without exclusion of the outlier, the pooled incidence 
estimate for ARDS was similar at 2.7% (1.9-3.9), though heterogeneity increased 
(I2=73.9%, p<0.01, Figure 3.7). 
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Figure 3.7. Sensitivity analysis: Random effects meta-analysis of ARDS incidence following 
lung resection (outlier included). 
 
Subgroup analysis 
Incidence data specific to subgroups of patients undergoing lobectomy and 
pneumonectomy was available for 6 lobectomy cohorts and three 
pneumonectomy cohorts for analysis of ALI incidence, four lobectomy and 7 
pneumonectomy cohorts for analysis of ARDS incidence and four lobectomy and 
four pneumonectomy cohorts for analysis of ALI/ARDS incidence. 
The incidence of ARDS and ALI/ARDS but not ALI was significantly higher in 
patients undergoing pneumonectomy than lobectomy p= <0.01, <0.01 and 0.16 
respectively (Figures 3.8-10). 
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Figure 3.8. Subgroup analysis: Random effects meta-analysis of ALI incidence by type of resection. 
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Figure 3.9. Subgroup analysis: Random effects meta-analysis of ARDS incidence by type of resection (outlier excluded). 
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Figure 3.10. Subgroup analysis: Random effects meta-analysis of ALI/ARDS incidence by type of resection. 
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The proportion of (between-cohorts) variance explained (R2) by subgroup 
membership was 34%, 63% and 86% respectively for ALI, ARDS and ALI/ARDS 
(Figure 3.11).  
 
 
Figure 3.11. Proportion of variance in the incidence of ARDS following lung resection 
explained by subgroup membership.  
Total variance is the sum of within-cohorts and between-cohorts variance. I
2
=79% - i.e. 79% 
(represented by the shaded area of upper box) of the total variance (total area of upper box) results 
from between-cohorts variation. Of this between-cohorts variance (total area of lower box), 63% 
(R
2
, the shaded area of the lower box) is explained by differences between subgroups, whilst 37% 
of the between-cohorts variance remains unexplained. 
 
Sensitivity analysis: When including the outlier, there remained a significant 
difference in the incidence of ARDS between patients undergoing lobectomy 
versus pneumonectomy p<0.001, R2=68% (Figure 3.12). 
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Figure 3.12. Sensitivity analysis: subgroup analysis, random effects meta-analysis of ARDS incidence by type of resection (outlier included)
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3.3.3.3 Detection of publication bias 
Funnel plots of standard error by Logit event rate are shown in Figures 3.13-16.  
 
Figure 3.13. Funnel plot of standard error versus Logit event rate for studies reporting 
incidence of ALI. 
 
Figure 3.14. Funnel plot of standard error by Logit event rate for studies reporting incidence 
of ARDS (outlier excluded). 
 
Chapter 3  132 
 
Figure 3.15.  Funnel plot of standard error by Logit event rate for studies reporting 
incidence of ALI or ARDS. 
 
 
Figure 3.16. Funnel plot of studies reporting incidence of ARDS (including outlier). 
 
Visual inspection of the plots reveals obvious asymmetry of the plots for ARDS 
and (less so) for ALI incidence, with studies apparently ‘missing’ to the lower 
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right hand side of the plots. This suggests publication bias, manifest in the 
under-reporting of small studies reporting higher incidences (more negative Logit 
event rates) of ALI and ARDS. 
The results of Duval and Tweedie’s trim and fill procedure to assess the impact 
of publication bias are shown in Table 3.3. Adjustment for the effects of 
publication bias results in increases in the pooled incidence estimates for ALI 
and ARDS, which are greater for ALI than ARDS.  A funnel plot demonstrating the 
trim and fill adjustment for the incidence of ARDS is shown in Figure 3.17 for 
illustration. 
Table 3.3. Results of Duval and Tweedie’s trim and fill procedure on pooled estimates of 
ALI, ARDS and ALI/ARDS incidence. 
Outcome  
Studies 
trimmed 
Point 
estimate 
Confidence interval Q-
statistic LL UL 
ALI Obs.  2.8 1.6 4.8 63.7 
Adj. 4 4.9 2.6 9.0 141.8 
ARDS 
(no outlier) 
Obs.  2.4 1.8 3.3 30.6 
Adj. 5 2.8 2.1 3.6 36.4 
ALI//ARDS Obs.  2.9 2.1 4.2 27.6 
Adj. 0 2.9 2.1 4.2 27.6 
ARDS 
(outlier included) 
Obs.  2.7 1.9 4.0 57.5 
Adj. 5 3.2 2.3 4.5 65.8 
Obs., observed values; Adj., adjusted values following trim and fill. Incidence presented as percent. 
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Figure 3.17. Funnel plot of standard error by Logit event rate for studies reporting incidence 
of ARDS (outlier excluded), demonstrating ‘trim and fill’ procedure. 
Open circles are observed studies, open diamond is observed point estimate. Imputed studies are 
shown as filled circles, and the imputed point estimate as the filled diamond. 
 
3.3.3.4 Meta-regression 
Incidence of ALI, ARDS and ALI/ARDS by year 
There was no significant relationship between median year of study recruitment 
and the incidence of ALI, ARD or ALI/ARDS. The odds ratio for ALI, ARDS and 
ALI/ARDS incidence per year was 1.01 (95% CI 0.89-1.14), 0.98 (0.92-1.04) and 
0.95 (0.86-1.05) respectively (Figures 3.18-21 and Table 3.4). 
Sensitivity analysis: When including the outlier, there remained no significant 
relationship between median year of study recruitment and the incidence of 
ARDS (OR = 0.98 (0.91-1.06)). 
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Figure 3.18. Incidence of ALI by median year of cohort recruitment.  
Event rate = incidence. Size of ‘bubbles’ are proportional to cohort weighting.  
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Figure 3.19. Incidence of ARDS (outlier removed) by median year of cohort recruitment. 
Event rate = incidence. Size of ‘bubbles’ are proportional to cohort weighting.  
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Figure 3.20. Incidence of ALI/ARDS by median year of cohort recruitment.  
Event rate = incidence. Size of ‘bubbles’ are proportional to cohort weighting. 
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Figure 3.21. Sensitivity analysis: Incidence of ARDS (outlier not removed) by median year of cohort recruitment.  
Event rate = incidence. Size of ‘bubbles’ are proportional to cohort weighting.  
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Table 3.4. Meta-regression analyses of ALI, ARDS and ALI/ARDS incidence by covariate 
Covariate Outcome Heterogeneity Meta-regression 
  
n Q df p I
2
 (%) Slope SE OR 
95% CI 
R
2
 (%) p 
LL UL 
Year ALI 12 63.7 11 <0.01 82.7 0.01 0.03 1.01 0.89 1.15 0 0.88 
ARDS (outlier excluded) 15 30.6 14 <0.01 54.3 -0.02 0.03 0.98 0.92 1.04 0 0.45 
ALI/ARDS 7 27.6 6 <0.01 78.3 -0.05 0.05 0.95 0.86 1.05 0 0.36 
ARDS (including outlier) 16 57.5 15 <0.01 73.9 -0.02 0.04 0.98 0.91 1.06 0 0.66 
Age ALI 9 36.5 8 <0.01 78.1 0.12 0.07 1.13 0.99 1.29 40 0.07 
ARDS (outlier excluded) 11 16.1 10 0.10 38.0 0.00 0.04 1.00 0.92 1.08 0 0.92 
ALI/ARDS 3 10.8 2 <0.01 81.5 -0.07 0.04 0.94 0.86 1.01 56 0.10 
ARDS (including outlier) 12 36.1 11 <0.01 69.5 0.02 0.05 1.02 0.92 1.14 0 0.66 
Sex ALI 9 51.2 8 <0.01 84.4 0.04 0.03 1.04 0.98 1.10 0 0.19 
ARDS (outlier excluded) 10 15.7 9 <0.01 42.5 0.01 0.02 1.01 0.96 1.05 0 0.80 
ALI/ARDS 6 26.2 5 <0.01 80.9 0.01 0.01 1.01 0.98 1.04 0 0.54 
ARDS (including outlier) 11 33.9 10 <0.01 70.5 0.03 0.02 1.03 0.99 1.07 26 0.12 
Side ALI 5 3.7 4 0.45 0.0 -5.32 3.30 0.00 0.00 3.12 0 0.11 
ARDS (outlier excluded) 5 2.9 4 0.57 0.0 -0.04 0.04 0.96 0.89 1.03 0 0.23 
ALI/ARDS 2 - - - - -  - - - - - 
ARDS (including outlier) 6 18.7 5 <0.01 73.3 -0.09 0.03 0.92 0.87 0.96 96 <0.01 
FEV1 ALI  6 12.6 5 0.03 60.4 0.02 0.04 1.03 0.95 1.10 0 0.49 
ARDS (outlier excluded) 5 2.3 4 0.69 0.0 0.02 0.11 1.02 0.82 1.27 0 0.85 
ALI/ARDS 0 - - - - - - - - - - - 
ARDS (including outlier) 6 18.2 5 <0.01 72.5 -0.06 0.15 0.94 0.70 1.27 12 0.69 
DLCO ALI 2 - - - - - - - - - - - 
ARDS (outlier excluded) 4 0.5 3 0.92 0.0 0.05 0.07 1.05 0.91 1.21 0 0.50 
ALI/ARDS 0 - - - - - - - - - - - 
ARDS (including outlier) 5 17.9 4 <0.01 77.7 0.11 0.03 1.12 1.06 1.18 100 <0.01 
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Pre-op 
chemo-  
therapy 
ALI  6 24.3 5 <0.01 79.4 0.01 0.01 1.01 0.99 1.02 0 0.33 
ARDS (outlier excluded) 8 49.5 7 <0.01 49.5 -0.01 0.01 0.99 0.97 1.00 65 0.10 
ALI/ARDS 2 - - - - - - - - - - - 
ARDS (including outlier) 9 28.6 8 <0.01 72.0 -0.02 0.01 0.98 0.97 1.00 44 0.06 
Pre-op 
radio-
therapy 
ALI  2 - - - - - - - - - - - 
ARDS (outlier excluded) 2 - - - - - - - - - - - 
ALI/ARDS 1 - - - - - - - - - - - 
ARDS (including outlier) 3 16.0 2 0.00 87.5 -0.01 0.02 0.99 0.95 1.03 0 0.57 
Duration 
of OLV  
ALI  6 12.6 5 0.03 60.5 0.02 0.02 1.02 0.98 1.05 0 0.41 
ARDS (outlier excluded) 0 - - - - - - - - - - - 
ALI/ARDS 0 - - - - - - - - - - - 
ARDS (including outlier) 0 - - - - - - - - - - - 
Duration 
of 
operation 
ALI  6 12.6 5 0.03 60.5 0.01 0.01 1.01 0.99 1.04 0 0.32 
ARDS (outlier excluded) 4 0.3 3 0.96 0.0 0.00 0.01 1.00 0.99 1.01 0 0.92 
ALI/ARDS 1 - - - - - - - - - - - 
ARDS (including outlier) N/A - - - - - - - - - - - 
Intra-op 
fluids 
ALI  4 2.8 3 0.43 0.0 0.00 0.00 1.00 1.00 1.00 0 0.29 
 ARDS (outlier excluded) 0 - - - - - - - - - - - 
 ALI/ARDS 1 - - - - - - - - - - - 
 ARDS (including outlier) 0 - - - - - - - - - - - 
Open vs 
thoraco-
scopic 
resection 
ALI  8 35.4 7 0 80.2 0.00 0.01 1.00 0.97 1.02 0 0.69 
ARDS (outlier excluded) 5 2.3 4 0.685 0 0.28 0.29 1.33 1 2.33 0 0.32 
ALI/ARDS 2 - - - - - - - - - - - 
ARDS (including outlier) 6 22.0 5 0.001 77.2 0.34 0.32 1.41 1 2.66 1.10251 0.29 
 n, number of cohorts in analysis;  df, degrees of freedom; SE, standard error; odds ratio per unit of covariate; LL, lower limit; UL, upper limit. 
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3.3.3.5 Incidence of ALI, ARDS and ALI/ARDS by other covariates 
Age 
There was a trend towards a significant positive relationship between the 
incidence of ALI and mean patient age (OR 1.13 (0.99-1.29) per year increase in 
mean patient age, R2=40%). There was a trend towards a significant negative 
relationship between the incidence of ALI/ARDS and mean patient age (OR 0.94 
(0.86-1.01) per year increase in mean patient age, R2=56%), though this finding 
must be interpreted with caution as data was only available from three cohorts 
for this comparison (Table 3.4). There was no significant relationship between 
the incidence of ARDS and mean patient age, with both exclusion and inclusion 
of the outlier (Table 3.4). 
Sex 
There was no significant relationship between the incidence of ALI, ARDS nor 
ALI/ARDS and the percentage of patients of male sex in each cohort (Table 3.4). 
Side of resection 
There was no significant relationship between the incidence of ALI, ARDS (outlier 
removed) nor ALI/ARDS and the percentage of patients undergoing right sided 
resection in each cohort (Table 3.4). Sensitivity analysis where the outlying 
study was retained, demonstrated a strong negative relationship between the 
incidence of ARDS and the percentage of patients undergoing right sided 
resection in each cohort (OR 0.92 (0.87-0.96) per percentage increase in 
patients undergoing right sided lung resection, R2=96%). 
FEV1 
There was no significant relationship between the incidence of ALI and ARDS 
(with both exclusion and inclusion of the outlier) and mean FEV1 (Table 3.4). 
There was insufficient data available (two cohorts or less) to explore any 
relationship between mean FEV1 and the incidence of ALI or ARDS. 
DLCO 
There was insufficient data available (two cohorts or less) to explore any 
relationship between mean DLCO and the incidence of ALI or ALI/ARDS. There 
was no significant relationship between DLCO and the incidence of ARDS (Table 
3.4). Sensitivity analysis where the outlying study was retained, demonstrated a 
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strong positive relationship between DLCO and the incidence of ARDS (OR 1.12 
(1.06-1.18) per percentage increase in mean (percent predicted) DLCO, 
R2=100%). 
Pre-operative chemotherapy 
 
There was no significant relationship between the percentage of patients 
undergoing induction chemotherapy in each cohort and the incidence of ALI. 
There was a trend towards a negative association between receipt of induction 
chemotherapy and the incidence of ARDS (outlier removed), (OR=0.99 (0.97-
1.00) per percentage increase in number of patient undergoing induction 
chemotherapy in each cohort, R2=65%). Sensitivity analysis where the outlying 
study was retained, strengthened the observed relationship (OR=0.98 (0.97-
1.00), R2=44%).  There was insufficient data available (two cohorts or less) to 
explore any relationship between receipt of induction chemotherapy and the 
incidence of ALI/ARDS (Table 3.4). 
Induction radiotherapy 
There was insufficient data available (two cohorts or less) to explore any 
relationship between receipt of induction radiotherapy and the incidence of ALI, 
ARDS (with outlier removed) and ALI/ARDS. There was no significant relationship 
between the percentage of patients undergoing induction radiotherapy in each 
cohort and the incidence of ARDS (Table 3.4). 
Duration of one-lung ventilation 
There was no significant relationship between the mean duration of one-lung 
ventilation in each cohort and the incidence of ALI. There was insufficient data 
available (two cohorts or less) to explore any relationship between the mean 
duration of one-lung ventilation in each cohort and the incidence of ARDS (with 
or without outlier removed) and ALI/ARDS (Table 3.4). 
Duration of surgery 
There was no significant relationship between the mean duration of surgery in 
each cohort and the incidence of ALI nor ARDS (without outlier). There was 
insufficient data available (two cohorts or less) to explore any relationship 
between the mean duration of one-lung ventilation in each cohort and the 
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incidence of ALI/ARDS. Duration of surgery was not recorded in the outlier study 
(Table 3.4). 
Intra-operative fluid administration 
There was no significant relationship between the mean volume of intra-
operative fluid infused in each cohort and the incidence of ALI. There was 
insufficient data available (two cohorts or less) to explore any relationship 
between the mean volume of intra-operative fluid infused in each cohort and 
the incidence of ARDS (with or without outlier) or ALI/ARDS (Table 3.4). 
Analgesic technique 
Of the 12 cohorts in which post-operative analgesic technique was reported, 10 
studies reported the use of thoracic epidural blockade in excess of 80% of cases, 
making any meaningful assessment of the relationship between analgesic 
technique and ALI, ARDS or ALI/ARDS incidence impossible. 
Open verses video assisted thoracoscopic resection  
There was no significant relationship between the percentage of patients 
undergoing open resection in each cohort and the incidence of ALI nor ARDS 
(with or without outlier removed). There was insufficient data available (two 
cohorts or less) to explore any relationship between the percentage of patients 
undergoing open resection in each cohort and the incidence of ALI/ARDS (Table 
3.4). 
3.3.4 Mortality from post-lung resection lung injury 
3.3.4.1 Detection of outliers 
Screening for potential outliers was performed by visual inspection of forest 
plots, and examination of standardized residuals (Figure 3.22). 
Outlier analysis - ALI mortality 
No potential outliers were identified (not shown). 
Outlier analysis - ARDS mortality 
As with the analysis of ARDS incidence, the study by Kim et al (2010)134 was 
identified as a potential outlier both from the appearances of the forest plot 
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where it appeared to stand alone (Figure 3.22a) and as having a standardized 
residual greater than 2.0 (2.11, Figure 3.22b). As this study appears to have 
been conducted in a ‘higher risk’ patient cohort, this study was removed from 
the analysis. Sensitivity analysis (including this outlying study) was performed 
throughout. 
ALI/ARDS mortality 
No potential outliers were identified (not shown). 
 
Figure 3.22. Outlier analysis for mortality from ARDS following lung resection.  
a) forest plot, b) standardized residual plot. Potential outliers (PO) are identified and labelled, labels 
reflect corresponding cohorts in figures a) and b). 
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3.3.4.2 Meta-analysis 
The pooled mortality estimates for ALI, ARDS and ALI/ARDS were 0.8% (0.3-1.8), 
1.2% (0.8-1.9) and 1.1% (0.6-2.3) respectively (Figures 3.23-5). There was 
evidence of ‘substantial’ to ‘considerable’ heterogeneity in all groups (I2=72.3%, 
56.9% and 84.5% for ALI, ARDS, ALI or ARDS mortality respectively (p<0.01 for 
all). 
 
Figure 3.23. Random effects meta-analysis of ALI mortality following lung resection. 
 
Figure 3.24. Random effects meta-analysis of ARDS mortality following lung resection. 
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Figure 3.25. Random effects meta-analysis of ALI/ARDS mortality following lung resection. 
 
Sensitivity analysis: Without exclusion of the outlier, the pooled mortality 
estimate for ARDS was similar at 1.4% (0.8-2.6), though heterogeneity increased 
(I2=82.2%, p<0.01, Figure 3.26). 
 
Figure 3.26. Sensitivity analysis: Random effects meta-analysis of ARDS mortality 
(including outlying study) following lung resection. 
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Subgroup analysis 
Mortality data specific to subgroups of patients undergoing lobectomy and 
pneumonectomy was available for three lobectomy cohorts and two 
pneumonectomy cohorts for analysis of ALI mortality, and four lobectomy and 
two pneumonectomy cohorts for analysis of ARDS mortality. For the endpoint 
ALI/ARDS mortality, data specific to subgroups was only available for one 
lobectomy cohort and not available for any pneumonectomy cohorts so no 
comparative analysis of ALI/ARDS mortality could be performed (Figures 3.27-8). 
There was a trend towards reduced mortality in patients undergoing lobectomy 
compared to pneumonectomy for both ALI and ARDS, p=0.10 and p=0.11 
respectively. The proportion of variance in ALI and ARDS mortality explained (R2) 
by subgroup membership was 80.0% and 83.3% respectively. 
Sensitivity analysis: Without exclusion of the outlier, there was a stronger trend 
towards a difference in the mortality from ARDS between patients undergoing 
lobectomy versus pneumonectomy, p=0.05, R2=85.7% (Figure 3.29). 
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Figure 3.27. Subgroup analysis: Random effects meta-analysis of ALI mortality by type of resection. 
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Figure 3.28. Subgroup analysis: Random effects meta-analysis of ALI mortality by type of resection. 
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Figure 3.29. Subgroup analysis: Sensitivity analysis.  Random effects meta-analysis of ARDS mortality (including outlying study)  following lung resection 
by type of resection. 
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3.3.4.3 Detection of publication bias 
Funnel plots of standard error by Logit event rate are shown in Figures 3.30-3.  
 
Figure 3.30. Funnel plot of standard error versus Logit event rate for studies reporting ALI 
mortality. 
 
 
Figure 3.31. Funnel plot of standard error by Logit event rate for studies reporting ARDS 
mortality (outlier excluded). 
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Figure 3.32.  Funnel plot of standard error by Logit event rate for studies reporting ALI or 
ARDS mortality. 
 
 
Figure 3.33. Funnel plot of standard error by Logit event rate for studies reporting ARDS 
mortality (including outlier). 
 
Visual inspection of the plots reveals obvious asymmetry of the plot for ARDS and 
(less so) for ALI and ALI/ARDS mortality, with studies again apparently ‘missing’ 
to the lower right hand side of the plots. This suggests publication bias, manifest 
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in the under-reporting of small studies reporting higher mortality (more negative 
Logit event rates) from ALI, ARDS and ALI/ARDS. 
The results of Duval and Tweedie’s trim and fill procedure to assess the impact 
of publication bias are shown in Table 3.5. Adjustment for the effects of 
publication bias results in increases in the pooled mortality estimates for ALI, 
ARD and ALI/ARDS.   
Table 3.5. Results of Duval and Tweedie’s trim and fill procedure on pooled estimates of 
ALI, ARDS and ALI/ARDS mortality. 
Outcome  Studies 
trimmed 
Point 
estimate 
Confidence interval Q-
statistic LL UL 
ALI Obs.  0.8 0.3 1.8 28.9 
Adj. 2 1.1 0.5 2.4 36.3 
ARDS 
(no outlier) 
Obs.  1.2 0.8 1.9 25.5 
Adj. 2 1.4 0.9 2.1 30.6 
ALI//ARDS Obs.  1.1 0.6 2.3 19.3 
Adj. 2 1.8 0.9 3.8 42.7 
ARDS 
(outlier included) 
Obs.  1.4 0.8 2.6 67.5 
Adj. 5 2.5 1.4 4.4 117.4 
Obs., observed values; Adj., adjusted values following trim and fill. Mortality presented as percent; 
LL & UL, lower & upper limit of 95% confidence interval. 
 
3.3.4.4 Meta-regression 
ALI, ARDS and ALI/ARDS mortality by year 
There was a trend towards reduced mortality over time for ARDS and ALI/ARDS, 
OR=0.95 (0.89-1.01) and 0.88 (0.77-1.0) per year respectively. There was no 
significant relationship between median year of study recruitment and ALI 
mortality, OR=1.06 (0.89-1.27) (Figures 3.36-9 and Table 3.6). The proportion of 
variance in ARDS and ALI/ARDS mortality explained (R2) by the median year of 
study recruitment was 48.2% and 50.2% respectively (Figures 3.34-5). 
Sensitivity analysis: where the outlying study was retained, revealed no 
significant relationship between median year of study recruitment and ARDS 
mortality, OR=0.96 (0.86-1.07).  
Chapter 3  154 
 
Figure 3.34. Proportion of variance in ARDS mortality explained by median year of study 
recruitment. 
 
 
 
Figure 3.35. Proportion of variance in ALI/ARDS mortality explained by median year of study 
recruitment. 
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Figure 3.36. ALI mortality by median year of cohort recruitment. 
Event rate = mortality. Size of ‘bubbles’ are proportional to cohort weighting. 
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Figure 3.37. ARDS mortality by median year of cohort recruitment.  
Event rate = mortality. Size of ‘bubbles’ are proportional to cohort weighting. 
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Figure 3.38. ALI/ARDS mortality by median year of cohort recruitment.  
Event rate = mortality. Size of ‘bubbles’ are proportional to cohort weighting. 
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Figure 3.39. Sensitivity analysis: ARDS mortality by median year of cohort recruitment (outlier included). 
Event rate = mortality. Size of ‘bubbles’ are proportional to study weighting  
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Table 3.6. Meta-regression analyses of ALI, ARDS and ALI/ARDS mortality by covariate.`  
Covariate Outcome Heterogeneity Meta-regression 
  
n Q df p I
2
 (%) Slope SE OR 
95% CI 
R
2
 (%) p 
LL UL 
Year ALI 9 28.9 8 0.00 72.3 0.06 0.09 1.06 0.89 1.27 8.1 0.48 
ARDS (outlier excluded) 12 25.5 11 0.01 56.9 -0.06 0.03 0.95 0.89 1.01 48.2 0.09 
ALI/ARDS 4 19.3 3 0.00 84.5 -0.13 0.07 0.88 0.77 1.00 50.2 0.05 
ARDS (including outlier) 13 67.5 12 0.00 82.2 -0.04 0.06 0.96 0.86 1.07 0.0 0.48 
Age ALI 5 12.7 4 0.01 68.6 0.07 0.11 1.08 0.87 1.34 0.0 0.50 
ARDS (outlier excluded) 5 10.8 4 0.03 63.0 -0.07 0.03 0.93 0.87 0.99 100.0 0.02 
ALI/ARDS 2 6.1 1 0.01 83.7 - - - - - - - 
ARDS (including outlier) 6 45.7 5 0.00 89.1 0.00 0.12 1.00 0.78 1.27 0.0 0.99 
Sex ALI 6 25.2 5 0.00 80.2 0.02 0.05 1.02 0.93 1.11 0.0 0.75 
ARDS (outlier excluded) 4 8.9 3 0.03 66.4 -0.02 0.02 0.98 0.94 1.02 61.5 0.23 
ALI/ARDS 3 14.2 2 0.00 86.0 0.00 0.01 1.00 0.98 1.02 0.0 0.96 
ARDS (including outlier) 5 40.5 4 0.00 90.1 0.03 0.04 1.03 0.94 1.12 0.0 0.52 
Pre-op 
chemo-  
therapy 
ALI  4 9.7 3 0.02 69.0 1.86 2.31 6.44 0.07 598.56 0.0 0.42 
ARDS (outlier excluded) 2 0.0 1 0.90 0.0 - - - - - - - 
ALI/ARDS 0 - - - - - - - - - - - 
ARDS (including outlier) 3 11.6 2 0.00 82.8 -8.70 5.03 0.00 0.00 3.20 100.0 0.08 
Duration 
of OLV  
ALI  4 3.535 3 0.32 15.14 0.02 0.02 1.02 0.97 1.06 0 0.48 
ARDS (outlier excluded) 2 - - - - - - - - - - - 
ALI/ARDS 0 - - - - - - - - - - - 
ARDS (including outlier) N/A - - - - - - - - - - - 
Duration 
of 
operation 
ALI  3 2.871 2 0.24 30.34 -0.07 0.07 0.94 0.81 1.08 8.379679 0.37 
ARDS (outlier excluded) 6 1.428 5 0.92 0.00 -0.01 0.01 0.99 0.97 1.01 0 0.37 
ALI/ARDS 1 - - - - - - - - - - - 
ARDS (including outlier) N/A - - - - - - - - - - - 
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Intra-op 
fluids 
ALI  3 2.871 2 0.24 30.34 -0.13 0.08 0.88 0.75 1.04 100 0.14 
ARDS (outlier excluded) 3 0.735 2 0.69 0.00 -0.07 0.08 0.93 0.80 1.09 0 0.40 
ALI/ARDS 1 - - - - - - - - - - - 
ARDS (including outlier) N/A - - - - - - - - - - - 
Open vs 
thoraco-
scopic 
resection 
ALI  6 10.853 5 0.05 53.93 -0.01 0.02 0.99 0.95 1.03 0.0 0.48 
ARDS (outlier excluded) 6 1.927 5 0.86 0.00 0.01 0.01 1.01 0.98 1.03 0.0 0.71 
ALI/ARDS 2 - - - - - - - - - - - 
ARDS (including outlier) 7 24.863 6 0.00 75.87 0.01 0.02 1.01 0.97 1.05 0.0 0.62 
 n, number of cohorts in analysis;  df, degrees of freedom; SE, standard error; odds ratio per unit of covariate; LL, lower limit; UL, upper limit. N/A, not applicable – the 
outlying study did not report the covariate concerned. 
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3.3.4.5 ALI, ARDS and ALI/ ARDS mortality by other covariates 
Age 
There was no significant relationship between patient age and ALI mortality 
(Table 3.6). There was a significant negative relationship between ARDS 
mortality and mean patient age (OR 0.93 (0.87-0.99) per year increase in mean 
patient age, R2=100%). This was not supported by sensitivity analysis where the 
outlying study was retained, which revealed no significant relationship (Table 
3.6). There was insufficient data available (two cohorts or less) to explore any 
relationship between patient age and ALI/ARDS mortality. 
Sex 
There was no significant relationship between ALI, ARDS nor ALI/ARDS mortality 
and the percentage of patients of male sex in each cohort (Table 3.6). 
Induction chemotherapy 
 
There was no significant relationship between the percentage of patients 
undergoing induction chemotherapy in each cohort and ALI mortality (Table 3.6). 
There was insufficient data available (two cohorts or less) to explore any 
relationship between receipt of induction chemotherapy and ARDS (outlier 
removed) or ALI/ARDS mortality. Sensitivity analysis where the outlying study 
was retained, revealed a trend towards a significant negative relationship 
between receipt of induction chemotherapy and ARDS mortality (OR=0.00 (0.00-
3.20), R2=100%, Table 3.6).   
Duration of one-lung ventilation 
There was no significant relationship between the mean duration of one-lung 
ventilation in each cohort and ALI mortality. There was insufficient data 
available (two cohorts or less) to explore any relationship between the mean 
duration of one-lung ventilation in each cohort and ARDS (with or without outlier 
removed) or ALI/ARDS mortality. 
Duration of surgery 
There was no significant relationship between the mean duration of surgery in 
each cohort and ALI or ARDS mortality (without outlier). There was insufficient 
data available (two cohorts or less) to explore any relationship between the 
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mean duration of one-lung ventilation in each cohort and ALI/ARDS mortality. 
Duration of surgery was not recorded in the outlier study (Table 3.6). 
Intra-operative fluid administration 
There was no significant relationship between the mean volume of intra-
operative fluid infused in each cohort and ALI or ARDS mortality (outlier 
removed). There was insufficient data available (two cohorts or less) to explore 
any relationship between the mean volume of intra-operative fluid infused in 
each cohort and ALI/ARDS mortality. Intra-operative fluid administration was not 
recorded in the outlier study (Table 3.6).  
Open verses video assisted thoracoscopic resection  
There was no significant relationship between the percentage of patients 
undergoing open resection in each cohort and ALI nor ARDS (with or without 
outlier removed) mortality. There was insufficient data available (two cohorts or 
less) to explore any relationship between the percentage of patients undergoing 
open resection in each cohort and ALI/ARDS mortality (Table 3.6). 
Side of resection, FEV1, DLCO and induction chemotherapy 
There was insufficient data available (two cohorts or less) to explore any 
relationship between side of resection, mean FEV1 , mean DLCO, induction 
chemotherapy and ALI, ARDS or ALI/ARDS mortality. 
Analgesic technique 
As with the analysis of ALI, ARDS and ALI/ARDS incidence, no meaningful 
assessment of the relationship between analgesic technique and ALI, ARDS or 
ALI/ARDS mortality was possible. 
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3.4 Discussion 
The main findings of this study are that whilst there is no evidence to suggest 
the incidence of ALI and/or ARDS post-lung resection is falling, mortality due to 
ARDS (but not ALI) does appear to be falling over time. 
From the 127 papers identified for full text review, the most common reason for 
exclusion from the current study was that ALI and ARDS were not defined 
according to the American-European Consensus Conference definition. Such 
variability in the definitions used to define PLR-ALI is the major limitation to the 
current study. By necessarily enforcing strict inclusion criteria, to ensure 
statistical comparisons made across studies reflect comparisons of patients 
experiencing the same clinical syndrome, study sample size was limited to just 
27 patient cohorts. Within these 27, further inconsistency in reporting the 
incidence of ALI and/or ARDS led to further reduction of the sample size. Whilst 
limitation in the number of available studies is a common problem in systematic 
reviews and meta-analyses (as discussed below), its repercussions are amplified 
within the methodology of meta-regression263, 265, 282. 
3.4.1 Publication bias  
Publication bias is more commonly considered in the case of interventional 
studies where it has been widely described that ‘negative’ results (i.e. 
demonstrating no benefit from the intervention), are less likely to be published. 
Such publication bias can result from the design or execution of individual 
studies, researchers electing not to submit results, journal editorial policies or 
withholding of results by trial sponsors283. Irrespective of source, as published 
results may consequently systematically differ from un-published ones, resultant 
systematic reviews and meta-analyses based only upon published data may be 
biased. Publication bias remains a problem in meta-analyses of observational 
data: The Meta-analysis Of Observational Studies in Epidemiology group 
(MOOSE), describe that “publication bias... represents a particular threat to the 
validity of observational studies”284. Indeed, observational studies have 
increased potential for bias (of all aetiologies), tend to show greater effect sizes 
and exhibit greater heterogeneity283. 
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Visual assessment of the funnel plots in Figures 3.13-6 and 3.30-3, suggests there 
may be significant publication bias in the current study, with studies 
demonstrating higher incidence and mortality perceived to be ‘missing’. It is not 
difficult to believe that a researcher may be disinclined to publish results which 
he or she feels reflect negatively on the performance of the institution in which 
they work. What then would be the implications of such publication bias on the 
outcomes of the current analyses? It is inherent that underreporting of studies 
demonstrating high incidence and mortality from ALI and/or ARDS might result in 
the pooled incidence and mortality estimates being unduly optimistic. This is 
suggested by the results of Duval and Tweedie’s trim and fill procedure, which 
demonstrates increased incidence and mortality estimates following adjustment 
for publication bias (Tables 3.3 and 3.5). It is interesting to reflect that 
following adjustment, the incidence of ALI is 2% higher than for ARDS; such an 
observation is intuitive given that ALI reflects a ‘milder’ degree of lung injury 
and therefore might be expected to occur more often. 
There appears to be no reason however, why the potential for publication bias 
may be different over time period studied; as such one might perceive that 
publication bias is unlikely to compromise the results of the meta-regression 
analyses against time. Unfortunately, such an assertion may be misguided. Meta-
regression is dependent on their being heterogeneity between studies included 
in the analysis; without between-study variation, there is no ‘proportion of 
variance’ to be explained by meta-regression. Systematic under reporting of 
studies demonstrating greater incidence and mortality (due to publication bias) 
will result in there being both a reduced number of studies available for 
analysis, and reduced between-cohort variability, decreasing the power of the 
analysis to detect a positive relationship between incidence / mortality and any 
cofounder. The effect of ‘missing’ studies on heterogeneity can be appreciated 
by the increases in the value of the Q-statistic observed when pooled incidence 
and mortality estimates are adjusted by Duval and Tweedie’s trim and fill 
procedure (Tables 3.3 and 3.5).  
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3.4.2 Incidence of ALI and/or ARDS following lung resection 
Prior to adjustment for publication bias, the pooled incidence estimates for ALI, 
ARDS and ALI/ARDS were 2.8% (1.6-4.9), 2.5% (1.8-3.3) and 3.0% (2.1-4.3) 
respectively (Figures 3.4-6). Unsurprisingly, there were high levels of 
heterogeneity in all groups (I2=84.3%, 54.3% and 78.3% for ALI, ARDS, ALI/ARDS 
respectively (p<0.01 for all). The remainder of this discussion concerns 
explanation of the heterogeneity. 
In contrast to trends reported in single institutions110, 155, there was no evidence 
to suggest that the incidence of either ALI, ARDS or ALI/ARDS was falling over 
time (p=0.88, 0.45 and 0.36 for ALI, ARDS and ALI/ARDS). The failure to 
demonstrate the hypothesised relationship between incidence and time, results 
in one of two possible conclusions. Firstly, the relationship may not exist (the 
results of the analyses are ‘true’), or secondly, the relationship does exist, but 
the study was inadequate to demonstrate it. Both possibilities will be considered 
in turn. 
3.4.2.1 There may be no relationship between ALI/ARDS incidence and 
time... 
Since 2005, there has been a dramatic increase in the number of patients 
undergoing lung cancer surgery in the UK5. Realisation that UK resection rates 
lagged behind those elsewhere, increased recognition that acceptable levels of 
peri-operative morbidity and mortality are achievable even in patients 
previously considered to be ‘very-high risk’, and evidence to suggest resection is 
efficacious in patients with more advanced disease means surgeons and 
anaesthetists are increasingly likely to offer surgery to patients previously 
considered unsuitable for resectionI. As a consequence, one might hypothesise 
that increased resection rates will be reflected by increasing patient age, co-
morbidity and disease stage. Evidence extracted from the ‘English Cancer 
Repository Dataset’, a database of over 280,000 patients undergoing lung cancer 
resection in England between 1998 and 2008 confirms the former to be the case; 
reporting an increase in the proportion of patients in older age groups 
undergoing surgical resection9. Age and co-morbidity (specifically alcohol 
                                         
I
 For a full explanation of the drivers behind increasing resection rate see the discussion in Section 
1.1.2. 
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consumption, ASA grade and pulmonary function are recognised risk factors for 
PLR-ALI. It seems likely therefore, that baseline risk of PLR-ALI will have 
increased during the time analysed by the study. If this is the case, then the 
finding that ALI and/or ARDS incidence is stable is a significant finding in itself. 
Stable incidence in the face of increased baseline risk would suggest reduced 
‘peri-operative’ risk. 
It was intended during this analysis, to perform multivariate logistic meta-
regression and so be able to ‘adjust’ for pre-specified confounders influencing 
‘baseline risk’. It is disappointing therefore that there was insufficient data 
available from which to generate a robust analysis. Analogously to 
recommendations that 10 data points are required per covariate entered into a 
conventional multivariate regression model272, it is advised that 10 studies are 
required per covariate entered into a multivariate meta-regression model267, 273. 
It can be seen from Table 3.4, that there were just 12, 16 and 7 studies 
reporting the incidence of ALI, ARDS and ALI/ARDS respectively, and that the 
number of studies reporting many other potential cofounders was much lower. In 
a paper entitled “Controlling the risk of spurious findings from meta-regression”, 
Higgins and Thompson comment: “Advice to systematic reviewers who wish to 
explore heterogeneity using statistical techniques is often to minimize the 
number of covariates investigated”. In this study, and with some regret, the 
author (B. Shelley) was obliged to heed such advice. 
3.4.2.2 A relationship may exist, but may not have been detected... 
 
“One should never use a non-significant finding to conclude that ... a 
covariate is not related to effect size.” 
Borenstein et al (2009)265  
 
It is common misconception, that the statistical power of meta-analysis is high. 
In meta-analysis, as in an individual study, statistical power depends upon the 
magnitude of the effect size, and the precision of the estimate of the effect 
size: 
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Equation 3.12 
 
Under fixed-effects, precision of the effect size is largely determined by the 
total sample size (cumulatively across all studies); as such precision for the 
summary effect (and hence power) is always greater in meta-analysis than in the 
individual studies. Under random-effects however, precision is dependent on 
two sources of error; the within- and between-studies variance. Precision 
therefore becomes a product of both sample size, and number of studies. If a 
random-effects meta-analysis contains a large number of studies (and patients), 
and the effect sizes are relatively consistent, then as in fixed effects, power will 
be high. If however, few studies are included and/or the effect size varies 
substantially between studies, the precision of the effect size estimate (and 
therefore power) will be lower265. 
It must be appreciated that the discussion above concerns the power of a meta-
analysis to test the ‘main effect’; commonly an assessment of a treatments 
effect and in the case of the current study the pooled ALI and/or ARDS incidence 
estimates. The main purpose of the investigation was not however to generate a 
pooled incidence estimate, but to assess the effect of the moderator variable 
year (median year of study recruitment) on the incidence of ALI and/or ARDS by 
meta-regression analysis. For the purpose of power analysis therefore, the 
‘effect size’ is not the incidence of acute lung injury (for example), but the 
difference between the incidence estimates in each cohort, which in many cases 
is smaller than the overall incidence. Power therefore falls, as the ‘effect size’ 
reduces with no change to the precision of the estimate265. As described by 
Hedges and Pigott: 
“Moderator analyses are conceptually analyses of interactions (the 
interaction of treatment and a moderator variable), and tests for 
interactions are less powerful than tests for main effects in the same 
designs” 
Hedges and Pigott (2004)285 
  
Hedges and Pigott provide a methodology by which the power of a meta-
regression analysis may be determined for an individual regression co-efficient 
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under random effects285. By using this algorithm (the full workings of which are 
described in Appendix two), it is possible to determine the power of the current 
study to detect the effect sizes demonstrated by Licker et al (for ALI incidence) 
and Tang et al (for ARDS incidence) in the single institution reports discussed 
previously. Licker et al reported a 2.9% decrease in the incidence of ALI, from a 
baseline of 3.8% over a study period of 5.3 years (OR 0.85)155. The power of the 
current study to detect such an effect size was 73%. Tang et al reported a 1.6% 
reduction in the incidence of ARDS form a baseline of 3.2% over a study period of 
5.4 years (OR 0.94)110. The power of the current study to detect such an effect 
size was 61%.  
It can be appreciated from these analyses that the current study, based on the 
totality of available literature, lacks sufficient power to confidently test for the 
effect sizes reported by Licker and Tang and colleagues within the pooled 
incidence estimates. In fact, as shown in Appendix two, the current study was 
powered to detect an effect size of OR=0.84 per year for ALI and OR=0.92 per 
year for ARDS. From a baseline incidence of ALI or ARDS of 4% (for example), this 
corresponds to an absolute risk reduction in ALI or ARDS incidence of 0.64% and 
0.32% in the first year respectively. 
A recent study by Lopez-Lopez et al offers some further insight into the concept 
of power analysis for meta-regression286. Lopez-Lopez et al performed a 
simulation study, examining the effects of the number of studies (k), and the 
number of patients per study (N), on the precision of the R2 estimate for a 
random-effects meta-regression analysis with one covariate, for seven different 
methods of estimating the variance of the true effect sizes (T2) (of which the 
DerSimonian and Laird ‘method of moments’ used in the current study was one 
such example264, 269). Where R2, is the proportion of true-variance explained by 
the moderator variable (see Page 116 and Figure 3.11 (Page 130) for 
explanation). By simulating 10,000 meta-analyses, for each of 325 combinations 
of k, N, T2, and R2, Lopez-Lopez et al concluded that the number of studies in 
the meta-analysis appears to have greatest effect on the predictive power of the 
model, and that ‘accurate’ estimation of R2 can only be expected in meta-
analyses containing in excess of 40 studies193.  
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3.4.2.3 Sub-group comparisons 
As anticipated, the incidence of ARDS and ALI/ARDS but not ALI was significantly 
higher in patients undergoing pneumonectomy than lobectomy p= <0.01, <0.01 
and 0.16 respectively (Figures 3.8-10). The absence of a difference in ALI 
incidence in patients undergoing lobectomy compared to pneumonectomy is 
surprising given the high levels of heterogeneity found in this group (I2=89%). 
Though there were six cohorts reporting the incidence of ALI after lobectomy, 
there were only three cohorts reporting the incidence after pneumonectomy. 
Given that sub-group comparisons within meta-analysis are subject to all of the 
limitations concerning power discussed above, it is plausible that with so few 
cohorts reporting ALI incidence after pneumonectomy this comparison lacked 
power.  
The proportion of (between-cohorts) variance explained (R2) by subgroup 
membership was 63%, 86% and 34% for ARDS, ALI/ARDS and ALI respectively. 
Given that over 60% of the between-cohorts variance in (ARDS and ALI/ARDS) 
incidence is explained by subgroup membership, it is evident that any effect of 
any other covariate (including year) must be relatively modest. This is likely to 
have further confounded the meta-regression versus median year of study 
recruitment analysis. In all situations, the maximum number of cohorts in any 
individual sub-group was seven (though in many as few as four), making within-
subgroup analysis by year unfeasible. 
3.4.2.4 Other covariates 
There were no consistent relationships demonstrated between any other 
covariate and the incidence of ALI and/or ARDS. In several comparisons, 
statistically significant results were returned for relationships between ARDS 
incidence and covariates when the outlier was included (for example 
relationships between ARDS incidence and side of resection, DLCO and pre-op 
chemotherapy; p = <0.01, <0.01 and 0.06 respectively (Table 3.4). This can be 
explained by the composition of the outlying patient cohort. This patient cohort 
predominantly underwent left sided pneumonectomy, had normal DLCO and did 
not undergo pre-operative chemotherapy. By visual inspection of the 
corresponding ‘bubble plots’ (not shown) reflecting these comparisons, the 
markedly influential effect of the outlying study on the regression slope was easy 
to appreciate. As such, these comparisons should be interpreted with caution. 
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It must be appreciated that all other covariate analyses besides age suffer from 
limited cohort numbers, due to the lack of availability of data from the primary 
papers. As such the analysis could only be based on the patient cohorts for which 
any given covariate was available, reducing the power of any analyses and 
introducing a further source of bias to the results.  
3.4.3 ALI and/or ARDS mortality following lung resection 
Prior to adjustment for publication bias, the pooled mortality estimates for ALI, 
ARDS and ALI/ARDS were 0.8% (0.3-1.8), 1.2% (0.8-1.9) and 1.1% (0.6-2.3) 
respectively (Figures 3.23-5). Again, there was marked heterogeneity between 
groups (I2=72.3%, 56.9% and 84.5% respectively (p<0.01 for all)). 
In contrast to the analysis between ALI and/or ARDS incidence and year, a 
statistically significant relationship was observed between ALI/ARDS mortality 
and median year of study recruitment (OR=0.88 (0.77-1.0). This was paralleled 
by a trend towards reduced ARDS, but not ALI mortality (OR=0.95 (0.89-1.01) 
and 1.06 (0.89-1.27) per year respectively (Figures 3.36-8, Table 3.6). The 
proportion of variance in ARDS and ALI/ARDS mortality explained (R2) by the 
median year of study recruitment was 48.2% and 50.2% respectively. 
Such a finding is in keeping with several reports suggesting reduced ALI/ARDS 
mortality in the wider critical care environment. Spragg et al performed an un-
weighted analysis examining ARDS mortality reported in the US Acute 
Respiratory Distress Syndrome Clinical Trials Network studies261. The authors 
reported that “studies from the Network permit comparison of mortalities in 
patients of similar disease severity and source, and in these studies [5 studies, 
2,944 patients] mortality has decreased from almost 40% in studies conducted in 
the mid to late 1990s to approximately 25% in the most recent reports”261. In a 
study reporting the outcome of 2,451 patients recruited into three of the same 
five studies, Erikson et al performed an un-weighted logistic regression analysis 
demonstrating a reduction in crude mortality (from 35% in 1996-7 to 26% in 2004-
5262. By observing the temporal trend to be robust to adjustment for 
demographic and clinical covariates including receipt of lower tidal volume 
ventilation, Eirckson et al concluded their “findings strongly suggest that other 
advancements in critical care aside from lower tidal volume ventilation, 
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accounted for [the] improvement in mortality”262. Zambon et al performed a 
mixed-effects meta-regression analysis, examining ALI/ARDS mortality reported 
in 72 studies287. The authors reported significant decrease in overall mortality 
rates of approximately 1.1%/yr over the period analyzed (1994 to 2006). The 
mortality reduction was observed for overall and hospital mortality, but not for 
ICU or 28-day mortality rates287. Zambon et al similarly suggest that (in addition 
to improvements in ‘respiratory management’, improvements in general ITU 
care, “such as improved hygiene, better glucose control, more judicious use of 
blood transfusions, improved imaging to identify sources of sepsis, and methods 
to control sepsis”, were the likely explanation for the reduction in mortality287.  
It seems likely that the reduction in mortality observed in the current study may 
be explained by patients requiring critical care for post-operative ARDS 
benefitting similarly from any such ‘advancements’ in general ITU care.  
In contrast to the findings of Spragg261, Erickson262, Zambon287 and colleagues, 
Phua et al observed no reduction in ARDS mortality between 1994 and 2006136. 
Phua et al performed a random-effects meta-regression analysis examining ARDS 
mortality reported in 42 (randomised and observational) studies. Only sub-type 
of study (with higher mortality in observational verses randomised studies), and 
patient age were found on meta-regression analysis to be independently 
associated with mortality. Phua et al suggest that ARDS mortality may not have 
improved for several reasons; firstly, the lack of available therapeutic 
strategies; secondly, failure to adopt therapies proven effective in randomised 
clinical trials into routine clinical practice (for example low tidal volume 
ventilation); thirdly because the patient population identified by the AECC 
definition is “extremely heterogeneous”262. The authors cite several 
methodological explanations for why their finding may be in opposition with 
those of Zambon et al262. 
Though there was no reduction in ALI and/or ARDS incidence in the current 
study, no assessment of ALI and/or ARDS severity could be made from the study. 
It is plausible that though the incidence of lung injury is not falling, due to the 
hypothesised improvements in lung protection, the severity of injury may be 
less, so explaining reduced mortality. 
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Following the comments made previously concerning the potential for type-II 
error in meta-regression analyses, the observation of any statistically significant 
result appears persuasive. The observed reduction in ALI/ARDS mortality should 
be nonetheless interpreted with caution.  Firstly, all meta-analysis and meta-
regression results must be considered ‘observational’263. Though classically 
meta-analysis is performed by combining the effects of multiple randomised 
controlled trials (just three of the 21 studies included in the current analyses 
were randomised), the meta-regression across studies does not benefit from 
randomisation.  As such, an association between covariate and outcome cannot 
be considered causal, and may represent an association between cofactor and 
another un-recorded covariate.  
Secondly, observational studies are more variable in design than randomized 
trials263. As such some of the marked heterogeneity between studies could result 
from the heterogeneity in study design, rather than clinical diversity. On this 
point, there was a large degree of variability between studies in which mortality 
end-point was reported (Table 3.2). A large number of studies did not report the 
duration of follow up, whilst others reported hospital, hospital and/or 30 day, 60 
or 90 day mortality. Whilst it would have been desirable to restrict data 
extraction to the same defined mortality end-point, such a course of action 
would have prohibitively compromised the number of cohorts available for 
analysis. Analysing ALI and/or ARDS ‘mortality’ measured over a variety of 
durations could clearly be a further source of bias in the current analysis. 
Thirdly, as Higgins and Thompson observe, “false positive results are more likely 
in meta-regression than in conventional regression because of the potential 
presence of heterogeneity”282. In a simulation study, Higgins and Thomson 
demonstrate that “standard meta-regression methods suffer from substantially 
inflated false-positive rates when heterogeneity is present, when there are few 
studies and when there are many covariates”. Further observing that “these 
[conditions] are typical of situations in which meta-regressions are routinely 
employed”. Though the risk of type-I error will decrease as the number of 
studies increases, “it is unclear at what point the risk becomes acceptably 
small282”. It should be emphasised that in Higgins and Thompson’s analysis, false 
positive rates were ‘unacceptably high’ from fixed-effects models conducted in 
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the presence of heterogeneity; performing analyses by random effects is a 
distinct strength of the current study. 
3.4.3.1 Sub-group analyses 
The analyses of ALI and/or ARDS mortality by subgroup were compromised by 
the limited number of studies available for analysis. There was a trend towards 
reduced mortality in patients undergoing lobectomy compared to 
pneumonectomy for both ALI and ARDS, p=0.10 and p=0.11 respectively.  
3.4.3.2 Other covariates 
There was a statistically significant negative association between age and ARDS 
mortality (OR = 0.93 (CI=0.87-0.99) per year increase in mean patient age)). 
Visual inspection of the relevant bubble plot (not shown) suggests that the 
regression line was being influenced by the data point representing the cohort of 
patients from the study by Kutlu et al, whose median age at 51.7 was ~7 years 
younger than the remaining four studies whose mean age falls in the range 58.4 
to 66.5 years. This finding was not robust to sensitivity analyses where the study 
of Kutlu et al was removed (not shown), or where the outlying study was 
included (Table 3.6).  
There were no other significant associations between any covariate and ALI 
and/or ARDS mortality. 
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3.4.4 Conclusion 
“The potential for robust conclusions from meta-regression analyses is clearly 
very limited”263. 
Thompson and Higgins (2002)263 
This statement from Thompson and Higgins above appears very pertinent to the 
current study. Though this study represents a methodologically robust attempt 
to describe any trends in ALI and/or ARDS mortality occurring over time from all 
the currently available published data, the analysis has been thwarted to an 
extent by inconsistencies in both the definitions used to describe PLR-ALI and 
the study endpoints reported such that sample sizes were reduced to the point 
that the potential for ‘robust’ conclusions is limited. 
What can be concluded from the current study? 
Firstly, the pooled incidence and mortality estimates though subject to 
publication bias, reflect the ‘best estimate’ of ALI, ARDS and ALI/ARDS incidence 
and mortality following lung resection available to date. Such estimates could 
provide useful information against which to bench-mark local practice and 
inform power analyses for future studies of PLR-ALI. Secondly, though it is 
possible to conclude that the incidence of ALI, ARDS and ALI/ARDS are not falling 
with time, the analyses do suggest that any effect of time on incidence is 
relatively modest. Finally, the mortality from PLR-ALI does appear to be falling, 
though no conclusion can be made from the current study as to why this is so.
 4 Investigation III: Utility of Pentraxin 3 and a 
multiple biomarker panel as biomarkers 
informative of lung injury following lung 
resection 
4.1 Introduction 
This investigation comprises two discrete studies examining the utility of 
Pentraxin 3 (PTX3) and a multiple (lung injury) biomarker panel in the early 
post-operative period following lung resection. Measurement of biomarkers 
informative of the pathogenesis or clinical progress of lung injury in this 
population could offer the potential to allow early identification of patients at 
risk80, 261, 288, guide clinical management13, 14, 17, identify severity of disease, 
stratify risk82, 289 and predict outcome80, 82, 261, 288, 290. 
Pentraxin 3 (PTX3) has been described as a potential biomarker of acute lung 
injury291. There is a sound biological plausibility for its use both as a lung injury 
biomarker in the critical care environment and in the early post-operative period 
following lung resection (described in detail in the next section). Measurement 
of PTX3 has not previously been described in the post-operative period following 
lung resection.  
Whilst a great deal of effort has gone into the search for a single ‘ideal’ 
ALI/ARDS  biomarker, combination of biomarkers into panels in order to improve 
validity has become an increasing focus of biomarker research244. Such panels 
have been selected from large numbers of potential biomarkers by multivariate 
regression modelling83, 292, and the resulting panels described include biomarkers 
representing many different components of the pathogenesis of ALI/ARDS. 
The purpose of this investigation is to assess the utility of PTX3, and a multiple 
biomarker panel described by Fremont et al83 in the early post-operative period 
following lung resection. Modified Lung Injury Score (mLIS) is defined as a 
surrogate endpoint of ALI (Table 4.6), and as the aim of this investigation is to 
examine the use of biomarkers in the identification of primary PLR-ALI, the 
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assessment of oxygenation, CXR-scores and mLIS were restricted to the first 48 
hours post-operatively (the time of peak incidence of primary PLR-ALI115). Both 
PTX3 and the multiple biomarker panel are assessed against the properties of 
the ‘ideal ALI/ARDS biomarker’ (as will be defined in Section 4.2.2). 
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4.2 Literature review: Biomarkers of Acute Lung Injury 
This review examines the theoretical principles behind biomarker research, 
asking ‘what is a biomarker?’ and ‘what are the properties of the ideal 
biomarker?’, before exploring the limited evidence from studies in the OLV / 
lung resection population to date. Clearly a comprehensive review of every 
biomarker would be laborious to collate, tiresome to read and be of little value 
to the overall goals of this thesis. Attention is focussed on the conceptual 
framework of biomarker research during which examples are drawn from the ALI 
biomarker literature. Finally, the case for the candidate biomarkers examined in 
Investigation III is presented. 
4.2.1 What is a biomarker? 
A biological marker (biomarker) has been defined by the ‘Biomarker Definitions 
Working Group’J as: 
“A characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes or pharmacologic responses to 
a therapeutic intervention.”  
Biomarker Definitions Working Group 293 
 
The World Health Organisation (WHO) provides a more general definition 
suggesting that a biomarker may be: 
“any substance, structure or process that can be measured in the body or its 
products and influence or predict the incidence or outcome of the disease.” 
   
World Health Organisation (2001)80  
 
From these definitions at their broadest and most literal interpretation, it can 
be understood that a biomarker may be a clinical sign, or the result from a 
monitoring modality (for example extravascular lung water)80. For the purposes 
of this discussion the term biomarker is reserved for the predominantly protein 
substances80 that are measured in plasma or broncho-alveolar lavage / 
                                         
J
 ‘Biomarker Definitions Working Group’ – a group convened by the US National Institute of Health 
charged to proposed terms, definitions and a conceptual model. 
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pulmonary oedema fluid discussed widely as being informative in patients with 
or at risk of ALI. 
According to the ‘Biomarker Definitions Working Group’, biomarkers can have a 
variety of applications293: 
 As a diagnostic tool 
 As a tool for staging of disease or classifying the extent of disease 
 As an indicator of disease prognosis 
 As a means of prediction and monitoring of response to an intervention 
 
4.2.2 Properties of the ‘ideal’ lung injury biomarker 
Several authors have suggested properties which they consider the ‘ideal’ lung 
injury biomarker should exhibit (Table 4.1). Whilst many are self-explanatory, 
each will briefly be considered in turn in the following discussion. 
Table 4.1. Properties of the ‘ideal’ lung injury biomarker. 
 Have ‘biological plausibility’294-297 
 Sample easily and safely obtained in the critically ill patient82, 294, 296 
 Highly sensitive and specific in predicting the outcome of interest82, 294, 295 
 Modified by an effective intervention82, 295, 296 
 Vary in proportion to the severity of injury295 
 Associated with clinically important outcomes296 
 Timely, highly reproducible and inexpensively quantified82, 294-296 
 
 
In a similar vein, Shehabi and Seppelt suggest that a biomarker needs to be 
‘SMART’ 80, 298 (Table 4.2). 
Table 4.2. Properties of a SMART biomarker.  
 Sensitive (and specific) 
 Measurable (with a high degree of accuracy) 
 Affordable (and safely attainable) 
 Responsive (and reproducible) 
 In a Timely fashion 
From Shehabi and Seppelt 80, 298. 
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4.2.2.1 Biological plausibility  
Biological plausibility confers face validity. From a researcher’s understanding of 
the biology of lung injury, if evidence exists that the biomarker measured is 
implicated in the pathogenesis of injury, then it is plausible to the researcher 
that changes in the biomarker will reflect changes in the clinical outcome. 
Biological plausibility is often provided by an accumulation of laboratory and 
clinical data demonstrating for example, that administration of the biomarker 
leads to injury in vitro, that manipulation of a biomarker pathway results in 
increased / decreased mortality in animal models and that in clinical studies 
patients with ALI/ARDS, more severe ALI/ARDS or suffering mortality have higher 
biomarker levels. In combination, such evidence provides the researcher with 
confidence that they are measuring the level of a molecule intimately involved 
in the pathogenesis of lung injury. The stronger the association  demonstrated 
between biomarker level and clinical outcome, the more likely the causal link, 
and the greater the plausibility of the biomarker297. In some circumstances 
potential biomarkers are identified as being so integral to the disease process 
that the biomarker pathway itself provides a potential target for therapeutic 
intervention294. 
The need for a candidate ‘ideal’ biomarker to have such ‘biological plausibility’ 
is controversial however. Whilst many authors suggest such a defined role is 
necessary294-296, Proudfoot et al argue that it is of little consequence whether 
the biomarker is involved in the pathogenetic process at all, provided it is 
suitably prognostic / diagnostic299. 
4.2.2.2 Sample easily and safely obtained 
For any biomarker to be useful outwith the research setting, it must be feasibly, 
easily and safely obtained from critically ill patients. Urine is easily and non-
invasively obtained, but lacks specificity to the lung. Nonetheless, urinary 
biomarkers have been associated with improved outcomes in patients with acute 
lung injury300. Plasma is easily (though marginally more invasively) obtained, but 
again specificity to the lung is lacking leaving the potential for the pulmonary 
‘signal’ to be swamped by the systemic. Despite this, plasma forms the site of 
interest of the majority of ALI biomarker research. Pulmonary oedema fluid or 
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bronchoalveolar lavage specimens collected at bronchoscopy offer the potential 
of a lung specific sample at the expense of a more invasive test. Bronchosopy 
however is impractical as a screening test in large populations of ‘at-risk’ 
patients and may be unsafe in patients with more severe disease. Exhaled breath 
condensate (EBC) offers the potential to non-invasively obtain a lung specific 
sample in intubated patients but is limited to analysis of small molecules. The 
role of EBC is yet to be defined with solutions required to the problems of  
quantifying the degree of dilution, improving reproducibility and avoiding of 
contamination301. 
4.2.2.3 Sensitivity and specificity for the outcome of interest 
The ALI/ARDS biomarkers literature is beset with scores of publications 
demonstrating statistically significant increases in a given biomarker in a group 
of patients with a given outcome. Demonstration of statistical significance 
however provides no index of how useful the test may be for differentiating 
between groups302. Assessment of biomarker performance requires assessment of 
sensitivity (the probability of a positive test given the presence of a disease) and 
specificity (the probability of a negative test given the absence of a disease) and 
the calculation of positive and negative predictive values80, 302. Furthermore, 
these predictive values require interpretation in the context of the clinical 
problem. A low positive predictive value (high potential for false positives) may 
not be a problem where a biomarker is to be used as a recruitment criterion in a 
clinical trial of an innocuous and cheap dietary supplement, but would perhaps 
be unacceptable for a trial of a novel therapy which carries a significant risk of 
side effects, and would certainly not be sufficient for use as a diagnostic 
criterion. 
4.2.2.4 Modification by an effective intervention 
It would be advantageous if a biomarker were not only capable of identifying the 
presence of lung injury for example, but that changes in biomarker levels 
reflected contemporaneous changes in the level of injury. Biomarkers could then 
be used as an indicator of clinical progression, with resolution of biomarker 
levels being interpreted as improvement in lung injury. 
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4.2.2.5 Variation in proportion to the severity of injury  
The ability to characterise patients into subgroups according to severity of 
illness (for example mild, moderate and severe lung injury) could allow early 
identification of at risk patients and appropriate intervention, prior to the need 
for critical care unit admission. Similarly, accurate characterisation of severity 
of illness could facilitate decision making in terms of who to triage to a critical 
care environment. 
4.2.2.6 Association with clinically important outcomes  
The need for biomarkers to be associated with clinically important outcomes is 
self evident. Observation of association with clinical endpoints reflecting 
severity of the disease process, morbidity and mortality adds validity to a 
biomarkers selection.  
4.2.2.7 Timely, highly reproducible and inexpensively quantified  
An ideal biomarker must be timely, both in terms of a timeous change in value in 
response to intervention, and in result availability. Griffiths et al discuss the 
potential utility of a biomarker of ALI in guiding titration of ventilator settings in 
order to minimise ventilator induced lung injury. In order to be clinically useful 
in such a setting, biomarker levels would need to change in hours rather than 
days296. Similarly, the result would have to be rapidly analysed and available 
promptly at the bedside. Biomarker research classically involves batched 
analysis of frozen samples in a research laboratory setting. After identification 
of a candidate biomarker, research would be required to provide rapid access to 
reliable (reproducible) results at the bed side. Undoubtedly, the cost of a 
biomarker would influence its uptake and the possibility of widespread use; cost-
effectiveness analyses would form a necessary part of the biomarkers 
evaluation. 
4.2.3 Classification of biomarkers 
Most currently described biomarkers of ALI/ARDS are proteins such as enzymes, 
receptors, polypeptides, lipoproteins and glycoproteins80. Due to the large 
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number of potential biomarkers, rationale classification is essential. A number of 
potential classifications have been suggested (Table 4.3). 
Table 4.3. Potential classification schemes for ALI/ARD biomarkers 
Classification Sample classes 
Clinical Cause of lung injury: direct, indirect 
Phase of disease: Early - exudative, late –fibroproliferative 
 
Molecular biologic Source: Genome, transcriptome, proteome, metabolome 
Compartment of 
origin 
 
Alveolar, vascular, urinary 
Pathophysiology Alveolar-capillary membrane injury, inflammation, activation of coagulation, 
increased permeability 
 
Cell or tissue of 
origin 
Epithelial, endothelial, extracellular matrix 
Table constructed by the author (B Shelley), based on the discussion in Barnett and Ware (2011)
80
.  
 
In practice, a hybrid pathophysiological / cell or tissue of origin classification has 
been unofficially adopted and is widely used (Figure 4.1)80, 289.  
 
Figure 4.1. Schematic representation of the alveolar capillary interface, demonstrating 
pathophysiology and source of potential biomarkers of ALI/ARDS. 
RBC,  red blood cell; T1,  type I epithelial cell; T2, type II epithelial cell; ICAM-1, Intercellular 
adhesion molecule 1; vWF, vonWillebrand factor; PAI-1, Plasminogen activator inhibitor 1; SP, 
surfactant protein; RAGE, Receptor for Advanced Glycation Products; HMGB1, Human Mobility 
Group Box 1 protein; TNFR-1, Tumour Necrosis Factor Receptor 1. From Barnett and Ware 
(2011)
80
. 
Chapter 4  183 
Such a classification allows identification of biomarkers by their role in the 
complex pathogenesis of ALI/ARDS. It can easily be understood that a potential 
therapy for ALI/ARDS which has its mechanism of action through the restoration 
of epithelial function for example, might be best targeted to a cohort of 
patients with elevated levels receptor for advanced glycation end-products 
(RAGE) or surfactant protein D (SP-D). 
4.2.4 The role of combining biomarkers into panels 
When developing the new ‘Berlin’ definition of ARDS, the ARDS Definition Task 
Force considered the potential for biomarkers to be included in the definition 
concluding that “despite a large number of candidate biomarkers and genetic 
markers studied,  none has currently demonstrated adequate sensitivity and 
specificity for use in the diagnosis of ARDS”66. Whilst the taskforce were only 
considering the use of biomarkers for diagnostic purposes, none have yet been 
shown to be of value outwith a research setting in order to establish any sort of 
clinical role. Combination of biomarkers into panels in order to improve validity 
has become an increasing focus of biomarker research244. To this end, the work 
of Freemont83, Ware292 and Calfee303 is worthy of mention. 
Fremont et al measured plasma levels of 21 biomarkers in 192 patients admitted 
to a trauma intensive care unit83. Levels of each biomarker were compared 
between 107 patients with ALI/ARDS (per the AECC definition) and 74 controls 
either with no or hydrostatic pulmonary oedema. Following univariate analysis, a 
backward elimination model was used to select seven biomarkers with the 
greatest predictive value. A multivariable logistic regression model was then 
constructed using these seven biomarkers to create a prediction model for the 
diagnosis of ALI/ARDS. In combination these seven biomarkers predicted 
ALI/ARDS with an area under the receiving operator characteristic 
curve(AUROCC) of 0.86 (95% CI, 0.82-0.92). Disappointingly the authors provide 
no estimate of the sensitivity, specificity, nor positive or negative predictive 
value of the model83. 
Ware et al constructed a similar model for prediction of mortality using eight 
candidate biomarkers in 549 patients with ALI/ARDS recruited to the ARDS 
Network low tidal volume ventilation trial99, 292. In this study (citing some of the 
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same authors as Freemont et al’s study) the biomarker panel tested included 
only one biomarker found in the previous panel and had been chosen 
‘qualitatively’ on the basis of previous work. In addition to studying the ability 
of the biomarker panel to predict ALI/ARDS mortality, Ware et al studied the 
effect of combining the biomarker panel with known clinical risk factors for 
ARDS mortality. Six clinical risk factors alone predicted mortality with an 
AUROCC of 0.82, the eight biomarkers with an AUROCC of 0.76 and a 
combination of the clinical risk factors and biomarker panel with an AUROCC of 
0.85. Relying on the result of a biomarker panel alone to predict outcome in 
patients with ALI/ARDS, whilst ignoring all existing clinical knowledge appears 
nonsensical. Combining clinical risk factors and biomarkers in such a fashion 
appears intuitive and is in keeping with the way biomarkers are used in other 
conditions, for example diagnosis of acute coronary syndrome where the use of 
biomarker (Troponin I or T) levels are combined with aspects of the clinical 
presentation and electrocardiographic changes304.  
Both the studies of Freemont et al83and Ware et al292 have sought to establish 
biomarker panels without attempt at validation. Calfee et al conducted a more 
rigorous study examining the prognostic value of a five biomarker panel in 
combination with clinical risk factors in a derivation cohort derived from the 
ARDS Network low tidal volume ventilation trial99 (n=547) and a replication 
cohort derived from the ARDS Network higher versus lower positive end-
expiratory pressure trial (n=500)303, 305. Biomarkers were selected from a panel of 
eight biomarkers “previously measured in both cohorts”. These eight were 
reduced to five, using a multivariate logistic regression model and ultimately 
included five of the same biomarkers used in Ware et al’s study292. Clinical risk 
factors predicted mortality with AUROCC values of 0.68 in the derivation cohort 
and 0.77 in the replication cohort. Combination of the five biomarker panel with 
clinical predictors yielded AUROCC values of 0.75 in the derivation cohort and 
0.79 in the replication cohort. Once again the authors provide no description of 
sensitivity of specificity of the models. 
It is disappointing that these three studies from high profile research groups, 
which form the culmination of the current understanding of the role of 
biomarkers in diagnosis and risk prediction in patients with ALI/ARDS fail to 
provide a rigorous statistical examination of the utility of the biomarker panels.  
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4.2.5 Heterogeneity of biomarker expression 
As previously highlighted, one of the great barriers to ALI/ARDS research is the 
significant heterogeneity of the condition of ALI/ARDS. A biomarker or panel of 
biomarkers which works well for one variant of the disease may lack specificity 
for another. 
Patients with ALI/ARDS of traumatic aetiology are recognised as having lesser 
mortality than those with non-traumatic aetiology. Though this partially reflects 
the fact that patients with trauma are often younger with less co-morbid 
disease, the mortality difference persists even after adjustment for these 
variables306. Calfee et al examined the biomarker profile of patients with 
traumatic and non-traumatic ALI/ARDS recruited to the same two US ARDS 
Network studies306. Biomarkers of acute inflammation (with the exception of 
Interleukin-6) and of disordered coagulation were no different between the two 
groups. Biomarkers of endothelial and epithelial cell dysfunction (four in total) 
however were significantly higher in the non-traumatic group even after 
adjustment for age, baseline co-morbidities and severity of illness. Furthermore, 
when the four biomarkers were incorporated as covariates into the multivariate 
regression model, the mortality difference between groups was attenuated. 
This, the authors conclude, suggests that patients with non-traumatic ALI are 
subjected to less endothelial and epithelial cell injury than patients with non-
traumatic ALI306.  
Septic and non-septic aetiologies for ALI/ARDS form another notable sub-
grouping. Moss et al similarly observed differences in biomarkers of endothelial 
dysfunction between patients with traumatic ALI/ARDS and patients with sepsis 
and ALI/ARDS; patients with a traumatic aetiology had biomarker levels no 
higher than controls and significantly lower biomarker levels than patients with 
ALI/ARDS and sepsis307. Calfee et al observed that Angiopoietin 2 had differential 
prognostic value for prediction of mortality in septic compared to non-septic 
patients with ALI/ARDS. Ang-2 levels were similarly elevated in septic survivors 
and non-survivors but significantly lower in survivors with non-infectious 
ALI/ARDS than in non-survivors308. 
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4.3 Literature review: Biomarkers of ALI/ARDS in patients 
undergoing lung resection 
A wide variety of potential ALI biomarkers informative of epithelial injury, 
endothelial injury, inflammation, oxidative stress and disordered coagulation 
have been measured in exhaled breath condensate,  urine, plasma and 
bronchoalveolar lavage fluid / epithelial lining fluid in patients undergoing lung 
resection. The result of these studies are summarised in Tables 7.1-4.  
Many of the studies summarised in Tables 7.1-4 were conducted with small 
sample sizes, often being referred to as ‘pilot studies’. Whilst these are 
informative of what ‘signal’ might be expected in terms of the trajectory of 
biomarker levels following lung resection, many make no comparison between 
biomarker levels and clinical outcomes. 
C-reactive protein (CRP)309-311, interleukin (IL)-1 receptor anatagonist40, 
interleukin- 6309, 310, 312, procalcitonin309, 311 and malondialdehyde165 in plasma 
were all associated with ‘complications’, but all of these studies reported an 
endpoint of composite complications. All of these biomarkers may be considered 
to be biomarkers of ‘systemic inflammation’ and it is therefore not surprising 
that these biomarkers might be associated with ‘systemic’ complications. 
Certainly the association between CRP and infectious complications has been 
well established in a variety of surgical populations313. None of these biomarkers 
can be considered to be specific to lung injury. With the possible exception of 
the study of Maeda et al, in which thrombomodulin was associated with post-
operative oxygenation (discussed below)314, none of the studies reported in 
Tables 7.1-4 sought nor reported any association between biomarker levels and 
lung injury. 
4.3.1.1 ‘Lung specific’ biomarkers 
In the early post-operative period following lung resection, for a biomarker to be 
informative of pulmonary pathophysiology it is inherently desirable that any 
biomarker measured is specific to the lung such that any signal from pulmonary 
inflammation / injury is not over shadowed by the systemic inflammatory 
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reaction. It would appear however, that measurement of lung specific 
biomarkers (e.g. biomarkers known to be derived solely from pneumocytes), 
does not provide a simple solution. Plasma levels of the ‘pulmonary epithelial’ 
biomarkers surfactant protein D (SP-D)315, thrombomodulin 314, and Krebs von 
den Lungen-6 (KL-6)314-316 have all been observed to fall post-operatively in 
proportion to the volume of lung tissue resected.   
Bastin et al determined plasma levels of KL-6 and SP-D, pre-operatively, post-
operatively and 24 hours post-operatively in 30 patients undergoing lung 
resection. Both plasma KL-6 and SP-D levels decreased after surgery, with 
significantly lower levels 24 hours post-operatively than pre-operatively.  The 
ratio of post-operative to pre-operative KL-6 and SP-D was associated with the 
amount of lung removed, with lower levels after lobectomy compared with 
lesser resections (Figure 4.2). 
 
Figure 4.2. Ratio of values of Krebs von den Lungen (KL)-6 and surfactant protein (SP)-D 24 
hours and immediately post-operatively verses pre-operatively in patients undergoing lung 
resection. 
Ratio of values at T2 : T1 and T3 : T1 for plasma KL-6 and SP-D after lobectomy (closed circles, n 
= 17) and lesser resection (open circles, n = 12); 
†
p=0.004, 
#
p=0.003, 
§
p=0.003, 
‡
P=0.048 (p-values 
for lobectomy vs lesser resection). From Bastin et al (2010)
315
. 
Similarly observing a fall in KL-6 levels following resection, Sakuma et al 
introduced the concept that predicted post-operative biomarker levels could be 
calculated from baseline levels by adjusting post-operative levels according to 
the residual number of segments remaining post-operatively316. By applying this 
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prediction to KL-6 in 10 patients undergoing lobectomy, the authors observed 
strong association between the lowest determined post-operative levels and 
predicted levels (r=0.89; p<0.005).  KL-6 levels were observed to be at their 
lowest around post-operative day seven and had not returned to baseline by one 
month post-operatively316.  
Maeda et al applied the same adjustment to KL-6 and thrombomodulin values 
determined from 60 patients undergoing lung resection and observed a similar  
association between predicted and actual post-operative levels (R2=0.82 and 
0.62 for KL-6 and thrombomodulin respectively)314. Mean actual post-operative 
thrombomodulin levels were however, higher than predicted (p=0.0002). Three 
of eight patients undergoing lobectomy who had increased (actual and so 
markedly higher than predicted levels) post-operative thrombomodulin levels 
had impaired oxygenation post-operatively whilst none of 34 patients 
demonstrating a fall in actual post-operative levels had impaired oxygenation 
(no statistical comparison made). The authors conclude that the increased levels 
of thrombomodulin post-operatively relative to predicted reflect a combination 
of non-pulmonary thrombomodulin production and pulmonary endothelial injury 
(thrombomodulin is widely but not exclusively expressed in the pulmonary 
endothelium and is described as being shed from the endothelium in response to 
injury), thus patients with markedly increased levels might be considered at risk 
of clinical sequelae of lung injury314. 
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4.4 Literature review: Pentraxin 3 as a candidate 
biomarker of lung injury following lung resection 
Pentraxin 3 (PTX3) is a novel acute phase protein with structural and familial 
links to C-reactive protein. In this section I shall discuss the function of PTX3, 
review its role in the innate immune response (specifically within the lung) and 
present the case for PTX3 as a candidate biomarker of lung injury following lung 
resection. 
4.4.1.1 Function of Pentraxin 3 
Pentraxins are a super-family of conserved proteins which play a key role in 
innate immunity and regulation of the acute inflammatory response. C-reactive 
protein (CRP) and serum amyloid P component (SAP) are classical short chain 
pentraxins and are produced in the liver in response to inflammatory stimuli. In 
contrast, Pentraxin 3 (PTX3), the first long chain pentraxin to be recognised is 
rapidly produced and released from a variety of cell and tissue types in response 
to primary inflammatory signals317. As such, in comparison to CRP, PTX3 may be 
more reflective of localised activation of innate immunity and inflammation than 
of the systemic host response318. Pentraxin 3 behaves as an acute phase protein; 
normal plasma PTX3 levels are less than 2ng/ml, but can increase to many times 
this level (up to 200-800ng/ml) during sepsis and other inflammatory 
conditions319, 320. Pentraxin 3 was originally identified as an immediate early 
gene; levels peak at six to eight hours following induction, considerably more 
rapidly than CRP320, 321. Studies measuring CRP and PTX3 in parallel have 
demonstrated weak or non significant association, suggesting PTX3 measurement 
may offer further or alternative information rather than simply being ‘another 
CRP’319, 320. 
4.4.1.2 PTX3 expression in the lung 
PTX3 expression may be induced by toll-like receptor agonists (e.g. 
lipopolysaccharide), primary inflammatory cytokines, interleukin-10 and oxidised 
low-density lipoprotein320. Several in-vitro, animal and clinical studies have 
demonstrated the increased expression and downstream effects of PTX3 
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expression in alveolar epithelial cells and endothelial cells in response to stimuli 
implicated in the pathogenesis of ALI/ARDS. 
Alveolar epithelial cells have been identified as a potent source of PTX3. PTX3 
gene and protein expression is induced in alveolar epithelial cells directly by 
tumour necrosis factor-α (TNF-α) and interleukin-1 (IL-1β) and indirectly by 
lipopolysaccharide322. Similar up-regulation of PTX3 expression has been 
observed in human endothelial cells in response to LPS / PeptidoglycanG, TNF-α 
and IL-1β 323, 324. (It should be noted that to date studies examining the 
interaction between PTX3 and endothelial cells have been carried out in 
endothelial cell lines of non-pulmonary origin, commonly human umbilical vein 
endothelial cells). 
PTX3 expression is induced by mechanical stretch 
Wu et al examined the effects of mechanical stretch on PTX3 release by alveolar 
epithelial cells in vitro325. Seeking to mimic the effects of ventilator-induced 
lung injury, cells were subject to ‘tightly controlled and physiologically relevant 
cyclic mechanical stretch’. Cells subjected to cyclic elongation of 20% 
demonstrated increased PTX3 gene expression, release of PTX3 protein and 
induced apoptosis. In addition there was strong correlation between PTX3 
expression and the magnitude of apoptosis325. 
PTX3 expression and oxidative stress 
The observation of a binding site for the redox-sensitive transcription factor 
nuclear factor κβ (NF-κβ) and the recognition that oxidative stress has 
consistently been demonstrated in patients with sepsis (as it also has in patients 
with ALI/ARDS160), led Galley et al to examine the effects of antioxidants on 
PTX3 expression326. In line with previous reports, PTX3 expression from 
endothelial cells was increased in response to stimulation with 
lipopolysaccharide / peptidoglycan G, TNF-α and IL-1β. Co-administration of the 
antioxidants N-Acetylcysteine and Trolox led to reduced PTX3 expression 
suggesting that in-vitro at least, PTX3 expression is regulated by antioxidants326. 
PTX3 and endothelial dysfunction 
Binding of P-selectin to P-selectin glycoprotein-1 expressed on the surface of 
neutrophils, facilitates rolling and tethering of neutrophils and transendothelial 
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migration to extravascular sites of inflammation. PTX3 binding to endothelial P-
selectin causes relocation of this molecule to the cell surface 327.  
PTX3 expression in response to ischaemia-reperfusion 
Increased serum levels of PTX3 have been recorded in patients and animals 
undergoing an ischaemic event, in the heart328, kidney329 or intra-abdominally330. 
In the lung, increased PTX3 levels have been associated with increased risk of 
primary graft dysfunction (a process in which ischaemia-reperfusion injury is 
implicated) after lung transplantation331. 
4.4.1.3 PTX3 in ALI/ARDS 
PTX3 in animal models of ALI/ARDS 
PTX3 is highly conserved in evolutionary terms, meaning results obtained from 
rodent studies are likely to be reflective of PTX3 activity in humans317, 319. 
Okutani et al determined PTX3 expression in the lung in a variety of rat models 
of ALI332. ALI was induced by either intravenous administration of 
lipopolysaccharide (LPS) or haemorrhage followed by resuscitation (HR) and rats 
were then subjected to high volume (12ml/kg, no PEEP) or low volume 
ventilation (6ml/kg, 5cmH2O PEEP). High volume ventilation enhanced PTX3 
expression in sham animals (no ALI) and in both models of ALI. Furthermore, the 
expression of PTX3 correlated with the severity of lung injury as determined by 
oxygenation, lung elastance and wet to dry ratio (r≥0.6; p<0.0001 for all). 
Importantly, the same signal was seen when PTX3 activity was quantified by 
measurement of PTX3 mRNA expression in the lung or PTX3 protein expression in 
lung or serum. In a second set of experiments, in order to evaluate the effect of 
injurious ventilation of PTX3 expression in isolation, ALI was induced by injurious 
ventilation (25ml/kg) or by LPS administration or by HR alone (i.e. no 
mechanical ventilation in LPS/HR groups).  Whilst LPS and HR induced little lung 
injury, injurious ventilation was associated with significant histological evidence 
of lung injury, increased wet to dry lung ratio and enhanced expression of 
PTX3332.  
He et al observed that PTX3 protein levels in bronchoalveolar lavage (BAL) fluid 
were associated with the severity of lung injury in a murine model333. Mice were 
subjected to increasing doses of intratracheal LPS administration.  He et al 
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additionally explored the interaction between PTX3 and tissue factor (TF) 
activity. TF activity was positively correlated with PTX3 expression. The authors 
then administered human anti-TF antibody to ‘humanised’ transgenic mice, 
subjected to the same LPS model. Lung injury was reduced as evidenced by 
reduced lung injury score and BAL cell count in antibody treated animals. 
Importantly antibody administration also reduced plasma TF activity and the 
expression of PTX3 in BAL fluid and lung tissue333. 
Real et al subjected genetically modified mice, both deficient and over 
expressing the murine PTX3 gene to lung injury induced by high tidal volume 
ventilation334. PTX3 deficient and wild type mice developed a similar degree of 
lung injury whilst PTX3 over expression led to more rapid development of lung 
injury334. These findings are in keeping with the hypothesised role of PTX3 in 
excess being responsible for causing enhanced injury.  
Pentraxin 3 in human ALI/ARDS 
Mauri et al measured plasma PTX3 levels in 21 patients with ALI/ARDS291. 
Pentraxin 3 levels on day one were observed to be significantly different 
between survivors and non-survivors (median 65 versus 100 ng/ml respectively; 
p=0.04), where SOFA and SAPS-II score were not. In addition, PTX3 levels 
correlated positively with lung injury score, number of organ failures and SOFA 
score.  BAL was performed ‘when clinically indicated’; BAL PTX3 levels were 
correlated with plasma PTX3 levels in 13 patients (r2=0.368; p<0.01)291.  
Pentraxin 3 as a candidate ALI/ARDS biomarker 
Though the literature surrounding PTX3 is in its infancy, there is much to suggest 
that PTX3 may have a role as a biomarker of lung injury. PTX3 has a biologically 
plausible role in the pathogenesis of ALI and being produced locally (though not 
exclusively) in the lung in response to tissue injury and inflammation has the 
potential to provide a more lung specific signal. Studies measuring PTX3 in 
pulmonary tissue (and mRNA), bronchoalveolar lavage specimens and plasma 
have provided similar results suggesting serum may be a safe and easily 
obtainable source for the sample291, 332. PTX3 has been associated with severity 
of illness in animal models of ALI332, 333 and in a single human study of patients 
with the condition291. In addition in humans PTX3 appears to be associated with 
ALI/ARDS mortality291. Furthermore, in animal models at least, PTX3 levels 
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appear to respond to therapeutic interventions (both low tidal-volume 
ventilation332 and anti-tissue factor antibody333). Though further testing is 
required, the early data suggests that PTX3 satisfies many of the requirements 
of the ‘ideal’ ALI biomarker. 
PTX as a biomarker of ALI after lung resection  
The pathogenesis of post-lung resection acute lung injury is discussed in detail in 
Chapter 1. There have been no reported studies of PTX3 as a biomarker of ALI in 
one-lung ventilation models of lung injury or in humans undergoing lung 
resection. Nonetheless, there are several features of the above discussion that 
make PTX3 an attractive candidate as a biomarker following lung resection. 
Firstly, the observation that PTX3 is induced by mechanical stretch and appears 
to behave as a biomarker of ALI in ventilator induced lung injury (VILI) models is 
suggestive, as VILI is implicated in the injury to the dependent, ventilated lung 
during lung resection. Secondly, the observation that PTX3 expression is 
regulated by red-ox balance; oxidative stress has been implicated in injury to 
both lungs during lung resection. Finally, the observation of increased PTX3 
expression following ischaemia and reperfusion, a mechanism responsible for 
injury to the non-ventilated, operative lung in all sub-total lung resections is 
suggestive of a potential role for PTX3 as a biomarker of lung injury following 
lung resection. 
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4.5 Methods 
This investigation comprises two discrete studies examining the utility of 
Pentraxin 3 (PTX3) and a multiple (lung injury) biomarker panel following lung 
resection. The PTX3 study was conducted in a cohort of 35 patients undergoing 
lung resection of presumed primary lung cancer, whilst the multiple biomarker 
panel study was conducted in a subset of 22 patients from the same cohort. The 
methods are presented as ‘generic methods’, which are common to both studies 
and then individually for each study. Comparison is made to the properties of 
the ‘ideal’ lung injury biomarker defined in Section 4.2.2 (Table 4.1). 
4.5.1 Generic Methods 
4.5.1.1 Ethical approval 
This study received ethical approval from the West of Scotland Research Ethics 
Committee 2 (REC reference 10/S0709/43). The additional measurement of the 
multiple biomarker panel was approved as a substantial amendment (AM-01).  
4.5.1.2 Patient population 
Thirty five patients undergoing elective lung resection at the Golden Jubilee 
National Hospital were recruited to the study by the author (Ben Shelley). 
Inclusion criteria were the provision of informed consent, age greater than 16 
years and planned elective open lung resection (by lobectomy or 
pneumonectomy) for presumed primary lung cancer. Patients were excluded if 
they were pregnant, had ongoing participation in any investigational research 
which could undermine the scientific basis of this study, were undergoing lung 
resection for non malignant disease or secondary malignancy, were planned to 
undergo a wedge / segmental lung resection, or a resection via a thoracoscopic 
/ minimal access technique or were taking over the counter ‘vitamin’ / 
‘antioxidant’ medication. 
All patients underwent a posterio-lateral muscle sparing thoracotomy, lung 
resection and meditational lymph node sampling as appropriate carried out by a 
single surgeon. Anaesthetic technique was standardised to total intravenous 
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anaesthesia with Propofol and Remifentanil; post-operative analgesia was 
provided by thoracic epidural blockade. Lung separation was achieved by double 
lumen endotracheal intubation (MallinckrodtTM, Medtronic, Dublin); the choice of 
left or right sided double-lumen endotracheal tube was left to the discretion of 
the anaesthetist responsible for the case. 
A smaller cohort of 22 patients were subsequently selected from the 35 patient 
cohort for the measurement of the multiple biomarker panel. This was a sample 
of convenience, with selection based simply on the availability of sufficient 
plasma samples to allow biomarker measurement. 
4.5.1.3 Laboratory sampling 
Biomarker sample handling 
Twenty millilitres of arterial blood was collected immediately prior to induction 
of anaesthesia (referred to hereafter as ‘pre-operatively’), immediately post-
operatively following admission to the post-operative care unit (‘post-
operatively’), and approximately 24 hours post-operatively in the high 
dependency unit (‘24 hours post-operatively’). All blood samples were taken 
from a radial arterial cannula where possible (routinely inserted prior to 
induction of anaesthesia), to avoid unnecessary venepuncture. Where an arterial 
cannula was no longer in situ at twenty-four hours post-operatively, a venous 
sample was obtained. Samples were collected in vacuum filled containers which 
were filled to the marked line. Samples were collected as follows: 
 1 x 4ml “LH Lithium Heparin” (Green top) tube (BD Vacutainer®) 
 2 x 4ml “Serum Sep Clot Activator (Yellow top) tube (BD Vacutainer®) 
All samples were transported to the clinical biochemistry laboratories at GJNH 
immediately after collection. One ‘yellow top’ (SST) bottle was processed as a 
routine clinical sample for the measurement of C-reactive protein (below). All 
other samples were centrifuged at room temperature immediately upon receipt, 
before plasma was manually separated and aliquoted into 0.5ml aliquots. 
Aliquots were frozen immediately and stored at -70oC prior to analysis.  
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4.5.1.4 Pre-operative data collection 
Patient demographics 
Patient demographics were collected prospectively at the time of recruitment by 
face to face questioning and by extraction of data from the patients’ ‘paper’ 
and ‘electronic’ medical notes. Data was collected on a dedicated case report 
form. 
Smoking history 
Smoking history was explored with the patient at recruitment. Patients were 
categorised into ‘current smokers’ (smoking regularly sometime in the last 
month), ‘ex-smokers’ (complete abstinence for greater than one month), and 
‘never smokers’. Smoking history was quantified in pack years according to 
standard formulae335.  
Pre-operative pulmonary function 
Data was extracted from routinely performed pulmonary function test (PFTs) 
results available within the paper or electronic medical record. When carried 
out at Golden Jubilee National Hospital, tests were performed by trained 
respiratory physiologists according to standard guidelines336-339.  Occasionally 
where PFTs were performed in the referring hospital, complete results were not 
available and results were extracted from referral letters. Where more than one 
set of PFTs had been performed, data was extracted from the most recent. The 
following parameters were collected: forced expiratory volume in one second 
(FEV1 - absolute value and as percent predicted), forced vital capacity (FVC), 
the ratio of FEV1 to FVC and diffusing capacity for carbon monoxide (DLCO - 
absolute and percent predicted). Oxygen saturation (on air at rest) was routinely 
recorded by nursing staff on admission to the ward pre-operatively.  
Pre-operative functional status 
At recruitment, a detailed history was taken from each patient concerning pre-
operative functional status. Patients were ‘talked through’ the World Health 
Organisation / Zubrod Performance status scale340, the New York Heart 
Association (NYHA) functional classification341 and the Medical Research Council 
(MRC) breathlessness scale342 in order to classify functional status. Detail was 
sought concerning limitation in exercise function or the performance of 
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activities of daily living in order to quantify pre-operative functional status in 
metabolic equivalents (METS) according to standard definitions343. 
Co-morbidities 
In the derivation of the Thoracoscore (below), number of co-morbidities was an 
independent predictor of hospital mortality344. In this study, 95% of the co-
morbidity was related to 10 major diagnoses; data was therefore sought on these 
10 co-morbidities.  Co-morbidities were defined either as described by Falcoz et 
al, or from accepted definitions as follows: 
1. Smoking addiction – defined as ‘currently smoking regularly or abstinent 
for less than one month’345346346346. 
2. History of cancer – history of diagnosis or treatment for any previous 
cancer (not including current presentation). 
3. Chronic obstructive pulmonary disease – defined as per the ‘Global 
Strategy for Management and Prevention of COPD (GOLD)’ (updated 
2010)346.  
4. Arterial hypertension – ‘either documented history of hypertension 
diagnosed and treated with medication, diet and/or exercise or currently 
on pharmacologic therapy to control hypertension’347. 
5. Heart disease – ‘history of either coronary artery disease (CAD) or 
congestive cardiac failure (CCF).  
 CAD as evidenced by one of the following: 
- Currently receiving medical treatment for CAD,  
- History of Myocardial Infarction,  
- Prior cardiovascular intervention including, but not 
limited to, CABG  and/or PCI347.  
 CCF - physician documentation or report of clinical symptoms of 
heart failure’347.  
6. Diabetes mellitus – ‘history of diabetes diagnosed and/or treated by a 
physician’347. 
7. Peripheral vascular disease - indicated by ‘claudication either with 
exertion or rest; amputation for arterial insufficiency; aorto-iliac 
occlusive disease reconstruction; peripheral vascular bypass surgery, 
angioplasty, or stent; documented AAA, AAA repair, or stent; positive 
non-invasive testing documented’347. 
8. Obesity – ‘Body mass index greater than 30’348. 
9. Alcoholism – ‘alcohol abuse was recorded if there was a documented 
(recent or ongoing) history of alcoholism or alcohol related medical 
diagnoses’. 
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10. Hyperlipidaemia – ‘history of hyperlipidaemia diagnosed and/or 
treated by a physician’. 
Pre-operative risk scoring 
American Society of Anaesthesiologists grade 
Following collection of demographic data, exploration of functional status and 
recording of patient co-morbidities, a subjective assessment of American Society 
of Anaesthesiologists (ASA) grade was made by the author (Ben Shelley).  
Thoracoscore 
The Thoracoscore was described by Falcoz et al, who derived the score in 15,183 
patients undergoing thoracic surgery349. The score is derived by calculation from 
a regression equation where coefficients are awarded based on parameters 
found to be significantly associated with in-hospital death on multivariate 
analysis:  patient age, sex, MRC dyspnea score, American Society of 
Anesthesiologists score, WHO/Zubrod performance status classification, priority 
of surgery (elective / urgent or emergency), diagnosis group (benign/malignant), 
procedure class (pneumonectomy / other), and the presence of comorbid 
disease (number of co-morbidities from the ten described above)349. 
Surgical Lung Injury Prediction score 
The Surgical Lung Injury Prediction score (SLIP), was described by Kor et al, who 
derived the score in 4366 patients undergoing surgery with anaesthesia lasting 
greater than three hours105. The score is easily calculated from readily available 
pre-operative risk factors spread over three domains: high risk surgical 
procedures (cardiac, vascular and thoracic), co-morbidities (diabetes mellitus, 
COPD or gastro-oesophageal reflux disease) and modifying conditions (alcohol 
abuse). In the derivation cohort (which included 646 thoracic surgical patients, 
19 of whom developed lung injury), the SLIP was able to predict patients who 
developed early post-operative ALI with an area under the receiver operating 
characteristic curve of 0.82 (95% CI 0.78-0.86)105. 
SLIP was determined per the description of Kor et al105 with the following 
exceptions:  
1. Alcohol abuse was recorded if there was a documented (recent or 
ongoing) history of alcoholism or alcohol related medical diagnoses, or the 
Chapter 4  199 
patient reported drinking greater than 28 units of alcohol per week (in 
keeping with Kor et al’s definition of “more than 14 alcohol-containing 
drinks per week”)105. 
2. The incidence of gastro-oesophaeal reflux disease (GORD) was not 
collected prospectively; as such the regular prescription of an H2 receptor 
antagonist or proton pump inhibitor was recorded as a surrogate of GORD. 
4.5.1.5 Intra-operative data collection 
Intra-operative ventilatory parameters 
Ventilatory parameters were collected continuously (and automatically) for the 
duration of the anaesthetic by the Recall AIMS electronic anaesthetic charting 
system (Informatics Clinical Information Systems Limited, Glasgow); data is 
recorded by the system at approximately 20 second intervals. Data concerning 
tidal volume (VT), peak airway pressure (Ppeak) and fraction of inspired oxygen 
(FiO2), were extracted against time, both for the duration of the operation, and 
during the period of one-lung ventilation (OLV). The area under the parameter 
vs time curve was determined in Microsoft Excel by the trapezoidal method in 
order to provide an index of cumulative exposure to each variable.  
Duration of surgery and one-lung ventilation 
Time of commencing anaesthesia was determined as the onset of consistent, 
stable end-tidal carbon dioxide (ETCO2) recording (representing intubation). 
Similarly extubation (anaesthetic end) was determined as the time that ETCO2 
recording was lost. In most cases the start and end of the period of one-lung 
ventilation were prospectively recorded in the RECALL system by the primary 
anaesthetist. Where this was not recorded, the onset and offset of OLV were 
determined by manual inspection of the VT, Ppeak and ETCO2 vs time curves.  
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4.5.1.6 Post-operative data collection 
Clinical endpoints 
Oxygenation 
The ratio of partial pressure of arterial oxygen (PaO2) to fraction of inspired 
oxygen (FiO2) (PaO2/FiO2 ratio) was derived from routinely measured arterial 
blood gas analyses (Siemens RAPIDLAB®, Siemens, Munich, Germany). PaO2 was 
not adjusted for patient temperature. The timing and frequency of arterial 
blood gas analysis was not protocolised.  
The fraction of inspired oxygen (FiO2) was recorded at the time of arterial blood 
gas analysis by the HDU nurses. Oxygen therapy was either provided by facemask 
via a humidified KendallTM Nebulizer Adapter (Covidien, Dublin, Ireland), where 
FiO2 was estimated according to the set FiO2 on the venture device or via nasal 
cannulae (Intersurgical, Wokingham, Berkshire) where FiO2 was estimated 
according to Table 4.4. 
Table 4.4. Estimation of FiO2 based on nasal cannula flow. 
Oxygen flow rate (L/min) Estimate FiO2 (%) 
1 
2 
3 
4 
24 
28 
32 
36 
 
In order to examine trends in oxygenation over time, and determine oxygenation 
contemporaneously with chest x-ray and biomarker sampling, mean PaO2/FiO2 
ratio was determined in 6 hourly segments; PaO2/FiO2 ratio at 6 hours post-
operatively was determined as mean PaO2/FiO2 ratio of all ABGs obtained from 
3:00-8:59 (hours:minutes) post-operatively. Mean PaO2/FiO2 ratios at 12, 18, 24, 
30, 36 and 42 hours post-operatively were determined in the same manner. 
In order to allow assessment of oxygenation in patients where ABG results were 
not available, or at time points where ABG sampling was not performed, the 
ratio of saturation of oxy-haemoglobin (SaO2) to FiO2 was determined 
(SaO2/FiO2). SaO2 and FiO2 are collected routinely in the hospital critical care 
electronic records system (Centricity CIS, GE Healthcare, Wilmington, 
Massachusetts), and so were available at the vast majority of time points. 
SaO2/FiO2 has been advocated as a surrogate for PaO2/FiO2 ratio in the diagnosis 
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of ALI/ARDS when PaO2/FiO2 ratio is unavailable
350, 351. Rice et al compared 
SaO2/FiO2 to PaO2/FiO2 ratio in 1074 patients with ARDS, demonstrating (in their 
derivation cohort; 672 patients, 2673 data points) that there was a strong linear 
relationship between PaO2/FiO2 and SaO2/FiO2 ratio (SaO2/FiO2 ratio = 64 + 0.84 
x [PaO2/FiO2]; r=0.89; p<0.0001)
350. Prior to use of SaO2/FiO2 as a study 
endpoint, the validity of SaO2/FiO2 as a surrogate for PaO2/FiO2 in this cohort 
was explored. PaO2/FiO2calculated was calculated from SaO2/FiO2 and compared to 
paired measured values of PaO2/FiO2 (PaO2/FiO2measured) by testing of linear 
association and Bland-Altman analysis. 
PaO2/FiO2 ratio and SaO2/FiO2 ratio were analysed both as continuous variables, 
and dichotomised into groups with PaO2/FiO2 ratio <300 and ≥ 300mmHg 
(equivalent SaO2/FiO2 ratio <316 or ≥316) in order to identify cohorts of patients 
with ‘good’ and ‘poor’ post-operative oxygenation. 
Chest X-ray scoring 
Chest X-ray scores were dual reported by the author (Ben Shelley, BS), and Dr 
Oona Tanner (OT - specialist trainee in anaesthesia, West of Scotland School of 
Anaesthesia and advanced intensive care medicine trainee). Images were 
provided to the reviewers in electronic format, anonymised and randomised by 
the hospital Picture Archiving and Communication System (PACS) administrator 
who had no other role in the conduct of the study. Image analysis took place in 
one sitting. Images were viewed electronically on the Centricity DICOM viewer 
v3.1.2 (GE Healthcare, Wilmington, Massachusetts). As neither the author nor Dr 
Tanner had any direct clinical role in caring for the study patients, neither 
reviewer had seen any of the images in any context prior to analysis. 
In line with the findings of Meade at al352  and the recommendations of the ARDS 
Definition Task Force66, a ‘consensus process’ was undertaken prior to X-ray 
scoring. Following agreement on a scoring system, BS and OT worked through the 
training guide “Chest X-Ray Interpretation for the Diagnosis of ARDS” provided 
by the ARDS Definition Task Force66, initially scoring films independently, and 
then together allowing discussion of the reasons for discrepancy and consensus 
to be reached concerning the application of the scoring proforma. 
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Chest X-rays were reported according to a novel scoring system devised by the 
author (Ben Shelley). Reporters were first asked to confirm the technical 
acceptability of the CXR film and to count the number of ‘scoreable’ quadrants 
of the X-ray. In this way, quadrants where lung had been excised (e.g. the two 
quadrants of a hemi-thorax where pneumonectomy had taken place) or where 
there was residual pneumothorax (e.g. incomplete re-expansion of residual lung 
tissue following lobectomy) were excluded from scoring.  
Reporters were then asked to score the presence of opacities in each ‘scoreable’ 
quadrant. Opacities  were defined as “opacities consistent with pulmonary 
edema (may be very mild, patchy, and asymmetric) that are not fully explained 
by pleural effusions, pulmonary nodules or masses, or lobar/lung collapse (i.e., 
radiographically consistent with the diagnosis of ARDS)” as per the guidance 
provided by the ARDS Definition Task Force66. 
Rather than simply scoring presence or absence of opacity, in order to provide 
more sensitive discrimination between images, scores (per quadrant) were then 
awards according to the intensity of infiltrate as previously advocated by Yang et 
al and Ahn et al 166, 218 (Table 4.5). 
Table 4.5. Awarding of scores during chest X-ray scoring. 
 Score 
No opacities 0 
Presence of opacities occupying: 
<1/3 of the quadrant 
1/3 to 2/3 of the quadrant 
>2/3 of the quadrant 
 
1 
2 
3 
 
Quadrant scores were added to provide an overall score. This score was then 
corrected according to the number of ‘scoreable’ quadrants to provide a total 
CXR score (minimum score = 0, maximum score = 12). The mean of the reviewers 
overall scores was then calculated to provide a ‘combined’ score which was used 
for analysis. 
Modified Lung injury score 
Lung injury score (LIS) was calculated in line with the principals of the original 
LIS described by Murray et al54. This was modified by the author (Ben Shelley) to 
allow use in the early post-operative period following lung resection as follows: 
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Oxygenation 
Oxygenation was determined as described above. Where PaO2/FiO2 was not 
available, SaO2/FiO2 was substituted according to the cut points described in 
Table 4.6. 
Chest radiography score 
Chest X-ray interpretation for the derivation of the lung injury score as originally 
described is derived as a simple count of the number of CXR quadrants 
containing ‘alveolar consolidation’. CXR scoring for derivation of the LIS was 
performed alongside scoring for CXR score detailed above. The number of 
quadrants in which opacities of any extent (consistent with the definitions of the 
ARDS Definition Taskforce) were observed was counted, and similarly corrected 
based on the number of ‘scoreable’ quadrants. Again a mean ‘combined’ score 
calculated from each review’s score was used for analysis. Use of a combined 
score for analysis allowed for non integer values of the overall modified LIS 
(mLIS). 
Table 4.6. Derivation of the ‘modified’ Lung Injury Score (mLIS) 
Chest X-ray score  
 Quadrant score 
No opacities consistent with pulmonary oedema  
Opacities consistent with pulmonary oedema confined to 1 quadrant 
Opacities consistent with pulmonary oedema confined to 2 quadrants 
Opacities consistent with pulmonary oedema confined to 3 quadrants 
Opacities consistent with pulmonary oedema confined to 4 quadrants 
0 
1 
2 
3 
4 
  
Overall CXR score derived as (quadrant score / number of ‘scoreable’ 
quadrants) x 4 
 
  
Hypoxaemia score   
(based on SaO2/FiO2 only if PaO2/FiO2 not available) Score 
PaO2/FiO2  ≥300 
PaO2/FiO2 225-299   
PaO2/FiO2 175-224    
PaO2/FiO2 100-174   
PaO2/FiO2   <100     
 (or SaO2/FiO2 ≥316)  
 (or SaO2/FiO2 253-315)  
 (or SaO2/FiO2 211-252)  
 (or SaO2/FiO2 148-210)  
 (or SaO2/FiO2 <148) 
0 
1 
2 
3 
4 
  
Total score = (Overall CXR score + Hypoxaemia score) / 2  
  
 
 
PEEP and Compliance 
No patients in the cohort required positive pressure ventilation in the first 48 
hours post-operatively and so no ‘PEEP score’ nor ‘Compliance score’ would be 
available.  
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Ventilatory support 
Ventilatory support was defined as any of intubation and mechanical ventilation, 
non-invasive ventilation or high flow nasal oxygen during the first 48 hours post-
operatively.  The airway interface is routinely recorded in the CIS critical care 
unit electronic charting system and so need for ventilatory support could be 
deduced by interrogation of the database. 
Length of stay 
High dependency unit stay 
High dependency unit (HDU) admission was defined as the time of the first 
recorded oxygen saturation recorded in the CIS critical care unit electronic 
charting system. As the timing of actual discharge from the HDU can vary 
considerably from the time of fitness for discharge for logistical reasons (such as 
time of day and availability of ward beds), for the purposes of this study, HDU 
discharge was defined as the time continuous oxygen saturation recording 
ceased. This is believed to reflect the timing of ‘step-down’ of perceived patient 
dependency (e.g. level 1 patients nursed in the HDU are often stepped down to 
four hourly intermittent vital signs observations rather than the continuous 
monitoring that is provided to level 2 patients). One patient was admitted from 
HDU to the intensive care unit and subsequently died. HDU stay for this patient 
was right censored and the patient given a value equivalent to the longest 
recorded length of stay.  
Hospital stay 
Whilst it is routine for patients to be admitted to our institution on the day 
before major lung resection, again for logistical reasons some patients are 
admitted earlier (e.g. some patients travel a considerable distance to access 
care at Golden Jubilee National Hospital and as such are often admitted for 
several days pre-operatively to allow time for clinical investigations and pre-
operative assessment). ‘Hospital stay’ for the purposes of the study was 
therefore defined as ‘post-operative’ hospital stay, that is the number of days 
elapsed between the day of surgery and the day of discharge. One patient died 
in hospital; hospital stay for this patient was right censored and the patient 
given a value equivalent to the longest recorded length of stay. 
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4.5.2 Utility of Pentraxin 3 as a biomarker of post-lung resection 
lung injury 
4.5.2.1 Biomarker measurement 
Pentraxin 3 measurement 
Pentraxin 3 was measured in duplicate using the commercially available ‘Duo 
Set’ enzyme immunoassay system (R and D Systems Europe Ltd, Abington, Oxon, 
UK) within the laboratories of Aberdeen University Academic Unit of Anaesthesia 
and Intensive Care under the supervision of Professor Helen Galley. 
Briefly, 96 well plates were prepared by coating with anti-PTX3 monoclonal 
antibody (the ‘capture’ antibody) and incubating overnight. Following washing, 
100μL recombinant human PTX3 (as a calibration standard) or plasma was added 
to each well. After incubation for 2 hours, plates were then washed again and 
then incubated with a biotinylated anti-PTX3 polyclonal antibody (the 
‘detection’ antibody) for 40 minutes. Following a further wash, samples were 
incubated for an hour with streptavidin-horseradish peroxidise, then a 
chromagen substrate, before the reaction was stopped by administration of 
hydrochloric acid. The reaction was then quantified spectrophotometrically at a 
wavelength of 450nm. A standard curve was generated from the averaged 
calibration standards, from which sample results were determined by comparing 
the optical density of the samples to the standard curve. The coefficient of 
variation of this assay was 5.7%. 
C-reactive protein measurement 
Samples for measurement of CRP were processed as routine clinical samples in 
the clinical biochemistry laboratories at Golden Jubilee National Hospital under 
the supervision of Dr Frank Findlay. CRP was determined by enhanced 
immunoturbidimetric assay run on a Roche Cobas 6000 analyser. The reference 
range is <10mg/L, with a lower limit of detection of 1.0 mg/L and a coefficient 
of variation (CV) of 1.72% at a CRP level of 18.9mg/L and CV of 1.75% at CRP 
level of 42.6 mg/L. 
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4.5.2.2 Comparison with the properties of the ideal ALI biomarker 
Sensitivity and specificity in predicting outcomes of interest  
The sensitivity and specificity of PTX3 in predicting increased modified lung 
injury score (mLIS), oxygenation and CXR score was assessed both 
contemporaneously (PTX3 measurement simultaneously with oxygenation, CXR 
score and mLIS measurement), reflecting ‘diagnostic’ value of PTX3 and in 
respect to future values (biomarker levels 24 hours post-operatively and 
oxygenation, CXR score and mLIS measurement between 24 and 48 hours post-
operatively) reflecting ‘prognostic’ value of the biomarker. 
Specifically, in order to examine the diagnostic value of PTX3, comparison was 
made between plasma PTX3 concentration 24 hours post-operatively and 
PaO2/FiO2 24 hours post-operatively and CXR score and mLIS at approximately 24 
hours postoperatively (on post-operative day one). In order to examine the 
prognostic value of PTX3, plasma PTX3 concentration 24 hours post-operatively 
was compared with ‘worst recorded’ oxygenation from 24-48 hours post-
operatively and CXR score and mLIS recorded on post-operative day two. 
Variation in proportion to the severity of injury 
To examine whether PTX3 or CRP levels vary in proportion to the severity of 
oxygenation impairment, association was sought between PaO2/FiO2 ratios at 24 
hours post-operatively (as a continuous variable) with biomarker levels 
determined 24 hours post-operatively. To examine whether PTX3 or CRP levels 
vary in proportion to the severity of chest x-ray score, post-operative day one 
CXR-scores (as a continuous variable) were compared with biomarker levels 
determined 24 hours post-operatively. 
Modification by an effective intervention 
The volume of lung tissue resected (or ‘size’ of the resection)127, 128, and the 
duration and conduct of one-lung ventilation128, 151, 152 have all been associated 
with increased incidence of PLR-ALI. As such a lesser lung resection, shorter 
duration of one-lung ventilation and a lung protective ventilatory strategy might 
be considered ‘effective interventions’ to which association might be expected 
of the ‘ideal’ ALI biomarker. Association was therefore sought between 
biomarker levels and the volume of lung resected, the duration of one-lung 
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ventilation and ventilatory parameters (peak airway pressure (Ppeak), tidal 
volume (VT) and fraction of inspired oxygen (FiO2) during the period of one lung 
ventilation).  
Volume of lung resected was characterised in two ways. Firstly, resections were 
divided into sub-lobar resectionK, lobectomy (including bilobectomy), and 
pneumonectomy. Secondly, to allow distinction between the anatomically larger 
lobar resections (e.g. right lower or left upper lobe - 5 segments) and smaller 
resections (isolated right middle lobectomy – 2 segments), the number of 
segments resected was calculated from the operation note based on a 19 
segment model of pulmonary anatomy. The number of segments resected was 
not amenable to division into quartiles (as the nine patients having 5 segments 
resected would necessitate an arbitrary quartile division in the middle of this 
group), therefore patients were divided into tertiles by number of pulmonary 
segments resected. For this analysis patients undergoing sub-lobar resection 
were excluded. 
The duration of one-lung ventilation (in minutes) and the areas under the Ppeak, 
VT and FiO2 verses time curves (section 4.5.1.5 – endpoints, intra-operative data) 
were divided into quartiles and association sought between quartiles and 
biomarker levels. 
Association with clinically important outcomes  
Association was sought between biomarker levels and ‘clinically important 
outcomes’, defined as the need for ventilatory support, and the duration of high 
dependency unit (HDU) and hospital stay. An HDU stay of greater than 48 hours 
was defined as ‘prolonged’ and biomarker levels compared between patients 
with an HDU stay of 48 hour or less, or greater than 48 hours. 
                                         
K
 Though the inclusion / exclusion criteria were explicit in recruiting patients planned to undergo 
lobectomy or pneumonectomy, on five occasions sub-lobar resection was performed. These 
patients were not excluded from the analyses in order not to compromise what was already a 
modest sample size. They do however constitute a cohort in which the surgical insult might be 
considered less severe. 
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4.5.2.3 Statistical handling 
All groups containing less than 10 patients were assumed to be non-parametric in 
distribution. Otherwise, data was tested for normality and the presence of 
outliers by visual inspection of box plots and by Shapiro-Wilk testing.  
Comparisons of parametrically distributed biomarker levels between groups were 
made using an independent-samples t-test using Levene’s test for equality of 
variances, or one way analysis of variance as appropriate. Comparisons of non-
parametrically distributed biomarker levels between groups were made with the 
Mann-Whitney U test or Kruskal-Wallis test as appropriate. Post-hoc testing was 
performed by least significant difference or Dunn’s procedure as appropriate. 
Linear association between continuous variables were assessed using Pearson 
correlation or Spearman’s rho as appropriate. 
Predictive value of the biomarkers for outcomes of interest was determined by 
the generation of receiver operating characteristic (ROC) curves, and the 
corresponding area under the curve (AUC). The optimal cut-off biomarker level 
was defined by calculation of the point at which the sum of sensitivity and 
specificity was maximal (Youden’s index). Positive and negative predictive 
values (PPV and NPV respectively) were then calculated as follows: 
 
Equation 4.1 
   
 
Equation 4.2 
  
Statistical analysis was performed using SPSS Statistics v21 (IBM Corporation, 
Armonk, New York). No adjustments were made for multiple comparisons. 
4.5.2.4 Power 
There have been no previous reports of the measurement of PTX3 in patients 
undergoing lung resection. The sample size of 35 constitutes a sample of 
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convenience for what must be considered a ‘hypothesis generating’ pilot study. 
On discussion between the author (Ben Shelley), the project supervisor 
(Professor John Kinsella) and statistical advisors from the Robertson Centre for 
Biostatistics (University of Glasgow), it was concluded this sample size should be 
adequate to detect ‘a signal’. Without conducting a pilot study in a modest 
sample size such as this, and at least confirming the presence of a detectable 
increase in PTX3 level following lung resection, it was felt there was insufficient 
grounds for recruitment of a larger cohort. 
 
4.5.3 Utility of a multiple lung injury biomarker panel following 
lung resection  
4.5.3.1 Composition of the panel 
Fremont et al described a 7 biomarker panel derived from 192 patients admitted 
to a trauma intensive care unit83. The composition of the 7 biomarker panel 
described by Fremont et al is detailed in Table 4.7: 
Table 4.7. Multiple biomarker panel as defined by Fremont et al (2010)
83
 
 
Biomarker  Source / Pathobiology  
Receptor  for Advanced Glycation End Products 
(RAGE)  
Epithelium (type 1 
pneumocyte)  
 
Procollagen Peptide III (PCP-III)  Fibroblast (collagen deposition)  
Angiopoietin 2 (Ang 2)  Endothelium  
Interleukin 6 (IL-6)  Pro-inflammatory cytokine  
Tumour Necrosis factor   (TNFa) Pro-inflammatory cytokine  
Interleukin  10 (IL-10) Anti-inflammatory cytokine  
B-type Natriuretic Peptide (BNP) Ventricular myocyte  
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4.5.3.2 Multiple biomarker panel measurement 
Single measurements for each marker in the multiple biomarker panel were 
performed by trained post-doctoral research assistants in the laboratories of 
Glasgow Biomedical Research Centre, University of Glasgow under the 
supervision of Dr Charles McSharry (Principal Clinical Scientist). All 7 biomarkers 
were measured using commercially available enzyme immunoassays.  
Receptor for advance glycation end product (RAGE), interleukins 8 and 10 (IL-8 & 
-10), Angiopoietin 2 (Ang-2) and Tumour Necrosis Factor alpha (TNF-α) were 
measured using the commercially available ‘Quanitkine’ enzyme immunoassay 
system (R and D Systems Europe Ltd, Abington, Oxon, UK). Pro-collagen peptide 
III (PCP-III) and B-type Natriuretic Peptide (BNP) were measured using 
commercially available enzyme-linked immunosorbent assays (Caltag 
Medsystems Ltd, Buckingham, UK). Both manufacturers employ a quantitative 
sandwich enzyme immunoassay technique. Briefly, a microplate is provided by 
the manufacturer, pre-coated with monoclonal antibody specific for the 
biomarker of interest. In a series of wash / incubation cycles, samples or 
calibration standards were added to the plate, incubated with an enzyme linked 
monoclonal antibody specific for the marker of interest, and incubated with a 
substrate solution.  The reactions were then quantified spectrophotometrically 
at a wavelength of 450nm. A standard curve was generated from the averaged 
calibration standards, from which sample results were determined by comparing 
the optical density of the samples to the standard curve. The precision of these 
assays wereL: RAGE 3.6%, IL-8 4.5%, Ang-2 7.7%, TNF-α 6.9%, PCP-III 15.6%, BNP 
14.3%.  
Generation of a risk of lung injury score 
Fremont et al derived this seven biomarker panel in a cohort of 192 patients 
admitted to a trauma intensive care unit 83. Plasma levels of 21 acute lung injury 
biomarkers were compared between 107 patients with ALI/ARDS (per the AECC 
definition) and 74 controls either with no or hydrostatic pulmonary oedema. 
Following univariate analysis, a backward elimination model was used to select 
                                         
L
 As the biomarkers were only determined by singular measurement, the CV described represents 
a CV determined from the duplicate measurement of the calibration controls, not the entire data 
set. 
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the seven biomarkers with the greatest predictive value. A multivariable logistic 
regression model was then constructed using these seven biomarkers to create a 
prediction model for ALI/ARDS (Figure 4.3). 
In this model, a value of each biomarker corresponds to a points scale (at the 
top of Figure 4.3). The sum of the individual biomarker points scores is then 
calculated, providing a total points score, which then corresponds to a 
probability for the diagnosis of ALI (at the bottom of Figure 4.3). In the current 
investigation, the prediction model provided by Fremont et al (Figure 4.3) was 
blown-up, and printed onto graphing paper allowing scores to be derived from 
individual patient biomarker levels.  
The total point score, derived in this way was then treated as a continuous 
variable in subsequent analyses. As the pre-test probability for the diagnosis of 
ALI in the study population (elective thoracic surgical patients) differs from that 
studied by Freemont et al (trauma intensive care patients), the ‘probability of 
ALI’ (bottom section of the model in Figure 4.3) for individual subjects was not 
calculated. 
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Figure 4.3. A prediction model for the probability of ALI.  
From Freemont et al (2010)
83
.  
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4.5.4 Comparison with the properties of the ideal ALI biomarker 
As in the investigation of Pentraxin 3, scores derived from the multiple 
biomarker panel were compared with the properties of the ideal ALI biomarker. 
Briefly, sensitivity and specificity of post-operative biomarker scores in 
predicting mLIS were sought and quantified as the area under the receiver 
operating characteristic curve. Association was determined between panel 
scores and the severity of post-operative oxygenation impairment and CXR score. 
The hypothesis that post-operative changes in biomarker panel score would be 
reduced in proportion to the volume of lung tissue resected, the duration of one-
lung ventilation and indices of lung protective ventilation (factor previously 
described as being independent predictors of the severity of lung injury) was 
tested. Finally association was sought between biomarker panel scores and the 
length of HDU and hospital stay. Statistical handling was as described in the 
PTX3 investigation.  
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4.6 Results – Biomarkers of ALI following lung resection 
4.6.1 Patient demographics  
Thirty five patients undergoing lung resection were recruited to the study. One 
patient was excluded as their tumour was found not to be resectable at 
thoracotomy and so no lung resection was performed, and one patient was 
excluded because (contrary to the surgical plan at the time of recruitment), lung 
was resected via a video assisted thoracoscopic technique. Demographic and 
pre-operative data for the remaining 33 patients are shown in Table 4.8. 
Surgical, length of stay and mortality data are shown in Table 4.9. 
4.6.2 Clinical outcomes 
4.6.2.1 Oxygenation following lung resection 
Arterial blood gas acquisition was not protocolised; arterial blood gas results 
displayed are therefore those taken when clinically indicated. Similarly, whilst 
placement of an arterial cannula is routine practice in patients undergoing 
thoracic surgery in our institution (and therefore all patients had an arterial 
cannula placed immediately pre-operatively), the maintenance of the cannula, 
the decision to remove it, and the decision whether to replace it if dislodged 
was that of the clinical team. Arterial blood gas data (and therefore PaO2/FiO2) 
was not available at any post-operative time point in 6 patients. In the 
remaining 27 patients, data was available with variable frequency. Median 
PaO2/FiO2 recorded for the study group as a whole is displayed over time in 
Figure 4.4. Each time point represents PaO2/FiO2 results obtained over the 6 
hour window three hours either side of the recorded value (or from 0 to 3 hours 
post-operatively for the ‘<3’ time point). Where more than one result was 
available in a given time-point, the mean value was computed and used for 
analysis. 
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Table 4.8. Demographic and pre-operative data for the study population 
Characteristics n  Frequency 
Patient demographics 
Age (years) 
Male sex  
Height (cm) 
Weight (kg) 
Body mass index 
 
33 
33 
33 
33 
33 
 
69.7 (61.1-69.7 [35.3-81.9]) 
17 (51.5%) 
165.4 (9.8) 
71.8 (14.8) 
26.1 (4.6) 
Smoking history  
Current smoker 
Pack years history 
 
33 
32 
 
11 (33.3%) 
38.0 (20.5-76.0 [0-158.0]) 
 
Pre-operative pulmonary function 
Forced expiratory volume1 (FEV1) (L) 
FEV1/Forced vital capacity (FVC) (%) 
FEV1 % predicted 
PPO FEV1 % predicted 
DLCO (mmol/min/kPa) 
DLCO % predicted 
PPO DLCO % predicted 
Oxygen saturation on air (%) 
 
33 
31 
33 
33 
27 
29 
29 
33 
 
2.0 (1.7-2.7 [0.9-3.9]) 
67.0 (60.0-71.0 [37.5-86.0]) 
83.0 (74.5-98.5 [30.0-117.0]) 
69.1 (54.2-78.2 [23.7-94.8]) 
5.6 (4.5-8.0 [3.1-9.5]) 
66.0 (57.5-91.5 [38.0-109.0]) 
54.7 (50.0-64.1 [33.7-106]) 
97 (96-98 [93-100]) 
 
Pre-operative functional status 
Zubrod Performance Status (0-4) 
NYHA (1-4) 
MRC dyspnoea scale (0-5) 
Estimated exercise tolerance  
(<4, 4-6, >6 metabolic equivalents) 
 
33 
33 
33 
 
33 
 
14 (42.4%) / 16 (48.5%) / 3 (9.1%) / 0 / 0 
15 (45.5%) / 14 (42.4%) / 4 (12.1%) / 0 
16 (48.5%) / 7 (21.2%) / 9 (27.3%) / 1 (3%) / 0 / 0 
 
9 (27%) / 16 (49%) / 8 (24%) 
 
Co-morbidities 
History of cancer 
COPD 
Essential hypertension 
Heart disease 
Diabetes mellitus 
Peripheral vascular disease 
Obesity  
Alcoholism 
Hyperlipidaemia 
 
Total no. of co-morbidities per patient
A
 
 
33 
33 
33 
33 
33 
33 
33 
33 
33 
 
33 
 
12 (36%) 
21 (64%) 
11 (33%) 
7 (21%) 
1 (3%) 
0 (0%) 
6 (18%) 
6 (18%) 
14 (42%) 
 
3.0 (1.5-4.0 [0-6]) 
 
Risk scores 
ASA (≥III) 
Thoracoscore (% predicted mortality) 
Surgical lung injury prediction score 
(SLIP) 
 
33 
33 
33 
 
15 (46%) 
1.9 (1.5-3.7 [0.5-16.2]) 
26 (16-33 [10-37]) 
Values are number (%) mean (SD) or median (IQR [range]). n
 
- number of patients from which 
result is derived
. A
Of the ten co-morbidities described in the derivation of Thoracoscore
344
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Table 4.9. Surgical, length of stay and mortality data for the study population 
Characteristic n Frequency 
Resection type 
Pneumonectomy 
Extended lobectomy 
Simple lobectomy 
Sub-lobar 
 
No of pulmonary segments resected 
33 
 
 
 
 
 
33 
 
5 (15%) 
2 (6%) 
22 (67%) 
4 (12%) 
 
4 (3-5 [0-10]) 
Right sided procedure 33 15 (45.5%) 
   
Duration of surgery (minutes) 33 162.9 (29.7) 
Duration of one-lung ventilation (minutes) 32 75.1 (24.2) 
   
Pathology 
Primary lung cancer 
Other (benign / malignant) 
33  
30 (91%) 
1 (3%) / 2 (6%)  
Lung cancer staging 
IA 
IB 
IIA 
IIB 
IIIA 
IIIB 
IV 
30  
7 (21%) 
9 (27%) 
1 (3%) 
2 (6%) 
10 (29%) 
1 (3%) 
0 
   
Length of stay   
            Length of HDU stay (hours) 33 44.5 (40.9-46.5 [39.0-493.5]) 
            Length of hospital stay (days) 33 7 (5.8-9.3 [4-16]) 
   
Mortality   
            Hospital mortality 33 1 (3.0%) 
Values are number (%), mean (SD) or median (IQR [range]). n
 
- number of patients from which 
result is derived. 
 
 
Figure 4.4 Median PaO2/FiO2 (mmHg) ratio recorded post-operatively.  
Values in the accompanying table represent the number of patients results (n) from which the 
median is derived. 
Chapter 4  217 
‘Poor’ post-operative oxygenation was defined as PaO2/FiO2 less than 300mmHg. 
The number of patients with PaO2/FiO2 values recorded as ‘poor’ at any given 
time point are displayed in Figure 4.5. 
 
Figure 4.5. Number of patients with ‘poor’ oxygenation at any given time point post-
operatively.  
‘Poor’ post-operative oxygenation defined as PaO2/FiO2 < 300mmHg. 
Visual inspection of Figures 4.4 and 4.5 suggests a similar trend. Patients appear 
to have relatively low PaO2/FiO2 ratio in the early post-operative period (and 
accordingly more patients have ‘poor oxygenation’), which improves by 12 hours 
post-operatively where PaO2/FiO2 appears to peak (low numbers of patients with 
‘poor’ oxygenation). Subsequently oxygenation appears to fall, with a nadir 
mean PaO2/FiO2 ratio recorded 18-24 hours post-operatively and a further peak 
in the number of patients recorded as having ‘poor’ oxygenation. 
Validity of SaO2/FiO2 ratio as a surrogate for PaO2/FiO2 ratio 
following lung resection 
Two hundred and fifteen paired PaO2/FiO2 and SaO2/FiO2 data points were 
available for analysis (representing data from 29 individual patients) over a 
range of PaO2/FiO2 from 70 to 940 mmHg and SaO2/FiO2 from 97 to 459. SaO2 
varied from 85 to 100%. There was a highly significant positive association 
between PaO2/FiO2measured and PaO2/FiO2calculated  (where PaO2/FiO2calculated  is 
calculated from SaO2/FiO2 according to the relationship described by Todd et 
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al350), but this was only moderate in strength (r=0.68, p<0.0001; n=215; Figure 
4.6). 
 
Figure 4.6. Association between measured and calculated values of PaO2/FiO2  following 
lung resection. 
 Line represents line of identity. r=0.68; p<0.0001; Spearman’s rho. n=215. 
 
 
Bland-Altman analysis revealed a mean bias (PaO2/FIO2measured – PaO2/FiO2calculated) 
of +55.0mmHg with limits of agreement of between +256.9 and -146.9mmHg 
(Figure 4.7). 
 
 
Figure 4.7. Bland-Altman analysis of the agreement between measured and calculated 
values of PaO2/FIO2.  
Solid line represents mean bias, dashed lines represent limits of agreement (±2SD).  
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Due to the (clinically) unacceptable level of bias between PaO2/FiO2measured and 
PaO2/FiO2calculated in this population, subsequent analysis of SaO2/FiO2 as a 
surrogate of post-operative oxygenation was abandoned. Visual inspection of 
Figure 4.6 suggests the linear relationship between PaO2/FiO2 and SaO2/FiO2 is 
compromised as oxygenation improves. Rice et al’s original validation of the 
relationship between PaO2/FiO2 and SaO2/FiO2 ratio was performed in patients 
with ARDS and SaO2 ≤ 97%350. Restricting the comparison of PaO2/FiO2measured and 
PaO2/FiO2calculated in the current study to values where SaO2 levels were ≤ 97% 
improved the strength of the association between variables markedly (r=0.96; 
p<0.0001; Spearman’s rho; Figure 4.8). 
 
Figure 4.8. Association between measured and calculated values of PaO2/FiO2 following 
lung resection when SaO2 ≤ 97%.  
Solid line represents line of identity. r=0.96; p<0.0001; Spearman’s rho. n=68. 
 
4.6.2.2 Chest X-ray score following lung resection 
Chest X-ray (CXR) acquisition was not protocolised; CXR results displayed are 
therefore those taken when clinically indicated. There were CXRs available for 
analysis for 28 patients on post-operative day 1 and 27 patients on post-
operative day 2. These 55 CXRs were dual reported and the mean CXR score used 
for subsequent analysis. Inter-rater reliability was explored by determining Type 
3 Intraclass Correlation Coefficient (two-way mixed model for agreement, 
average measures). This revealed ‘substantial’ agreement between raters 
(ICC=0.61). 
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In patients for whom paired CXR scores were available on post-operative days 
one and two, median CXR score was higher on day two post-operatively 
compared to day one (Figure 4.9), though this difference was not statistically 
significant (p=0.21, Wilcoxon Signed Ranks Test, n=22).  
 
Figure 4.9. Post-operative chest X-ray scores by day.  
p=0.21, Wilcoxon Signed Ranks Test, n=22. 
 
Representative chest X-rays demonstrating the derivation of the CXR score are 
shown in Figure 4.10. 
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Figure 4.10. Sample chest X-rays illustrating derivation of the chest x-ray score. 
Top panel: 72 year old female on post-operative day one following left pneumonectomy. Both left 
sided quadrants contain no lung, therefore the number of scoreable quadrants = 2. Both right sided 
quadrants contain no ‘opacities not fully explained by effusions, lobar / lung collapse, or nodules’, 
yielding a quadrant score of 0 for each. The overall CXR-score therefore = (0/2)x4=0 [(quadrant 
score / number of ‘scoreable’ quadrants) x 4]. Bottom panel: 68 year old male on post-operative 
day two following multiple wedge resection on right lung. All quadrants are deemed scoreable. 
‘Opacities’ can be seen occupying 1/3 to 2/3 of the RUQ (score=2), <1/3 of the RLQ (score=1) and 
1/3 to 2/3 of the LLQ (score=2). There are no opacities in the LUQ. Total quadrant score therefore 
= 5 and overall CXR-score therefore = (2+1+2/4)x4=5. 
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4.6.2.3 Modified lung injury score following lung resection 
Paired post-operative CXRs were available for all 21 patients for whom 
PaO2/FiO2 data was available at 24 hours post-operatively, allowing calculation 
of modified lung injury score (mLIS) 24 hours post-operatively in all 21 patients. 
The distribution of mLIS 24 hours post-operatively is demonstrated in Figure 
4.11. It is evident from this figure, that the distribution of mLIS 24 hours post-
operatively is bimodal. As might be expected, the majority of patients had low 
mLIS scores, however there is second peak in LIS representing those with LIS 
greater than 1.5. It is hypothesised that this group of patients with mLIS over 1.5 
are a distinct group of patients (comprising 6 of the 21 patient cohort), who 
demonstrate evidence of post-operative lung injury. Only one patient had a mLIS 
greater than 2.5, classified (according to Murray et al’s original derivation54) as 
‘severe’ lung injury. A mLIS of greater than 1.5 was therefore defined as a 
‘positive’ clinical outcome against which the sensitivity and specificity of the 
candidate lung injury biomarkers could be examined. 
 
Figure 4.11. Distribution of modified LIS on post-operative day one.  
(n=21). 
 
Paired arterial blood gas results and chest x-ray scores, allowing calculation of 
mLIS were available in 14 patients on post-operative day two (POD-2). As on 
POD-1, whilst the majority of patients had low mLIS on POD-2, there remained a 
population of patients (4 of the 14 patients) who had mLIS greater than 1.5 
(Figure 4.12). 
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Figure 4.12. Distribution of modified LIS on post-operative day two. 
(n=14). 
 
4.6.3 Pentraxin 3 as a biomarker of lung injury following lung 
resection 
4.6.3.1 Changes in Pentraxin 3 and C-reactive protein following lung 
resection 
PTX3 levels were not available immediately post-operatively for one patient, 
and CRP levels were not available for one patient immediately post-operatively 
and one patient 24 hours post-operatively. These patients were excluded from 
the longitudinal analysis of biomarker levels.  
There were no significant increases in PTX3 and CRP levels immediately post-
operatively, however by 24 hours post-operatively, both biomarkers 
demonstrated a marked increase (p<0.01 for both; Friedman test; Figures  4.13 
and 4.14). 
Three patients demonstrated no post-operative PTX3 rise. These patients were 
retained in the analysis, but for each comparison a sensitivity analysis was 
performed excluding these three patients from the analysis. 
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Figure 4.13. Changes in plasma PTX3 following lung resection. 
p<0.01; Friedman test. n=32. 
 
 
Figure 4.14. Changes in plasma CRP following lung resection.  
p<0.01; Friedman test. n=32. 
 
4.6.3.2 Sensitivity and specificity of PTX3 and CRP for predicting clinical 
outcomes of interest 
Diagnostic utility of PTX3 and CRP  
Modified lung injury score on post-operative day one was available in 21 
patients. Dichotomising these patients into groups of patients with mLIS > 1.5 
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and those with mLIS ≤ 1.5 left 6 and 15 patients per group respectively. Median 
PTX3 level 24 hours post-operatively was significantly higher in patients with 
mLIS >1.5 on post-operative day 1 (p=0.03, Mann-Whitney U test; Figure 4.15).  
 
Figure 4.15. Modified lung injury score on post-operative day one versus PTX3 
concentration.  
p=0.03; Mann-Whitney U test. n=21.  
 
Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX3 response to surgery, there remained a trend towards increased PTX3 levels 
in patients with LIS>1.5 (p=0.05, Mann-Whitney U test; n=19, not shown).  
There were no significant differences in CRP levels 24 hours post-operatively in 
patients with mLIS ≤ 1.5 compared to  > 1.5 (p=0.35; Mann-Whitney U test; not 
shown). 
Sensitivity and specificity 
A receiver operating characteristic curve was constructed to determine the 
predictive value of 24 hour post-operative PTX3 levels for mLIS > 1.5 (Figure 
4.16). 
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Figure 4.16. ROC curve describing the predictive value of PTX3 24h post-operatively for 
modified lung injury score greater than 1.5 on post-operative day one.   
AUC=0.81 (95% CI=0.62-0.99).  
The optimal cut off value of PTX3 (defined as the point of maximal summative 
sensitivity and specificity from the ROC curve analysis) was 767.2pg/ml. The 
performance of this cut-off level for predicting mLIS>1.5 24 hours post-
operatively is described in Table 4.10. 
Table 4.10. Predictive performance of a cut-off of 24 hour post-operative PTX3 of 767.2 
pg/ml for modified lung injury score > 1.5 on post-operative day one. 
Parameter Value 
Area under the ROC Curve 
(95% Confidence interval) 
0.81 
(0.62-0.99) 
Sensitivity 100% 
Specificity 67% 
Positive predictive value 55% 
Negative predictive value 100% 
 
As there was no significant difference in CRP levels in patients with elevated 
mLIS, ROC curve analysis of CRP data was not performed. 
Prognostic utility of PTX3 and CRP  
Modified lung injury score on post-operative day two was available in 14 
patients. Dichotomising these patients into groups of patients with mLIS >1.5 and 
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those with mLIS ≤1.5 left 4 and 10 patients per group respectively. Median PTX3 
level 24 hours post-operatively was significantly higher in patients with mLIS 
>1.5 (p=0.05; Mann-Whitney U test; Figure 4.17).  
 
Figure 4.17. Modified lung injury score on post-operative day two versus PTX3 
concentration.  
p=0.05; Mann-Whitney U test. n=14.  
Sensitivity analysis: After exclusion of a single patient who demonstrated no 
PTX3 response to surgery (and for whom a mLIS could be calculated on POD2), 
there remained a non-significant trend towards increased PTX3 levels in patients 
with LIS>1.5 (p=0.06, Mann-Whitney U test; n=13; not shown).  
There were no significant differences in CRP levels 24 hours post-operatively in 
patients with mLIS ≤ or > than 1.5 (p=0.77, Mann-Whitney U test; n-14; not 
shown).  
Sensitivity and specificity 
A receiver operating characteristic curve was constructed to determine the 
predictive value of 24 hour post-operative PTX3 levels for mLIS greater than 1.5 
on post-operative day 2 (Figure 4.18). 
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Figure 4.18. ROC curve describing the predictive value of PTX3 24h post-operatively for 
modified lung injury score greater than 1.5 on post-operative day two.   
AUC=0.85 (95% CI=0.64-1.00).  
The optimal cut off value of PTX3 (defined as the point of maximal summative 
sensitivity and specificity from the ROC curve analysis) was 914.2pg/ml. The 
performance of this cut-off in predicting mLIS>1.5 on POD-2 is described in Table 
4.11. 
Table 4.11. Predictive performance of a cut-off of 24 hour post-operative PTX3 of 914.2 
pg/ml for modified lung injury score > 1.5 on post-operative day two. 
Parameter Value 
Area under the ROC Curve 
(95% CI) 
0.85  
(0.64-1.0) 
 
Sensitivity 100% 
Specificity 70% 
Positive predictive value 57% 
Negative predictive value 100% 
As there was no significant difference in CRP levels in patients with elevated 
mLIS on POD-2, ROC curve analysis of CRP data was not performed. 
Predictive value of PTX3 for post-operative oxygenation and chest X-
ray score 
Similar ROC curve analysis was performed to examine the predictive value of 
PTX3 level 24 hours post-operatively for post-operative oxygenation (positive 
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end-point defined as PaO2/FiO2 less than 300mmHg) and post-operative CXR 
score (positive endpoint defined as CXR score greater than 3). These 
comparisons were made of both the diagnostic and prognostic value of PTX3 for 
poor oxygenation and elevated CXR score (Table 4.12). 
In view of the lack of association between CRP and post-operative modified lung 
injury score, these analyses were not performed for C-reactive protein. 
Table 4.12. Predictive value of PTX3 for poor post-operative oxygenation and elevated chest 
X-ray score 
Parameter PaO2/FiO2 CXR score 
Comparison Diagnostic Prognostic Diagnostic Prognostic 
Time point 
24h post-
op 
‘Worst’ recorded 24-
48h post-op 
POD1 POD2 
Cut off 
914.2 
pg/ml 
914.2 
pg/ml 
937.8 
pg/ml 
914.2 
pg/ml 
Area under the 
Receiving Operating 
Characteristic Curve 
(95% Confidence 
interval) 
 
0.76 
(0.55-0.97) 
0.76 
(0.52-1.0) 
0.87 
(0.73-1.00) 
0.64 
(0.40-0.87) 
Sensitivity 
 75% 75% 86% 60% 
Specificity 
77% 78% 76% 71% 
Positive predictive value 
 66% 75% 86% 54% 
Negative predictive 
value 
 
83% 78% 76% 75% 
No of patients in 
analysis (n) 21 16 28 27 
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4.6.3.3 Variation in proportion to the severity of injury 
Relationship between PTX3 level and severity of oxygenation 
impairment 
There was a trend towards a linear relationship between PTX3 levels and 
PaO2/FiO2 24 hours post-operatively (r=-0.40, p=0.08, Spearman’s rho; Figure 
4.19). 
 
Figure 4.19. Association between PaO2/FiO2 and PTX3 concentration 24 hours post-
operatively.  
r=-0.40, p=0.08; Spearman’s rho. n=21. 
 
Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, there remained a trend towards a linear relationship 
between PTX3 levels and PaO2/FiO2 24 hours post-operatively (r=-0.38, p=0.10, 
Spearman’s rho; not shown). 
Paired CRP levels and ABG data 24 hours post-operatively was available in 21 
patients. There was no linear relationship between CRP level and PaO2/FiO2 24 
hours post-operatively (r=-0.09, p=0.70, Spearman’s rho; not shown). 
Relationship between PTX3 level and chest X-ray scores 
On post-operative day one, chest X-rays were performed a median of 4.1 (3.0-
5.6) hours before ’24 hour’ plasma samples were obtained. There was a linear 
relationship between PTX3 levels 24 hours post-operatively and CXR score on 
post-operative day one (r=0.38, p=0.04, Spearman’s rho; n=28; Figure 4.20). 
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Figure 4.20. Plasma PTX3 level 24 hours post-operatively versus post-operative day 1 CXR 
score. 
 r=0.38, p=0.04, Spearman’s rho, n=28. 
 
Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, the statistically significant relationship between PTX3 
level and CXR was lost (r=0.31, p=0.14, Spearman’s rho; n=25; not shown). 
There was a similar (but stronger) linear relationship between CRP levels 24 
hours post-operatively and CXR score on post-operative day one (r=0.46, p=0.02, 
Spearman’s rho; n=27; Figure 4.21). 
 
Figure 4.21. Plasma CRP level 24 hours post-operatively versus CXR score on post-
operative day one.  
r=0.46, p=0.02, Spearman’s rho; n=27. 
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4.6.3.4 Modification by an effective intervention 
Lesser resection 
Type of resection 
Of the 33 patient cohort, 4 patients underwent sub-lobar resection, 24 patients 
underwent lobectomy and 5 patients underwent pneumonectomy. There was no 
difference in PTX3 level across the three resection types (p=0.33, Kruskal-Wallis 
test; n=33; not shown). 
Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, there remained no significant differences in PTX3 level 
across the three resection types (p=0.56, Kruskal Wallis test; n=30; not shown). 
Of the 32 patients in whom a CRP sample 24 hours post-operatively was 
available, there was no significant difference in CRP level across the three 
resection types (p=0.59, Kruskal-Wallis test; n=32, not shown). 
Volume of lung resected 
Four of the 33 patient cohort underwent sub-lobar resection and so were 
excluded from this analysis. The remaining 29 were divided into tertiles by the 
number of pulmonary segments resected. There were no significant differences 
in PTX3 level across the tertiles (p=0.25, Kruskal-Wallis test; Figure 4.22). 
 
 
Figure 4.22. No of pulmonary segments resected versus PTX3 level 24 hours post-
operatively. 
p=0.25, Kruskal-Wallis test. n=29.  
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Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, there remained no significant differences in PTX3 level 
across the three resection types (p=0.33, Kruskal-Wallis test; n=26; not shown). 
Of the 32 patients in whom a CRP sample 24 hours post-operatively was 
available, 4 patients underwent sub-lobar resection and so were excluded from 
the analysis. The remaining 28 patients were divided into tertiles by the number 
of pulmonary segments resected. There were no differences in PTX3 level across 
the tertiles (p=0.93, Kruskal-Wallis test; n=28; not shown). 
 
Duration of one-lung ventilation 
The duration of one-lung ventilation (OLV) could be determined for 32 patients. 
Mean duration of OLV was 75.1 +/- 24.2 minutes. There was no significant 
difference in PTX3 level across quartiles of OLV time (p=0.28, Kruskal-Wallis 
test; n=32; Figure 4.23). Visual inspection of figure 4.23 suggests the possibility 
of a threshold effect in the relationship between PTX3 and OLV time; the 
median PTX3 level in the quartile of patients undergoing the longest duration of 
OLV appears markedly higher than in the other three quartiles (no statistical 
comparison made). 
 
Figure 4.23. Plasma PTX3 24 hours post-operatively versus quartile of one-lung ventilation 
time.  
p=0.28, Kruskal-Wallis test. n=32. 
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Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, there remained no significant difference in PTX3 levels 
across quartiles of OLV time (p=0.11, Kruskal-Wallis test; n=29; not shown). 
 
There was no significant difference in CRP level across quartiles of OLV time 
(p=0.70, Kruskal-Wallis test; n=31; not shown). 
 
Lung protective ventilation 
Ventilatory parameters during the period of one-lung ventilation were available 
in 31 patients. Figure 4.24 shows a representative series of Ppeak, VT and FiO2 
versus time curves for a single patient. 
PTX3 versus peak airway pressure 
There were no significant differences in PTX3 level across all quartiles of area 
under the Ppeak versus time curve (Ppeak(AUC)) (p=0.20 Kruskal-Wallis test, n=31, 
Figure 4.25). 
 
Figure 4.24. Plasma PTX3 24 hours post-operatively versus quartile of area under the peak 
airway pressure versus time curve.  
Ppeak(AUC) area under the peak airway pressure versus time curve. p=0.20, Kruskal-Wallis test; 
n=31. 
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Figure 4.25. Example peak airway pressure (Ppeak), tidal volume (VT) and fraction of 
inspired oxygen (FiO2) versus time curves for a patient undergoing lung resection.  
The period of one-lung ventilation (recorded on this occasion on the anaesthetic record) is marked 
between the dashed lines and is clearly discernible from the characteristic changes in Ppeak and 
VT curves. 
 
Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, there remained no significant difference in PTX3 level 
across all groups of Ppeak(AUC) (p=0.67, Kruskal-Wallis test; n=28; not shown). 
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PTX3 versus tidal volume 
There were no significant differences in PTX3 level across all quartiles of area 
under the tidal volume versus time curve (VT(AUC); p=0.15, Kruskal-Wallis test; 
Figure 4.26). 
 
Figure 4.26. Plasma PTX3 24 hours post-operatively versus quartile of area under the tidal 
volume versus time curve, 
 VT(AUC), area under the tidal volume versus time curve. p=0.15, Kruskal-Wallis test; n=31. 
Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, there remained no significant difference in PTX3 level 
across all across all quartiles of VT(AUC) (p=0.56, Kruskal-Wallis test; n=28; not 
shown).  
PTX3 versus fraction of inspired oxygen 
There were no significant differences in PTX3 level across quartiles of area 
under the FiO2 versus time curve during the period of OLV (FiO2(AUC); p=0.34, 
Kruskal-Wallis test; n=31; Figure 4.27). 
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Figure 4.27. Plasma PTX3 24 hours post-operatively versus quartile of area under the FiO2 
versus time curve. 
FiO2(AUC), area under the FiO2 versus time curve. p=0.34, Kruskal-Wallis test, n=31. 
 
Visual inspection of Figure 4.27, is again suggestive of a threshold effect in the 
relationship between FiO2 and PTX3 level; median PTX3 level in the quartile of 
patients exposed to the highest FiO2 appears markedly higher than in the other 
three quartiles (no statistical comparison made). 
Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, there remained no significant differences in PTX3 level 
across quartiles of  FiO2(AUC) (p=0.45, Kruskal Wallis test; n=28; not shown). 
CRP versus ventilatory parameters  
There were no significant differences in CRP level across quartiles of area under 
the Ppeak, VT nor FiO2 verses time curves (Table 4.13). 
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Table 4.13. Relationship between CRP level and lung protective ventilation. 
Parameter CRP level mg/L  
  
Quartile of parameter 1 2 3 4 p n 
Ppeak(AUC) 
130.4 
(101.2-144.2) 
91.6 
(84.1-123.9) 
128.9 
(107.4-142.6) 
124.6 
(43.8-139.6) 
0.42 30 
VT(AUC) 
125.1 
(101.2-132.6) 
113.6 
(83.5-152.5) 
123.7 
(111.3-139.6) 
90.1 
(74.8-134.3) 
0.52 30 
FiO2(AUC) 
130.4 
(101.2-144.2) 
106.4 
(84.1-124.9) 
107.4 
(84.9-135.9) 
134.3 
(75.1-148.4) 
0.51 30 
p by Kruskal Wallis test. n, no of patients from which result derived. 
 
4.6.3.5 Association with clinically important outcomes 
Need for ventilatory support 
One patient required nasal CPAP, and one patient required mechanical 
ventilation post-operatively. As ventilatory support was only required in two 
patients, no further statistical comparison regarding association between PTX3 
and CRP levels and need for ventilatory support was made. 
High dependency unit stay 
Median high dependency unit stay in the 33 patient cohort was 44.5 (42.8-46.6) 
hours. (As might be expected) visual inspection of the distribution of HDU stay 
duration revealed a strongly positively skewed distribution (Figure 4.28). 
 
Figure 4.28. Distribution of HDU stay.  
Data points represent individual patients, n=33. 
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Eighty per cent of HDU stay values lay in the range 40-48 hours post-operatively, 
reflecting standard practice in our institution where patients are routinely 
‘stepped-down’ to ward care on the morning of post-operative day two. As such, 
an HDU stay of greater than 48 hours was defined as ‘prolonged’.  
There was a trend towards higher PTX3 levels in patients with prolonged HDU 
stay (p=0.08, Mann-Whitney U test; n=33; Figure 4.29).   
 
Figure 4.29. PTX3 level 24 hours post-operatively value versus duration of HDU stay.  
p=0.08, Mann-Whitney U test, n=33. 
Sensitivity analysis: Exclusion of the three patients who demonstrated no PTX3 
response to surgery, weakened the relationship between PTX3 level and 
prolonged hospital stay (p=0.13, Mann-Whitney U test; n=30; not shown).  
There was no significant difference in CRP values between patients with normal 
and prolonged HDU stay (p=0.61, independent samples t-test; n=32; not shown).  
Hospital stay 
Median hospital stay in the 33 patient cohort was 7 (6-9.5) days. There was a 
modest positive correlation between LOS and PTX3 level (r=0.44, p=0.01, 
Spearman’s rho; Figure 4.30). 
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Figure 4.30. Association between length of hospital stay and PTX3 level 24 hours post-
operatively. 
r=0.44, p=0.01, Spearman’s rho; n=33. 
 
Sensitivity analysis: After exclusion of the three patients who demonstrated no 
PTX response to surgery, there remained a modest positive correlation between 
LOS and PTX3 level (r=0.40, p=0.03; n=30; not shown). 
There was a trend towards a statistically significant association between LOS and 
CRP level 24 hours post-operatively (r=0.30, p=0.10, Spearman’s rho; Figure 
4.31). 
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Figure 4.31. Association between length of hospital stay and CRP level 24 hours post-
operatively.  
r=0.30, p=0.10 Spearman’s rho; n=32. 
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4.6.4 Utility of a multiple (lung injury) biomarker panel following 
lung resection 
4.6.4.1 Changes in individual biomarkers following lung resection 
Receptor for advanced glycation end product 
There were significant changes in plasma receptor for advanced glycation end 
products (RAGE) levels across the three time points (p<0.01, Friedman test; 
n=22, Figure 4.32). Post-hoc testing by pairwise comparisons (adjusted for 
multiple comparisons) revealed median RAGE was increased immediately post-
operatively, but then fell significantly 24h post-operatively (p≤0.01 for both). 
There was no significant difference between RAGE levels pre-operatively and 
24h post-operatively. 
 
Figure 4.32. Changes in plasma RAGE following lung resection.   
#p<0.01, Wilcoxon signed ranks test. n=22. 
Post-hoc analysis: Relationship of changes in plasma RAGE to volume of lung 
resected 
Volume of resected lung tissue was quantified as number of pulmonary segments 
resected and was then compared with change in plasma RAGE level between 
pre-operative levels and those observed immediately and 24 hour post-
operatively (∆RAGE). There was a trend towards a negative association between 
volume of lung resected and ∆RAGE24h post-op – pre-op (r=-0.40, p=0.07; Spearman’s 
rho; n=22; not shown) and a significant negative association between volume of 
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lung resected and ∆RAGEpost-op – pre-op (r=-0.43, p=0.046; Spearman’s rho; n=22; 
Figure 4.33). 
 
Figure 4.33. Relationship between change in plasma RAGE level immediately post-
operatively and volume of lung tissue resected.  
r=-0.43, p=0.046; Spearman’s rho. n=22. 
In view of this relationship, post-operative plasma RAGE levels were then 
adjusted for the number of pulmonary segments present at the time of sample 
draw, to provide a value of RAGE per lung segment (RAGEadj). Analysis of 
changes in plasma RAGEadj, revealed a similar significant change in plasma 
RAGEadj level across all three time-points (p<0.01, Friedman test with pairwise 
comparisons), but appeared to magnify the immediate post-operative increase 
(p<0.01 for immediately post-operatively vs pre-operatively and 24 hours post-
operatively), however following adjustment, RAGEadj levels 24 hours post-
operatively remained non-significantly different from pre-operatively (p=0.50, 
Wilcoxon signed ranks, n=22, Figure 4.34).  
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Figure 4.34. Plasma RAGE level adjusted for volume of lung resected following lung 
resection.  
#
p<0.01, Wilcoxon signed ranks test; n=22. 
Procollagen Peptide III 
 
There were significant changes in PCPIII level across the three time points 
(p<0.01, Friedman test; n=22; Figure 4.35). Post-hoc testing by pairwise 
comparisons (adjusted for multiple comparisons) revealed median PCPIII level 
fell immediately post-operatively (p<0.01, pre-operatively vs immediately post-
operatively), before returning to baseline 24h post-operatively (p=1.0, pre-
operatively vs 24 hours post-operatively). 
 
Figure 4.35. Changes in plasma PCPIII following lung resection.  
#p<0.01, Wilcoxon signed ranks test; n=22. 
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Post-hoc analysis: Relationship between changes in plasma PCPIII and volume 
of lung resected 
In view of the observed post-operative fall in plasma PCPIII, volume of resected 
lung tissue in segments was compared with change in plasma PCPIII level 
between pre-operative levels and those observed immediately post-operatively 
(∆PCPIII). There was no association between volume of lung resected and 
∆PCPIIIpost-op – pre-op (r=-0.007, p=0.98, Spearman’s rho; not shown). No analysis of 
PCPIII values adjusted for the volume of lung resected was therefore performed. 
B-type Natriuretic Peptide 
Results for B-type natriuretic peptide (BNP) are summarised in Figure 4.36. 
Returned BNP levels were considerably larger than expected. 
 
Figure 4.36. Plasma BNP level following lung resection.  
Horizontal dashed line at 100pg/ml. 
As can be seen in Figure 4.36 for the majority of patients (in fact all but two),  
pre-operative BNP levels were greater than 100pg/ml, a cut off which has been 
recommended as being diagnostic for congestive cardiac failure353. Furthermore 
BNP levels were greater than 1.5 times the upper reference range of the assay 
(i.e. greater than 3000pg/ml), in six patients pre-operatively, seven patients 
immediately post-operatively and six patients 24 hours post-operatively. Such 
levels of BNP are far in excess of what might be expected in patients with NYHA 
grade IV heart failure353, findings clearly at odds with the clinical condition of 
the patients in this cohort. In view of these obvious uncertainties surrounding 
Chapter 4  246 
the validity of the measured BNP levels, no further analysis of peri-operative 
BNP levels was performed. 
Angiopoietin-2 
There were significant changes in Angiopoietin 2 (Ang-2) level across the three 
time points (p<0.01, Friedman test; n=22, Figure 4.37). Post-hoc testing by 
pairwise comparisons (adjusted for multiple comparisons) revealed a 
significantly increased Ang-2 level 24h post operatively (p<0.01 and p=0.06 for 
Ang-2 24 hours post-operatively verses pre-operatively and immediately post-
operatively respectively). 
 
Figure 4.37. Changes in plasma Ang-2 following lung resection.  
#p<0.01, Wilcoxon signed ranks. n=22. 
Interleukin-8 
Observation of the data over the three time points reveals IL-8 levels are 
essentially constant at <0.10 pg/ml across all three time points in the majority 
of patients (Figure 4.38). There were no significant changes in IL-8 levels across 
the three time points (p=0.23, Friedman test; n=22). 
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Figure 4.38. Plasma IL-8 level following lung resection.  
Data points represent individual patients. p=0.23, Friedman test; n=22. 
Interleukin-10 
There were significant changes in Interleukin-10 (IL-10) level across the three 
time points (p<0.01, Friedman test; n=22, Figure 4.39). Post-hoc testing by 
pairwise comparisons (adjusted for multiple comparisons) revealed a 
significantly increased median IL-10 level both post-operatively and 24 hours 
post-operatively (compared to pre-operatively; p=0.03 and p<0.01 respectively). 
There were no significant differences between median IL-10 level immediately 
post operatively and IL-10 level 24 hours post-operatively (p=0.91). 
 
Figure 4.39. Changes in plasma IL-10 following lung resection.  
#
p<0.01, Wilcoxon signed ranks. n=22. 
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Tumour necrosis factor alpha 
Tumour necrosis factor alpha (TNF-α) was not detected in any sample.  
4.6.4.2 Application of a risk of lung injury score 
Following the observations above concerning the changes in individual biomarker 
levels following lung resection, the risk of lung injury score described by 
Freemont et al, was modified to allow its use in this cohort. Firstly, data for BNP 
(where the results were of dubious validity) and for TNF-α (where TNF-α levels 
were not recorded in any sample) were excluded. Scores were then obtained for 
the remaining five biomarkers using the prediction tool described by Freemont 
et al (see Figure 4.3, Section 4.5.3.2). Observed levels of plasma RAGE were 
adjusted prior to scoring to reflect the volume of lung resected: 
               
                       
  
       
Equation 4.3 
 
This provided a cumulative ‘risk of lung injury score’ for a five biomarker panel. 
Figures 4.40 and 4.41 show the results of the five biomarker panel, scored 
immediately post- and 24 hours post-operatively in each individual patient.  
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Figure 4.40. Cumulative ‘risk of lung injury’ scores per patient, immediately post-operatively 
for a five biomarker panel.  
n=22. 
 
 
 
Figure 4.41 Cumulative ‘risk of lung injury’ scores per patient, 24 hours post-operatively for 
a five biomarker panel.  
n=22. 
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Visual inspection of Figures 4.40 and 4.41 reveals that the overwhelming 
majority of the cumulative score is attributable to PCPIII, such that changes in 
the other biomarkers are to a degree ‘swamped’ by the PCPIII score. In view of 
this, and the observation that PCPIII scores in fact fell immediately post-
operatively, and were no different from baseline 24 hours post-operatively, 
results for PCPIII were excluded and a further score was thus obtained for a four 
biomarker panel (comprising RAGE (adjusted for the volume of lung resected), 
Ang-2, IL-8 and IL-10). Figures 4.42 and 4.43 demonstrate the individual patient 
scores for the four biomarker panel. 
 
Figure 4.42. Cumulative ‘risk of lung injury’ scores per patient, immediately post-operatively 
for a four biomarker panel.  
n=22. 
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Figure 4.43. Cumulative ‘risk of lung injury’ scores per patient, 24 hours post-operatively for 
a four biomarker panel.  
n=22. 
Sensitivity and specificity of a multi-biomarker ‘risk of lung injury 
score’ for predicting clinical outcomes 
Assessment was made of the relationship between post-operative multiple 
biomarker panel scores 24 hours post-operatively (for both a four and five 
biomarker panel) and modified Lung Injury Score (mLIS) on post-operative day 
one, to assess the diagnostic value of the panels. To assess the prognostic value 
of the panels, biomarker panel scores immediately post-operatively were 
compared with mLIS on post-operative day one and biomarker panel scores 24 
hours post-operatively were compared with mLIS on post-operative day two.   
Diagnostic value of biomarker panel score for predicting modified lung injury 
score on post-operative day one  
Modified lung injury score on post-operative day one was available for 14 
patients in whom the multi-biomarker panel was measured. Dichotomising these 
patients into groups of patients with mLIS on post-operative day one > 1.5 and 
those with mLIS ≤ 1.5 left 5 and 9 patients per group respectively.  
There was no difference in either median five or four biomarker panel score 24 
hours post-operatively between the two groups of mLIS (p=0.46 and 0.18 
respectively, Mann-Whitney U test; n=22; not shown). In the absence of any 
significant difference in four or five biomarker panel score 24 hours post-
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operatively and mLIS on post-operative day one, receiver operating 
characteristic curve analysis was not performed. 
Prognostic value of biomarker panel score for predicting modified lung injury 
score on post-operative days one and two  
There was no difference in either median five or four biomarker panel score 
immediately post-operatively between the two groups of mLIS (p=0.54 and 0.12 
for a five and four biomarker panel respectively, Mann-Whitney U test; n=22; not 
shown). 
Modified lung injury score on post-operative day two was available for 9 patients 
in whom the multi-biomarker panel was measured. Dichotomising these patients 
into groups of patients with mLIS on post-operative day one greater than 1.5 and 
those with mLIS less than or equal to 1.5 left 2 and 7 patients per group 
respectively. There was no significant difference in either median five or four 
biomarker panel 24 hours post-operatively and between the two groups of mLIS 
on post-operative day two (p=0.38 and 0.19 respectively, Mann-Whitney U test; 
n=22; not shown). 
In the absence of any significant difference in four or five biomarker panel score 
at any time point between groups of mLIS on post-operative days one and two, 
receiver operating characteristic curve analysis was not performed. 
Variation in proportion to the severity of injury 
 
To examine whether multiple biomarker panel scores vary in proportion to the 
severity of oxygenation impairment, ‘worst’ recorded PaO2:FiO2 ratios at 6 and 
24 hours post-operatively were compared with multiple biomarker panel scores 
immediately and 24 hours post-operatively respectively. There were no 
significant associations between biomarker panel score for either a five or four 
biomarker panel and oxygenation at any time point (Table 4.14). 
To examine whether multiple biomarker panel scores vary in proportion to the 
severity of chest x-ray score, post-operative day one CXR scores were compared 
with biomarker panel scores. There were no significant associations between 
biomarker panel score for either or five or four biomarker panel and CXR score 
(Table 4.14).  
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Table 4.14. Association between five and four biomarker panel score and severity of post-
operative oxygenation impairment and chest X-ray score. 
  PaO2/FiO2 6h post-
op 
PaO2/FiO2  24h 
post-op 
CXR Score 24h 
post-op 
5 biomarker score  
 
- immediately 
post-op 
r 
p 
n 
-0.3 
0.28 
15 
  
     
- 24h post-op r 
p 
n 
 -0.1 
0.72 
14 
-0.27 
0.32 
15 
4 biomarker score  
  
- immediately 
post-op 
r 
p 
n 
0.23 
0.40 
15 
  
     
- 24h post-op r 
p 
n 
 0.06 
0.83 
14 
-0.49 
0.06 
15 
r and p, association by Pearson correlation or Spearman’s rho as appropriate; n, no of patients on 
which analysis is based. 
 
Modification by an effective intervention 
Lesser resection 
Type of resection 
Of the 22 patient cohort for whom the multiple biomarker panel was measured, 
one patient underwent sub-lobar resection, 18 patients underwent anatomic 
lobectomy, and three patients underwent pneumonectomy. Due to the small 
numbers in the sub-lobar resection and pneumonectomy group, no statistical 
comparison was made between these groups. 
Volume of lung resected 
One of the 22 patient cohort underwent sub-lobar resection and so was excluded 
from this analysis. The remaining 21 were divided into tertiles by the number of 
pulmonary segments resected. There were no differences in multiple biomarker 
panel score between tertiles of number of pulmonary segments resected (for 
either a four or five biomarker panel, immediately or 24 hours post-operatively, 
Table 4.15) 
 
Chapter 4  254 
Table 4.15. Multiple biomarker panel scores immediately and 24 hours post-operatively by 
number of pulmonary segments resected.  
 
Time-
point 
Median multiple biomarker panel 
score 
  
Tertile of ‘number of pulmonary 
segments resected’ 
1 (least) 2 3 (most) p n 
       
Five biomarker panel 
Post-op 
101.5 
(73.5-
122.0) 
95.0 
(84.0-
112.0) 
111.5 
(78.5-
119.0) 
0.74 21 
       
 
24h 
113.0 
(74.0-
126.0) 
113.0 
(70.0-
117.0) 
102.0 
(74.5-
104.0) 
0.58 20 
       
Four biomarker panel 
Post-op 
33.5 
(20.0-44.5) 
22.0 
(12.0-
28.0) 
28.5 
(24.5-
34.5) 
0.36 21 
       
 
24h 
14.0 
(7.0-31.0) 
15.0 (8.0-
17.0) 
16.0 
(2.5-32.5) 
0.95 20 
Biomarker panel scores are median (IQR). p values by Kruskall-Wallis test for all. n, no of patients 
on which analysis is based. 
Lung protective ventilation and duration of one-lung ventilation 
Of the 22 patients for whom results of the multi-biomarker panel were available, 
ventilatory parameters during the period of one-lung ventilation were available 
in 21 patients; the duration of one-lung ventilation could be deduced in all 
patients.  As with the analysis of PTX3 and CRP, to explore the association 
between ventilatory parameters during the period of OLV and total risk of lung 
injury scores, the areas under the curve (AUC) from the peak airway pressure 
(Ppeak), tidal volume (VT) and FiO2 versus time curves and the duration of one-
lung ventilation were divided into quartiles. ‘Risk of lung injury’ scores 
determined immediately and 24 hours post-operatively for a five and four 
biomarker panel were compared with ventilatory parameters using one way 
analysis of variance or Kruskal Wallis test as appropriate (Table 4.16).  
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Table 4.16. Risk of lung injury scores across quartiles of peak air way pressure, tidal 
volume, fraction of inspired oxygen and one-lung ventilation time for a five biomarker panel. 
 Time 
point 
Multiple biomarker panel score 
  
Quartile of parameter: 1 2 3 4 p n 
        
Ppeak(AUC) Post-op 85.0 
(84.0-
98.0) 
102.0 
(95.0-
123.0) 
112.0 
(103.0-
115.0) 
83.0 
(49.0-
108.0) 
0.35KW 21 
 
     
  
 24h 113.5 
(113.0-
126.0) 
108.5 
(105.0-
114.0) 
101.0 
(70.0-
117.0) 
63.5 
(41.0-
91.0) 
0.20KW 21 
        
VT(AUC) Post-op 75.8 
(31.3) 
100.5 
(15.9) 
95.8 
(47.5) 
102.2 
(32.3) 
0.57AN 21 
 
     
  
 24h 113.0 
(74.0-
114.0) 
111.0 
(105.0-
117.0) 
108.0 
(46.0-
115.0) 
85.5 
(59.0-
102.0) 
0.40KW 21 
        
FiO2(AUC) Post-op 98.0 
 (85.0-
108.0) 
70.0  
(49.0-
96.0) 
103.0 
 (83.0-
105.0) 
112.0 
(108.0-
115.0) 
0.26KW 21 
        
 24h 114.0 
 (113.0-
115.0) 
91.5 
 (48.0-
113.0) 
79.0  
(70.0-
105.0) 
105.5 
 (102.0-
112.5) 
0.58KW 21 
        
OLV time 
(mins) 
Post-op 85.0 
(56.0-
98.0) 
117.5 
 (105.0-
128.0) 
89.5 
 (49.0-
103.0) 
108 
 (95.0-
115.0) 
0.09KW 21 
        
 24h 96.2 
(38.0) 
117.8 
(9.4) 
78.0 
(35.7) 
89.5 
(29.2) 
0.17AN 21 
Values are mean (SD) or median (IQR). p by 
KW
Kruskall Wallis test or 
AN
analysis of one-way 
variance as appropriate. n, no of patients on which analysis is based. 
There was no difference in total lung injury score for a four or five biomarker 
panel, immediately- and 24 hours post-operatively across quartiles of any 
ventilatory parameter (Tables 4.16 and 4.17) with the possible exception of OLV 
time. Immediate post-operative total risk of lung injury score (for a five 
biomarker panel) demonstrated a non-significant trend towards a difference 
across the quartiles of OLV time (p=0.09, Kruskall-wallis test, Table 4.16). 
Pairwise comparisons were not performed as the result was not statistically 
significant; visual inspection of the data (Figure 4.44) does not suggest any 
linear trend between total risk of lung injury score and OLV time. This trend was 
not supported by the results of the four biomarker panel (where p=0.95 
(Kruskall-wallis test), for the same comparison, Table 4.17). 
Chapter 4  256 
Table 4.17. Risk of lung injury scores across quartiles of peak air way pressure, tidal 
volume, fraction of inspired oxygen and one-lung ventilation time for a four biomarker 
panel. 
 Time 
point 
Multiple biomarker panel score 
  
Quartile of parameter: 1 2 3 4 p n 
        
Ppeak(AUC) Post-op 12.0 (7.0-
28.0) 
25.5 (18.0-
40.0) 
38.0 (12.0-
55.00) 
31.0 
(26.0-
31.0) 
0.51KW 21 
        
 24h 15.0 (14.0-
26.0) 
11.5 (7.0-
23.0) 
17.0 (14.0-
31.0) 
7.0 (2.0-
17.5) 
0.68KW 21 
        
VT(AUC) Post-op 30.2 (19.3) 19.8 (9.3) 25.2 (18.4) 38.0 (12.6) 0.28
AN 21 
        
 24h 26.4 (27.5) 15.7 (8.2) 12.0 (11.9) 19.8 (16.4) 0.60AN 21 
        
FiO2(AUC) Post-op 26.0 (16.2) 29.5 (18.6) 29.8 (18.6) 26.0 (12.6) 0.97
AN 21 
        
 24h 28.0 (26.3) 13.7 (11.7) 10.6 (10.0) 22.5 (12.9) 0.35AN 21 
        
OLV time 
(mins) 
Post-op 113.0 
(74.0-
114.0) 
116.0 
(113.0-
126.0) 
74.5 (48.0-
109.0) 
102.0 
(73.5-
105.5) 
0.95KW 21 
        
 24h 26.4 (27.5) 18.2 (9.2) 13.2 (10.7) 18.3 (17.4) 0.65AN 21 
Values are mean (SD) or median (IQR). p by KWKruskall Wallis test or ANanalysis of one-
way variance as appropriate. n, no of patients on which analysis is based. 
 
 
Figure 4.44. Risk of lung injury score immediately post-operatively for a five biomarker 
panel verses duration of one-lung ventilation.  
p=0.09, Kruskall-wallis test. n=21. 
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Association with clinically important outcomes 
High dependency unit stay 
High dependency unit (HDU) stay of greater than 48 hours was defined as 
prolonged. In the 22 patient cohort in which the multiple biomarker panel was 
measured, HDU was ‘prolonged’ in four patients. There were no significant 
differences in multiple biomarker panel score between patients with ‘normal’ or 
‘prolonged’ HDU stay (for either a four or five biomarker panel, immediately or 
24 hours post-operatively, Table 4.18) 
Table 4.18. Multiple biomarker panel score by duration of HDU stay. 
 
Time point Multiple biomarker panel score 
  
HDU stay:  ‘Normal’ ‘Prolonged’ p n 
      
Five biomarker panel Post-op 101.5 
(83.0-122.0) 
94.0 
(74.5-109.0) 
0.77 22 
      
 24h 109.0 
(79.0-115.0) 
85.5 
(58.0-119.5) 
0.57 21 
      
Four biomarker panel Post-op 24.5 
(13.0-31.0) 
40.5 
(23.0-51.0) 
0.23 22 
      
 24h 15.0 
(7.0-26.0) 
26.0 
(7.0-52.5) 
0.57 21 
p by Mann Whitney U test for all. n, no of patients on which analysis is based. 
Hospital stay 
There was no association between multiple biomarker panel score and length of 
hospital stay (for either a four or five biomarker panel, immediately or 24 hours 
post-operatively, Table 4.19) 
Table 4.19 Association between multiple biomarker panel score and length of hospital stay.  
 
Time point r p n 
     
Five biomarker panel Post-op -0.05 0.82 22 
 24h 0.06 0.79 21 
     
Four biomarker panel Post-op -0.15 0.50 22 
 24h 0.03 0.91 21 
r and p by Spearman’s rho for all. n, no of patients on which analysis is based. 
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4.6.5 Summary of results 
In order to summarise how well PTX3, CRP and both the four and five biomarker 
panels compare to the properties of the ‘ideal’ lung injury biomarker, the 
strength of evidence provided for each property has been graded as follows: 
++ Consistent evidence provided, in agreement with hypotheses, 
sensitivity analyses support main analysis. 
+ Some evidence provided, in agreement with hypotheses, but is 
either inconsistent, or results of sensitivity analyses and main 
analysis are not consistent. 
—  No supportive evidence provided 
  
Table 4.20. Summary of results – Utility of PTX3, CRP and a multiple biomarker panel as 
biomarkers of lung injury following lung resection. 
 PTX3 CRP 
Five 
biomarker 
panel 
Four 
biomarker 
panel 
Sensitivity and specificity for the 
outcome of interest ++ — — — 
Variation in proportion to the 
severity of illness ++ — — — 
Modification by an effective 
intervention + — — — 
Association with clinically 
important outcomes ++ + — — 
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4.7 Discussion 
4.7.1 Pentraxin 3 as a biomarker of post-lung resection lung 
injury 
There have been no previous reports of the measurement of PTX3 following lung 
resection. Others however have reported elevated PTX3 levels following other 
types of surgery. Akerfeldt et al measured PTX3 on days four and 30 post-
operatively in patients undergoing orthopaedic and cardiac surgery, observing a 
peak in PTX3 on post-operative day four, and concluding that PTX3 “shows a 
much smaller increment in humans in comparison with CRP”354. Part of the 
rationale for selecting PTX3 as a candidate lung injury biomarker for this study 
were the reports of previous observations suggesting that PTX3 levels peak more 
rapidly than CRP following an inflammatory insult321, 355. Peri et al (for example) 
measured PTX3 levels in patients admitted to the coronary care unit (CCU) with 
symptoms of acute myocardial infarction, observing that PTX3 levels peaked at 
7.5 hours following CCU admission whilst C-reactive protein did not peak until 24 
hours after admission356. It is plausible that Akerfeldt et al’s conclusion reflects 
CRP measurement at close to peak values whilst PTX3 levels may have attained 
peak levels some time previously and begun to wane. Kunes et al determined 
PTX3 levels in patients undergoing both ‘on-pump’ and ‘off-pump’ coronary 
artery bypass grafting357. In patients undergoing cardiopulmonary bypass PTX3 
levels were significantly higher than baseline by then end of the operation; peak 
levels were observed on the first post-operative day. Mirroring the findings of 
the current study in thoracic surgical patients, in patients undergoing ‘off-pump’ 
surgery (without use of cardiopulmonary bypass), PTX3 levels were unchanged 
from baseline immediately post-operatively, but again appeared to peak on 
post-operative day one, returning to baseline by day three (Kunes et al made no 
assessment of interval PTX3 level between the end of the operation and 24 hours 
post-operatively)357. Having detected an elevated PTX3 level at a single time 
point following lung resection, it is impossible on the basis of the current study 
to conclude whether PTX3 levels were detected before or after their peak. It 
would be of value to better determine the trajectory of PTX3 levels following 
lung resection, the observation of an elevated level at 6 or 12 hours post-
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operatively (for example) could greatly increase the potential prognostic utility 
of the biomarker.  
Pre-operative PTX3 levels were <20 pg/ml in all patients whilst 24 hours post-
operatively PTX3 values varied from <2 pg/ml to 2630 pg/ml reflecting in excess 
of a thousand fold variation in PTX response. In three patients, 24 hours post-
operative PTX3 level remained below the level of detection of the assay (<2 
pg/ml). Whilst these results reflect samples which were measured in duplicate, 
in an assay with an acceptable coefficient of variation of approximately 5% and 
so are presented with some confidence, a sensitivity analysis excluding these 
three patients was performed throughout. In almost all cases, this was 
supportive of the primary analysis. It is evident that there is a large degree of 
heterogeneity in the PTX3 response - a finding which could prove an asset in a 
potential biomarker. To serve as illustration, Muller et al observed mean PTX3 
levels to vary 1000-fold between patients with septic shock and controls, whilst 
variation in excess of a 100-fold was evident within the septic shock group355. 
Whilst such heterogeneity may represent variation in the severity of 
inflammatory stimulus, it will also be to some extent determined by the host 
response.  
The results of the current study suggest that PTX3 offers potential as a 
biomarker informative of lung injury in the thoracic surgical population. PTX3 
compared favourably to properties of the ‘ideal’ lung injury biomarker, and 
appeared to identify a population of patients with elevated post-operative lung 
injury score with high sensitivity. Johnson has suggested that in the research 
field of clinical risk prediction, an area under the receiver operatic 
characteristic curve of “0.75 is good and greater than 0.8 is exciting”358. In this 
context the values obtained in the current study of 0.81 for diagnostic predictive 
value and 0.85 for prognostic predicative value are encouraging, though it must 
be acknowledged the confidence intervals for these estimates are wide, 
reflecting the modesty of the sample size.  
At the cut-offs described, the sensitivity (and consequently negative predictive 
value) of PTX3 for predicting elevated lung injury score was high, whilst 
specificity was (67-70%) with PPV of 55-7%. Given these values, it is interesting 
to speculate what clinical role PTX3 levels might have. Putting concerns 
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regarding the confidence of the estimates observed aside temporarily, from the 
negative and positive predictive values observed in this study one could be 
confident that a patient with a ‘negative’ PTX3 value will not develop ‘lung 
injury’ (i.e. an elevated mLIS), whilst a ‘positive’ value suggests that a patient 
has an approximately 55% chance of developing the outcome. Such values are 
arguably satisfactory grounds on which to base clinical decisions such as whether 
to discharge from high dependency early (if ‘negative’), or whether to maintain 
a watchful eye, re-site an arterial line (!), induce a diuresis, start inhaled 
broncho-dilators or commence a trial of high flow nasal oxygenation if ‘positive’.  
It is an ambition of the author that PTX3 may serve as a suitable surrogate end-
point for use in clinical research in this population. In addition to providing 
benefit to the thoracic surgical population, one-lung ventilation has been 
described as a ‘human model’ of lung injury299. Such a model therefore, if 
validated, could facilitate early phase clinical investigation of therapeutic or 
preventative therapies before translation to wider critical care environment359. 
To this end, the lack of association between PTX3 level and indices of lung 
protective ventilation require further consideration. The ‘ideal’ lung injury 
biomarker must modifiable by an ‘effective intervention’; a property that would 
clearly be pre-requisite if the biomarker was the endpoint of a clinical study of a 
novel therapy. Whilst there was some suggestion from the data that PTX3 levels 
were highest in the quartiles of patients exposed to the longest duration of one-
lung ventilation and the highest fractional inhaled oxygen concentrations 
(signified by the visual appearances of Figures 4.23 and 4.27), there was no 
association between PTX3 and the area under either the peak airway pressure or 
tidal volume verses time curves.  
Quantifying ‘exposure’ to ventilatory parameters in this way (by area under the 
parameter verses time curve), was a novel initiative introduced by the author 
(Ben Shelley), seeking to take advantage of the rich data source provided by the 
Recall AIMS charting system (as illustrated in Figure 4.24) Such a method has not 
been described previously though is analogous to the “ventilator hyperpressure 
index” described by Licker at al128. Licker et at determined airway hyperpressure 
index as the “product of inspiratory plateau pressure >10 cmH2O and the 
duration of OLV”, observing the index to be an independent predictor of the 
development of ALI (OR=3.53 (CI1.7-8.6, p<0.01))128. Licker’s observations were 
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however made over ten years ago, during which time (as described in chapters 
one and two) the practice of one-lung ventilation has ‘evolved’. Though 
ventilators settings were not protocolised in this study, it is the author’s 
anecdotal opinion that lung protective ventilation is widely practiced locally 
(mean VT during the period of OLV was 6.9 ml/kg in the study cohort (data not 
shown)). 
Bastin et al reported significant elevations in the established lung injury 
biomarkers receptor for advanced glycation products (RAGE), von-Willebrand 
factor and interleukin (IL)-6 following lung resection but similarly were unable to 
demonstrate any association between biomarker levels and OLV duration, 
plateau pressure or tidal volume315. It seems reasonable to hypothesise that the 
lack of association observed between PTX3 levels and ventilatory parameters 
may be because the practice of lung protective ventilation has yielded any 
variation in ventilator settings insufficient to influence an injury, which is only in 
part ‘ventilator induced’. This may be especially so if the relationship between 
tidal volume / peak airway pressure and ‘injury’ is non-linear. Evidence from 
animals models has suggested that ventilator induced lung injury may occur in 
such a non-linear fashion90. Using a scintigraphic technique to simultaneously 
determine epithelial and endothelial permeability in a rat model of VILI, de 
Prost et al demonstrated the existence of a ‘threshold effect’ with ‘dramatic’ 
changes in both epithelial and endothelial permeability occurring as end-
inspiratory pressure was increased between 20 and 25 cmH2O
360. 
PTX3 consistently outperformed C-reactive protein as a lung injury biomarker. 
This is supportive of previous findings suggesting heterogeneity between the 
PTX3 and CRP response. C-reactive protein and PTX3 levels 24 hours post-
operatively were not significantly associated in the current study (r=0.32, 
p=0.08; Spearman’s rho; n=32; data not shown)69, 70. Though PTX3 is an acute 
phase protein from the same pentraxin ‘super-family’ as CRP, it would appear 
conclusively that measurement of PTX3 offers additional information than that 
obtained from CRP measurement. 
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4.7.2 Utility of a multiple lung injury biomarker panel following 
lung resection 
There is no evidence from the results presented that the ‘risk of lung injury 
score’ as presented by Fremont et al83 has any utility in the lung resection 
population. Freemont et al derived this score in a population of patients with 
ALI/ARDS of traumatic aetiology and its adoption for this study was made on the 
basis that lung injury after lung resection may more closely resemble sterile, 
traumatic lung injury than that of septic, atraumatic origin. Furthermore, this 
panel constitutes an aesthetic combination of epithelial, endothelial, fibrotic, 
pro-inflammatory, anti-inflammatory and heart failure markers, leading one to 
believe that multiple aspects of the complex pathophysiology of ALI/ARDS are 
well represented. There are a number of potential explanations for the 
‘negative’ findings observed. 
Firstly, the score was devised in a population of critically ill patients with 
established ALI/ARDS; a degree of lung injury of markedly greater severity than 
that seen in the post-operative population studied. Given the dramatic 
difference in pre-test probability for the diagnosis of ALI/ARDS, simply applying 
the same scores (based on the same individual biomarker cut-off levels) was 
likely naive and represents a significant methodological flaw. Given a much 
larger patient cohort, it would have been more appropriate to construct a new 
multivariate regression model (either with the same or alternative biomarkers). 
Secondly the seven biomarker panel was reduced to five due to the necessity to 
exclude the BNP results (discussed below), and the failure to detect TNF-α in any 
sample. Unknown to the author (B. Shelley) at the time of planning this study, 
Bastin et al, collecting plasma samples at the same time points, were similarly 
unable to detect any TNF-α response in patients undergoing lung resection315. 
Yim et al reported the generation of TNF-α to be ‘minimal’ in all patients 
(undergoing lung resection by either thoracotomy or video assisted thoracoscopic 
technique) both during and after surgery361. The mean values of observed TNF-α 
were ≤10pg/ml at all time points361, values below the lower level of detection of 
the assay kit used in this study. 
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Time from onset of surgery to attaining peak levels of any potential biomarker is 
a further challenge to studies of this sort in the post-operative population. 
Whilst in a critically ill patient with trauma or sepsis a sustained elevation of 
biomarker levels might be expected in most cases, the trajectory of many 
biomarkers in surgical models is of a discrete intra- or post-operative peak 
followed by resolution. Receptor for advance glycation end products (RAGE) 
peaked immediately post-operatively, whilst angiopoietin-2 and interleukin (IL)-
10 peaked on post-operative day one. Mismatch between sample timing and that 
of biomarker peak is also a likely explanation for elevated IL-8 levels being 
detected in so few patients in the current study. Yim et al documented a peak in 
IL-8 levels occurring four hours post-operatively with virtual resolution by 24 
hours post-operatively361. Komatsu et al reported similar findings362; it seems 
likely that if an IL-8 peak did occur in the current patient cohort, it was simply 
not detected due to it having occurred between the sample time points 
selected. Such differences between the timing of peak biomarker levels add 
further complication when considering combination of biomarkers into a score 
such as that described by Fremont et al83. Either a panel of biomarkers must be 
selected where peak levels can be anticipated to occur simultaneously (for 
example IL-10, Ang-2 and PTX3), or biomarker assays must be made at different 
time points and combined once all results available; a strategy that is likely to 
reduce any practical clinical utility of the panel. 
It is inherently desirable for a lung injury biomarker to be sufficiently ‘lung 
specific’ so as to be able to distinguish between pulmonary injury and systemic 
inflammation. To this end, biomarkers of pulmonary epithelial function are an 
obvious candidate (there are no markers truly specific to the pulmonary 
endothelium). In the specific context of patients undergoing lung resection 
however, lung specificity conveys a further complication. As observed previously 
for Krebs von den Lungen (KL)-6 and Surfactant protein (SP)-D, both pulmonary 
epithelial biomarkers315, 316, in this study post-operative RAGE levels were 
observed to vary in proportion to the volume of pulmonary tissue resected (r=-
0.43, p=0.046; Figure 4.33). Whilst adjustment of biomarker values to account 
for their anticipated fall (as subsequently performed for RAGE in the current 
study and previously advocated by both Maeda314 and Sukama316 and colleagues) 
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is an attractive solution, such models need further validation before they can be 
recommended and add further complexity to any investigation. 
4.7.3 Limitations 
Not protocolising the timing of arterial blood gas analysis nor maintenance of 
intra-arterial cannula has proved a significant limitation of this study and can 
only be described as a learning experience for the author.  
It must be recognized that the FiO2 values used in the calculation of PaO2/FiO2 
were estimates, based on the set FiO2 on the venturi device (which are held 
generally to be very reliable273) or on the flow rate through nasal cannuale.  No 
direct measurement of FiO2 was made; this was felt to be impractical in the 
clinical context of study (where PaO2/FiO2 was calculated over multiple time 
points in each individual patient over a prolonged period of time). It is widely 
recognized however that the performance (in terms of delivered FiO2) of oxygen 
delivery devices varies substantially in relation to tidal volume72 and pattern of 
respiration (in the case of nasal cannulae, nose verses mouth breathing282). 
Inaccuracy in estimation of FiO2 is therefore a limitation of this study, though 
one shared by the majority of the literature on the topic, where for pragmatic 
reasons it is not routine practice to measure FiO2 in spontaneously breathing 
patients. 
Whilst duration of HDU stay was taken as the duration of continuous pulse 
oximetry monitoring in attempt to avoid artefactual extension of the duration of 
HDU stay by non-clinical reasons (such as time of day and availability of ward 
beds), hospital stay can also be artefactually extended by similar ‘non-clinical’ 
reasons. It is a limitation of this study therefore that no assessment was made to 
distinguish between ‘fitness for discharge’ and ‘actual’ hospital discharge. 
Whilst no formal power analysis was performed for this pilot study, the further 
reduction in sample size from the original 35 to just 14 patients for whom 
modified lung injury score could be determined  on post-operative day two is 
disappointing. As a result the potential for negative findings to be the result of 
type-I error is considerable. Given the multiple comparisons made in a small 
cohort of patients, the potential for type-I error must also be appreciated; all 
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positive results must be considered ‘hypothesis generating’ rather than 
evidential. It must be emphasised however, in the study of PTX3, no single 
positive result is being championed in isolation and the results form a consistent, 
coherent argument in favour of PTX3 as a lung injury biomarker. 
The lack of results for IL-8 and TNF-α are discussed above. The implausible 
results from the B-type Natriuretic Peptide (BNP) analysis, necessitating their 
exclusion from analyses was a further limitation. Due to constraints of plasma 
availability and funding, these analyses were made as singulate assays with no 
possibility to rerun the assay. Inspection of the optical density verses BNP 
concentration ‘standard curve’ suggested no problems with the assay procedure. 
‘Standards’ were measured in duplicate; the coefficient of variation of the 
standard results was 14.3%, a value which, though high, is inadequate to explain 
yielded results being hundred times greater than anticipated.  
4.7.4 Conclusions 
The results of the current investigation reveal that PTX3 appears to conform to 
many of the properties of the ‘ideal’ lung injury biomarker in patients 
undergoing lung resection suggesting therefore that post-operative PTX3 
measurement may have a role in this population. Though encouraging, there 
remains however much further work to be done before PTX3 measurement could 
be routinely advocated. Firstly, the current study needs to be replicated in a 
larger cohort in order to confirm the predictive values observed. Secondly, the 
predictive value of PTX3 needs to be confirmed against the ‘hard’ end-points of 
ARDS diagnosis (as defined by the ‘Berlin’ definition), need for post-operative 
mechanical ventilation and mortality, rather than the surrogate endpoints of 
modified Lung Injury Score, oxygenation and chest X-ray score as studied in the 
current investigation. Thirdly, the post-operative kinetics of PTX3 require 
further exploration in order to more accurately characterise the optimal timing 
of blood sampling.  
In contrast, the current investigation demonstrates no role for the multiple 
biomarker panel studied. Much was learnt however of the challenges of 
biomarker measurement in the thoracic surgical population; such knowledge will 
be useful in the planning of future studies. Firstly, the importance of 
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appropriately timing blood sampling to biomarker kinetics was illustrated. In all 
future studies the author (B. Shelley) would advocate a preliminary pilot study 
of lesser sample size but measuring biomarker levels at more frequent time 
points in order to establish kinetics before seeking validation of a biomarkers 
utility. Secondly, due to the subtleties of differing pathogenesis, and a lower 
grade (sub-clinical) lung injury seen in post-operative patients compared to 
critical care patients, caution must exercised in the translation of findings from 
the wider critical care environment to post-operative populations. Thirdly, 
whilst ‘pulmonary specificity’ may be desirable in distinguishing pulmonary 
inflammation from systemic, measurement of pulmonary epithelial biomarker 
levels following lung resection brings the additional challenge of the need to 
adjust post-operative values; such adjustments require further validation.  
Angiopoietin-2, RAGE and IL-10 were all elevated in the majority of patients 
following lung resection. These three biomarkers may therefore be suitable for 
use individually or in combination with others following lung resection and the 
significance of the post-operative increases observed requires further 
exploration. 
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Appendix One 
5 Investigation IV: Reproducibility and construct 
validity of transpulmonary thermodilution 
derived extravascular lung water and pulmonary 
vascular permeability index following lung 
resection 
5.1 Introduction 
Measurement of extravascular lung water (EVLW) and pulmonary vascular 
permeability index (PVPI) by transpulmonary thermodilution (TPTD) has the 
potential to be a useful monitoring modality in the early post-operative period 
following lung resection115, 363. EVLW and PVPI have the potential to aid clinical 
decision making in this population and may in addition provide a useful surrogate 
endpoint for clinical research. Though yet to find an established role in clinical 
practice, EVLW and PVPI have been widely measured in the general critical care 
and post-operative populations. The validity of TPTD derived indices has been 
established in the critical care population (discussed in detail in the following 
literature search), but reproducibility and validity have not been established in 
post-operative patients who have undergone lung resection, where anatomical 
disruption of the pulmonary vascular bed and post-operative changes in 
pulmonary-vascular interaction might be hypothesised to compromise validity. 
In this study, the reproducibility and construct validity (cross-sectional and 
longitudinal) of TPTD derived EVLW and PVPI is examined in patients undergoing 
lung resection. Reproducibility is derived from replicate TPTD measurements 
according to standard equations. Post-operative oxygenation (PaO2/FiO2 ratio), 
chest X-ray score and fluid balance are defined as ‘constructs’ with which 
association between construct and EVLW / PVPI would be expected. Specifically, 
the premise of this investigation is that construct validity of TPTD derived EVLW 
and PVPI could be inferred by the observation of negative association between 
EVLW / PVPI and PaO2/FiO2, positive association between EVLW / PVPI and CXR 
score and positive association between EVLW and cumulative fluid balance. 
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As will be discussed in detail in the following literature search, current clinically 
available monitors for the measurement of TPTD derived indices rely on there 
being a fixed and linear relationship between pulmonary blood volume (PBV) and 
intra-thoracic blood volume (ITBV)M. In is intuitive however that following lung 
resection, where the volume of the pulmonary vascular bed is by definition 
reduced, that this relationship is unlikely to be maintained. It has been 
suggested therefore that the methodology of TPTD be amended for use following 
lung resection248 (discussed in detail in Appendix 5). It is the secondary 
hypothesis of this investigation that such adjustment of TPTD methodology will 
improve construct validity of EVLW and PVPI measurement following lung 
resection. 
  
                                         
M
 ITBV – the volume of blood within the thorax encompassing great veins, cardiac chambers, 
pulmonary vasculature and aorta. A fuller explanation follows in Section 5.3.2.1. 
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5.2 Literature review: Assessing utility of a diagnostic 
test 
Investigation IV of this thesis concerns the utility of extravascular lung water 
(EVLW) and pulmonary vascular permeability indices (PVPIs) measurement using 
the single indicator transpulmonary thermodilution technique as a clinical 
monitor in the post-operative period following lung resection. Prior to discussion 
of the specifics of the technique, I will firstly consider the purpose of collecting 
diagnostic information and secondly examine the criteria by which the 
usefulness of a diagnostic test may be assessed. For example purposes, 
reference is made to cardiac output measurement because the measurement of 
cardiac output is inherent to the measurement of EVLW/PVPIs, and a large 
evidence base already exists concerning the reproducibility and validity of 
cardiac output measurement. 
Whilst diagnostic tests are commonly performed in order to make a diagnosis, 
Sackett et al 364 describe four further purposes for the data obtained: 
 “To judge severity of illness”. 
 “To predict subsequent clinical course and prognosis of the illness and 
the patient”. 
 “To estimate the likely responsiveness to therapy in the future”. 
 “To determine the actual response to therapy in the present”. 
 
Sackett et al go on to describe that whatever the reason for applying the 
diagnostic test the “conscious clinician” is mandated to make some assessment 
of the usefulness of the diagnostic criteria. Whilst Sackett et al are discussing 
the use of commonly applied diagnostic tests in clinical practice, the 
introduction of a novel test (such as EVLW measurement) be it for clinical or 
research purposes requires (at least) the same consideration. To this end, 
Sackett et al provide eight criteria which can be applied “for deciding the 
usefulness of a diagnostic test”364. 
1. “Has there been an independent, ‘blind’ comparison with a ‘gold 
standard’ of diagnosis? 
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2. Has the diagnostic test been evaluated in a patient sample that included 
an appropriate spectrum of mild and severe, treated and untreated, 
disease? 
3. Was the setting for this evaluation, as well the filter through which study 
patients passed, adequately described? 
4. Have the reproducibility of the test result (precision) and its 
interpretation (observer variation) been determined? 
5. Has the term normal been defined sensibly as it applies to this test? 
6. If the test is advocated as part of a cluster or sequence of tests, has its 
individual contribution to the overall validity of the cluster or sequence 
been determined? 
7. Have the tactics for carrying out the test been described in sufficient 
detail to permit their exact replication? 
8. Has the utility of the test been determined?” 
 
Whilst some of the criteria are more applicable in the context of EVLW and PVPI 
measurement than others, in reviewing the background and evidence to date 
concerning measurement of EVLW and PVPI in the diagnosis and quantification of 
lung injury (Sections 5.4 and 5.6 respectively), attempt has been made to apply 
many of these criteria. Criterion 1 and 4, ‘validity’ and ‘reproducibility’ merit 
special consideration. 
5.2.1 Validity 
The ‘Oxford Dictionary of Epidemiology’ defines validity of a clinical 
measurement as “an expression of the degree to which a measurement 
measures what it purports to measure”365. Most commonly in medicine this is 
ascertained by comparison of the performance of a novel diagnostic test with 
that of a ‘gold standard’ (Sackett et al’s first criterion364). The gold standard 
represents a ‘definitive diagnosis’ and may be established in a variety of ways in 
different circumstances; the key point is that the gold standard is taken to 
represent the ‘truth’. Such an approach for example is commonly used in the 
field of cardiac output monitoring in which novel cardiac output monitors are 
compared to the pulmonary artery catheter366. Difficulty occurs however, in 
cases (such as the diagnosis of ALI/ARDS) where there is no gold standard. 
Though both the ‘American-European Consensus Conference’55 and ‘Berlin’50 
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definitions of ALI/ARDS attempt to provide criteria by which ALI/ARDS may be 
diagnosed, fundamentally ALI/ARDS is a clinical syndrome which lacks a gold 
standard diagnostic test.  
Several discrete types of validity have been described. These are discussed 
below, and summarised, with reference to examples reflecting the diagnosis of 
ALI/ARDS in Table 5.1. 
5.2.1.1 Criterion validity 
Criterion validity concerns the “extent to which a measurement correlates with 
an external criterion of the phenomenon under study”365. In the case of 
correspondence to a gold standard (discussed above), the gold standard is the 
criterion to which the novel measurement is compared, often referred to as the 
reference measurement. Two further types of criterion validity are recognised: 
Concurrent validityN 
Concurrent validity concerns the assessment of association between criterion 
and the measurement when both refer to the same point in time; in assessing 
agreement between a novel cardiac output monitor (measurement) and the 
pulmonary artery catheter (criterion) both measurements are taken 
simultaneously. Concurrent validity is also interpreted to reflect the ability of 
the measurement to appropriately distinguish between groups of patients 
determined by an alternative criterion; for example the ability of the 
measurement to identify presence of disease (where the criterion maybe an 
alternative or gold-standard diagnostic test) or to identify patients who have 
increased severity of disease (where the criterion may be a measure of disease 
severity). 
Predictive validityN 
Predictive validity concerns the assessment of association between criterion and 
the measurement when they are separated in time; the ability of the 
measurement to predict the criterion is assessed. Predictive validity may be 
                                         
N
 There is some discrepancy in reported definitions for types of validity. Some authors consider 
concurrent and predictive validity to be subsets of criterion validity, whilst others recognise them 
to be types of validity in their own right. In either situation the broad meanings of the terms as 
they are applied appears to be consistent. 
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Table 5.1. Types of validity. 
Validity 
measure 
Explanation Example as applied to ALI/ARDS 
Face validity Test appears ‘on its face’ to represent lung injury Patients identified by test to have lung injury appear to clinicians 
to do so. 
Test “feels right” to clinicians. 
   
Criterion validity Test corresponds to a gold standard measure of lung injury Not available. Diffuse alveolar damage on histology represents 
closest parallel.  
   
- ConcurrentA 
validity 
Test is able to distinguish between groups that it theoretically 
should be able to distinguish between. 
Test is able to identify groups of patients with or without 
ALI/ARDS or distinguish between mild, moderate or severe lung 
injury. 
Test is able to distinguish patients with cardiogenic and non-
cardiogenic pulmonary oedema. 
   
- PredictiveA 
validity 
Test is able to predict something it theoretically should be able to 
predict. 
Test is able to identify a group of patients with poor outcome 
e.g. prolonged duration of mechanical ventilation or death. 
   
Construct validity Extent to which the test corresponds to other measurements that 
would theoretically support the concept (or construct) being 
measured. 
Association observed between test and (for example) 
PaO2/FiO2, CXR score, lung injury score or pulmonary 
compliance. 
   
Content validity Extent to which the test reflects all of the aspects of the 
phenomena being studied. 
Patients identified by the test to have lung injury must 
demonstrate clinical, physiological and pathological components 
of the syndrome. 
PaO2, - partial pressure of oxygen; FiO2  - fraction of inspired oxygen; CXR – chest X-ray. 
A - There is some discrepancy in reported definitions for type of validity. Some authors consider concurrent and predictive validity to be subsets of criterion 
validity, whilst others recognise them to be types of validity in their own right. In either situation the broad meanings of the terms as they are applied appears to 
be consistent. 
Based on, though modified from Rubenfeld (2003)367 and Ferguson et al (2012)66. 
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observed if the measurement is able to identify patients who go on to develop a 
specific outcome (where the criterion may be mortality or prolonged hospital stay 
for example), or to identify patients who will respond to therapy (where the 
criterion reflects an alternative measurement of treatment response). 
Quantitative evaluation of criterion validity 
As discussed above, criterion validity concerns the “extent to which a 
measurement correlates with an external criterion” 365; it is perhaps unsurprising 
therefore that traditionally criterion validity has been assessed by the use of 
correlation and regression analysis. In their 1986 landmark paper, Bland and Altman 
challenged such a practice highlighting the subtle but important difference 
between association (as determined by calculation of a correlation coefficient) and 
agreement. Agreement they argue should be assessed by the use of bias and 
precision statistics, providing mean bias between the measurements and upper and 
lower limits of agreement, within which 95% of bias measurements should lie368, 369. 
What is less certain however is what constitutes an acceptable level of bias, in the 
face of which a monitoring technique can be considered valid. In 1999, Critchley 
and Critchley performed a meta-analysis of studies using bias and precision 
statistics to compare cardiac output measurement techniques369. They reported a 
lack of clearly defined criteria for acceptance of a new technique. Using graphical 
methodology, Critchley and Critchley illustrate that consideration must be made of 
the individual limits of precision of both the comparator and reference technique. 
As such where limits of precision of individual techniques are commonly in the 
range of 10-20%, then limits of agreement between the techniques of up to ±30% 
may be considered acceptable369.  
5.2.1.2 Validity in the absence of a gold standard 
Whilst the observance of correspondence to a gold standard is undoubtedly a proof 
of validity and classically the method by which validity of a clinical monitor is 
tested, such ‘criterion validity’ represents one of a number of different measures 
of validity365, 367, 370 (Table 5.1). In such circumstances (as in ALI/ARDS), where a 
gold standard is not available, resource to one of the other described forms of 
validity may be useful. 
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Construct validity 
Construct validity concerns the selection of one or more “logical consequences” of 
the disease. Observation of these consequences is taken to represent the gold 
standard; in such cases the “logical consequences” are called constructs and the 
validity test is referred to as construct validity364. 
The concept of construct validity is demonstrated by Ely et al, who in a study of 38 
intensive care patients sought to assess the reliability and validity of the Richmond 
Agitation-Sedation Scale (RASS)371. No gold standard for level of sedation exists, 
and whilst there are a number of sedation scales in common use there is no single 
objective assessment to which they could compare the RASS. Consequently Ely et al 
explored the construct validity of the RASS concluding that construct validity would 
be provided by observation of association with five characteristics: 1. Attention 
screening examination, 2. Glasgow Coma Scale (GCS) score, 3. Quantity of 
psychoactive medication administered, 4. Successful extubation and 5. Bispectral 
electroencephalography. Conceptually, the RASS scale would have construct 
validity if lower RASS score (more sedated) is associated with patients who have 
poorer attention, lower GCS, are receiving greater doses of sedative medication, 
are less likely to be successfully extubated and have lower bispectral index (and 
vice versa). 
Construct validity and ARDS 
In the process of deriving an updated definition of ARDS, the ‘ARDS Definition Task 
Force’ defined a ‘conceptual model’ of ARDS50:  
“The panel agreed that ARDS is a type of acute diffuse, inflammatory lung 
injury, leading to increased pulmonary vascular permeability, increased 
lung weight, and loss of aerated lung tissue. The clinical hallmarks are 
hypoxemia and bilateral radiographic opacities, associated with increased 
venous admixture, increased physiological dead space, and decreased lung 
compliance. The morphological hallmark of the acute phase is diffuse 
alveolar damage (i.e., oedema, inflammation, hyaline membrane, or 
haemorrhage)”.   
 ‘ARDS Definition Task Force’ (2012)50 
Whilst such a model does not provide a definition nor diagnostic criteria for 
ALI/ARDS it can be appreciated that from this, a number of ‘constructs’ can be 
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derived, against which a novel definition, diagnostic test or modality could be 
assessed. For example, if association is found between test X and the clinical 
findings of decreased oxygenation and typical radiological appearances; 
physiological evidence of increased shunt or decreased lung compliance and; the 
presence of diffuse alveolar damage in pathological specimens (in animal models or 
ex vivo human specimens), then it seems likely that test X is a measure of 
ALI/ARDS; ergo test X has construct validity as a measure of ALI/ARDS. Clearly the 
strength of the relationship observed and the finding of a quantitative relationship 
between test X and the associated variables would increase confidence in such 
validity. 
There has been no explicit discussion of what constitutes ‘construct validity’ for 
ALI/ARDS in the literature to date, however a multitude of studies have looked at 
clinical, physiological and pathological endpoints when studying lung injury for a 
variety of reasons. 
Content validity 
Primarily a tool of the social scientist, content validity concerns the extent to 
which a measurement reflects all of the components of the phenomena being 
studied365, 367, 370. The Oxford Dictionary of Epidemiology provides the following 
example: in order to have content validity a measurement of functional health 
status must incorporate all of the components of functional health: occupational, 
family and social functioning etc 365. If ALI/ARDS is taken to be represented by the 
conceptual model of the ARDS Definition Task Force reproduced above50, then any 
new definition of ALI/ARDS would have to encompass all of the elements described. 
Similarly for any measure of lung injury to exhibit content validity as a measure of 
ARDS (on the assumption ARDS is represented by the above model), it would be 
required to demonstrate the ability of the measure to identify patients with 
clinical, physiological and pathological features of ARDS. 
5.2.2 Reproducibility 
Where validity is taken to be “an expression of the degree to which a 
measurement measures what it purports to measure”365, ‘reproducibility’ (also 
referred to as ‘repeatability’ or ‘reliability’) reflects the ability of a test to 
consistently make a measurement and obtain the same results on repeated 
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measurements370. Any measurement is to some extent liable to error, and as such 
repeated measurements (of a constant) will rarely yield exactly the same result but 
rather will tend towards consistency.  Reliability is the assessment of this 
‘tendency towards consistency’ observed across repeated measurements. 
Unsurprisingly therefore “the best way to examine repeatability is to take 
repeated measurements on a series of subjects”368. Importantly to ensure 
assessment of reliability, such repeated measurements or ‘replicates’ require to be 
taken on the same individual in identical conditions and are commonly therefore 
performed in quick succession372. Where physiological measurements are prone to 
errors, such as in the measurement of cardiac output (where for example, 
respiration induces cyclical changes in cardiac output), the precision of a 
measurement can be improved by performing repeated measurements and 
averaging their results369; the averaged result is then taken to be the ‘true’ result 
for clinical interpretation.  
5.2.2.1 Quantitative evaluation of reliability 
Whilst the mean of repeated measurements can be used to provide an individual 
summary value for clinical use, the same mean value could be obtained from 
dramatically different data sets. For illustration, though the triplicate cardiac 
output values 4.8, 4.9, 5.3 L/min and 2.9, 4.5, 7.6 L/min both yield the same mean 
cardiac output (5.0L/min), the clinician can be more confident in the mean result 
of the former dataset than the latter due to the narrower range over which the 
data is spread. Quantitative evaluation of such ‘confidence’ in the mean value 
obtained can be determined by the use of precision statistics: 
Coefficient of variation (CV) is first determined as 
    
  
    
 
Equation 5.1 
From which coefficient of error (CE) and precision can be derived: 
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Equation 5.2 
Where n is the number of repeated measurements. Precision is then calculated as: 
                 
Equation 5.3 
As in the discussion above, concerning what can be considered to be an acceptable 
level of bias, there is no clearly defined limit at which precision may be considered 
acceptable. Holm et al describe that “according to usual practice”  a coefficient of 
variation of less than 10% may be considered ‘good’; between 10 and 15% 
considered ‘acceptable’ and greater than 15% considered ‘poor’373. Whilst no 
reference is provided for the derivation of such ‘usual practice’, the use of the cut-
offs described are supported by others374-377.  
Pragmatically, the importance of the precision of any monitoring technique is 
dependent upon the magnitude of the change in the variable the clinician wishes to 
be able to detect. Even the most imprecise of monitors is likely to be able to 
detect a change of 50% whilst a change of 5% (if perceived to be of clinical 
significance) would require an implausibly precise monitor. The minimum change 
that can be reliably recognised by a device may be determined by calculation of 
the least significant change (LSC)366, 374, where: 
                   
Equation 5.4 
Whilst no reference is provided for the derivation of the precision statistics 
described, these definitions have found widespread acceptance within the 
literature366, 374, 376, 378, 379. 
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5.3 Literature review: Principles of Trans-pulmonary 
Thermodilution  
This section describes the principles of indicator dilution measurement of blood 
flow, and explains how from these measurements, volumes may be determined. A 
detailed discussion is made of the assumptions underlying TPTD, and their potential 
for error in various states of normal and abnormal physiology.  
5.3.1 Measurement of flow 
5.3.1.1 The principle of indicator dilution 
As described by Reuter et al, indicator dilution techniques can be conceptualised in 
three discrete stages 380, 381:  
1) A known amount of an exogenous substance (the ‘indicator’) is injected into the 
circulation;  
2) The circulation carries the indicator through the heart where it is mixed and 
diluted;  
3) A detector positioned downstream measures and records the concentration of 
indicator over time. 
When an indicator is injected into a blood vessel, its concentration is promptly 
diluted by flowing blood. The speed at which this dilution takes place is a function 
of the magnitude of flow. If flow between injection point and detector location is 
high, then due to rapid dilution, the concentration of the indicator will fall quickly 
and the change in indicator concentration detected downstream will be small. 
Conversely, if flow is low, the indicator concentration will be diluted less and the 
concentration detected downstream will be greater. 
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Figure 5.1. Sample change in blood temperature verses time curves during thermodilution 
measurement of cardiac output.  
As measured by thermistors in the pulmonary artery or distal aorta. From Isakow and Schuster 
(2006)
382
. 
In practice, to determine cardiac output (CO) the indicator is injected into the 
central circulation via a venous cannula located in a central vein and its passage is 
detected at a point downstream either in the pulmonary artery (trans-cardiac 
thermodilution, TCTD), or in the distal aorta (trans-pulmonary thermodilution, 
TPTD). The passage of the indicator is determined against time with the generation 
of a thermodilution (concentration vs time) curve (Figure 5.1) from which flow can 
be derived (Equation 5.5  – known as the ‘Stewart-Hamilton’ equation after the two 
(independent) researchers responsible for the initial description and subsequent 
refinement of the technique383). 
 
Equation 5.5. 
Where Q is flow, A is the quantity of the indicator injected, and the integral 
represents the area under the concentration-time curve. 
Though a number of indicators have been used over the years for the clinical 
measurement of cardiac output (CO), the indicator most commonly used is 
temperature; either through the injection of cold saline or through the heating of 
blood via a thermal filament incorporated into the structure of the catheter. 
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Equation 5.5 has consequently been modified so that temperature can be used as 
the indicator:   
 
Equation 5.6. 
Where Tb is blood temperature at the time of injection, Ti is the injectate 
temperature, Vi is injectate volume
O, K is a catheter specific correction factorP, 
and the integral represents the area under the thermodilution curve.  
Thus CO is proportional to the duration of transit of warmed or cooled blood, and 
inversely proportional to the mean change in blood temperature. 
5.3.1.2 Assumptions / differences between trans-cardiac and trans-pulmonary 
thermodilution  
The accuracy and reproducibility of thermodilution measurements depend on a 
multitude of physical (relating to the injectate and injection), physiological 
(relating to the monitored patient) and numerical factors. Discussion will be made 
of those factors which relate specifically to TPTD measurements in clinical use. 
Shape of the thermodilution curve  
The temperature vs. time curves obtained during TPTD are broader and flatter 
when compared to those obtained from TCTD; consequently the observed change in 
blood temperature (T) is of lesser magnitude (Figure 5.1). TPTD measurements 
are therefore more vulnerable to errors caused by baseline drift and recirculation 
artefact (below). 
                                         
O
 Ti: injectate temperature after taking into account factors such as the intra-corporeal fraction of the 
injection catheter dead space, dead space of the injection catheter, injector set, any extension 
tubing, and temperature of both the blood before injection and of the extracorporeal dead space 
before injection. 
P
 K: correction factor accounting for the differences in the specific gravity and specific heat capacity of 
blood vs. saline, and dead space of the intravascular portion of the injecting catheter. 
Chapter 5  282 
Recirculation, loss, and detainment of indicator 
Indicator recirculation 
Whilst in theory the decay in the temperature verses time curve is assumed to be 
represented by a mono-exponential decay (Figure 5.2), in practice, recirculation of 
indicator occurs. To overcome this ‘recirculation artefact’, in calculation of the 
integral of the thermodilution curve in modern equipment, the thermodilution 
curve is anticipated to be monoexponential and free of recirculation artefact from 
80 to 50% of peak temperature change382, after which point the curve is truncated. 
The monitor then fits a straight line to the assumed mono-exponential decay, 
extrapolating the curve beyond the point of recirculation (Figure 5.2). 
Given the broader shape of the curve in TPTD compared to TCTD (reflecting the 
greater distance between superior vena cava and distal aorta), it is possible that 
recirculation artefact (stemming from the recirculation of indicator via fast 
pathways (e.g. cardiac and renal) being superimposed on the primary aortic 
thermodilution curve384) may be present before mono-exponential decay becomes 
established382. Such an occurrence would lead to an artefactual over-recovery of 
indicator reducing estimated cardiac output.  
By simultaneous assessment of pulmonary arterial and aortic thermodilution curves 
in a canine model, Bock et al demonstrated that during trans-pulmonary 
thermodilution, mono-exponential extrapolation of the thermodilution curve 
downslope leads to a calculated return of indicator of in excess of 100%, a 
physically impossible finding implying ‘recirculation artefact’ is routinely 
present385. The same authors went on to quantify the effect of indicator 
recirculation on the TPTD determination of CO reporting that indicator 
recirculation typically led to an underestimation of CO by TPTD of 2-3% when 
compared to TCTD.  
Indicator loss 
The properties of the ideal indicator have been defined by a number of authors382. 
Amongst these is the necessity that the indicator is confined to (and therefore not 
lost from) the intravascular compartment between injection and detection sites. If 
indicator is lost from the circulation, cardiac output will be over-estimated as less 
indicator will be detected downstream. Where the indicator is cold saline the 
potential exists for conductive re-warming of indicator by surrounding tissue. This 
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Figure 5.2. Diagrammatic representation of temperature-time curve during a thermodilution 
measurement.  
Change in temperature vs. time (upper curve) and on a semi-log scale (lower curve). Solid lines 
represent recorded values showing effects of indicator recirculation. The dotted lines represent the 
monoexponential decay ‘fit’ by the monitor in order to overcome the effects of recirculation. Note that 
the decay of the thermal curve becomes linear when graphed on the semi-log scale (bottom). Also 
shown are typical points used to measure the mean transit time (MTt) and the downslope time (DSt). 
From Isakow and Schuster (2006)
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might be expected to present more of an issue during low flow states or when the 
indicator travels a longer distance en route to the detector as is the case in TPTD. 
The presence of extra-vascular heat sinks as might occur in pericardial or pleural 
effusion might be expected to further compromise TPTD measurements.  
By simultaneously measuring cardiac output using TCTD and TPTD in 48 intensive 
care patients, Bock et al were able to calculate the amount of thermal indicator 
loss, demonstrating a 7% thermal loss between pulmonary artery and distal aorta 
and resulting in a systematic overestimation of CO by TPTD386. 
Clearly, there is some loss of cold indicator from the circulation during TPTD, an 
occurrence which leads to errors in the estimation of CO by TPTD, but which is 
capitalised upon in the measurement of intrathoracic volumes (below).  
Indicator detainment  
Whilst some indicator is irrecoverably ‘lost’ during thermodilution, much of the 
cold indicator that is ‘lost’ into the pulmonary extravascular space eventually 
returns to the intravascular space. Although preserved, this ‘detained’ indicator 
arrives late, abnormally prolonging the TPTD curve. Furthermore the potential 
exists for detained indicator to arrive at the detection point after the downslope of 
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the thermodilution curve has been truncated (in order to avoid recirculation 
artefact) and so be methodologically ‘lost’.  
The effects of indicator loss (leading to an artifactual increase in the estimated 
cardiac output) and the effects of recirculation artefact and indicator detainment 
(leading to an artifactual reduction in the estimated cardiac output) will to an 
extent cancel one another out;  as pointed out by Reuter however “which 
mechanism is of greater quantitative significance remains unclear”380. 
Changes in CO during measurement 
During spontaneous or mechanical ventilation, stroke volume varies with 
respiration by 10 to 50%387. Reproducibility of thermodilution readings can be 
improved by ensuring injection takes place at the same point in the respiratory 
cycle388. Conventionally reproducibility is further improved by averaging multiple 
consecutive measurements though it is important to ensure serial measurements 
are made at a time of relative stability as CO can of course change between 
measurements. Harris et al reported that during measurement, as cold injectate 
traverses the pulmonary circulation an approximately 10% reduction in heart rate is 
observed in 20% of patients; an effect postulated to be a direct effect of 
temperature on the sinus node389. 
Tricuspid regurgitation  
TCTD cardiac output measurements are generally considered to be unreliable in the 
presence of significant tricuspid regurgitation. Reverse flow of indicator from right 
ventricle to right atrium can result in indicator detainment, where regurgitated 
indicator leads to prolongation of the thermodilution curve or ‘loss’ of the 
indicator, as the regurgitated indicator arrives at the PA thermister too late, after 
the thermodilution curve has been truncated. Consequently tricuspid regurgitation 
can lead to an increase or decrease in the estimated CO. In TPTD, where the 
thermodilution curve is broader and measurement takes place over several cardio-
respiratory cycles, it might be hypothesised that TPTD derived estimates of CO 
might be more resilient to inaccuracies induced by tricuspid regurgitation. There 
are no reported studies of the effect of tricuspid regurgitation on TPTD. 
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5.3.1.3 Direct comparisons between trans-cardiac and trans-pulmonary 
thermodilution cardiac output measurement 
In general it can be seen that good correlation is observed between the TCPD and 
TPTD measurements whilst CO is consistently overestimated (bias < 10%) by TPTD 
techniques380. The overestimation of CO by TPTD has been variously attributed to 
the transient reduction in HR (and therefore cardiac output) resulting from 
administration of a cold bolus390-392, unaccounted for loss of thermal indicator 
during pulmonary transit386, 390, 391, 393-396 and early recirculation artefact391, 397. Most 
authors agree however that the modest difference between COTCTD and COTPTD is 
within the realms of what could be considered acceptable in the clinical context. It 
should be appreciated however that errors in determination of CO will be 
compounded during thermodilution measurement of volumes (discussed in the next 
section) which utilise CO (often more than once) in their calculation. 
5.3.2 Measurement of volumes 
As a result of observations that the shape of the thermodilution curve depends both 
on the flow and the volume of blood into which dye is distributed, methodologies 
have been derived to enable simultaneous measurement of blood volumes using 
indicator dilution techniques.  
5.3.2.1 ‘Mean transit time’ method for the measurement of volume of 
distribution 
The volume of distribution of an indicator during TPTD measurement consists of the 
blood volume between the site at which the bolus is delivered (the tip of the 
central venous cannula in the superior vena cava) to the site at which passage of 
indicator is detected (the tip of a femoral arterial catheter in the distal aorta) and 
so includes the volume of a portion of the SVC, all four cardiac chambers, the 
pulmonary blood volumes and the aorta. As such this volume is conventionally 
referred to as the intrathoracic blood volume (ITBV, Figure 5.3). Where 
temperature is the indicator concerned, thermal indicator is not restricted to the 
vascular space, but may be lost into the vessel walls and the surrounding lung 
parenchyma. This volume of distribution for a thermal indicator (which is 
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significantly greater than the ITBV) is referred to as the intrathoracic thermal 
volume (ITTV, Figure 5.3).  
The volume of distribution (Vd) of an indicator can be calculated as the product of 
flow (cardiac output) and the average or mean transit time for the indicator from 
the site of injection to the site of detection (MTt).  
           
Equation 5.7 
 
Intrathoracic blood volume, ITBV. 
Shaded area represents ITBV. RA, RV, LA & LV-EDV, right and left atrial 
and ventricular end-diastolic volumes. PBV, pulmonary blood volume.   
 
Intrathoracic thermal volume, ITTV. 
Shaded area represents ITTV. PTV, pulmonary thermal volume. 
 
Figure 5.3. Schematic representation of volumes measured during trans-pulmonary 
thermodilution techniques.  
Adapted from Brown et al (2009)
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MTt is determined form the thermodilution curve as the ratio of two integrals: 
 
            Equation 5.8. 
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Where AT (appearance time) is the elapsed time between injection of the indicator 
and its appearance at the detection site and c is the concentration of the 
indicator. 
Consequently, in the case of transpulmonary thermodilution, the total volume of 
distribution of the thermal indicator the intra-thoracic thermal volume (ITTV) can 
be determined from the mean transit time of the indicator. 
                    
Equation 5.9. 
  
It is evident from equations 5.8 & 9 that measurement of volumes derived from the 
transit time method are the function of three integrals (one for measurement of CO 
and two for measurement of MTt), and so the potential exists for errors in 
measurement of CO and MTt to be compounded in the final measurement result 378, 
382. 
5.3.2.2 ‘Slope volume’ methods for measurement of chamber volumes 
The ‘slope volume’ method represents a second method by which a volume can be 
derived during thermodilution. If an amount of indicator (A) is injected into a 
chamber of static volume (V) (Figure 5.4), then the concentration of the indicator 
in the chamber (C) can be represented as: 
 
   
 
 
   
Equation 5.10. 
 
 
Figure 5.4. Schematic representation of an indicator in a closed chamber.  
Drawn by the author (B Shelley), 2014. 
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If the indicator is delivered into a chamber of constant volume, but with a constant 
flow (Q) through the chamber (Figure 5.5) then assuming mixing is instantaneous 
and complete, the initial concentration of the indicator at the time of injection (t0) 
would also be represented by equation 5.10. 
 
Figure 5.5. Schematic representation of an indicator in an open chamber with constant flow. 
Drawn by the author (B Shelley), 2014. 
The subsequent rate of change in the amount of indicator in the chamber (dA/dt) 
would then be determined by the flow through the chamber, the volume of the 
chamber and the amount of indicator introduced such that: 
  
  
    
  
 
      
Equation 5.11. 
Substitution Equation 5.10 into Equation 5.11 and dividing both sides of this 
equation by V gives: 
  
  
  
  
 
 
Equation 5.12. 
Solution of Equation 5.12 by integration yields:  
      
 
      
Equation 5.13. 
Where k is the constant of integration.  To evaluate k, the known solution for the 
equation at t0 is used i.e. that at t0 the moment of injection of indicator, C0 = A/V. 
Substituting these values into Equation 5.13 yields: 
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Equation 5.14. 
A semi logarithmic plot of this function with concentration on the Y axis and t on 
the x axis is a straight line with a negative slope of Q/V. 
Q can be calculated simultaneously by estimation of the area under the 
thermodilution curve as above. As such by interrogation of the linear down-slope of 
the logarithmic thermodilution curve in addition to the AUC to determine Q, V can 
be estimated. 
What volumes are measured?  
Whilst cardiac output (or total flow in L/min) remains relatively constant as blood 
passes from the superior vena cava to distal aorta, the circulation cannot of course 
be represented by a single chamber of volume (V) as in the simplified model above, 
rather it is composed of a number of chambers of varying volume connected in 
series (superior vena cava, right atrium, right ventricle, pulmonary blood volume, 
left atrium, left ventricle, aorta). The question then is which if any of these 
volumes does Vslope-volume represent? 
Insight is provided by the frequently cited work of Newman et al398. Newman et al 
demonstrated in a series of experiments (both in laboratory models and in 
humans), that for a system of chambers connected in series, whilst the time to 
peak concentration (the peak of the thermodilution curve) is effected by the 
volumes of the smaller chambers, the subsequent downslope of the curve is 
determined solely by the volume of the largest chamber in the series. As the flow 
through each chamber is assumed to be uniform, then for each chamber the linear 
slope of the logarithmic thermodilution curve would be the chamber flow divided 
by the chamber volume. With smaller chambers therefore, the slope Q/V will be 
greater; indicator is described as rapidly ‘washing out’ of smaller chambers. As 
such, the downslope observed at the downstream detection site must represent the 
decay of the concentration-time curve from the largest volume chamber.  
During TPTD, the pulmonary circulation constitutes the largest chamber such that 
where dye is the indicator used, pulmonary blood volume (PBV) is determined from 
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the downslope of the dye-dilution curve (Equation 5.15, Figure 5.3). In the case of 
thermal indicator, pulmonary thermal volume (PTV) is determined (Equation 5.16, 
Figure 5.3). 
                
Equation 5.15. 
 
                   
Equation 5.16. 
In the clinical practice of TPTD, in must be emphasised that rather than the slope 
of the logarithmic thermodilution curve, the ‘down-slope time’ (DSt) is used in the 
calculation of volumes. The DSt is derived from the thermodilution curve (as 
indicated in Figure 5.2), and is time taken for the temperature decay to fall from 
85% to 45% of its maximum response399. Whilst DSt is therefore linearly related to 
the down-slope of the curve, all volumes derived will be ‘virtual’ volumes rather 
than accurate representations of the chamber volumes. 
Assumptions 
Before proceeding to discuss the role of these volumes in the derivation of EVLW, it 
is worth pausing to consider some of the assumptions inherent to the ‘down-slope 
time technique’ of volume measurement. In the narrative above, it is inherently 
assumed that the chamber volume in which mixing takes place is of constant 
volume, that mixing is complete and instantaneous, that no recirculation occurs 
and that flow is constant398. 
Constant volume 
Though the mixing volume of any indicator during trans-pulmonary thermodilution 
comprises the volumes of the cardiac chambers and the pulmonary blood volume, 
the volume derived from the DSt technique is that of the pulmonary blood (or 
thermal) volume alone. Though the volumes of the cardiac chambers change during 
the cardiac cycle, as pulmonary blood volume is assumed to remain constant, 
Newman concluded that modification of the theory to account for the contractile 
nature of the heart is not necessary398. 
Complete mixing 
Mixing is an important issue; incomplete mixing of indicator would lead to 
erroneously low results – the volume derived from the slope volume method 
represents the apparent volume into which the indicator is mixed398. In Newman’s 
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laboratory validation of the slope-volume technique, the right sided cardiac 
chambers, the pulmonary blood volume and the left sided cardiac chambers were 
each represented by a single chamber.  Though it is likely that complete mixing 
takes place in the chambers of the heart (it is an inherent assumption of the Fick 
method of CO measurement that mixing is complete), it is less likely that the 
pulmonary vasculature can be considered a single mixing chamber. As such, it is 
being assumed that complete mixing has taken place in the heart and main 
pulmonary artery prior to reaching the pulmonary circulation. 
Recirculation 
Whilst inaccuracies in the measurement of cardiac output resulting from indicator 
recirculation (where CO determination relies on the area under the thermodilution 
curve) are relatively modest, the estimation of mean transit time is more sensitive 
to the changes in the slope of the monoexponential decay function384. Using a 
deconvolution technique (requiring simultaneous assessment of pulmonary arterial 
and aortic thermodilution curves) Bock et al, explored the quantitative effect of 
indicator recirculation on TPTD estimates of EVLW, reporting that the 
overestimation of the mean transit time of heat is approximately 10%384. Such an 
overestimation resulted in an overestimation in EVLW of approximately 2ml/kg 
(20%) in baseline conditions and in excess of 4ml/kg (13%) in conditions of raised 
EVLW. Though initially suggesting that monoexponential extrapolation (as 
commonly employed) was therefore “unsuited for the determination of thermal 
recovery385”, in favour of the more complex deconvolution technique, Bock et al 
later concluded that the deconvolution technique appeared less practical for 
clinical practice and that “overall the gain in accuracy appears to be small 
compared to the more invasive procedure” 400. 
Constant flow 
Any variation in flow during the measurement period could potentially change the 
shape of the thermodilution curve. The prolonged duration of TPTD means that a 
subject is required to breathe during the measurement and as such, flow (cardiac 
output) will vary through the respiratory cycle by between 10 and 50%387. The 
effects of variations in flow with respiration on the validity of the down-slope time 
technique have not been explored.  
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5.4 Literature review: Single indicator trans-pulmonary 
thermodilution measurement of extra-vascular lung 
water 
Extravascular lung water (EVLW) is a theoretical construct representing the fluid 
volume of the lung, and encompasses all of the fluid within the lung but outside of 
the vascular compartment, including extravasated plasma in addition to 
intracellular water, lymphatic fluid and surfactant363. Conceptually increased EVLW 
is taken to represent the clinical syndrome of pulmonary oedema and as such EVLW 
has been described as “the morphologic correlate of pulmonary oedema”29. 
Measurement of EVLW relies on the assumption that a proportion of thermal 
indicator delivered into the pulmonary vascular compartment (as part of a TPTD 
measurement) is able to rapidly diffuse across the vascular wall and equilibrate 
within the lungs extravascular water content. In this section, the methodology, 
reproducibility and validity ‘single’ indicator trans-pulmonary thermodilution are 
explored. 
Whilst its validity has been well demonstrated, the technique of ‘double indicator’ 
thermo-dye dilution (where simultaneous injection of both cold and dye indicators 
is required) is time consuming, cumbersome and expensive, and despite promise 
has failed to become established in routine clinical practice396, 401, 402. An 
alternative to the thermo-dye dilution approach is provided by the ‘single’ 
(thermal / cold) indicator thermodilution (STD) such that by a series of calculations 
and assumptions EVLW may be derived from an injection of a thermal indicator 
alone. 
5.4.1 Methodology of STD measurement of EVLW 
Recall from Equations 5.9 and 5.16 above, that intra-thoracic thermal volume 
(ITTV) can be determined as the volume of distribution of cold indicator, and that 
pulmonary thermal volume (PTV) may determined from the same injection of cold 
indicator by the down-slope time technique. As the name suggests, ITTV is greater 
than PTV by an amount which is approximately equivalent to the thermal volume of 
the non-pulmonary chambers in series, i.e. the blood volumes of the cardiac 
chambers. As the blood volumes of the cardiac chambers are largest at end-
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diastole this volume has by convention become known as the global end-diastolic 
volume (GEDV, Figure 5.6) where: 
              
Equation 5.17. 
 
It is evident from Figure 5.6 that EVLW may be determined by subtraction of ITBV 
from ITTV.  
                  
Equation 5.18 
This is the methodology of ‘double’ indicator thermo-dye dilution (TDD) where ITBV 
may be determined from the volume of distribution of and indicator dye, and ITTV 
from the volume of distribution of a cold indicator (Equation 5.9). Whilst ITTV may 
be measured in the same way, ITBV however cannot be directly measured by STD 
but must be derived.  
The observations of Sakka et al396 are fundamental to the determination of EVLW 
by STD. Sakka et al demonstrated in a population of 57 critically ill patients (with 
the diagnoses of sepsis and subsequent multiple organ dysfunction (n = 23), ARDS (n 
= 17), polytrauma (n = 6), and after major surgery (n = 11)) that there is a constant 
and linear relationship between ITBV and GEDV (Figure 5.7) such that: 
                             
Equation 5.19. 
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Intrathoracic thermal volume, ITTV. 
Shaded area represents ITTV. PTV, pulmonary thermal volume.  RA, RV, LA & 
LV-EDV, right and left atrial and ventricular end-diastolic volumes. 
 
 Pulmonary thermal volume, PTV. 
 
Global end-diastolic volume, GEDV. 
Shaded area represents GEDV. GEDV = ITTV-PTV. 
 
Intrathoracic  blood volume, ITBV. 
Shaded area represents ITBV. ITBV = 1.25 x GEDV. 
 
Extravascular lung water, EVLW. 
EVLW = ITTV – ITBV. 
Figure 5.6. Schematic representation of volumes from which EVLW is derived during ‘single 
indicator’ trans-pulmonary thermodilution.  
Adapted from Brown et al (2009)
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Figure 5.7. Relationship between ITBV and GEDV in 57 critically ill patients.  
ITBV = (1.25 x GEDV)-28.4 (ml). From Sakka et al (2000)
403
. 
Sakka et al went on to validate this relationship in a further cohort of 209 patients 
(with diagnoses of sepsis (n = 99), ARDS (n = 31), severe head injury (n = 38), 
haemorrhagic shock (n = 19), intracranial haemorrhage (n = 19), and cerebral 
infarction (n = 3)) by comparing ITBV index (ITBVI, indexed to body surface area) 
derived from STD according to Equation 5.19 and ITBVI measured by TDD. They 
observed good correlation r=0.97 (p<0.0001) and very little bias between the two 
observations. 
The relationship observed by Sakka et al (Equation 5.19) has since been simplified 
to: 
                   
Equation 5.20. 
From which, once ITBV is known, it is a simple step to derive EVLW: 
                      
Equation 5.21. 
 
By substitution of Equations 5.9, 5.16, 5.17 and 5.20 into 5.21, EVLW can thus be 
derived from a STD injection: 
                                                            
 
                                                     
Equation 5.22. 
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5.4.2 Reproducibility of STD measurement of EVLW 
Whilst there are a plethora of studies measuring EVLWSTD in human subjects, few 
authors make any assessment of the reliability of the measurements obtained. 
Table 5.2 summarises studies examining the reliability of single thermodilution 
measurements in humans; it is noteworthy that it contains so few studies. Quoted 
values for the CV range from 4.8 to 8% with a least significant change value for 
EVLWSTD of 7.8-12%, suggesting the reproducibility of EVLWSTD to be ‘good’. 
Table 5.2. Reproducibility of single indicator trans-pulmonary thermodilution measurements. 
Study Pop N (n) Dup. Statistic CO GEDV ITBV EVLW PVPI 
Gondos 
et al. 
404
 
(2009) 
General ICU 30 
(30) 
2 
3 
4 
5 
CE 
CE 
CE 
CE 
4.7% 
4.9% 
4.9% 
4.8% 
4.9% 
4.8% 
4.8% 
4.8% 
- - - 
          
Craig et 
al. 
405
 
(2010) 
Intensive care – 
ALI/ARDS 
44 3 CV - - - 5.2% - 
          
Tagami et 
al. 
402
 
(2010) 
Ventilate ICU 30 3 CV - - - 7.4% - 
          
Monnet et 
al. 
376
 
(2011) 
Haem. unstable 
ICU  
91 
(91) 
3 
3 
Precision 
LSC 
8%  
12% 
8% 
12% 
- 8% 
12% 
- 
          
Tagami et 
al. 
374
 
(2012) 
Hypothermic 
post cardiac 
arrest 
88 
(462) 
3 CV 
LSC 
4.8% 
7.8% 
5.2% 
8.5% 
- 4.8% 
7.8% 
7.4% 
12.1% 
          
Wolf et al. 
406
 (2013) 
Elective 
neurosurgery 
101 
(635) 
‘At 
least’ 
3 
CV    10.1%  
N, number of patients; n, number of measurement sets; CE, coefficient of error; CV, coefficient of 
variation; LSC, least significant change. 
How many duplicates? 
The manufacturers of both TPTD monitors available for clinical use recommend 
that for each measurement, a triplicate set of thermodilution measurements are 
performed and the average values taken407, 408. There is little to suggest where the 
recommendation for triplicate injections originated409, but it is likely that it stems 
from observations of the precision of TCTD cardiac output measurement; Stetz et 
al demonstrated that in order to reliably detect a clinical change of 12 to 15%, 
three measurements per determination would be required410.  
The validity of direct extrapolation of such recommendations to TPTD 
measurements is however questionable. On one hand, due to the longer transit 
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time of indicator during TPTD, by making an assessment over a greater number of 
heartbeats, the effects of arrhythmias and variations in CO to respiration might be 
minimised, and so TPTD has the potential to be more reproducible than TCTD. On 
the other hand the long transit time provides the potential for greater 
susceptibility to errors resulting from baseline temperature drift during the course 
of the measurement373. Furthermore, whilst a given number of replications may be 
adequate for the measurement of CO (the only volume measured directly by 
TCTD), measurement of derived parameters from TPTD may require an increased 
number of replications. In order to measure EVLW by TPTD, cardiac output and the 
mean transit time and downslope time of thermal indicator must be determined. 
Each measurement has the potential for error, whilst synchronous variation may 
improve the precision of the estimate, asynchronous variation could potentially 
decrease precision, an effect which Godje et al describe “is a basic problem in 
mathematically combining multiple measurements to a new parameter” 375. 
In recent years, several authors have tackled the question of how many 
thermodilution replicates are required in order to provide a clinically acceptable 
level of precision. Tagami et al, examined the precision of TPTD measurement in 
88 patients following successful resuscitation after cardiac arrest, a population 
undergoing (and being re-warmed following) therapeutic hypothermia and as such 
high risk for variability secondary to changes in thermal baseline374. By performing 
10 successive thermodilution estimates of CI, GEDVI and pulmonary vascular 
permeability index (PVPI - see section 5.6), Tagami et al explored the effect of 
number of replications on the coefficient of variation, precision and least 
significant change statistics for the estimates concluding that in order to maintain 
precision less than 10% for all variables, at least three injections are required374. 
Monnet et al assessed the relationship between precision and number of 
replications in 91 haemodynamically stable intensive care patients and similarly 
observed that three replications are required to maintain precision less than 10% 
for CI, global end-diatolic volume index (GEDI) and extravascular lung water index 
ELWIQ376. 
                                         
Q
 Extravascular lung water index (ELWI), EVLW indexed to body weight (ml/kg). A discussion of the 
rationale for indexing EVLW is provided in Section 5.4.5. 
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From the work of Tagami374, Monnet376 and others (Table 5.2), it is evident that the 
precision of directly measured variables (CO and GEDV) is greater than for derived 
variables (EVLW and PVPI), where mathematical compounding or errors is a risk. 
In contrast to the conclusions of Tagami374 and Monnet376, in a study of 30 general 
ICU patients, Gondos et al 404 concluded that a coefficient of error of less than 5% 
(their predefined criteria of ‘scientific precision’) could be reliably obtained for CI 
and GEDVI by taking the average of just two individual injections. The authors 
made no assessment of the precision of EVLW estimates obtained from two 
injections.  
5.4.3 Validity of STD measurement of EVLW 
5.4.3.1 Criterion validity 
Since the original description of the STD technique by Sakka et al 403 and their 
validation against EVLWTDD there have been a large number of studies exploring the 
validity of EVLWSTD against the ‘gold standards’ of gravimetry and EVLWTDD.  
Comparisons with gravimetry 
There have been four animal studies which compare EVLWSTD to gravimetric EVLW 
(Table 5.3). These studies examine the relationship both in control animals and 
animals with pulmonary oedema, demonstrating across a wide range of EVLW 
values that there is good agreement between EVLWGRAV and EVLWSTD, but a 
systematic over-estimation of EVLW by STD techniques (mean bias +2.4 to 
+5.4ml/kg, Table 5.3).  
Much of the discrepancy observed between EVLWSTD and EVLWGRAV in the studies of 
Katzenelson et al and Rossi et al is likely to be reflected by the fact that these two 
studies use a commercially available STD TPTD monitor validated for human use, 
which determines EVLW based on the ‘ITBV=1.25xGEDV’ relationship described by 
Sakka et al403. As Kirov et al point out in their article of the same name, “animals 
and humans are not the same” 411. Whilst in humans the linear regression equation 
for the relationship between ITBV and GEDV is ITBV=1.25xGEDV-28.4ml (the 28.4ml 
intercept is dropped for simplicity in commercially available monitors), in pigs the 
linear regression equation has been reported to be ITBV=1.73xGEDV-7.7ml412 and in 
Chapter 5  299 
sheep ITBVI=1.43xGEDVI+13.48ml/kg411. In their study comparing EVLWSTD with 
EVLWGRAV in pigs, Rossi et al simultaneously establish the regression equation 
ITBV=1.52xGEDV+49.7ml (Table 5.3)413. By substituting the ITBV=1.25xGEDV 
equation for this one, the bias between EVLWSTD and EVLWGRAV reduced to a 
statistically not significant +2.34ml/kg 413. 
Table 5.3. Studies examining the validity of transpulmonary thermodilution derived EVLW 
verses gravimetry. 
Author 
(year) 
Species N  Pathology 
Correlation 
(EVLWSTD vs 
EVLWGRAV) 
Mean Bias 
(EVLWSTD – 
EVLWGRAV) 
Mean 
EVLWSTD/EVLWGRAV 
Kirov et al
414
 
(2004) 
Sheep 18 
4 
7 
7 
Overall 
Sham   
ALI - IV LPS 
ALI - IV OA  
r=0.85; p<0.01  
 
 
+4.9ml/kg  
 
 
 
 
1.44 
1.66 
1.54 
       
Katzenelson 
et al 
415
 
(2004) 
Dogs 15 
 
5 
5 
5 
 
Overall 
 
Control 
IV OA 
Hydrostatic 
oedema  
r=0.97; 
p<0.001 
+3.01ml/kg   
 
1.33 
1.13 
1.19 
       
Rossi et al 
413
 
(2006) 
Pigs 15 
 
6 
5 
Overall 
 
Sham 
LPS  
r=0.94; 
p<0.001 
 
 
+5.4ml/kg  
 
+5.11ml/kg 
+5.74ml/kg 
 
       
Kuzkov et al. 
416
 (2010) 
Sheep 11 
 
Control / 
OA 
r=0.85; p not 
provided. 
+2.4ml/kg   
 LPS, lipopolysaccharide; OA, Oleic acid. 
Kirov et al  (Table 5.3)  substituted the human coefficient of 1.25 with an ‘ovine’ 
coefficient of 1.34 previously established by the authors414. Even with this 
correction however, EVLWSTD continued to overestimate EVLWGRAV (mean bias 
=+4.91ml/kg)414. The authors hypothesise this could be explained by “heat 
exchange of the thermal indicator with extra-vascular intrathoracic structures, 
and by recirculation of indicator”414, the same explanations offered by others for 
the systematic overestimation of EVLWGRAV by TDD
400, 417. 
Comparisons with thermo-dye dilution measurement of EVLW 
Thermo-dye dilution (TDD) techniques (in which ITBV is directly measured and 
therefore not dependent on relationship between ITBV and GEDV) have been used 
as a ‘gold standard’ in comparison to which the validity of STD has been explored. 
Neumann compared EVLWSTD and EVLWTDD in 13 pigs with lung injury induced by 
oleic acid injection412, and observed a systematic over estimation of EVLWTDD by 
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EVLWSTD of 0.5-1ml/kg, which could be ameliorated by correcting the ITBV:GEDV 
relationship to ITBV=1.73xGEDV-7.7ml which he determined from the population. 
Clearly, the requirement to establish the ITBV:GEDV relationship in the study 
population (by TDD) undermines the value of a STD technique. As such, validity of 
STD (when compared to TDD) depends on the reliability and linearity of the 
ITBV=1.25xGEDV relationship; if the relationship is true, that is ITBV derived by 
calculation from GEDV (ITBVSTD) is equivalent to ITBV measured by TDD (ITBVTDD), 
then EVLWSTD will equal EVLWTDD.  
As previously discussed, Sakka et al derived the ITBV=1.25xGEDV in a cohort of 57 
critically ill patients and then validated the relationship in a further 209 
patients403. Sakka et al conclude their paper with the comment that “further 
validation studies are needed in the future to test our algorithm in other patient 
populations” 403. Despite this, and similar calls from others382, 412, there are only 
two studies which have subsequently attempted to confirm in humans the 
relationship observed by Sakka et al403 (Table 5.4). 
Table 5.4. Studies examining the validity of transpulmonary thermodilution derived EVLW 
verses thermo-dye dilution in humans. 
Author 
(year) 
N Population  
Correlation 
(EVLWSTD vs 
EVLWTDD) 
Mean Bias 
(EVLWSTD – 
EVLWTDD) 
ITBV=a.GEDV+b 
Buhre et al 
418 (1998) 
10 Neurosurgery   a = 1.16 
b = +86 
      
Sakka et al 
403 (2000) 
57 
(n=209) 
Critically ill r=0.96; p<0.0001 -0.2ml/kg a= 1.25 
b = -28.4 
      
Reuter et al 
419 (2002)  
19 Post-op cardiac 
surgery 
 
 
 a = 1.10 
b =+180 
      
Kuntscher et 
al 
420
 (2003) 
18 
(n=290) 
Burns r=0.83; p<0.01 +1.5ml/kg  
      
Hofmann et 
al 
421 (2005) 
174 Critically ill r=0.94; p value not 
provided 
0.0ml/kg  
      
Michard et al 
248 (2005) 
48 
(n=192) 
Surgical 
intensive care 
r=0.96; p value not 
provided 
-0.5ml/kg a = 1.16 
b = +97 
N, number of subjects; n, number of comparisons. 
From Table 5.4, it can be seen that bias between EVLWSTD and EVLWTDD tends to be 
modest. It must be appreciated however, that this data reflects mean bias. Sakka 
et al observe that EVLWSTD tends to overestimate EVLWTDD at low/normal values 
and underestimate EVLWTDD at higher values, as can be appreciated in Figure 5.8.  
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Michard et al similarly observed underestimation of EVLWTDD by STD at higher levels 
of EVLW, suggesting that a systematic correction factor should be applied at 
EVLWSTD levels > 7ml/kg
248.  
 
Figure 5.8. Relationship between extravascular lung water determined by single-thermo and 
thermo-dye dilution in 209 critically ill patinets.  
Line of identify is dashed. From Sakka et al (2000)
403.
 
Reuter et al  determined the relationship between ITBV and GEDV in 19 post-
operative patients following cardiac surgery (Table 5.4)419. By TDD they determined 
the relationship to be ITBVI=1.16xGEDVI+180ml/kg. They then estimated ITBVSTD 
using this equation, and the conventional ITBVSTD=1.25xGEDV. By comparing these 
estimated figures to ITBVTDD they demonstrated greater bias using the ‘1.25’ 
relationship (33ml/m2 vs 0.5ml/m2; no statistical comparison provided). 
Analogous to Mihm et al’s gravimetric validation of EVLDTDD in organ donors
422, 
Tagami et al performed a similar study comparing EVLWSTD and EVLWGRAV in 30 lung 
specimens harvested at autopsy402. Whilst unfortunately they did not measure 
gravimetric EVLW, Tagami et al observed good association between EVLWSTD and 
post-mortem lung weight (r=0.90; p<0.001). 
In summary it is evident that both EVLWTDD and EVLWSTD systematically 
overestimate EVLWGRAV, but that the relationship between EVLWTDD and EVLWSTD is 
dependent on EVLW level, with EVLWSTD tending to underestimate EVLWTDD (and so 
approximate EVLWGRAV) as EVLW rises.  
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5.4.3.2 Concurrent validity 
In a prospective observational cohort of 51 patients admitted to a mixed ITU with 
shock, Chew et al examined the utility of EVLW measurement as a diagnostic tool 
in the diagnosis of ALI/ARDS423. By utilising an EVLW cut-off of >10ml/kg, they 
demonstrated that EVLW added diagnostic value; an ELWI >10ml/kg increased the 
post-test odds ratio for the diagnosis of lung injury (ALI, ARDS or LIS>2.5) by up to 
three-fold whilst an ELWI <10ml/kg reduces the post-test odds by almost half. The 
sensitivity and specificity of ELWI for the diagnosis of both ALI and ARDS were 
approximately 70 percent423. 
Clinically, it would be arguably of more value if EVLW could serve as an early 
marker of impending ALI/ARDS allowing for example, identification of at risk 
patients and targeting of therapies. Le Tourneau et al measured EVLW on admission 
to intensive care in 29 patients424. They demonstrated that an EVLW cut off of 
10ml/kg had had a positive predictive value of 83%, and negative predictive value 
of 70% to predict progression to acute lung injury. Whilst these values are 
impressive, it must be acknowledged that the author’s claim that “extravascular 
lung water predicts progression to acute lung injury in patients with increased 
risk” is a bold claim from the sample size presented (8 patients had ‘progression to 
ALI’ in the study) and that the positive predictive value quoted though noteworthy 
may be over estimated in the context of the high prevalence of ‘progression to ALI’ 
found in the study425. Nonetheless the potential for EVLW measurement to identify 
patients at risk of progressing to ALI over two days before they fulfil ALI/ARDS 
criteria is an exciting one. 
5.4.3.3 Construct validity of EVLW measurement 
Though no established criteria exist against which the construct validity of a 
technique seeking to measure ALI/ARDS can be compared, the ‘Berlin’ ARDS 
Definition Task Force50 provided a clinical, physiological and pathological 
framework from which constructs can be createdR. Thus, if association is found 
between measured values of EVLW and the clinical findings of decreased 
oxygenation and typical radiological appearances; physiological evidence of 
increased shunt or decreased lung compliance and; the presence of diffuse alveolar 
                                         
R
Discussed in detail in Section 5.2.1. 
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damage in pathological specimens (in animal models or ex-vivo human specimens) 
then it could be concluded that EVLW has construct validity as a measure of 
pulmonary oedema / lung injury. There have been numerous such findings (either 
directly sought or collected as a by product during clinical studies) suggestive of 
the construct validity of EVLW in the measurement of pulmonary oedema in 
critically ill humans with or without ALI/ARDS using both TDD and STD techniques 
(Table 5.5).  
As can be seen from Table 5.5, association has been observed between EVLW 
measurements and oxygenation (determined as PaO2/FiO2
402, 405, 423, 426-434, 
respiratory index435, oxygenation index405) , chest X-ray scores423, 428, 430, 436, 437, lung 
injury score402, 405, 423, 428-430, 432, 433, venous admixture 438, pulmonary compliance 405, 
430, 432, pulmonary dead space fraction (VD/VT) 
429 and level of PEEP427, 439 in both 
post-operative and critically ill intensive care patients. In addition EVLW has been 
shown to be associated with severity of illness (determined as Sequential Organ 
Failure Assessment (SOFA) score in critically ill patients429. 
Whilst there have been few studies directly comparing EVLW with biological 
markers of infection, inflammation or lung injury, EVLW has been demonstrated to 
be associated with levels of procalcitonin439, neutrophil elastase443 and endothelin-
1430 in peripheral blood. 
Whilst there are many studies suggesting construct validity of EVLW measurement 
several have been negative428, 438, 441. The failure to find any association between 
EVLW and physiological variables in the studies of Patroniti et al438 and Groeneveld 
et al441 could potentially be explained by the modest sample size in each study 
(n=14 and 16 respectively). Furthermore in the study of Groeneveld et al441 TDD 
estimates of EVLW were made in post-operative patients following major vascular 
surgery where the degree of lung injury (and therefore variation in EVLW and other 
physiological variables) might be expected to be modest. Perhaps more surprising is 
the finding of no identifiable relationship between EVLW and fluid balance in 
several studies381, 428, 433.  
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Table 5.5. Studies exploring the construct validity of extravascular lung water measurement in 
humans. 
Author (year) Population Method N  
Comparator 
(EVLW vs....) 
Findings 
Baudendistel 
et al.
436 
(1982) 
Blunt trauma 
following RTA 
TDD 12 
(n=70) 
CXR score r=0.623; ‘significant,’ p 
not provided 
      
Halperin et 
al.
440
 (1985) 
Intensive care 
patients with 
respiratory failure 
TDD 12 
(n=73) 
CXR score r=0.51; p<0.05 
No correlation between 
∆EVLW and ∆CXR score 
      
Davey-Quinn  
et al.
431
 
(1999) 
Intensive care – ALI 
& ARDS 
TDD 11 PaO2/FiO2 
 
ELWI independent 
predictor of PaO2/FiO2 
(B=-2.8±0.45; p<0.0001) 
      
Szakmany et 
al. 
427
 (2004) 
Intensive care – 
septic shock and 
ALI/ARDS 
STD 23 PaO2/FiO2 
PEEP 
r=-0.36; p<0.001 
r=0.56; p<0.001 
      
Martin et al.
428
 
(2005) 
Medical intensive 
care – severe 
sepsis 
STD 29 PaO2/FiO2 
LIS 
CXR score 
Fluid bal. 
r=-0.52; p<0.0001 
r=0.42; p<0.0001 
r=0.53; p<0.0001 
No association 
      
Patroniti et al. 
438
 (2005) 
Intensive care – 
ARDS 
TDD 14 Compliance 
PaO2/FiO2 
Venous 
admixture 
-0.43; NS 
0.47; NS 
-0.57; p<0.05 
      
Wan et al. 
426
 
(2005) 
Intensive care – 
septic shock 
STD 23 PaO2/FiO2 ∆ELWI vs ∆PaO2/FiO2 
over consecutive 
measurement days: 
r = -0.33; p <0.01 
      
Groeneveld et 
al. 
441
 
(2006) 
Post-operative - 
major vascular 
surgery 
TDD 16 Pulmonary 
leak index 
PaO2/FiO2 
Compliance 
CXR score 
LIS 
No significant difference 
in any parameter in 
patients with EVLW ≤ 7 
compared with EVLW > 
7. 
      
Kuzkov et al. 
430
 
(2006) 
Intensive care – 
septic shock and 
acute lung injury 
STD 38  
Compliance 
PaO2/FiO2 
LIS  
CXR score 
 
Endothelin 1 
Day 1 
r =0.48 
r=-0.5 
r=0.46 
r=0.39 
Day 3 
r=0.51 
r=-0.49 
r=0.53 
(p<0.01 for 
all) 
Significantly higher in 
patients with EVLW ≥ 7 
      
Sato et al. 
435
 
(2007) 
Post-operative - 
oesophagectomy 
STD 23 Respiratory 
index 
r=0.64; p<0.00001 
      
Berkowitz et 
al 
433
 
(2008) 
Medical and 
surgical intensive 
care 
STD 30 
(225) 
LIS 
PaO2/FiO2 
 
Fluid bal. 
EVLWPBW: r=0.62;   
EVLWPBW: r=-0.50;   
p<0.01 for all 
No association  
      
Oshima et al. 
432
 
(2008) 
Post-operative – 
oesophagectomy 
STD 25 PaO2/FiO2 
Compliance 
LIS 
r=-0.36; p=0.014 
r=-0.625; p=0.0001 
r=0.614; p=0.0001  
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Author (year) Population Method N  
Comparator 
(EVLW vs....) 
Findings 
Phillips et al. 
429
 
(2008) 
Intensive care – 
sepsis induced 
ARDS 
STD 19 LIS 
SOFA 
PaO2/FiO2 
VD/VT 
r=0.53; p=0.02 
r=0.61; p=0.006 
r=-0.53; p=0.02 
r=0.62; p=0.005 
      
Bognar et al. 
439
 
(2010) 
Intensive care - 
>20% burns 
STD 28 PEEP 
PCT 
r=0.50; p=0.017 
r=0.60; p=0.008 
      
Chung et al. 
442
 
(2010) 
Intensive care – 
severe sepsis 
STD 67  
SOFA 
Day 1 
r=0.70; 
p<0.001 
Day 3  
r=0.77; 
p<0.001 
       
Craig et al. 
405
 
(2010) 
Intensive care – 
ALI/ARDS 
STD 44 LIS 
Oxygenation 
index 
PaO2/FiO2 
Compliance 
r=0.50; p=0.0005 
r=0.56; p=0.0001 
 
r=-0.57; P<0.0001 
r=-0.06; p=0.71 
      
Tagami et 
al.
402
  
(2010) 
Ventilated ITU STD 30 LIS 
PaO2/FiO2 
r=0.61; p<0.001 
r=-0.41; p<0.02 
 
      
Tagami et al. 
443
 
(2011) 
HDU/ITU – 
community 
acquired 
pneumonia 
STD 14 
(6 in 
ITU) 
Plasma 
neutrophil 
elastase 
 
Day 1 r=0.88, p<0.02 
Day 2 r=0.83, p<0.04 
 
      
Aman et al. 
381
 (2012) 
Intensive care – 
septic and 
nonseptic 
TDD 63 PaO2/FiO2 
 
 
Fluid balance 
∆PaO2/FiO2 associated 
with ∆EVLW (r=0.36; 
p=0.004) 
∆EVLW no assoc. with 
fluid administration  
      
Chew et al. 
423
 
(2012) 
Intensive care – 
SIRS and 
‘circulatory failure’ 
STD 51 PaO2/FiO2 
CXR score 
PEEP 
LIS 
 
r=-0.37 to -0.49; p=0.001 
r=0.26 to 0.46; p=0.002 
No association 
Increasing ELWI with 
increasing strata of LIS 
(p<0.01) 
      
Kushimoto et 
al. 
434
 
(2012) 
Intensive care – 
multicentre 
predominantly 
ALI/ARDS 
STD 266  
 
 
PaO2/FiO2 r=-0.21; p<0.01 
      
Mallat et al. 
444
 
(2012) 
Intensive care – 
septic shock 
STD 55 LIS 
PaO2/FiO2 
 
 
Compliance 
r=0.52, 0.55, 0.6  
r=-0.32, -0.37,  -0.37 
days 1-3 respectively,  
p<0.05 for all. 
No association over all 3 
days. 
      
Wolf et al. 
406
 
(2013) 
Intensive care -
elective neuro-
surgery 
STD 101 Fluid balance EVLW increased by 3.4% 
per litre fluid gain 
(p=0.04) 
      
Brown et al 
437
 
(2013) 
Intensive care – 
ALI/ARDS 
STD 59 
n=476 
CXR score r=0.35; p<0.001 
STD – ‘single’ thermodilution. TDD – thermo-dye dilution.  LIS – ‘Lung Injury Score’. Fluid bal., fluid 
balance. LIS, lung injury score.  
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Positive fluid balance has been associated with poor oxygenation, increased lung 
injury score, and prolonged ventilator requirement in patients with ALI/ARDS445. It 
might be expected therefore that patients with more positive fluid balance are 
likely to have greater EVLW. Aman et al explored the relationship between fluid 
loading and changes in EVLW in 63 mechanically ventilated patients. By defining 
changes in EVLW of ≥ 10% as a positive response, the authors observed that 
increases in EVLW following fluid loading are dependent on cardiac index and 
pulmonary vascular filling (determined as PBVI) but independent of the volume and 
type of fluid administered. One hypothesis for the lack of association between 
EVLW and fluid balance may be the existence of a threshold effect for the 
influence of fluid balance on EVLW such that in studies where standard practice (in 
the wake of the US ARDS Network Fluid and Catheters Treatment trial445) may be to 
restrict fluid administration, fluid balance does not accumulate sufficiently to 
levels where a dependent increase in EVLW might be expected. Such a hypothesis 
is supported by the finding of Phillips et al who observed a linear relationship 
between EVLW and fluid volume administered in a porcine model of haemorrhage 
and resuscitation where fluid volumes administered were commonly in excess of 
50ml/kg; visual inspection of the scatter plot of fluid volume vs ELWI provided by 
the authors suggest that with fluid volumes of <50ml/kg such linear association is 
unlikely to be present446. 
5.4.3.4 Predictive validity of EVLW measurement for mortality 
There have been a large number of studies assessing the prognostic validity of 
EVLW (Table 5.6). ELWI has been demonstrated to be consistently higher in non-
survivors than survivors in critically ill patients with a wide variety of pathologies, 
both with and with-out ARDS. This might be anticipated as ELWI is likely to reflect 
overall severity of illness; however in the study by Craig et al, this effect was 
maintained after adjustment for covariates reflecting severity of illness405, 
suggesting that in critically ill patients with ALI/ARDS ELWI has prognostic value in 
addition to being a simple marker of disease severity. Similarly several other 
authors found EVLW to be an independent predictor of mortality442, 447, 448.  
Though the estimates of AUROCC, sensitivity and specificity of ELWI reported in 
(Table 5.6) are encouraging, many of the studies listed have a small sample size, 
(all but two are in less than 100 patients, most less than 50) resulting in broad 
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confidence intervals for the estimates. In attempt to provide some clarity, Zhang 
et al recently published a systematic review in which they conducted a meta-
analysis exploring the relationship between ELWI and mortality in critically ill 
patients449. Pooling the results of 11 studies including 670 individual patients they 
demonstrated significantly higher ELWI in nonsurvivors than in survivors (mean 
difference of 5.06 ml/kg [95%CI -7.523 to -2.58]). Though their analysis was 
hampered by significant heterogeneity (I2=90%), small sample sizes in many studies 
and variations in body weight to which EVLW was indexed (actual or predicted body 
weight), Zhang et al report an overall 81% sensitivity [95% CI 72-88] and 66% 
specificity [95% CI 0.55-0.76] for ELWI for the prediction of mortality in critically ill 
patients. 
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Table 5.6. Summary of studies examining predictive validity of EVLW. 
Author 
(year) 
Population Method N Survivors v. nonsurvivors AUROCC Cut off Sens Spec 
Davey-Quinn  
et al.
431
 
(1999) 
Intensive care – 
ALI/ARDS 
TDD 11 Initial ELWI higher in nonsurvivors. 
(31.0 vs 20.7 ml/kg; p=0.013) 
- - - - 
         
Sakka et 
al.
447
 (2002) 
Surgical intensive 
care 
TDD 373 Maximum ELWI higher in nonsurvivors. 
 (10.2 vs 14.3ml/kg; p<0.001) 
 
0.649 
 
9.2ml/kg 
6.5ml/kg 
 
69.4% 
 
50.8% 
         
Martin et al. 
428
 (2005) 
Medical intensive care STD 29 EVLW higher in nonsurvivors  
(14 ml/kg vs 8.0 ml/kg; p<0.001) 
- - - - 
         
Kuzkov et al. 
430
 (2006) 
Intensive care – septic 
shock and acute lung 
injury 
STD 38 Day 3, EVLW higher in nonsurvivors. 
 (6.6 vs 11.1ml/kg; p<0.05) 
- - - - 
         
Yang et al.
450
 
(2006) 
Intensive care – septic 
shock 
STD 50 Baseline: No significant difference in EVLW between 
survivors and nonsurvivors. 
Day 3. ELWI significantly higher in nonsurvivors. (14.3 
vs 8.1 ml/kg; p=0.001) 
 
 
0.74 
 
 
 
7.5ml/kg 
 
 
83% 
 
 
54% 
         
Chung et al. 
451
 (2008) 
Medical intensive care 
– severe sepsis 
STD 33 Proportion of patients surviving with ELWI > 10ml/kg: 
15% vs 68%; p=0.0008 
- 10ml/kg 88.2% 68.7% 
         
Philips et al. 
429
 (2008) 
Intensive care STD 19 Day 1.ELWI higher in nonsurvivors. 
(20.6 vs 11.6ml/kg; p=0.002). 
  
0.988  16ml/kg 100% 
 
86% 
 
         
Bognar et al. 
439
 (2010) 
Intensive care - >20% 
burns 
STD 28 Day 1 & 3. ELWI higher in nonsurvivors (data not 
provided; p<0.01, <0.001 respectively) 
- - - - 
         
Chung et al. 
442
 (2010) 
Intensive care – 
severe sepsis 
STD 67 Day 1. Pulmonary sepsis - ELWI higher in nonsurvivors 
(25.0 vs 11.8ml/kg; p=0.001). Non-pulmonary sepsis - 
ELWI higher in nonsurvivors (22.0 vs 12.8 ml/kg; 
p=0.012).  
0.88 
 
10ml/kg 94.7% 66.7% 
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Author 
(year) 
Population Method N Survivors v. nonsurvivors AUROCC Cut off Sens Spec 
Craig et al. 
405
 (2010) 
Intensive care – 
ALI/ARDS 
STD 44 First reading within 48hrs of diagnosis.  
ELWI higher in nonsurvivors. 
 (17.5 vs 10.6ml/kg; p=0.003) 
0.80  
 
16ml/kg 
 
75% 
 
78% 
 
         
Chew et al. 
423
 (2012) 
Intensive care – SIRS 
and ‘circulatory failure’ 
STD 51 First measurement (within 6 hours of admission). ELWI 
higher in non survivors. 
(10.6 vs 9.1ml/kg; p=0.05) 
- 10ml/kg - - 
         
Mallat et al. 
444
 (2012) 
Intensive care – septic 
shock 
STD 55 ELWI higher on day 3 in non survivors (p<0.001),  (no 
difference day 1 & 2). 
OR of death ELWI = 1.7 per SD (95% CI 1.1-3.7; 
p=0.02). 
0.85  14ml/kg 75% 
 
76%  
         
Brown et al 
437
 (2013) 
Intensive care – 
ALI/ARDS 
STD 59 
 
Baseline ELWI higher in non survivors. 
(17 vs 12 ml/kg; p=0.05) 
 
0.68  - - - 
         
Jozwiak et 
al. 
448
 (2013) 
Medical intensive care 
- ARDS 
STD 200 Day 1. ELWI not significantly different between non 
survivors and survivors. 
Maximum ELWI higher in non survivors 
(24 vs 19 ml/kg p<0.001) 
- 21ml/kg 
(max) 
54% 
 
73% 
 
STD, ‘single’ thermodilution; TDD, thermo-dye dilution; AUROCC, area under the receiver operating characteristic curve; Sens., sensitivity; Spec., specificity. 
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5.4.4 Sensitivity and specificity of extravascular lung water 
measurement. 
Rather than examining the sensitivity and specificity of EVLW according to the 
numerical definitions of the terms, this section is concerned with the following 
questions: Firstly, are changes in EVLW specific to changes in interstitial and 
alveolar oedema?  Secondly, how sensitive are TPTD techniques to small changes in 
EVLW?  
5.4.4.1 Specificity of EVLW measurement 
Clinical measurement of EVLW is made on the assumption that EVLW is “the 
morphologic correlate of pulmonary oedema”29, in the belief that the extravascular 
thermal volume is the fluid volume of the lung interstitium and alveolar spaces 
with which thermal indicator may exchange. It is plausible that the presence of 
pleural or pericardial effusions could provide a further extravascular fluid volume 
into which cold indicator could distribute, leading to an artefactual over-estimate 
of the EVLW volume. 
Pulmonary oedema 
Bongard et al created a porcine hydrostatic pulmonary oedema model by variable 
inflation of a left atrial balloon29. By titrating cuff inflation to a predetermined 
level of EVLW (measured by TDD) and examining histological autopsy specimens at 
progressively increasing levels of EVLW, they describe a familiar progression of 
pulmonary oedema evolving from inter-alveolar septal thickening, to perivascular 
cuffing before fulminant alveolar flooding. Bongard et al provide compelling 
evidence for the ability of TPTD to characterise progressive accumulation of 
pulmonary oedema, by demonstrating that perivascular cuff width:vessel diameter 
correlated linearly with EVLW (r=0.87; p<0.0001) and  inter-alveolar septal width 
was linearly related to EVLW in animals with EVLW> 11.2ml/kg (r=0.89; p<0.001). 
Alveolar flooding did not occur until EVLW exceeded 11.4ml/kg, but then increased 
linearly with EVLW (r=0.87; p<0.001)29. 
Pleural effusion 
Blomquist et al systematically evaluated the effects of incremental increases in 
pleural fluid volume (warmed normal saline introduced bilaterally via intercostal 
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catheters) on EVLWTDD in otherwise healthy dog lungs
452. They reported a slight, but 
not statistically significant rise in EVLW and though “a minor, and for practical 
purposes negligible loss of thermal indicator [cold] to the pleural fluid could not 
be excluded”, they ultimately concluded that installation of up to 20ml/kg of fluid 
into the pleural cavity has no effect on EVLWTDD. In 30 human autopsies in patients 
who had undergone EVLWSTD measurement in the 48 hours preceding autopsy, 
Tagami et al examined the relationship between EVLWSTD and lung weight. They 
report no significant difference in the relationship between EVLW and lung weight 
(as a surrogate estimate of ‘true’ EVLW) in patients with pleural effusion volumes 
of less than or more than 500 mL, suggesting no effect of pleural effusion on EVLW 
measurement. Several authors have similarly reported that pleural fluid volume 
does not contribute to measured EVLW in clinical studies in medical intensive care 
patients undergoing thoracocentesis453, 454. Saguel et al in fact observed a 
statistically significant increase in EVLW following ‘large volume thoracocentesis’, 
hypothesising that expansion of lung tissue following removal of pleural fluid may 
both lead to further fluid extravasation (re-expansion pulmonary oedema), and 
lead to increased perfusion of previously atelectatic regions of lung thus increasing 
the volume of lung ‘visible’ to cold indicator. 
5.4.4.2 Sensitivity of EVLW measurement 
Fernandez-Mondejar et al examined the ability of STD EVLW measurement to 
detect ‘small changes’ in EVLW (defined by the authors as 10-20%) in pigs both with 
and without pulmonary oedema455. By measuring EVLWSTD immediately before and 
after intratracheal administration of 50mls of saline solution (so increasing EVLW 
(alveolar fluid) by 50ml), they were able to demonstrate that STD technology was 
able to detect the increase in EVLW. In normal lungs a mean of 84% and in 
oedematous lungs 77% of the administered bolus was detected. Putting these 
results in context with the observations of Bongard et al29 (above) which suggest 
that increases in EVLW in excess of 100% are required before hypoxaemia  or chest 
radiography changes are observed makes the exciting suggestion that EVLW 
measurement may be able to sensitively detect sub-clinical increases in EVLW. As 
in 2005 when Fernandez-Mondejar et al made their observations, “the clinical 
significance of these changes... has yet to be elucidated” 455.  
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Interpretation of ‘sensitivity’ in terms of how small a change in EVLW can be 
detected by TPTD techniques must incorporate examination of the ‘least significant 
change’ (LSC) values determined from studies examining the reproducibility of the 
technique (Table 5.2). From Table 5.2, it can be seen that quoted LSC values for 
EVLWSTD range from 7.8-12%; that is to say that observed changes in EVLW of less 
than ~10% cannot reliably be interpreted as clinical changes and may represent 
measurement artefact.  
5.4.5 Indexing of EVLW values 
Raw data obtained from both STD and TDD estimates of EVLW return an absolute 
value for EVLW; that is volume of EVLW measured in millilitres. It is unsurprising to 
observe however that larger people have larger lungs, and more lung water. It has 
become conventional therefore to provide EVLW data indexed for (actual) body 
weight. Such indexing of a physiological trait is performed to remove its 
dependence on height, weight or gender and thus facilitate a comparison between 
patients406. Yet in the context of EVLW, indexing to actual body weight might be 
ineffectual.  Recommendations from the American Thoracic Society 
(ATS)/European Respiratory Society Task Force on pulmonary function standards, 
clearly states that “lung volumes are related to body size, with standing height 
being the most important factor”338. Crapo et al performed a large observational 
study aiming to determine ‘reference spirometric values’ by performing pulmonary 
function testing in 251 health men and woman456. They report that the addition of 
weight to regression equations predicting lung volumes on the basis of height and 
age did not improve predictability of the equations; suggesting minimal influence 
of weight on pulmonary volumes. It is interesting to observe the prediction 
equations for pulmonary volumes on the basis of age and height are different for 
males and females456; there have been no suggestions that EVLW be indexed any 
differently according to sex.  
In 1974 in response to the problem that weight based estimation of creatinine 
clearance might result in gentamicin toxicity in obese patients, Devine published  
equations for calculation of predicted body weight (PBW), providing a height based 
estimate of lean body weight457. In recognition that lean body weight represents 
“the weight at which 99% of the body’s metabolic processes occur”, this and other 
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similar calculations of lean or ideal body weight have been incorporated both into 
pharmacokinetic and wider clinical practice458; the US ARDS Networks trial of low 
tidal volume ventilation for example recommends a tidal volume of 6ml/kg based 
on predicted body weight99. 
In obese subjects it seems implausible that lung size increases in proportion to 
increases in actual body weight (indeed in obese subjects lung volumes are 
reported to be reduced due to reductions in absolute and chest wall 
compliance459). As such, EVLW indexed to actual body weight might be falsely low 
in obese subjects whilst EVLW indexed to predicted body weight might reflect a 
patient’s condition more accurately406, 429. This is supported by a number of studies 
which have demonstrated that the predictive validity of EVLW measurement (for 
mortality) is improved when EVLW is indexed for ideal body weight405, 429.  
Similarly, Berkowitz et al observed that indexing EVLW to PBW resulted in a 
stronger correlation with Lung Injury Score and PaO2:FiO2 ratio
433. In contrast 
Mallet et al were unable to demonstrate any improvement in the predictive value 
of ELWIPBW over ELWIACT
444 whilst Chew et al demonstrated ELWPBW to have a 
weaker statistical relationship to mortality than ELWACT
423. 
Nonetheless, on the strength of the evidence suggesting improved predictive 
validity, indexing to PBW has become accepted practice; so much so that both 
commercially available clinical monitors provide EVLW indexed to PBW by 
default407, 408. It wasn’t until 2013 that the relationship between EVLW and 
biometric variables was explored in more detail, challenging the validity of 
indexing to PBW. Wolf et al performed a multivariate analysis of raw and indexed 
EVLW data examining the relationship with age, gender, height, body surface area 
and actual and predicted body weight in a cohort of 101 elective neurosurgical 
patients. They observed that indexing EVLW to height was the only method of 
indexing  where a value could be obtained independent  (as is desirable) of any 
statistically significant relationship to age, height, weight or gender460. Huber et al 
performed a similar analysis in 234 consecutive intensive care patients finding 
markedly different ELWI values between different weight based methods of 
indexing; the difference being most pronounced in female patients with 
BMI≥30kg/m2. Huber et al conclude that height is the only biometric parameter 
independently associated with EVLW and that “EVLW should be indexed to 
height”461. Supporting such a conclusion, the authors performed a post-hoc analysis 
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demonstrating ELWIHEIGHT to have greater discriminatory value than ELWIPBW in 
determining a population of patients with PaO2/FiO2 < 200mmHg (AUROCC 0.77 vs 
0.71). 
5.4.6 What is normal range of EVLW?  
5.4.6.1 Determining normality 
Establishing a normal range for EVLW has been challenging with several authors 
reporting a lack of consensus as to what constitutes ‘normal’402, 405. In laboratory 
medicine, standard methods for determining the normal range are to make 
nonparametric estimates of the 95% reference interval in at least 120 healthy 
individuals463. Measurement of EVLW requires invasive haemodynamic monitoring 
and as such, large cohorts of healthy patients with the appropriate monitoring 
simply do not exist, or arguably would be unethical to pursue. Studies attempting 
to establish a reference range for EVLW have necessitated more innovative 
approaches. 
5.4.6.2 Quoted normal ranges 
‘Normal’ EVLW is variously quoted in the literature as <5 ml/kg431, 3-8ml/kg406, 5-
7ml/kg382, <7ml/kg74, 382, 405, 464-466, <7-10 ml/kg438, 467 or <10 ml/kg428, 433, 434, 468. 
Many authors provide no indication to determine on what basis the quoted value 
has been derived, many others simply reference the un-explained values provided 
by others. It seems likely that the origin of many of the values lies in animal data; 
Lewis et al (for example) report that “numerous studies show that EVLW [is] 6-7 
ml/kg in normal animals measured by the thermal technique”469. 
5.4.6.3 Studies attempting to identify ‘normal’ EVLW in humans 
In 1983 using the TDD technique, Sibbald et al sought to identify the normal range 
for EVLW. From a group of 79 critically ill patients requiring invasive 
haemodynamic monitoring, the authors identified a sub-group of 16 critically ill 
patients with no radiological evidence of pulmonary oedema, no evidence of 
systemic infection and normal pulmonary capillary wedge pressure. The mean ± SD 
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EVLW in this subgroup was 5.6 ± 1.8 ml/kg suggesting that the upper limit of the 
normal range (+2SD) would be around 9 ml/kg 470.  
Normal range derived from autopsy specimens 
In their autopsy study, Tagami et al attempted to define a normal range for 
EVLWSTD
402. In 30 autopsy specimens who had undergone EVLWSTD measurement in 
the 48 hours preceding autopsy, Tagami et al derived a regression equation 
reflecting the relationship between EVLWSTD and lung weight. Then by reference to 
‘normal’ lung weights derived in a previous study, using their regression equation 
they estimate that normal ELWISTD values (indexed to predicted body weight)  were 
7.5±3.3ml/kg (±SD) in males and 7.3±3.3ml/kg in females. Whilst this approach is 
undoubtedly novel it has significant limitations. Firstly, given that by definition all 
of the subjects were deceased it seems likely that EVLW could have increased as 
disease progressed in the interval between EVLWSTD estimation and death (though 
the authors report that EVLWSTD was determined “just before death”, no timings 
are provided). Secondly, as highlighted by the authors, cardiopulmonary 
resuscitation was performed in 16 cases (53%); the effects of which upon EVLW are 
unknown. Thirdly, as discussed by Zhang et al471, the authors calculate ‘normal’ 
EVLW from a regression equation determined by observing the relationship 
between EVLW and lung weight in critically ill patients. The proportion EVLW 
makes of lung weight is however likely to vary as EVLW increases, making 
extrapolation of this relationship questionable. 
Studies measuring EVLW in peri-operative patients 
Table 5.7 summarises the available data from studies utilising EVLW measurement 
in the peri-operative period.  Where a pre-operative value of EVLW is reported, 
this may provide some insight into the ‘normal’ EVLW, though it must be 
emphasised that by definition, patients in these populations are not ‘healthy’, 
‘normal’ subjects. Indeed in some circumstances for example patients undergoing 
lung resection, patients may have significant perfusion deficits such that EVLW 
might be underestimated.  
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Table 5.7. Studies reporting ‘normal’ pre-operative values for EVLW in patients undergoing 
elective surgery. 
Author (year) N Method Population 
Pre-operative  
‘normal value’ (ml/kg) 
Byrick et al (1977)
472
 17 TDD Cardiac surgery 5.77 ± 0.24 
Sivak et al (1982)
473
 9 TDD Cardiac surgery 5.47 ± 1.67  
Honore et al (2001)
474
 13 
8 
TDD Cardiac surgery 6.9 ± 3.3 
6.7 ± 1.7 
von Spiegel et al (2002)
475
 10 
10 
TDD Cardiac surgery 5.8 ± 1.0 
5.4 ± 1.1 
Michelet et al (2006)
149
 52 STD Oesophagectomy ~5.5 
Licker et al (2008)
476
 20 STD Pneumonectomy 9.1 ± 4.4 
STD, ‘single’ thermodilution; TDD, thermo-dye dilution  
In summary it might pragmatically be concluded from the assembled expert opinion 
and clinical data and that ELWI > 10 ml/kg is likely to be pathological, ELWI < 7 
ml/kg is likely to be normal, but that any absolute cut-off defining the upper limit 
of ‘normal’ EVLW is likely to lie in a grey area between 7-10 ml/kg. 
5.4.7 Sackett’s test as applied to ‘single indicator’ trans-pulmonary 
thermodilution measurement of extravascular lung water 
Has there been an independent, “blind” comparison with a “gold standard” of 
diagnosis? 
Yes. EVLWSTD has been evaluated against gravimetric EVLW in animals and as 
far as possible in humans, and against EVLWTDD. Sakka et al performed a 
classical derivation / replication study in 57 / 209 critically ill patients 
demonstrating the ITBV=1.25xGEDV was well maintained403. 
Has the diagnosis test been evaluated in a patient sample that included an 
appropriate spectrum of mild and severe, treated and untreated, disease...? 
Yes. Sakka et al’s validation study included critically ill patients with a wide 
variety of different pathologies403. Studies have however shown the criterion 
validity of EVLWSTD to be compromised in conditions of altered regional 
distribution of pulmonary blood flow and in some aetiologies of acute lung 
injury. No assessment has been made of whether such changes influence 
construct or predictive validity and so are of significance in clinical practice. 
Was the setting for this evaluation, as well as the filter through which study 
patients passed, adequately described? 
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Yes. On the whole the majority of the available literature refers to well 
conducted scientific evaluations. 
Have the reproducibility of the test result (precision) and its interpretation 
(observer variation) been determined? 
Yes. Reproducibility values have been well established in several studies. In 
addition, Tagami et al have provided validation to the widespread practice 
of performing three duplicate thermodilution injections374. Clinicians and 
researchers must be aware of the limitations of the technique (and 
consequently observe the ‘least significant change’ values observed). Inter-
observer variation has been neglected by the literature to date. 
Has the term normal been defined sensibly as it applies to this test? 
Whilst a definitive upper limit of the normal range has not been defined, 
normality has been pursued as far as is practicable. The concept of normal 
below 7ml/kg, definitely pathological above 10ml/kg, with an area of 
uncertainty in between, though unwritten appears well established.  
If the test is advocated as part of a cluster or sequence of tests, has its individual 
contribution to the overall validity of the cluster or sequence been determined? 
Not fully. Chew et al reported that ELWI measurement increased the post-
test probability of ALI/ARDS, where pre-test probability was that of ‘being in 
intensive care with shock’423. In general however authors have examined the 
role of ELWI as a diagnostic tool, early predictor of subsequent lung injury 
development, or predictor of mortality in isolation. Further studies are 
required examining the diagnostic or predictive information ELWI adds to 
clinical variables (such as oxygenation, lung injury score, lung injury 
prediction score and acute physiology and chronic health evaluation score). 
Have the tactics for carrying out the test been described in sufficient detail to 
permit their exact replication? 
Yes. The methodology of TPTD is well described, with little variation 
between studies. 
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Has the utility of the test been determined? 
No. Whilst several authors have promoted the incorporation of ELWI into a 
novel definition of ALI/ARDS, this has not yet been established. Greater 
consensus regarding normal or cut off values representing ALI/ARDS would be 
needed first. The (Berlin) ‘ARDS Definition Task Force’ examined the 
possibility of incorporating ELWI into a novel definition of ALI/ARDS, but 
concluded “at the present time, technology to measure EVLW is relatively 
costly, invasive, not widely available and has significant methodological 
limitations”66. 
The effects of pathology (including lung injury resulting from a range of 
differing aetiologies), and other ‘methodical limitations’ are discussed in 
section 5.5.  
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5.5 Literature review: The influence of pulmonary 
ventilation-perfusion relationships on thermodilution 
EVLW measurement 
In this section factors, both physiological and pathological, which can influence 
trans-pulmonary thermodilution measurement of extravascular lung water are 
discussed. Particular attention is paid to EVLW measurement in patients with 
ALI/ARDS, and other pathophysiological states which may be encountered in the 
early post-operative period following lung resection. 
By the nature of the indicator dilution technique involved, TPTD methods for 
measuring EVLW (both STD and TDD) can only measure lung water in perfused areas 
of lung and so rely upon a homogeneous distribution of pulmonary perfusion in 
order to accurately determine EVLW; a large perfusion deficit will lead to 
underestimation of EVLW. 
In many circumstances, this assumption of a homogeneous distribution of 
pulmonary perfusion may be unjustified. In the normal lung, pulmonary perfusion is 
physiologically heterogeneous with an almost linear decrease in blood flow from 
bottom to top of an upright lung23. In the diseased lung, many authors have 
demonstrated further heterogeneity to the distribution of pulmonary perfusion477-
480. Regional pulmonary perfusion is influenced by many factors pertinent to the 
lung resection population or critically ill population in which EVLW measurement 
might be desirable. The effects of hypoxic pulmonary vasoconstriction, acute lung 
injury, vascular obstruction and positive end-expiratory pressure will each be 
considered in turn. 
5.5.1 Hypoxic pulmonary vasoconstriction 
By a direct effect of low partial pressure of oxygen in alveolar gas on vascular 
smooth muscle, hypoxic pulmonary vasoconstriction (HPV) serves to direct blood 
away from hypoxic regions of the lung thus maintaining ventilation-perfusion 
relationships23. Any factor influencing HPV is likely therefore to alter the 
distribution of pulmonary blood flow and so influence EVLW measurement. 
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The effect of such changes in pulmonary blood flow on EVLWSTD measurement were 
elegantly demonstrated by Easley et al479. In a canine model of ALI Easley et al 
reported a linear relationship between EVLW and a reference value (‘CT water’) 
obtained from computed tomography.  This relationship was lost however following 
pharmacological manipulation of the distribution of pulmonary perfusion following 
the administration of lipopolysaccharide endotoxin (LPS), which according to the 
authors will disrupt hypoxic pulmonary vasoconstriction, but not acutely alter the 
distribution of lung water (Figure 5.9). This resulted in an abrupt increase in the 
measured EVLW value due, the authors hypothesise, to the recruitment of 
“previously thermally silent” areas of lung. 
 
Figure 5.9. Relationship between single thermodilution derived EVLW and computed 
tomography derived ‘tissue water’.  
Following disruption of hypoxic-pulmonary vasoconstriction by administration of lipopolysaccharide, 
the distribution of pulmonary perfusion is altered leading to loss of the linear relationship between 
EVLW and CT ‘tissue water’. From Easley et al
479
. 
It should be appreciated that in addition to pathophysiological processes (such as in 
ALI as discussed below), the effects of HPV may also be altered by administration 
of anaesthetic drugs; volatile anaesthetic agents are described as inhibitors of 
HPV481 whilst the intravenous anaesthetic agent propofol is described as 
augmenting HPV482. The clinical significance of such findings are uncertain, though 
in patients undergoing thoracic surgery (the subject of this thesis), oxygenation 
during the period of one lung ventilation has been reported to be better 
maintained in patients with undergoing propofol anaesthesia compared to volatile 
anaesthesia; an effect attributed to maintenance of HPV483. 
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5.5.2 Acute lung injury 
The reported effects of lung injury on pulmonary perfusion are inconsistent. Whilst 
it is generally accepted that hypoxic pulmonary vasoconstriction serves to 
homeostatically divert blood away from areas of injury and so maintain ventilation-
perfusion relationships, demonstrating such an effect has been challenging. Work in 
animal models has demonstrated changes in pulmonary perfusion with the onset of 
lung injury484, 485 (interpreted to reflect HPV, direct vascular injury or mechanical 
compression of vasculature due to oedema). Schuster et al. were however unable 
to replicate such findings in humans with non-ALI or ALI pulmonary oedema, 
hypothesising that in humans (in this study at least), the effects of HPV are blunted 
in ALI478. Whilst this could reflect physiological differences between humans and 
animal models, it is also likely that pulmonary perfusion (and indeed the integrity 
of HPV mechanisms) will differ according to the severity and mechanism of lung 
injury. 
5.5.2.1 Type of lung injury 
The implications of differences in pulmonary blood flow occurring in ALI on EVLW 
measurement are illustrated in a study by Roch et al who compare EVLWTDD with 
‘gold-standard’ gravimetric measures in two different porcine models of lung 
injury486. In one group ALI was induced by intra-tracheal hydrochloric acid, 
purportedly generating a heterogeneous lung injury; in the other group ALI was 
induced by intravenous oleic acid leading to a diffuse homogenous lung injury. Both 
models induced a significant lung injury as evidenced by the onset of hypoxaemia 
and a significant increase in gravimetric EVLW, however whilst in the (homogenous) 
IV oleic acid group good correlation was observed between EVLWTDD and EVLWG 
(r=0.88, p<0.0001), in the (heterogeneous) hydrochloric acid group no correlation 
between EVLWTDD and EVLWG could be observed. Carlile and Gray made a similar 
observation in canine models of focal (hydrochloric acid inhalation) and diffuse 
lung injury (alloxan or α-naphthylthiourea intra-pulmonary arterial)487. They 
demonstrated a marked reduction in the ratio of EVLWTDD to extravascular lung 
mass in animals with focal lung injury despite a similar severity of lung injury in 
both groups. Strikingly, EVLWTDD was reduced when compared to baseline in all 11 
of the 15 animals exposed to focal (HCl acid induced) injury. The authors 
hypothesise that such a discrepancy reflects redistribution of pulmonary blood flow 
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away from injured areas in conditions of focal injury; a supposition which is 
supported by the observation of correlation between the EVLW / ELM and shunt 
(r=0.70)487.  
Carlile et al offer an alternative to the ‘thermally silent’ lung tissue theory to 
explain the underestimation of EVLW in patients with acute lung injury485. They 
suggest that it is not an absence of perfusion to injured lung units that leads to 
inaccuracies but that indicator is detained in injured lung units. Carlile et al 
estimate the regional mean transit time (in injured lung units) to be in the region 
of 40 seconds. As such, this detained indicator will reach the sensor after the point 
at which the mono-exponential decay curve is truncated (to avoid recirculation 
artefact – Section 5.3.1.2), and so will be ‘lost’ to the sensor. 
5.5.3 Vascular obstruction 
‘Thermally silent’ lung tissue (i.e. lung tissue which is not perfused, as would occur 
in vascular obstruction) cannot be accessed by thermal indicator, and so makes no 
contribution to TPTD derived EVLW. By its very existence however, the lung tissue 
concerned would contribute to EVLWGRAV; as such it would be expected that the 
presence of thermally silent lung tissue (due to vascular obstruction or any other 
mechanism) would lead to underestimation of EVLW. This is illustrated by the study 
of Schreiber et al, who measured EVLWTDD before, during and after branch 
pulmonary artery occlusion in pigs462. They demonstrated a significant reduction in 
measured EVLW during occlusion followed by a return to baseline when occlusion 
was released. Whilst such overt arterial occlusion is unlikely to go unnoticed in the 
clinical environment, a similar reduction might be expected in more diffuse 
microvascular obstruction. Exploring the effects of  diffuse, small vessel occlusion, 
Oppenheimer et al embolised glass beads 500μm in diameter into mongrel dogs488. 
They observed good agreement between gravimetric and TDD derived EVLW in 
normal animals, embolised animals without lung injury and animals with lung injury 
but not embolised, but significant underestimation in EVLW in embolised animals 
with lung injury488. Beckett et al conducted a similar study subjecting dogs to a 
‘low’ or ‘high’ dose embolic shower489. In ‘high’ dose embolisation the authors 
demonstrated a reduction in EVLWTDD (as seen by Oppenheimer et al
488) alongside a 
reduction in TDD measured pulmonary blood volume (PBV). In contrast, following 
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‘low’ dose embolisation they observed a paradoxical increase in EVLWTDD alongside 
a significant reduction in measured PBV. This they attribute to the TDD technique, 
suggesting that small areas of injured lung are accessed thermally by diffusion from 
adjacent lung units, but are ‘silent’ to dye perfusion; as a result PBV (measured 
from the dye-dilution curve) is underestimated and EVLW (measured from the 
thermo-dilution curve) is consequently assumed to compose a greater proportion of 
the ITTV (Equation 5.17 EVLWTDD = ITTV-ITBV, where ITBV = PBV+GEDV). There are 
no studies of STD EVLW measurement in similar models of vascular obstruction to 
allow comparison with TDD techniques. One might hypothesise that the potential 
for spurious overestimation of EVLW as observed by Beckett et al489 in ‘low’ dose 
embolisation (in reality probably more of a theoretical entity than a clinical one) 
might not exist but that similar potential for underestimation of EVLW in cases of 
vascular obstruction still exists. 
5.5.4 Positive End-Expiratory Pressure  
The potential effects of positive end expiratory pressure (PEEP) on both the 
development and thermodilution measurement of EVLW are multiple and have 
been the subject of much debate with studies reporting increases, decreases and 
no effect of PEEP on EVLW. Whilst the discrepancies between the various reports 
may partly be accounted for by variations in the methodology of EVLW 
measurement, variations in the model of ALI studied and timing of PEEP 
application483, 490, some common themes emerge. It is apparent that PEEP may 
affect the value of EVLW obtained following thermodilution measurement by either 
directly influencing the amount of EVLW present (a ‘true’ effect) or by 
artefactually influencing the measured value of ELVW due to alterations in 
pulmonary blood flow. 
5.5.4.1 Direct effects 
Positive end-expiratory pressure is widely used in critically ill patients with acute 
lung injury with the aim of maintaining functional lung volume and preventing 
damaging atelectotrauma90, 305. It is intuitive therefore that if application of PEEP 
is able in some way to directly improve lung injury, or arrest the development of 
injury, then PEEP may lead to decreased EVLW. Such an effect has been 
demonstrated in animal models490, 491. Colmenero-Ruiz et al490 studied the effects 
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of PEEP on the accumulation of EVLWTDD in a porcine (oleic acid) model of lung 
injury. PEEP was applied at the onset of lung injury. They observe that though the 
effects of PEEP on oxygenation were evident (compared to controls) early in the 
experimental protocol, any effect on EVLW took longer to occur with significant 
differences in EVLW between PEEP and zero-PEEP controls taking 180 minutes to 
emerge. The same group subsequently demonstrated (in the same porcine / oleic 
acid model of lung injury) that the protective effect of PEEP on EVLW accumulation 
is dependent on application of PEEP early in the disease process491. This 
observation potentially explains why other authors have failed to observe a direct 
effect of PEEP on EVLW when PEEP has been applied late in the experimental 
protocol. In both of these studies, the reduced EVLW in the PEEP groups was 
confirmed gravimetrically, confirming the presence of a direct effect of PEEP on 
EVLW accumulation490, 491. 
5.5.4.2 Indirect effects 
Application of PEEP however has the potential to indirectly increase or decrease 
the measured value of EVLW. Firstly it is possible that high levels of PEEP may 
directly compress pulmonary blood vessels leading to vascular obstruction (and an 
increase in the amount of thermally silent lung tissue – an increased West Zone 1),  
and consequently an artefactual reduction in measured EVLW. In a canine model, 
Hedenstierna et al 492 demonstrated marked reductions in pulmonary blood flow 
following the application of ~20cmH2O PEEP. Blood flow was greatly reduced in the 
uppermost portions of the lung with Zone I conditions being demonstrated half to 
two thirds of the way down the upper and middle lobes. Interestingly such changes 
could be negated by maintaining cardiac output at the same level as before the 
onset of PEEP492. Secondly, by recruitment of alveoli, and subsequent redistribution 
of pulmonary perfusion to recruited lung areas (decreasing the amount of thermally 
silent lung tissue), PEEP may increase measured EVLW. Such an effect was 
demonstrated by Carlile et al in a canine model of lung injury485. Administration of 
15cmH20 of PEEP led to an acute and reversible increase in perfusion of the injured 
lung area which was paralleled by an increase in measured EVLW485. 
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5.6 Literature review: Trans-pulmonary thermodilution 
estimates of pulmonary vascular permeability  
Ratios of EVLW to TPTD derived blood volumes have been utilised in an attempt to 
provide an estimate of pulmonary vascular permeability. These ratios are intended 
to reflect EVLW in the context of, or indexed to preload, and were first described 
in 2001 by Honore et al474. The concept is intuitive; a high EVLW in a hypovolaemic 
patient (and therefore an elevated ratio) would suggest capillary permeability is 
the primary pathology whilst low EVLW in a patient with elevated preload (and 
therefore a low ratio) would suggest capillary permeability to be intact. Similarly 
the diagnosis of hydrostatic pulmonary oedema is suggested by high EVLW in a 
patient with high preload and therefore a normal ratio of EVLW to preload (Figure 
5.10).  
 
Figure 5.10. Schematic diagram explaining rationale behind measuring ratios of EVLW to 
preload indices as indicative of pulmonary permeability.  
PVPI, pulmonary vascular permeability index. Modified from Sakamoto et al
493
. 
Before considering the utility of these ratios however, I will first discuss the 
concept of TPTD derived measurement of preload. 
5.6.1 Trans-pulmonary thermodilution derived indices of preload 
In cardiovascular physiology, attempts to measure preload involve direct or indirect 
assessment of right or left ventricular end diastolic volume494. In general, rather 
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than as a measure of preload per se, the motivation for such measurements is an 
attempt to ascertain preload responsiveness. That is, an attempt to identify where 
a patient lies on the Frank-Starling curve and so identify the potential for a 
meaningful increase in stroke volume following fluid administration. Intrathoracic 
blood volume (ITBV)430, 467, 474, 495, global end-diastolic (GEDV)79, 495 and pulmonary 
blood volume (PBV) 79, 423, 424, 434, 443, 467, 495, 496 are indices of cardiac preload derived 
from TPTD to which EVLW has been indexed in the estimation of pulmonary 
vascular permeability. When considering these variables as measures of cardiac 
preload a number of important observations require to be made. 
Firstly, it must be emphasised that none of these ‘volumes’ are measured during 
STD TPTD. The only volumes measured directly by STD are cardiac output (from the 
area under the thermodilution-time curve), intra-thoracic thermal volume (ITTV - 
as the volume of distribution of the thermal indicator) and pulmonary thermal 
volume (PTV - from the linear down-slope of the logarithmic thermodilution curve). 
Global end-diastolic volume is then derived by subtraction of PTV from ITTV 
(Equation 5.20, Page 319). ITBV and PBV are derived from these measurements 
based on the ITBV = 1.25 x GEDV relationship (Equation 5.20) described by Sakka et 
al396, where PBV is the difference between ITBV and GEDV: 
              
Equation 5.23 
 
Substituting Equation 5.20 into Equation 5.23 yields: 
                
Equation 5.24 
  Secondly, it must be appreciated that the volumes derived have little if any 
anatomic equivalent, and as such can only be considered “virtual volumes”. The 
normal range of GEDV provided by the manufacturer of the most widely studied 
TPTD monitor in clinical use (PiCCO, Pulsion Medical Systems) is 680-800mls; a 
range several times larger than the combined end-diastolic volumes of the right 
and left heart in reality497.  
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There is nonetheless a strong and consistent evidence base suggesting that STD 
derived ITBV and GEDV are robust markers of cardiac preload. Whilst detailed 
examination of this data is beyond the scope of this thesis, a review article Della 
Rocca et al, summarises 18 articles in which GEDVI and ITBVI were compared to CI 
or SVI in a range of patient populations498.  In all of these studies moderate to good 
association was observed between GEDVI and ITBVI and SVI or CI, or between 
changes in GEDVI and ITBVI and corresponding changes in SVI or CI. In many of 
these studies TPTD derived volumes consistently out-performed other ‘static’ 
estimates of preload such as central venous pressure and pulmonary artery 
occlusion pressure498. Hofer et al compared GEDVI derived from TPTD to left 
ventricular end-diastolic area index measured by transoesophageal 
echocardiograpy. Good agreement was observed between changes in GEDVI and 
corresponding change in LVEDAI (r=0.81; p<0.001) with a mean bias between 
percentage changes in the two parameters of just -3.2%499.  This suggests that 
whilst the absolute value of GEDV may be considered to be a ‘virtual volume’, its 
physiological behaviour closely tracks ‘anatomic volumes’.  
Pulmonary blood volume has not been subjected to the same degree of 
investigation as a marker of preload as ITBV and GEDV; indeed there is little 
rationale to use an estimate of pulmonary blood volume as a surrogate estimate of 
cardiac chamber volumes. There might however be an appropriate rationale for 
incorporating PBV into an index of pulmonary vascular permeability.  Analogous to 
the common historical practice of using central venous pressure as a surrogate for 
right ventricular end-diastolic volume, EVLW is indexed to preload indices 
(volumes) as surrogates for pulmonary capillary hydrostatic pressure (Pc – Section 
1.2.2). Intuitively, pulmonary blood volume may be a better surrogate for 
pulmonary capillary pressure, than cardiac volumes.  
5.6.2 Reproducibility of pulmonary vascular permeability indices 
The reproducibility of PVPI measurement has to an extent been covered above, 
alongside the reproducibility of EVLW measurement. Where the available literature 
examining reproducibility of EVLW was sparse, the available evidence base of 
studies directly examining the reproducibility of PVPI measurement is limited to 
the study of Tagami et al. Table 5.2 (which summarises the available literature 
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from studies examining the reproducibility of EVLW, GEDV, ITBV, PBV and PVPI 
measurement), clearly demonstrates that whilst reproducibility of directly 
measured variables (CO and GEDV), is good, reproducibility is poorer for derived 
variables. As such, measurements of PVPIs, which rely on precise measurement of 
CO and PTV directly from the STD curve and subsequent derivation of EVLW and 
ITBV or PBV are at risk of compounded errors. This is reflected by the increased 
‘least significant change’ (LSC) values for these indices. As a consequence 
clinicians and researchers must be aware of the errors involved and the 
substantially larger ‘least significant change values’ that need to be demonstrated 
by the monitor before this can be interpreted as a clinical change.  
5.6.3 Validity of pulmonary vascular permeability indices 
Attempts to establish the validity of PVPIs are challenged by the technical 
complexities involved in determining a ‘gold standard’ measure of pulmonary 
vascular permeability. In addition, having been first described in 2004415, the 
available evidence base for PVPIs is small when compared to EVLW (TDD 
measurement of EVLW began as early as 1966)500. 
Criterion validity  
In clinical practice the diagnosis of increased pulmonary vascular permeability 
pulmonary oedema is generally made on clinical grounds; the presence of cardiac 
failure is excluded and as such, in the face of pulmonary oedema, pulmonary 
vascular permeability is assumed to be increased. No gold standard measure of 
pulmonary vascular permeability exists501. Historically, in animal models, increased 
protein flux in cannulated lymph vessels has been considered pathognomic of 
capillary leak 30, whilst in humans the presence of protein in pulmonary oedema 
fluid and increases in the oedema fluid protein to plasma protein ratio have been 
studied116. More recently, several studies have used radioisotopes to facilitate non-
invasive, quantitative evaluation of permeability; the extent and rate of 
accumulation of radiolabelled protein in the lung reflecting permeability125, 467, 495. 
Notably, Schuster’s group have conducted numerous studies using Positron Emission 
Tomography (PET scanning) to evaluate pulmonary capillary permeability in 
patients with ARDS, but have not reported any comparison with TPTD derived 
indices502.  
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Groeneveld et al performed two studies examining criterion validity of TPTD 
derived pulmonary vascular permeability indices using pulmonary leak index (PLI, 
as determined by assessing the rate of transport of 67Gallinium labelled transferrin) 
as a criterion. These studies demonstrated modest associations between 67Ga-
transferrin determined PLI and EVLW/ITBV, EVLW/PBV and EVLW/GEDV both in 
septic 467 and non septic patients495 (r=0.43-0.50 for all; p≤0.05). The association 
appeared particularly strong when PLI was low (as occurred in extra-pulmonary 
sepsis - PLI vs EVLW/PBV, r=0.71, p=0.02) 467, but was lost in patients with 
pneumonia and high PLI (r-values not provided). The authors conclude that TPTD 
derived permeability indices are “imperfect measures of increased protein 
permeability”467. Unfortunately these two studies were not performed in parallel 
so no simultaneous estimate of the indices ability to distinguish between the 
different aetiologies of increased EVLW could be made. 
Concurrent validity 
Much of the clinical potential of PVPIs measurement concerns the possibility of 
their use in aiding clinicians in distinguishing between patients with pulmonary 
oedema (and raised EVLW) of hydrostatic or increased permeability aetiology. It is 
on this question that most investigators studying PVPIs have concentrated. As with 
EVLW, some proponents have gone as far as to suggest that PVPIs could be 
incorporated into a novel definition for ALI/ARDS73, 74, 79.  
Animal studies 
In the first study to examine the utility of TPTD derived PVPIs, Katzenelson et al 
studied the EVLW/ITBV in three groups of dogs; control animals, animals subjected 
to ALI induced by intravenous injection of oleic acid and dogs who developed 
hydrostatic pulmonary oedema following the inflation of a left atrial balloon and 
administration of excess intravenous fluids (n=5 per group)415. EVLW/ITBV was 
markedly increased in animals with ALI and only modestly increased compared to 
controls in those with hydrostatic pulmonary oedema (Figure 5.11).  
Chapter 5  330 
 
Figure 5.11. Trans-pulmonary thermodilution derived pulmonary vascular permeability in an 
animal model of pulmonary oedema.  
From Katzenelson et al (2004)
415
. 
Though animals in the hydrostatic oedema group exhibited markedly elevated 
levels of EVLW, these animals had an elevated preload, so maintaining a relatively 
low level of EVLW/ITBV. 
Human studies 
Three human studies have examined the role PVPIs might play in the diagnosis of 
ALI/ARDS. In a study analogous to the animal study performed by Katzenelson et al 
(discussed immediately above415), Monnet et al retrospectively identified two 
cohorts of medical intensive care patients; one with hydrostatic pulmonary oedema 
and one with ALI/ARDS79. Studying both the ratio of EVLW/PBV and EVLW/GEDV, 
Monnet et al demonstrated significantly higher values of both ratios in patients 
with ALI/ARDS. Perhaps of greater significance however are the observations that 
EVLW/PBV ≥3 and EVLW/GEDV >1.8x10-2 both had 85% sensitivity and 100% 
specificity for diagnosis of ALI/ARDS (AUROCC = 0.92 ± 0.04 for both), strongly 
suggesting a potential diagnostic role for PVPIs. An accompanying editorial urges 
caution however; firstly observing that Monnet et al restricted their study to a 
population with relatively high EVLW values (ELWI≥12) and secondly highlighting 
the existence of population of 5 patients (~15% of the study’s sample) who had 
ELWI ≥12ml/kg, EVLW/PBV <3 yet were clinically classified as having ALI/ARDS73.  
In a mixed ITU population, Chew et al examined the utility of EVLW measurement 
as a diagnostic tool in the diagnosis of ALI/ARDS423. EVLW/PBV was higher in 
patients with ALI and ARDS compared to those without ALI/ARDS (2.1 vs 1.6; p=0.02 
and 2.3 vs 1.7; p<0.05 for ALI/ARDS respectively). Though not specifying the cut off 
value of EVLW/PBV used, the authors demonstrated that EVLW/PBV added 
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diagnostic value; EVLW/PBV increased the post-test odds ratio for the diagnosis of 
ALI or ARDS by 1.8 and 1.6 times respectively. A ‘negative’ EVLW/PBV reduced the 
post-test probability markedly. The sensitivity and of EVLW/PBV for the diagnosis 
of both ALI and ARDS was 87% and 89% respectively, whilst specificity was 47% and 
52% respectively. 
In the largest study to report measurement of PVPIs to date, Kushimoto et al 
performed a prospective, multi-centre observational study seeking to establish 
“quantitative differential criteria of ALI/ARDS on the basis of PVPI” (PVPI defined 
as EVLW/PBV)434. Two hundred and sixty-six adult intensive care patients requiring 
mechanical ventilation with PaO2/FiO2 <300mmHg and bilateral infiltrations on 
chest radiography were enrolled. An expert panel (blinded to the PVPI values) 
retrospectively classified patients into categories of ALI/ARDS (n=207), cardiogenic 
oedema (n=26) and pleural effusion without atelectasis (n=33). The authors 
demonstrated that PVPI was higher in ALI/ARDS patients than in patients with 
cardiogenic oedema or pleural effusion with atelectasis (3.2 vs 2.0 vs 1.6 
respectively). In the group of ALI/ARDS patients, ELWI increased with PVPI (r=0.73; 
p<0.01) and admission PVPI had an area under the receiver operating characteristic 
curve of 0.89 (CI 0.84-0.94) for prediction of ALI/ARDS. The authors, arguing that 
TPTD is a relatively invasive measurement, chose to select a cut off value in favour 
of maximising specificity and report that PVPI values of 2.6 to 2.85 provided a 
‘definitive diagnosis’ of ALI/ARDS with a specificity 0.90 to 0.95 respectively and 
that a PVPI value < 1.7 to 2.0 ruled out an ALI/ARDS with a specificity of 0.95 and 
0.90; sensitivity of the proposed cut offs was 0.54, 0.64 and 0.50, 0.70 
respectively. Again this study is not without its limitations as an accompany 
editorial points out; exclusion of several patients was questionable, blinding was 
poor and the size of the non ALI/ARDS group was limited503. 
A further limitation of several of the studies examining the diagnostic utility of 
PVPIs is that the authors chose to exclude patients with EVLW in the borderline 
area of 10-12ml/Kg79, 434. Arguably it is in the patients with less overt pulmonary 
oedema that such a diagnostic tool may be of greatest value to the clinician.  
Predictive validity 
Le Tourneau et al measured EVLW on admission to intensive care in 29 patients424. 
They demonstrated that PVPI (defined as EVLW/PBV) on the day of admission was 
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higher in patients who went on to develop acute lung injury, compared to patients 
who did not (3.32 vs 1.58; p=0.03). Unfortunately the authors did not present any 
assessment of the sensitivity or specificity of a defined level of PVPI in the 
diagnosis of ALI/ARDS. 
Construct validity 
As with EVLW (Table 5.5), construct validity of PVPIs is suggested by observed 
association with pulmonary compliance430, PaO2/FiO2 ratio
79, 423, 430, chest X-ray 
score423 and Lung Injury Score423, 430, 441 (Table 5.11). 
The study of Tagami et al which demonstrates strong correlation between PVPI 
(defined as EVLW/PBV) and plasma neutrophil elastase is particularly worthy of 
comment (Table 5.8)443. By demonstrating such strong association between 
thermodilution measurements and an objective assessment of the severity of the 
disease process, these authors offer further suggestion (so strengthening ‘construct 
validity’) that permeability indices reflect the pathophysiological process taking 
place at an alveolar level. 
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Table 5.8. Studies examining the construct validity of trans-pulmonary thermodilution derived indices of pulmonary permeability in humans. 
Author 
(year) 
Population Method N  Index Comparator Association / measure of validity 
Groeneveld 
et al. 
(2006)
441
 
Post-operative - 
major vascular 
surgery 
TDD 16 EVLW/ITBV 
EVLW/PBV 
 
LIS EVLW/ITBV and EVLW/PBV higher in patients with 
LIS >1 (p<0.05 and not significant respectively). 
       
Kuzkov et al.  
(2006)
430
 
Intensive care – 
septic shock and ALI 
STD 38 EVLW/PBV 
EVLW/ITBV 
 
Compliance 
PaO2/FiO2 
LIS 
 
On day 1 of ITU stay: 
r=-0.43, r= -0.47 respectively; p<0.01 
r=-0.58, r=-0.58 respectively; p<0.01 
r=0.52, r=0.53 respectively; p<0.01 
(Variables reported also to correlate on day 3, but 
data not provided). 
       
Monnet et al.  
(2007)
79
 
Intensive care 
 
STD 48 
(36 with 
ALI/ARDS) 
EVLW/PBV 
EVLW/GEDV 
PaO2/FiO2 In patients with ALI/ARDS, EVLW/PBV associated 
with (r=0.42; p not provided). No comparison made 
for EVLW/GEDV. 
       
Tagami et al.  
(2011)
443
 
HDU/ITU – 
community acquired 
pneumonia 
STD 14 
(6 in ITU) 
EVLW/PBV Plasma 
neutrophil 
elastase 
Correlation observed between PVPI and plasma 
neutrophil elastase on day 1 (r=1.0, p<0.001) and day 
2  (r=0.98, p<0.001) but not day 4 (r=0.17, p=0.74). 
       
Chew et al.  
(2012)
423
 
Intensive care – SIRS 
and ‘circulatory 
failure’ 
STD 51 EVLW/PBV PaO2/FiO2 
CXR score 
PEEP 
LIS 
 
r=-0.37 to -0.49; p=0.001 
r=0.26 to 0.46; p=0.002 
No association 
Increasing ELWI/PBV with increasing strata of LIS 
(p<0.01) 
N, number of patients. STD, single thermodilution; TDD, thermo-dye dilution; LIS, lung injury score. 
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5.6.4 Factors influencing trans-pulmonary thermodilution derived 
indices of pulmonary vascular permeability 
Factors influencing the measurement of EVLW by STD have been described in detail 
in Section 5.5. Whilst all of these factors will be applicable to the measurement of 
PVPIs given that these indices are ratios of EVLW to other volumes, many of the 
same limitations will also apply to the measurement of PBV, ITBV and GEDV.  
Perhaps the greatest limitation of EVLWSTD is its dependence on a uniform 
distribution of pulmonary perfusion such that if regional perfusion varies, measured 
EVLW can be artefactually reduced as the thermal indicator is unable to gain 
access to hypo-perfused areas of the lung (‘thermally silent’ lung tissue).  
Schreiber et al determined ITBV and GEDV using a thermo-dye dilution technique in 
a porcine model where pulmonary perfusion was varied by clamping of the right 
lower and middle lobe branch of the pulmonary artery462. They observed that that 
pulmonary artery clamping led to an approximately 10% reduction in measured ITBV 
and GEDV, which was reversible on removing the clamp. Whilst the authors offer a 
number of hypotheses as to why measured ITBV and GEDV might decrease, it would 
seem that these preload indices exhibit perfusion dependence in a similar way to 
EVLW. Whilst such an observation may be disadvantageous to those seeking to use 
these measures as markers of preload in order to guide volume therapy, it may be 
an asset when combining them with EVLW to estimate pulmonary vascular 
permeability. If EVLW and ITBV / GEDV are similarly affected by pulmonary 
perfusion defects, then whilst the absolute values measured may be artefactually 
reduced their ratio may remain a true reflection. Unfortunately, the ratio 
determined will reflect the ratio of EVLW to ITBV / GEDV in the perfused lung and 
not in the hypo-perfused and likely pathological areas. There are no reports on the 
effect of pulmonary perfusion distribution on TPTD measured PBV, however as 
PBVSTD is obtained mathematically as one fifth of GEDV it is inherent that its 
measurement will also be perfusion dependent.  
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5.6.5 Comparisons between described pulmonary vascular 
permeability indices 
As discussed above, three different ratios of EVLW to preload have been described 
as PVPIs. In what is such a limited evidence base there is little guidance on which 
may be the more robust marker. It is evident from Table 5.8, that the ratio of 
EVLW to PBV has been most extensively studied; this is unsurprising considering 
both of the STD TPTD monitors currently commercially available provide this index 
as standard408, 504, describing it simply as “pulmonary vascular permeability index” 
(PVPI). 
Groeneveld’s group studied the ratio of EVLW to PBV and ITBV in septic patients441 
and EVLW to PBV, ITBV, and GEDV in non septic patients495. In their comparisons 
between these indices and 67Gallinium labelled transferrin derived pulmonary leak 
index (PLI – the closest to a gold standard criterion reported in the PVPIs 
literature), there is little difference between the performance of the indices 
(r=0.43-0.50 for all; p≤0.05), though the authors report in their study of septic 
patients that they “observed a tendency to a closer relationship of PLI to 
EVLW/PBV than to EVLW/ITBV”, though they provide no statistics to support their 
conclusion.  Kuzkov et al examined the ratio of EVLW to PBV and ITBV and observed 
little if any difference in performance between them496 (Table 5.8). Given that 
ITBV and PBV are each determined by mathematical manipulation of GEDV it is 
perhaps unsurprising that the performance of the three indices is similar. 
5.6.6 What is normal range of pulmonary vascular permeability 
indices?  
Determining a ‘normal’ range for TPTD derived PVPIs faces the same problems as 
determining a normal range for EVLW; PVPIs have not been (and are unlikely to be) 
measured in large cohorts of healthy patients from which a normal range can be 
derived. In the case of PVPIs this is further complicated by the comparatively 
smaller evidence base spread across the three different indices. As with EVLW, 
rather than a normal range per se, it is the threshold at the upper limit of the 
normal range at which normal can be said to become pathological that is of 
primary interest to clinicians. 
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5.6.6.1 Quoted normal values 
Quoted normal values for the three PVPIs are provided in Table 5.9. The majority 
of authors provide no evidence to suggest from where the normal values have been 
derived.  
As PVPI is an index which is derived as the ratio of two values, it would seem 
appropriate to determine the normal range by examination of the normal ranges of 
the two components. Whilst the upper limit of ‘normal’ ELWI is poorly defined, the 
normal ranges of PBV, ITBV and GEDV are less well described. This is further 
compounded by varied descriptions of the indices; whilst most authors describe the 
indices as a ratio of volumes (in ml), some authors study a ratio of indexed volumes 
(where EVLW is indexed to weight and ITBV and GEDV indexed to body surface 
area)79. 
For purposes of illustration, ‘normal’ values of PBV, ITBV and GEDV (quoted by the 
manufacturers of the two clinically available monitors505, 506)  are also provided in 
Table 5.12. From these values, based on the dimensions of the average UK man (of 
height 175.3cm, weight 83.6kg and body surface area 1.995m2 507) estimations of 
‘normal’ values of the respective indices have been derived; ‘stringently’ as lowest 
quoted ‘normal’ EVLW against highest ‘normal’ denominator, and ‘permissively’ as 
highest EVLW over lowest  denominator. This exercise serves to highlight the wide 
range of potentially ‘normal’ values of PVPIs. 
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Table 5.9. Quoted normal ranges of pulmonary vascular permeability indices, preload indices 
and derived values. 
Description Value 
 
EVLW/PBV ‘about 1’
441
, <1.5 
423
, 3.0
505
,  3.0
506
 
EVLW/ITBV 0.2-0.32
474
,  0.2-0.3 
441
, 0.2-0.3  
508
 
EVLW/GEDV No normal values quoted 
  
ELWI (ml/kg) Conservative upper limit 7.0
A
 
Permissive upper limit 10.0
A
 
PBV (ml) No normal values quoted 
ITBVI (ml/m
2
) 850-1000
505
, 850-1000
506
 
GEDI (ml/m
2
) 680-800
505
, 650-800
506
 
  
Derived ‘Stringent’  
upper limit of normal
B
 
EVLW/ITBV: 0.29 
EVLW/GEDV: 0.36 
Derived ‘Permissive’  
upper limit of normal
B
 
EVLW/ITBV: 0.49 
EVLW/GEDV: 0.64 
A 
As described in the text – ‘What is the normal value of EVLW?’, Section 5.4.2.6; 
B
Derivation as 
described above, ‘stringent’ – lowest ‘normal’ EVLW to highest ‘normal’ preload index, ‘permissive’ – 
highest ‘normal’ EVLW to lowest ‘normal’ preload index.  
5.6.6.2 Studies measuring PVPIs in peri-operative patients 
Honore et al reported a normal range for EVLW/ITBV of 0.2-0.32 in elective cardiac 
surgical patients474. The authors described the patient cohort as having “ELWI 
values within the normal range (<7ml/kg) and ITBVI values at the top of the normal 
range”, concluding (but with little evidence provided to support their conclusion) 
that “in our study these values were compatible with an intact pulmonary 
permeability”474. Groeneveld et al measured PVPIs in patients undergoing major 
vascular surgery441. Though no pre-operative values are provided, observed median 
values of EVLW/ITBV and EVLW/PBV in patients with ELWI≤7 and Lung Injury Score 
≤ 1 (suggesting no clinical evidence of increased permeability) were 0.21-0.22 and 
1.1 respectively. Whilst sub-clinical levels of capillary permeability cannot be 
excluded these values are in keeping with quoted ‘normal’ values (Table 5.9). 
In summary, it appears ‘normal’ values of PVPIs are poorly defined. Furthermore 
whilst there is no consensus regarding which index to report, nor whether to 
perform a ratio of volumes, or indexed volumes, it seems unlikely that established 
normal values will be defined.   
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5.6.7 Sackett’s test as applied to trans-pulmonary thermodilution 
measurement of pulmonary vascular permeability indices 
1. Has there been an independent, “blind” comparison with a “gold standard” of 
diagnosis? 
Only partially. Some of the problem lies with lack of ‘gold standard’ 
comparators. Groeneveld et al’s two studies comparing PVPIs to 67Gallinium 
labelled transferrin derived pulmonary leak index are the closest to ‘gold 
standard’ comparisons available467, 495; in these studies PVPIs performed as 
“imperfect measures of increased protein permeability”467. 
2. Has the diagnostic test been evaluated in a patient sample that included an 
appropriate spectrum of mild and severe, treated and untreated, disease...? 
Yes. PVPIs have been evaluated in a wide range of lung injury aetiologies, 
though unfortunately, for clarity, many studies have avoided the ‘grey area’ 
of mildly elevated EVLW, the setting in which TPTD measurement might 
arguably be of greatest value. 
3. Was the setting for this evaluation, as well as the filter through which study 
patients passed, adequately described? 
Yes. On the whole the majority of the available literature refers to well 
conducted scientific evaluations. 
4. Have the reproducibility of the test result (precision) and its interpretation 
(observer variation) been determined? 
Reproducibility has been evaluated in several studies. Though reproducibility 
is at the edge of what can be considered clinically acceptable, provided 
clinicians and researchers are aware of the limitations of the technique (and 
consequently observe the ‘least significant change’ values reported), then 
reproducibility should be no impediment to future adoption of the 
technique. As with EVLW, inter-observer variation has been relatively 
neglected by the literature to date. 
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5. Has the term normal been defined sensibly as it applies to this test? 
No. Quoted and theoretical normal values differ over a wide range. Similarly 
there is no consensus regarding which index to report, nor whether to 
perform a ratio of volumes, or indexed volumes. 
6. If the test is advocated as part of a cluster or sequence of tests, has its 
individual contribution to the overall validity of the cluster or sequence been 
determined? 
No. The studies of Monnet et al79, Chew et al423 and Kushimoto et al434, all 
reported that PVPIs may be utilised to make the diagnosis of ALI/ARDs with 
acceptable sensitivity and specificity (depending on the cut-off chosen and 
the desire to pursue sensitivity over specificity or vice versa). All three 
studies however sought to examine the utility of PVPIs alone rather than in 
combination with clinical findings; in reality, PVPIs values will be 
interpreted in the context of clinical findings. A study of the contribution of 
PVPIs to aid the clinical diagnosis of ALI/ARDs would be a valuable addition. 
7. Have the tactics for carrying out the test been described in sufficient detail to 
permit their exact replication? 
Yes. The methodology of TPTD is well described, with little variation 
between studies. 
8. Has the utility of the test been determined? 
No. Whilst several authors have promoted the incorporation of PVPIs into a 
novel definition of ALI/ARDS, this has not yet been established. Greater 
consensus regarding normal values and which of the three potential PVPIs is 
most valid is likely to be required first. Whilst the (Berlin) ‘ARDS Definition 
Task Force’ advocate the development of  “reproducible and valid methods 
for the direct measurement of pulmonary vascular permeability” (which 
would be) “important advances over current methods of assessing the 
presence and origin of lung oedema, and could be incorporated into the 
future definition of ARDS66”, the same “significant methodological 
limitations66” as applied to EVLW apply to PVPIs. 
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5.7 Literature review: Trans-pulmonary thermodilution 
measurement of extravascular lung water and 
pulmonary vascular permeability indices in patients 
undergoing lung resection 
This investigation concerns the application of trans-pulmonary thermodilution 
(TPTD) measurement of extravascular lung water (EVLW) and pulmonary vascular 
permeability indices (PVPIs) in patients undergoing lung resection. A number of 
authors have suggested that quantification of EVLW may be of value in this 
population48, 115, 363, 509-511, and there have been several clinical studies, conducted 
in the lung resection population where TPTD derived EVLW has been a study 
endpoint235, 245, 476. 
There are however a number of theoretical considerations, concerning the 
methodology of single thermodilution (STD) TPTD that at very least require 
consideration, and at worst may compromise its validity in the lung resection 
population. So much so in fact that several experts recommend against TPTD 
measurements in patients undergoing lung resection. In their original validation of 
the STD technique, Sakka et al, when discussing patients undergoing 
pneumonectomy concluded that “we therefore advise against using the single 
thermodilution technique under these circumstances”396. Schreiber et al have also 
counselled that “therapeutic consequence based on transpulmonary double 
indicator measurement in these [lung resection] patients... may be misleading”462. 
As will be discussed, the validity of TPTD monitoring following lung resection has 
seen little study. It is of concern therefore that EVLWSTD is being employed as an 
endpoint to clinical studies; in some circumstances to confirm the safety of clinical 
practices. Haas et al, and Assaad et al, for example use the absence of a post-
operative rise in EVLW as confirmation of the safety of liberalized fluid 
administration protocols235, 245.  
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5.7.1 Theoretical considerations in application of TPTD techniques 
following lung resection 
Theoretical considerations potentially compromising the validity of TPTD 
measurements in patients undergoing lung resection include: 
 Changes in the ITBV:GEDV ratio 
 Shortened pulmonary transit time 
 Physiological changes occurring in spontaneously rather than mechanically 
ventilated patients 
 Post-operative hyperinflation 
 
Each will be explored in turn. 
5.7.1.1 Changes in the ITBV:GEDV ratio 
The fundamental assumption intrinsic to STD techniques is that of there being a 
linear relationship between intrathoracic blood volume (ITBV) and global end-
diastolic volume (GEDV) (such that the ratio of ITBV:GEDV remains constant at 
1.25) as reported by Sakka et al392, 403. Such an assumption does not allow for the 
possibility of independent changes in pulmonary blood volume PBV and/or global 
end-diastolic volume, yet both ITBV and GEDV have the potential to change 
independently following lung resection. 
Changes in intrathoracic blood volume following lung resection 
Resection of lung tissue is likely to result in reduced pulmonary blood volume and 
so lead to a reduction in ITBV independent of GEDV512. Findings from studies 
exploring the changes in the relationship of ITBV:GEDV following lung resection are 
summarised in Table 5.10. In the three animal models, there is a relatively 
consistent fall in ITBV (13-21%) and PBV (22-30%) following pneumonectomy which 
is reflected in a significant reduction in the ITBV:GEDV ratio. Failure to account for 
a theoretical reduction in PBV following lung resection would lead to an 
overestimation of ITBV and a consequent underestimation of EVLW. It should also 
be appreciated that in the two studies examining the regression equation for the 
relationship between ITBV and GEDV, both demonstrated increases in the intercept 
value. As this value is conventionally ignored in the
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Table 5.10. Studies investigating changes in blood volumes and ITBV:GEDV following lung resection. 
Author 
(year) 
Species Methodology Sample size, study 
protocol 
Observed changes in blood volumes following lung resection 
 
Kirov et al
411
. 
(2006) 
Sheep TDD N=93 
Mechanical ventilation 
(n=51) 
Pneumonectomy (n=42) 
 
ITBVTDD -  ↓21% following pneumonectomy (p<0.05) 
PBVTDD-  ↓30% following pneumonectomy (p<0.05) 
GEDVTDD  -  ↓16% following pneumonectomy (p<0.05) 
ITBV:GEDV – ↓ from 1.46 to 1.39 following pneumonectomy (p<0.05) 
Regression equation – Pre pneumonectomy ITBVI=1.43(GEDVI)+13.48, post 
pneumonectomy ITBV=1.21(GEDVI)+73.72. 
     
Kuzkov et 
al
A
,
512
 
(2007) 
Sheep STD 
TDD 
 
N=18 
Sham operation n=4 
Left pneumonectomy, 
n=7 
Right pneumonectomy, 
n=7 
 
ITBVTDD - ↓18% following left pneumonectomy, 19% fall following right (both 
p<0.05) 
PBVTDD - ↓22% following left pneumonectomy (p<0.05), 23% fall following right 
(NS) 
ITBV:GEDV -  ↓ from 1.47 to 1.43 following left pneumonectomy, from 1.48 to 1.45 
following left (both not significant). 
     
Kuzkov et 
al
A
,
512
.  
(2007) 
Sheep STD 
TDD 
 
N=12 
Pneumonectomy 
followed by 4 hrs: 
Injurious vent n=6 
(12ml/kg, ZEEP) 
Protective vent n=6 
(6ml/kg, 2cmH20 PEEP) 
Injurious ventilation resulted in a significant ↓ in ITBV:GEDV 1.46 to 1.30 (p<0.05) 
 
Moderate correlation in EVLWSTD bias and ITBVITDD/GEDVITDD. (r=0.49, P<0.01) 
     
Roch et al
509
. 
(2005) 
Pigs STD 
TDD 
 
Pneumonectomy 
N=27 
 
ITBVITDD – ↓13% post pneumonectomy (p<0.01) 
ITBV:GEDV -  Change from 1.42 to 1.29 following pneumonectomy (no p-value 
provided) 
Regression equation – Pre pneumonectomy ITBVI=1.29(GEDVI)+ 49ml, post-
pneumonectomy  ITBVI=1.42(GEDVI)+53ml. 
     
Naidu et al
513
. 
(2009) 
Humans STD 
TDD 
N=3 
Pneumonectomy, n=1 
Lobectomy, n=2 
Marked variability observed in ITBV:GEDV for approximately 2 hours post-
operatively before remaining relatively stable for the remaining 12 hours. 
Post resection ITBV:GEDV – LUL = 1.36, LLL = 1.23, LPn =1.15. 
A
Kuzkov et al. Parallel investigations reported in a single paper. STD – ‘single’ thermodilution. TDD – thermo-dye dilution. ITBV(I) – Intrathoracic blood 
volume (index), GEDV(I) – Global end-diastolic volume (index), PBV – Pulmonary blood volume. LLL – left lower Lobectomy, LPn – left pneumonectomy, LUL 
– left upper Lobectomy. 
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two commercially available thermodilution monitors, an increase in the 
intercept could further compromise the ability of the monitor to make an 
accurate estimate of EVLW following lung resection; ignorance of an increased 
intercept value would lead to underestimation of ITBV and consequent 
overestimation of EVLW.  
Interestingly, the study of Kuzkov et al512  demonstrated a more pronounced 
change in ITBV:GEDV in sheep exposed to an injurious ventilation protocol. The 
injurious ventilation protocol led to the development of lung injury as evidenced 
by a significant fall in PaO2:FiO2 ratio and a significant increase in 
gravimetrically determined EVLW. There have been no studies specifically 
examining changes in the ITBV:GEDV in patients with lung injury (and two lungs), 
though the potential for lung injury and consequent redistribution of pulmonary 
blood flow to compromise the validity of STD is well recognised and has been 
discussed in detail in Section 5.5. The changes observed by Kuzkov et al 
represent a relative decrease in pulmonary blood volume, or increase in GEDV. It 
is plausible that both could occur in the context of lung resection and lung 
injury. Vascular constriction (in response to hypoxic pulmonary vasoconstriction 
or extrinsic compression by oedematous lung tissue) might lead to a reduction in 
the volume of the already compromised pulmonary vascular bed. The potential 
for GEDV to increase in the face of right ventricular dysfunction is discussed 
below. Pneumonectomy in combination with lung injury could lead to markedly 
increased right ventricular afterload, leading to RV dilatation and consequently 
increased GEDV. In support of this hypothesis, both pulmonary artery pressure 
and pulmonary vascular resistance index increased significantly in animals 
subjected to pneumonectomy and an injurious ventilation protocol. 
The single human study by Naidu et al513 demonstrates that whilst ITBV:GEDV is 
relatively uniform pre-operatviely, there are large and inconsistent changes in 
ITBV:GEDV following lung resection (Figure 5.12). This study is limited by its 
small sample size; though published under the title of ‘work in progress report’, 
this study has been abandoned due to technical difficulties with the indocyanine 
green reader (personal communication B. Naidu, April 2012).  
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Figure 5.12. Changes in GEDV/ITBV ratio in three patients undergoing lung resection.  
From Naidu et al (2009)
513
. 
Changes in global end-diastolic volume following lung resection 
Several studies have described a reduced right ventricular (RV) function 
following both lobectomy and pneumonectomy514-518 S. RVEF appears to be at its 
lowest on post-operative day two with incomplete recovery evident by three 
weeks514, 515. Such dysfunction is associated with increased RV end-diastolic 
(EDV) and end-systolic volumes (increases in  RVEDV in excess of 40% have been 
reported517). Such increases in RVEDV will lead to increased GEDV, potentially 
altering the ratio of ITBV:GEDV. In theory, increases in GEDV independent of PBV 
would lead to overestimation of ITBV and therefore underestimation of EVLW. 
5.7.1.2 Shortened pulmonary transit time 
Kuzkov et al and Schreiber et al have hypothesised that lung resection will lead 
to a shortening of the time that the thermal indicator takes to transit the 
pulmonary vascular bed147, 462; according to the Venturi effect519, if  an 
unchanged cardiac output is forced to pass through a restricted pulmonary 
circulation post-operatively, velocity and therefore transit time of indicator 
would be expected to decrease.  Reduced mean transit time of indicator would 
result in an under-estimation of intrathoracic thermal volume (ITTV is derived 
from the product of cardiac output and mean transit time - Section 5.3.2.1, 
Equation 5.9) and a consequent under-estimation of EVLW. It must be 
emphasised however that these concerns are theoretical; there have been no 
                                         
S
 The potential and importance of RV dysfunction in the post-operative period is discussed more 
extensively in Chapter 7, ‘future work’. 
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studies examining the effect of lung resection on pulmonary transit time or the 
velocity of pulmonary blood flow. It is possible that following lung resection, 
recruitment of previously hypoperfused pulmonary vasculature might mitigate 
any restriction. Against this hypothesis are the consistent observations of 
increased pulmonary vascular resistance following lung resection suggesting 
there is some ‘restrictive’ effect within the pulmonary vascular bed 125, 174. 
5.7.1.3 Spontaneous vs. mechanical ventilation  
The constant relationship between ITBV and GEDV observed and subsequently 
validated by Sakka et al392, 396 was made in critically ill patients undergoing 
positive pressure ventilation. Similarly, subsequent validation studies of TPTD 
measurement of EVLW were made in ventilated cohorts. If TPTD were to be a 
useful monitoring methodology in the post-operative period following lung 
resection however, validity would be required in spontaneously breathing 
patients. 
During mechanical ventilation, increases in intra-thoracic pressure result in 
reduced inferior vena caval blood flow and a reduction in pre-load to the right 
ventricle520.  Reduced preload (and consequently reduced GEDV) in the context 
of an unchanged pulmonary blood volume would result in an increase in the 
ITBV:GEDV ratio. Kirov et al411 determined ITBV/GEDV ratio by TDD and 
demonstrated an increased ITBV:GEDV (1.46 compared with 1.31 (p<0.05)) in 
mechanically ventilated sheep when compared to spontaneously breathing. ITBV 
was unchanged, whilst GEDVI was 16% lower in mechanically ventilated animals 
(p<0.05).  
In many studies of EVLW measurement in humans following lung resection, post-
operative estimates made whilst spontaneous breathing are compared with a 
mechanically ventilated pre-operative estimates (Table 5.11, right most 
column); potentially leading to a relative underestimation of EVLW post-
operatively. 
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5.7.1.4 Post-operative hyperinflation 
Hyperinflation of the residual lung tissue is well described after pneumonectomy 
as excessive negative pressure in the operative hemithorax leads to acute 
mediastinal shift114, 158. Similarly, following lobectomy, residual lung tissue on 
the operative side expands to a degree to occupy the post-lobectomy space. 
As pulmonary volume increases, pulmonary vascular resistance rises as a result 
of both increased transmural pressure and a stretching effect, leading to 
thinning of alveolar walls and mechanical compression23. Pulmonary inflation to 
supra-normal volumes post-operatively is likely therefore to be associated with 
increased pulmonary vascular resistance, altering the distribution of pulmonary 
perfusion and potentially further reducing the ‘visible’ portion of pulmonary 
vasculature. Conversely post-operative recruitment of previously hypo-perfused 
pulmonary vasculature could increase the volume of lung ‘visible’ to the thermal 
indicator.  
5.7.2 Reproducibility and validity of single thermodilution EVLW 
and PVPI measurement after lung resection 
Though the reproducibility and validity of STD measurement of EVLW has to 
some degree been established in ventilated patients without lung resection, 
despite theoretical concerns, there has been little attention to the 
reproducibility of the technique in either spontaneously breathing patients or 
patients undergoing lung resection. 
Similarly, the validity of EVLW measurement following lung resection has 
received little attention. The limited data available to assess criterion and 
construct validity are presented below; no assessment of concurrent or 
predictive validity has been made. 
5.7.2.1 Criterion validity 
Both Kuzkov et al511 and Roch et al509 have compared EVLWSTD with the ‘gold 
standards’ of  EVLWTDD and EVLWGRAV in animal models of pneumonectomy (sheep 
and pigs respectively).   
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Roch et al assessed bias between EVLWGRAV and both EVLWTDD and EVLWSTD in two 
lung and one lung (post-pneumonectomy) animals509. In two lung animals Roch et 
al observed that EVLWTDD underestimated and EVLWSTD marginally overestimated 
EVLWGRAV (mean bias -1ml/Kg and +1.5ml/kg respectively). Following 
pneumonectomy however, whilst EVLWTDD maintained good agreement with 
EVLWGRAV (mean bias +2ml/kg), EVLWSTD markedly overestimated EVLWGRAV (mean 
bias +5ml/kg)487. This observed increase in the overestimation of EVLWGRAV by 
EVLWSTD following pneumonectomy is at odds with much of the theory 
presented; a fall in PBV relative to GEDV, reduced mean transit time of thermal 
indicator and post-operative hyperinflation (altering the distribution of 
pulmonary perfusion) are each expected to lead to an underestimation in EVLW. 
Roch et al were no more able to explain the apparent paradox in their findings 
than the author (B. Shelley)487. It must be emphasised however, that though at 
odds with the theory presented, the findings of Roch et al represent those of a 
single study and are inconsistent with the findings of others. 
Kuzkov et al determined EVLW by TDD, STD and gravimetrically following 
pneumonectomy in a sheep model l511. Though these authors didn’t assess mean 
bias between EVLWSTD and EVLWGRAV in two-lung animals pre-operatively, post-
operative mean bias was +3ml/kg. This post-operative value includes a control 
group of animals undergoing ‘sham’ surgery (lateral thoracotomy only, no lung 
resection) in whom the bias between EVLWSTD and EVLWGRAV appears similar 
(from inspection of the scatter / Bland-Altman plots provided, reproduced in 
Figure 5.13) to that in animals undergoing pneumonectomy. 
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Figure 5.13. Linear regression analysis and Bland–Altman plot for comparison between 
single thermodilution and gravimetric estimates of EVLW following pneumonectomy in 
sheep.  
From Kuzkov et al (2007)
511
. 
There are no reports from which to assess criterion validity of PVPIs following 
lung resection. 
5.7.2.2 Construct validity 
Animal studies 
In Kuzkov et al’s sheep model of pneumonectomy followed by injurious 
ventilation, EVLWSTD can be observed to rise in parallel with the development of 
lung injury, represented by the constructs of falling PaO2/FiO2 and increased 
shunt (no statistical comparison made)147. Similarly, in two further reports from 
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the same research group, utilizing the same model of pneumonectomy and 
injurious ventilation in sheep, Subarov et al present data in which EVLW can be 
observed to rise in parallel with increasing venous admixture and lung injury 
score and falling oxygenation and both total lung and chest compliance228, 521. 
In all three studies, PVPI (as EVLW indexed to pulmonary blood volume) is 
observed to rise in parallel to EVLW147, 228, 521. 
Human studies 
In 2008, Licker et al studied the effects of inhaled bronchodilators on the 
resolution of pulmonary oedema in 24 patients undergoing lung resection, using 
EVLW to quantify pulmonary oedema. Post-operative administration of 
bronchodilator led to decreases in mean EVLW and increases in mean PaO2/FiO2. 
Change in PaO2/FiO2 following bronchodilator administration was associated with 
change in EVLW (R2=0.55, p<0.001). Licker et al also report a parallel reduction 
in both mean chest X-ray score and mean EVLW on post-operative day one 
compared to immediately post-operatively (no statistical comparison were 
made)476.  
Licker et al observe a significant fall in PVPI (as ELWI / GEDVI) following 
administration of  bronchodilator on the day of surgery, but not on post-
operative day one476. 
 
5.7.3 Observed changes in EVLW following lung resection 
Human studies evaluating the observed changes in EVLW following lung resection 
are summarised in Table 5.11; it can be seen that there is some variety in the 
findings, with EVLW being observed to fall, remain the same or increase post-
operatively. 
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Table 5.11. Summary of studies reporting changes in EVLW determined by TPTD after lung 
resection in humans. 
Author 
(year) 
Study design 
Study 
population* 
 
Change Pre- vs 
Post-op  
Subsequent 
post-op 
change  
B/L  
Kuzkov et 
al 
512
. 
(abs) 
2005 
Prospective 
observational 
No intervention 
N=7 
All P 
 
 
↓35% (p=0.02) ↑55% to a peak 
at 36hrs 
N/S 
      
Kuzkov et 
al 
511
 
(abs) 
2007 
Prospective 
observational 
No intervention 
N=27 
P=16 
L=11 
 
P: ↓30% (p<0.05) 
L: no sig change 
P: ↑24% to peak 
at 36hrs 
“significantly”  
L: no sig change 
MV 
      
Licker et 
al 
476
. 
(2008) 
Randomised 
cross-over trial of 
inhaled 
bronchodilator 
N=21 
 
B=5 
L=16 
↑31% 
 (p=0.009)  
 
 
No sig. diff on 
POD 1 vs pre-op 
 
 
SB 
      
Leo et al 
522
. 
(2008) 
Prospective 
observational - 
No intervention 
N=15 
All P 
 
↓32% 
“significantly 
decreased” 
No sig. change 
over 1
st
 24hrs 
MV 
      
Haas et al 
235
. 
(2012) 
Prospective 
observational - 
SVV guided, goal 
directed fluid 
therapy 
N=27 (11 
having lung 
resection) 
B= 2 
L= 9 
N/S No sig. change 
pre- vs 24hrs 
post-op 
MV 
      
Assaad et 
al 
234, 245
 . 
(abs) 
(2012) 
 
Prospective 
observational - 
Lliberalized fluid 
protocol 
N=11 
 
P=1 
L=8 
W=2 
N/S No sig change to 
POD 3 
MV 
P, pneumonectomy; BL, bi-lobectomy; L, lobectomy; SL, sub-lobar resection. B/L, whether baseline 
measurement made whilst mechanically ventilated (MV) or spontaneously breathing (SB). N/S, not 
specified. 
5.7.3.1 Immediate post-operative changes 
What might be expected to occur following lung resection? 
 
If one considers a lung with a given EVLW, it is assumed that that the EVLW is 
uniformly distributed throughout the lung (i.e. that EVLW per unit lung tissue is 
uniform throughout the lung). Following lung resection therefore it would 
anticipated that the lung resection would result in a reduction in total EVLW in 
proportion to the volume of resected lung tissue (with the unlikely assumption, 
that the resection takes place in such fashion that EVLW is unaltered).  That is 
to say that the volume of EVLW per unit lung is unchanged, but there is less lung 
therefore less total EVLW post-operatively. 
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As such one might expect to observe an approximate fall in EVLW of 47 / 53% for 
a left / right pneumonectomy respectively and between 10% and 26% for an 
anatomic lobectomy (based on a 19 segment model of pulmonary anatomy). 
Studies reporting immediate peri-operative changes 
Several human studies using STD following lung resection report either a less 
substantial reduction than might be anticipated511, 512, 522 in EVLW post-
operatively or recognise no change234, 235 (Table 5.11). 
There are several possible explanations for the fall in EVLW to be less than 
hypothesised: Firstly, resection of lung tissue may result in a proportional 
reduction in EVLW as hypothesised, but the EVLW per unit of residual lung tissue 
is increased as a result of pathological processes occurring during the peri-
operative period. Secondly, resection of lung tissue may result in a proportional 
reduction in EVLW as hypothesised, but following lung resection, STD 
measurement of EVLW results in a systematic overestimation of lung water (as 
reported by Roch et al)509.  
It is notable from Table 5.11, that Licker et al476 are the only group to report an 
increase in EVLW (immediately) post-operatively whilst all others either 
demonstrate no significant change or a fall in EVLW post-operatively. This is 
potentially explained by the following observations: Firstly Licker et al made 
their baseline assessments of EVLW prior to the induction of anaesthesia / onset 
of mechanical ventilation; as such, they compare an estimate of EVLW made 
whilst spontaneously breathing pre-operatively with one made whilst 
spontaneously breathing post-operatively. The majority of the others (as far as it 
can be deduced from the text) appear to have made their baseline estimate of 
EVLW after induction of anaesthesia and so compare a mechanically ventilated 
baseline value with a spontaneously breathing post-operative value, an 
observation that will lead to a relative underestimation of EVLW post-
operatively. Secondly, Licker et al report data from a predominantly lobectomy 
group. As such, the lesser anatomical reduction in EVLW seen following 
lobectomy may be insufficient to mask a pathological increase observed 
following resection.  
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It seems likely that whilst total EVLW might reduce following lung resection due 
to the anatomical loss of lung tissue (and its associated EVLW), due to the 
parallel intra-operative insults to both the operative and contra-lateral lung 
(discussed in detail in Chapter 1) resulting in development of sub-clinical lung 
injury, EVLW per unit of lung tissue is likely to be increased post-operatively.  
Such disparity of study findings may also be symptomatic of the relatively small 
number of patients included in each study or differences in baseline cardio-
respiratory function or intra-operative conditions (ventilator settings, duration 
of OLV, fluid administration, etc). Unfortunately as several of the investigations 
were only reported in abstract form it is not possible to obtain this data for all 
studies.  
 
5.7.3.2 Changes during the post-operative period 
In both their studiesT, Kuzkov’s group observed a significant increase in EVLW 
over the first 36 hours post-operatively511, 512. Though this might represent the 
development of lung injury in a high risk group of patients (pneumonectomy), 
the authors observed that this change “was not accompanied by changes in 
pulmonary artery pressure, pulmonary artery occlusion pressure and PaO2/FiO2
”. 
As these papers were only published in abstract form, it is difficult to apply 
much further analysis. Whilst it is possible these changes represent sub-clinical 
oedema formation, it is plausible that these changes represent fluctuation in the 
GEDV:ITBV ratio occurring post-operatively. Naidu et al observed marked 
changes in GEDV:ITBV occurring immediately post-operatively, before relative 
stability from 4-6 hours onwards. 
All other studies demonstrate no increase in mean EVLW post-operatively. 
Only the study of Licker et al reported PVPI post-operatively (ELWI/GEDVI)476. 
This demonstrated increased PVPI compared to baseline on post-operative day 
one (1.3 vs 2.0, p<0.05) before return to baseline on post-operative day two. 
  
                                         
T
 Which may in fact represent a preliminary sub-group of the same group of patients. 
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5.7.4 Summary 
Whilst the reproducibility and validity of STD measurement of EVLW and PVPI 
appear to be well established in the general critical care population, it is clear 
that as regards EVLW and PVPI measurement after lung resection, the literature 
is in its infancy. There are significant theoretical considerations which appear to 
challenge the validity of STD measurement following lung resection though these 
have yet to be explored fully in humans. Regrettably there are also 
methodological concerns concerning the use of TPTD in patients with lung 
injury, and so it seems that the very population in which the author is seeking to 
apply TPTD monitoring (i.e. for the detection of lung injury following lung 
resection), is the very population in which its application may be most 
challenging. 
It has been suggested that adjustment of the GEDV/ITBV relationship might 
improve the validity of TPTD monitoring following lung resection248. This concept 
is discussed in detail in Appendix three, and is a secondary aim of this 
Investigation IV. The primary aim is to establish the reproducibility and construct 
validity of trans-pulmonary thermodilution derived extravascular lung water and 
pulmonary vascular permeability index in patients undergoing lung resection. 
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5.8 Methods 
5.8.1 Ethical approval 
The need for ethical approval was waived following correspondence with the 
Scientific Officer and Service Manager of the West of Scotland Research Ethics 
Committee (WOSREC). This was because the project was considered by the 
committee to be “an evaluation of a new CE marked device with a view to 
introducing the device into routine clinical practice” (personal communication 
Dr Judith Godden, WOSREC Scientific Officer/Manager, February 2012). 
5.8.2 Patient population 
This patient population is a sample of convenience of nine patients undergoing 
elective lung resection by open thoracotomy at Golden Jubilee National 
HospitalU. Inclusion criteria were, age greater than 16 years and planned 
elective open lung resection (by lobectomy or pneumonectomy) for presumed 
primary lung cancer. Patients were excluded if they were pregnant, were 
undergoing lung resection for non malignant disease or secondary malignancy, 
were planned to undergo a wedge / segmental lung resection, or a resection via 
a thoracoscopic / minimal access technique. In addition, patients were excluded 
if they had a contraindication to femoral arterial catheterisation e.g. peripheral 
vascular disease, or localised skin infection. Anaesthetic technique was 
standardised, to total intravenous anaesthesia with Propofol and Remifentanil by 
target controlled infusion; post-operative analgesia was provided by thoracic 
epidural analgesia.  
5.8.3 Trans-pulmonary thermodilution 
TPTD measurements were performed using the Edwards Lifesciences EV1000 
clinical platform in combination with the VolumeView set according to the 
manufactures instructions (Edwards Lifesciences, Irvine, California, USA). The 
VolumeView set comprises VolumeView sensor, thermodilution manifold and the 
                                         
U
 Support for loan of equipment and provision of consumables was provided for this ‘pilot study’ by 
Edwards Lifesciences (Irvine, California, USA). The sample size of nine patients was dictated 
by the limits of the support available. 
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femoral arterial catheter. The components and set up are described in Figure 
5.14. 
 
Figure 5.14. Schematic representation of the patient and equipment set-up for 
transpulmonary thermodilution monitoring using the Edwards E1000 clinical platform.  
From: http://www.edwards.com/eu/products/mininvasive/Pages/volumeviewsetup.aspx. 
The VolumeView femoral arterial transducer is a 4 or 5F, 16cm cannula, 
equipped with a monitoring port (providing conventional arterial access for 
blood pressure monitoring and blood aspiration) and incorporating a thermister. 
This was inserted by the author (B Shelley), under ultrasound guidance in the 
patients’ femoral artery (on the contra-lateral side to the surgery) prior to the 
induction of general anaesthesia using an aseptic seldinger technique. Arterial 
pressure monitoring was instituted by connecting the monitoring port of the 
femoral arterial cannula to the VolumeView sensor. In addition to routine 
arterial pressure monitoring, following calibration by TPTD, the VolumeView 
allows continuous cardiac output monitoring by pulse contour analysis (not used 
for this investigation). Central venous cannulation was performed under 
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ultrasound guidance immediately following induction of anaesthesia using a 
triple lumen, 16cm, 7F, cannula (Edwards Lifesciences). The VolumeView 
thermodilution manifold was then connected to the distal lumen of the central 
venous cannula. This manifold allows monitoring of injectate temperature by the 
EV1000 system. The VolumeView sensor, thermodilution manifold, femoral 
arterial thermistor were then connected to the EV1000 monitor as shown in 
Figure 5.14. 
TPTD monitoring was then performed by rapid injection of known volume (15 or 
20ml) of cold normal saline through the thermodilution manifold; the 
temperature change in the femoral artery is determined by the thermister in the 
femoral arterial cannula and leads to generation of a thermodilution curve 
(Figure 5.15). From this curve, cardiac output, global end-diastolic volume index 
(GEDI) and extravascular lung water index (ELWI) are determined by the 
monitor.  
 
Figure 5.15. Screenshot from the Edwards EV1000 monitor demonstrating acquisition of 
thermodilution curves during TPTD. 
The results from injection 3 lie in excess of 10% from the mean value and so have been discarded 
and a further injection performed. It can be appreciated that the shape of the thermodilution curve 
during injection 3 is different from that observed during injections 1, 2 and 4. 
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The manufacturers recommend performing triplicate thermodilution on each 
occasion and the monitor then determines the mean values from the triplicate 
sets (Figure 5.15). 
5.8.3.1 TPTD monitoring for assessment of construct validity 
For routine clinical monitoring, the manufacturers recommend performing 
triplicate TPTD measurements, but rejecting any measurement whose cardiac 
index value lies greater than 10% from the mean value408. In the example shown 
in Figure 5.15 therefore, the results from measurement three have been 
discarded and a fourth measurement has been performed. The mean value, 
determined from injections one, two and four is taken as the result and was 
used in subsequent analyses. 
5.8.3.2 TPTD monitoring for assessment of reproducibility 
For the purposes of assessing reproducibility, sequentially discarding curves until 
the returned cardiac output results lay within 10% of the mean value would lead 
to an artefactual overestimation of the monitor’s reproducibility. 
Reproducibility statistics were therefore determined based on the results of the 
first three thermodilution injections. In the example in Figure 5.15, means and 
standard deviations (from which subsequently reproducibility statistics would be 
derived) would be determined from the results of injections one, two and three. 
5.8.4 Adjustment of TPTD value for the volume of lung resected 
To test the hypothesis that adjustment of TPTD derived ELWI and PVPI for the 
volume of lung resected would lead to an improvement in construct validity, two 
further estimates of ELWI / PVPI were derived by mathematical manipulation of 
the raw ELWI / PVPI results returned by the monitor (referred to from here 
onwards as ‘unadjusted’ results (ELWIUNadj / PVPIUNadj).  
From the unadjusted data, two modified values were derived. Derivation of the 
modified values is described in Appendix three.  Briefly, in the derivation of the 
first modified value, the coefficients utilised in equations used to derive ELWI 
and PVPI are adjusted in order to account for the hypothesised reduction in 
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pulmonary blood value following lung resection - resulting in the proposed 
‘anatomical’ adjustment (yielding ELWIANadj and PVPIANadj). In the second, TPTD 
derived indices were calculated using the original equations, but the ELWI and 
PVPI results yielded were ‘corrected’ to reflect that they have been determined 
from less than a whole lung. Correcting the result based on the number of 
pulmonary segments remaining following resection is the basis of the proposed 
‘segment corrected’ result (ELWISEGcorr and PVPISEGcorr). 
5.8.5 Post-operative data collection 
5.8.5.1 Clinical endpoints 
Oxygenation and Chest X-ray scoring 
 
Collection of data pertaining to oxygenation, and chest X-ray scoring were 
performed as described previously in Section 4.5.1.6. 
Fluid balance 
Post-operative fluid balance recording is routinely performed by the high 
dependency unit nursing staff, in the hospital critical care electronic records 
system (Centricity CIS, GE Healthcare, Wilmington, Massachusetts). The ‘zero 
point’ was defined as the point of admission to the high dependency unit, from 
which cumulative fluid balance was calculated hourly. 
 
5.8.6 Statistical handling 
5.8.6.1 Reproducibility 
Reproducibility statistics were determined for each triplicate set of TPTD 
measurements according to the definitions provided in Section 5.2.2.1.  
Median CV, CE, precision and LSC values were then derived by pooling all 
measurement sets. Confidence interval for medians were determined based on 
the Binomial distribution using Confidence Interval Analysis software, version 
2.2.0, (University of Southampton, Southampton, UK)523. 
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Reproducibility was assessed according to the criteria described by Holm et al to 
represent “usual practice” (Table 5.12)373. The use of the cut-offs described are 
supported by others374-377. 
Table 5.12. Quantitative interpretation of coefficient of variation (CV) of a clinical monitor. 
CV Interpretation 
<10% Small 
10-15% Acceptable 
>15% Poor 
From Holm et al (2005)
373
 
5.8.6.2 Construct validity 
Cross-sectional construct validity 
Contemporaneous values of EVLW / PVPI and post-operative PaO2/FiO2, CXR 
score and fluid balance were pooled across all time points and association 
determined using Pearson’s rho or Spearman rank correlation as appropriate. 
Strength of association was quantified according to the precedent described by 
Cohen524 (Table 5.13). 
Table 5.13. Interpretation of the strength of association by correlation coefficient. 
r Interpretation 
0.10 Small 
0.30 Moderate 
0.50 Large 
From Cohen, 1988
524
. 
Whilst pooled analyses such as these are a widely accepted and reported method 
of handling clinical data419, 427-429, 433, 525, such a pooled analysis fails to take into 
account repeated measures (where often, as in this study, many observations 
are made per subject). As Bland and Altman describe, in a comparison such as 
this, where one is interested in whether a subject’s PaO2/FiO2 is related to that 
subject’s ELWI, the association of interest is that within-subjects, and it is 
therefore desirable to remove any differences observed between-subjects526. To 
assess within-subject correlation, alongside the pooled analysis as described, 
analysis of covariance (ANCOVA) was performed (covariate = EVLW or PVPI and 
factor=patient) allowing within-subject variability to be partitioned out526. 
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Longitudinal construct validity 
Changes in paired EVLW / PVPI results and PaO2/FiO2, CXR score and fluid 
balance between sequential time-points were similarly subjected to pooled 
analysis for determination of association and ANCOVA. In addition, trending 
ability of EVLW / PVPI was determined by the construction of four quadrant 
plots and direction of change analysis. As advocated by Monge Garcia et al, to 
exclude random measurement error a central exclusion zone equivalent to the 
least significant change value for EVLW or PVPI was defined527. Concordance was 
defined as the number of data points falling into one of the quadrants of 
agreement, expressed as a percentage of the total number of data points used in 
the plot528.  
Following Fisher’s r-to-z transformation, comparisons between correlation 
coefficients were made according to Steiger’s method529 using computer 
software available made available online by Lee and Preacher530. Though this 
method was originally described for comparison of Pearson’s correlation 
coefficients, Myers and Siriois have reported “treating Spearman coefficients as 
though they were Pearson coefficients and using the standard Fisher's z-
transformation and subsequent comparison” (in order to compare coefficients) 
to be more robust than alternative methods531. 
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5.9 Results 
5.9.1 Patient demographics 
Trans-pulmonary thermodilution monitoring was instituted in 9 patients. 
Unfortunately in one patient, a disconnection occurred on transfer from the 
operating table to the patient trolley, comprising the sterility of the monitoring 
system and no further TPTD could be performed. As this patient had not had any 
post-operative TPTD measurements made, this patient’s data was excluded from 
the study. The demographic and surgical details of the remaining eight patients 
are summarised in Table 5.14. Whilst planned lobar lung resection or 
pneumonectomy was an a priori inclusion criteria of the study, in one case the 
operative plan was modified intra-operatively and the patient underwent sub-
lobar lung resection; this patient’s data was included in all analyses. 
Table 5.14. Demographic and surgical data from 8 patients included in reproducibility and 
validity of ELWI and PVPI study. 
Patient 1 2 3 4 5 6 7 8 
Age  64 68 61 74 70 66 63 52 
Sex M M F F M F F M 
Side Right Right Right Right Right Right Left Left 
Resection 
2x 
wedge 
Lung 
Lower 
lobe 
Upper 
lobe 
Middle 
& lower 
lobe 
Upper & 
middle 
lobe 
Upper 
lobe 
Upper 
lobe 
OLV time 37 106 23 107 99 176 70 57 
Op. time 154 147 104 218 184 261 163 128 
OLV, one lung ventilation; Op., operation. ‘wedge’, refers to sub-lobar resection. 
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5.9.2 Changes in ELWI and PVPI following lung resection 
There were no peri-operative changes in ELWI for both ‘un- adjusted’ values 
(ELWIUNadj) and those following ‘anatomical adjustment’ (ELWIANadj) Figure 5.16. 
Following correction of the ELWI value for the number of pulmonary segments 
resected (ELWISEGcorr), ELWISEGcorr was significantly higher immediately post-
operatively compared to pre-operative values (p=0.02, Wilcoxon signed rank 
test). All comparisons between pre- and post-operative values should be 
interpreted with caution however, as pre-operative measurements were made 
under conditions of positive pressure ventilation and are being compared to 
post-operative measurements made whilst spontaneously breathing. 
Unadjusted pulmonary vascular permeability index (PVPIUNadj) was significantly 
lower immediately post-operatively than pre-operatively and continued to fall 
up to 6 hours post-operatively (Figure 5.17). Both PVPIANadj and PVPISEGcorr 
increased significantly immediately post-operatively with little subsequent 
change through the monitored period. The same caution applies in the 
comparison of pre- vs post-operative PVPI values. 
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Figure 5.16. Changes in ELWI following lung resection.  
UNadj, unadjusted result; ANadj, ITBV/GEDV adjusted by ‘anatomical approach’; SEGcorr, result 
corrected to reflect no. of pulmonary segments remaining. Data presented as median, IQR. 
*p<0.05 vs pre-operative values, Wilcoxon signed rank test for both. N=8. 
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Figure 5.17. Changes in PVPI following lung resection.  
UNadj, unadjusted result; ANadj, ITBV/GEDV adjusted by ‘anatomical approach’; SEGcorr, result 
corrected to reflect no. of pulmonary segments remaining. Data presented as median, IQR. 
*
p<0.05 
vs pre-operative values, 
#
p<0.05 vs 0 hours (immediately post-operatively), Wilcoxon signed rank 
test for both. N=8. 
Whilst there was little change in median ELWI and PVPI through the post-
operative period (Figures 5.16 and 5.17), it is evident that in some individual 
patients, there was marked variation in both ELWI and PVPI. ELWIUNadj and 
PVPIUNadj values for individual patients are provided for illustration in Figure 
5.18. Arguably the purpose of the remainder of this investigation is to examine 
the clinical significance of such variation. 
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Figure 5.18 Changes in un-adjusted ELWI and PVPI over time for individual patients.  
Legend indicates patient number. Patient 5 demonstrates marked peaks in ELWI and PVPI on two 
occasions post-operatively whilst in patient 3 both ELWI and PVPI appear to be rising from 18 to 42 
hours post-operatively. No statistical comparisons made. 
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5.9.3 Reproducibility of TPTD derived values following lung 
resection 
Triplicate sets of TPTD derived measurements were made immediately post-
operatively and at six hourly intervals to 42 hours post-operatively in all 
patients, yielding 64 triplicate data sets. In addition a further 26 measurements 
were performed when required for calibration, following disconnection of the 
power supply (for example to facilitate transfer from recovery to the high 
dependency unit) or when the system was disconnected from the patient to 
allow mobilisation. All 90 measurement sets were subject to analysis in order to 
derive coefficient of variation (CV), precision and least significant change 
statistics (LSC) for the following TPTD derived variables: cardiac output (CO), 
global end-diastolic volume (GEDV), extravascular lung water (EVLW) and 
pulmonary vascular permeability index (PVPI determined as EVLW indexed to 
pulmonary blood volume). 
Table 5.15 Reproducibility statistics for TPTD derived parameters following lung resection. 
 Median value CV (%) Precision (%) LSC (%) 
CO 5.6 L/min 
(4.8-6.2 [2.6-8.1]) 
5.3 
(4.9-6.1) 
6.1 
(5.7-7.0) 
8.5 
(7.9-9.8) 
GEDV 1078 ml 
(960-1301 [697-1509]) 
6.5 
(5.1-8.0) 
7.5  
(5.9-9.2) 
9.0 
(7.3-11.6) 
EVLW 471 ml 
(412-543 [291-857]) 
8.3  
(6.7-9.3) 
9.6  
(7.6-10.7) 
11.5  
(9.4-14.3) 
PVPI 1.73 
(1.57-2.20 [0.90-3.40]) 
13.0  
(9.8-15.1) 
15.0 
(11.3-17.4) 
17.7 
(13.9-23.2) 
Values are presented as median (IQR [range]). CV, precision and LSC statistics for all variables 
were not normally distributed and are presented as median and 95% confidence interval for the 
median. 
 
The CV of all variables could be described as ‘good’, with the possible exception 
of PVPI where the 95% confidence interval for the mean just exceeds 15% (Table 
5.15). The sequential loss in reproducibility (increasing CV, precision and LSC) 
from CO to GEDV to EVLW to PVPI is evident from Figure 5.19 where the 
distribution of the individual measurements can be observed; the tight grouping 
of triplicate measurements seen in cardiac output separates progressively whilst 
moving through the sequence described. It is also evident from Figure 5.19 that 
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there is some loss of reproducibility in GEDV and EVLW measurement towards 
the higher extremes of the measured values.  
 
Figure 5.19. Distribution of triplicate cardiac output (CO), global end-diastolic volume 
(GEDV), extravascular lung water (EVLW) and pulmonary vascular permeability index 
(PVPI).  
For each parameter, measurement sets have been ordered according to increasing mean value. 
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5.9.3.1 Post hoc analysis: Reproducibility of TPTD derived variables by 
volume of lung resected 
When working with the TPTD data, it became apparent that whilst the overall 
median coefficients of variation for the four TPTD derived variables were 
acceptably low (as reported above), there was a marked variability between 
patients. To explore whether the variability between patients was related to the 
volume of lung tissue resected, comparison was made between median CV for 
each individual patient, and the number of pulmonary segments resected.  There 
was a consistent positive association between CV and number of pulmonary 
segments resected for all four parameters (Figure 5.20, Table 5.16). 
 
Figure 5.20. Median coefficient of variation (CV) verses number of pulmonary segments 
resected.  
CO, cardiac output; GEDV, global end-diastolic volume; EVLW, extravascular lung water; PVPI, 
pulmonary vascular permeability index. 
 
Table 5.16. Association between coefficient of variation for TPTD derived parameters and 
volume of lung tissue resected. 
 r p N 
CO 0.72 0.04 8 
GEDV 0.68 0.07 8 
EVLW 0.56 <0.01 8 
PVPI 0.68 0.07 8 
Spearman’s rho. 
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5.9.4 Construct validity of ELWI and PVPI following lung resection 
5.9.4.1 Cross-sectional construct validity of ELWI 
Association between ELWI and PaO2/FiO2 
There were 62 paired ELWI and PaO2/FiO2 results available for analysis (Figure 
5.21). There was a negative association between both ELWIUNadj and ELWIANadj 
and PaO2/FiO2, though this was significantly stronger for ELWIUNadj than ELWIANadj 
(r=-0.52 vs -0.36, p<0.01, Fig 5.21a & b, Table 5.17). On pooled analysis there 
was no relationship beween ELWISEGcorr and PaO2/FiO2 (Figure 5.21c). Following 
within-subject (ANCOVA) analysis, there was a moderate association between all 
ELWI values and PaO2/FiO2 with no significant differences between values (Table 
5.17).
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   a) 
 
 
b)
 
c)
 
Figure 5.21 Extravascular lung water index (ELWI) versus PaO2/FiO2.  
a) UNadj, unadjusted result, r=-0.52, p<0.01. b) ANadj, GEDV/ITBV adjusted by ‘anatomical 
approach’, r=-0.36, p<0.01. c) SEGcorr, result corrected to reflect no. of pulmonary segments 
remaining, r=0.04, p=0.75. Spearman correlation, N=8, n=62 for all. 
Association between ELWI and Chest X-ray score 
There were 19 paired ELWI and CXR scores available for analysis. These 19 CXRs 
were dual reported and the mean CXR score used for subsequent analysis. Inter-
rater reliability was explored by determining Type 3 Intraclass Correlation 
Coefficient (two-way mixed model for agreement, average measures). This 
revealed ‘substantial’ agreement between raters (ICC=0.72). 
There was a positive association between all ELWI values and post-operative CXR 
score, though this was weaker and lacked statistical significance for ELWISEGcorr 
than for ELWIUNadj and ELWIANadj (Figures 5.22a-c). There was however no 
statistically significant differences in the associations observed (Table 5.17).   
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On within-subject ANCOVA analysis there was a similar strong association 
between ELWI and CXR score for all ELWI values, with no differences between 
values (Table 5.17). 
 a) 
 
b) 
 
 
c) 
 
Figure 5.22. Extravascular lung water index (ELWI) versus CXR score. 
a) UNadj, unadjusted result, r=0.51, p=0.03. b) ANadj, ITBV/GEDV adjusted by anatomical 
‘segment counting approach’, r=0.59, p<0.01. c) SEGcorr, result corrected to reflect no. of 
pulmonary segments remaining, r=0.40, p=0.09. Spearman correlation, N=8, n=19 for all. 
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Association between ELWI and fluid balance 
There were 56 paired ELWI and fluid balance values available for analysis. There 
was no association between fluid balance and ELWI values in either pooled or 
within-subject analyses (Figs 5.23a-c and Table 5.17). 
a) 
 
b) 
 
c) 
Figure 5.23 Extravascular lung water index (ELWI) versus fluid balance.  
a) UNadj, unadjusted result, r=-0.20, p=0.15. b) ANadj, ITBV/GEDV adjusted by anatomical 
‘segment counting approach’, r=-0.11, p=0.44. c) SEGcorr, result corrected to reflect no. of 
pulmonary segments remaining, r=0.11, p=0.41. Spearman correlation, N=8, n=56 for all. 
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Table 5.17. Cross-sectional construct validity of ELWI following lung resections: Association between post-operative ELWI values and oxygenation, CXR 
score and fluid balance. 
 
ELWIUNadj ELWIANadj ELWISEGcorr n rmax v rmin
A 
Pairwise comparisonsA 
rUNadj v rANadj rANadj v rSEGcorr rSEGcorr v rUNadj 
Pooled analysis (Spearman) 
PaO2/FiO2 
r 
p 
-0.52 
<0.01 
-0.36 
<0.01 
0.04 
0.75 
62 
z 
p 
-4.35 
<0.01 
-2.71 
<0.01 
-4.41 
<0.01 
-4.35 
<0.01 
CXR score 
r 
p 
0.51 
0.03 
0.59 
<0.01 
0.40 
0.09 
19 
z 
p 
1.13 
0.26 
- - - 
Fluid balance 
r 
p 
-0.20 
0.15 
-0.11 
0.44 
0.11 
0.41 
56 
z 
p 
- - - - 
Within-subject analysis (ANCOVA) 
PaO2/FiO2 
r 
p 
-0.42 
<0.01 
-0.40 
<0.01 
-0.41 
<0.01 
62 
z 
p 
-1.64 
0.10 
- - - 
CXR score 
r 
p 
0.57 
0.06 
0.57 
0.06 
0.64 
0.03 
19 
z 
p 
-1.24 
0.21 
- - - 
Fluid balance 
r 
p 
-0.19 
0.19 
-0.20 
0.17 
0.18 
0.21 
56 
z 
p 
- - - - 
UNadj, unadjusted result; ANadj, ITBV/GEDV adjusted by ‘anatomical approach’; SEGcorr, result corrected to reflect no. of pulmonary segments remaining. n, number 
of comparisons from which result derived (N=8 patients). 
A
p-value by Steiger’s method following Fisher’s r-to-z transformation
529
. 
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5.9.4.2 Cross-sectional construct validity of PVPI 
Association between PVPI and PaO2/FiO2 
There were 62 paired ELWI and PaO2/FiO2 results available for analysis. For both 
PVPIANadj and PVPISEGcorr, there was a moderate positive association with 
PaO2/FiO2 which was supported by within-subject analysis (Figures 5.24b & c, 
Table 5.18). Conversely, there was a moderate (though not statistically 
significant, p=0.08) negative association between PVPIUNadj and PaO2/FiO2 which 
was strengthened (and became statistically significant) on within-subject 
analysis (Figure 5.24a and Table 5.18). The observed differences in correlation 
coefficient between ELWIANadj and ELWISEGcorr vs ELWIUNadj were significant in both 
pooled and within-subject analysis (Table 5.18). 
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a) 
 
 
b) 
 
c) 
 
Figure 5.24. Pulmonary vascular permeability index (PVPI) versus PaO2/FiO2.  
a) UNadj, unadjusted result, r=-0.23, p<0.08. b) ANadj, ITBV/GEDV adjusted by anatomical 
‘segment counting approach’, r=0.39, p<0.01. c) SEGcorr, result corrected to reflect no. of 
pulmonary segments remaining, r=0.47, p=<0.01. Spearman correlation, N=8, n=62 for all. 
 
Association between PVPI and CXR score 
There were 19 paired ELWI results and CXR scores available for analysis. There 
was no association between PVPI values and CXR scores in either pooled or 
within-subject analyses (Figures 5.25a-c and Table 5.18). 
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a)  
 
 
b) 
 
c) 
 
Figure 5.25. Pulmonary vascular permeability index (PVPI) versus CXR score.  
a) UNadj, unadjusted result, r=-0.08, p=0.74. b) ANadj, ITBV/GEDV adjusted by ‘anatomical’ 
approach, r=-0.06, p=0.82. c) SEGcorr, result corrected to reflect no. of pulmonary segments 
remaining, r=-0.16, p=0.50. Spearman correlation, N=8, n=19 for all. 
 
Association between PVPI and post-operative fluid balance 
There were 56 paired ELWI results and post-operative fluid balance values 
available for analysis. Whilst there was no association between PVPIUNadj and 
post-operative fluid balance, on pooled analysis there was a moderate positive 
association between both PVPIANadj and PVPISEGcorr and post-operative fluid 
balance. There was no association between any PVPI parameter and fluid 
balance on within-subject analysis. 
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a) 
 
b) 
 
c) 
 
 
Figure 5.26. Pulmonary vascular permeability index (PVPI) versus fluid balance.  
a) UNadj, unadjusted result, r=0.11, p=0.44. b) ANadj, ITBV/GEDV adjusted by ‘anatomical 
approach’, r=0.36, p<0.01. c) SEGcorr, result ‘corrected’ to reflect no. of pulmonary segments 
remaining, r=0.38, p<0.01. Spearman correlation, N=8, n=56 for all. 
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Table 5.18. Cross-sectional construct validity of PVPI following lung resections: Association between post-operative ELWI values and oxygenation, CXR 
score and fluid balance. 
 
PVPIUNadj PVPIANadj PVPISEGcorr n rmax v rmin
A 
Pairwise comparisonsA 
rUNadj v rANadj rANadj v rSEGcorr rSEGcorr v rUNadj 
Pooled analysis (Spearman) 
PaO2/FiO2 
r 
p 
-0.23 
0.08 
0.39 
<0.01 
0.47 
<0.01 
62 
z 
p 
-5.02 
<0.01 
-4.52 
<0.01 
-2.82 
<0.01 
-5.02 
<0.01 
CXR score 
r 
p 
-0.08 
0.74 
-0.06 
0.82 
-0.16 
0.50 
19 
z 
p - - - - 
Fluid balance 
r 
p 
0.11 
0.44 
0.36 
<0.01 
0.38 
<0.01 
56 
z 
p 
-1.80 
0.07 
- - - 
Within-subject analysis (ANCOVA) 
PaO2/FiO2 
r 
p 
-0.49 
<0.01 
0.46 
<0.01 
0.46 
<0.01 
62 
z 
p 
-12.98 
<0.01 
-12.98 
<0.01 
-0.18 
0.86 
-12.06 
<0.01 
CXR score 
r 
p 
0.30 
0.34 
0.43 
0.17 
0.35 
0.28 
19 
z 
p - - - - 
Fluid balance 
r 
p 
0.13 
0.38 
0.12 
0.43 
0.06 
0.70 
56 
z 
p - - - - 
UNadj, unadjusted result; ANadj, GEDV/ITBV adjusted by ‘anatomical approach’; SEGcorr, result corrected to reflect no. of pulmonary segments remaining. n, number 
of comparisons from which result derived (N=8 patients). 
A
p-value by Steiger’s method following Fisher’s r-to-z transformation
529
. 
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5.9.4.3 Longitudinal construct validity of ELWI 
Concordance between contemporaneous changes in ELWI and 
PaO2/FiO2 
There were 54 paired sequential changes in ELWI and PaO2/FiO2 available for 
analysis. Four quadrant analysis of ∆EVLWUNadj and ∆PaO2/FiO2 revealed a weak 
negative association between the parameters (r=-0.28, p=0.04) (Figure 5.27a). 
An exclusion zone of ∆EVLWUNadj +/-11.5% (equivalent to the LSC value for 
EVLW), was applied to the data such that only data points demonstrating 
∆EVLWUNadj greater than 11.5% in either direction were included in the 
concordance analysis. The concordance rate for a change in ∆EVLWUNadj of 
greater than 11.5% to be accompanied by an opposing change in ∆PaO2/FiO2 (of 
any magnitude) was 64% (Figure 5.27a). The same methodology was applied to 
comparisons of ∆ELWIEDadj, ∆ELWIANadj and ∆ELWISEGcorr verses ∆PaO2/FiO2. There 
was a similar degree of association and concordance between ∆ELWIANadj and 
∆ELWISEGcorr and ∆PaO2/FiO2 as with   ∆EVLWUNadj and ∆PaO2/FiO2, with no 
statistically significant difference observed between the performance of any of 
the parameters (Figures 5.27a-c, Table 5.19). The observed negative association 
between ∆ELWI and ∆PaO2/FiO2 was supported by with-in subject analysis (Table 
5.19). 
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                       a) 
 
b) 
 
c) 
 
Figure 5.27. Four quadrant plot of changes in ELWI against corresponding changes in 
PaO2/FiO2.  
a) UNadj, unadjusted result, r=-0.28, p=0.04, concordance=64%. b) ANadj, ITBV/GEDV adjusted 
by ‘anatomical’ segment counting approach, r=-0.25, p=0.07, concordance=65%. c) SEGcorr, 
result corrected by no. of pulmonary segments remaining, r=-0.29, p=0.03, concordance=64%. 
Spearman correlation. Quadrants of agreement defined as top left and bottom right. Data falling in 
dashed area (corresponding to ∆EVLW less than +/-11.5%) not included in the concordance 
analysis. N=8, n=54. 
Concordance between contemporaneous changes in ELWI and CXR 
score 
There were 11 paired sequential changes in ELWI score and post-operative CXR 
score available for analysis. There was no significant association observed 
between ∆ELWI and ∆CXR score for any ELWI parameter on pooled analysis 
(Figures 5.28a-c, Table 5.19); due to small numbers, with-in patient analysis 
could not be performed. Most of the returned data fell within the +/-11.5% 
exclusion zone meaning concordance analyses were based  on just 3-4 data 
points and so should be interpreted with caution (Figs 5.28a-c, Table 5.19). 
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a) 
 
b) 
 
 
c) 
 
Figure 5.28. Four quadrant plot of changes in ELWI against corresponding changes in CXR 
score.  
a) UNadj, unadjusted result, r=0.24, p=0.48, concordance=50%. b) ANadj, GEDV/ITBV adjusted by 
‘anatomical’ approach, r=0.37, p=0.26, concordance=67%. c) SEGcorr, result corrected by no. of 
pulmonary segments remaining, r=0.26, p=0.48, concordance=50%. Spearman correlation. 
Quadrants of agreement defined as top right and bottom left. Data falling in dashed area 
(corresponding to ∆EVLW less than +/-11.5%) not included in the concordance analysis. N=8, 
n=11. 
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Concordance between contemporaneous changes in ELWI and fluid 
balance 
There were 49 paired sequential changes in ELWI and post-operative fluid 
balance available for analysis. There was no significant association observed 
between ∆ELWI and ∆Fluid balance score for any ELWI parameter, either on 
pooled or within subject analysis (Figures 5.29a-c, Table 5.19). Concordance 
between ∆ELWI and ∆Fluid balance was low at 52-57%. 
a) 
 
b) 
 
c) 
 
Figure 5.29. Four quadrant plot of changes in ELWI against corresponding changes in fluid 
balance.  
a) UNadj, unadjusted result, r=-0.08, p=0.58, concordance=57%. b) ANadj, ITBV/GEDV adjusted 
by ‘anatomical’ approach, r=-0.05, p=0.72, concordance=52%. c) SEGcorr, result corrected by no. 
of pulmonary segments remaining, r=-0.08, p=0.57, concordance=56%. Spearman correlation. 
Quadrants of agreement defined as top right and bottom left. Data falling in dashed area 
(corresponding to ∆EVLW less than +/-11.5%) not included in the concordance analysis. N=8, 
n=49. 
Chapter 5  383 
 
 
Table 5.19 Longitudinal construct validity of ELWI following lung resection: Association and concordance between changes in post-operative ELWI values 
and corresponding changes in oxygenation, CXR score and fluid balance. 
 
∆ELWIUNadj (%) ∆ELWIANadj(%) ∆ELWISEGcorr(%) n rmax v rmin
A 
Pairwise comparisons (p for difference)A 
rUNadj v rANadj rANadj v rSEGcorr rSEGcorr v rUNadj 
Pooled analysis (Spearman) 
∆PaO2/FiO2 
r 
p 
C 
-0.29 
0.03 
64% 
-0.25 
0.07 
65% 
-0.29 
0.03 
64% 
54 
z 
p 
 
1.848 
0.06 
 
- 
 
 
- 
 
 
- 
 
 
∆CXR score 
r 
p 
C 
0.24 
0.48 
50% 
0.37 
0.26 
67% 
0.24 
0.48 
50% 
11 
z 
p 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
∆Fluid balance 
r 
p 
C 
-0.08 
0.58 
57% 
-0.05 
0.72 
52% 
-0.08 
0.57 
56% 
49 
z 
p 
 
- 
 
 
- 
 
- 
 
- 
 
Within-subject analysis (ANCOVA) 
∆PaO2/FiO2 
r 
p 
-0.29 
0.04 
-0.25 
0.08 
-0.30 
0.04 
54 
z 
p 
-1.842 
0.07 
- - - 
∆CXR score 
r 
p 
- - - 11B 
z 
p 
- - - - 
∆Fluid balance 
r 
p 
0.14 
0.36 
0.15 
0.35 
0.14 
0.36 
49 
z 
p 
- - - - 
UNadj, unadjusted result; ANadj, GEDV/ITBV adjusted by ‘anatomical approach’; SEGcorr, result corrected to reflect no. of pulmonary segments remaining. C, 
concordance (%). 
A
p-value by Steiger’s method following Fisher’s r-to-z transformation
529
. 
B
Within-patient analysis not possible due to small numbers. 
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5.9.4.4 Longitudinal construct validity of PVPI 
Concordance between contemporaneous changes in PVPI and PaO2/FiO2 
There were 54 paired sequential changes in PVPI and PaO2/FiO2 available for 
analysis. There was a similar degree of association between ∆PVPIUNadj,  
∆PVPIANadj and ∆PVPISEGcorr  and ∆PaO2/FiO2, with no statistically significant 
difference observed between the performance of any of the parameters (Figures 
5.30a-c, Table 5.20). Applying an exclusion zone of +/-17.7% (equivalent to the 
LSC value of PVPI), and excluding ∆PVPI values falling within this zone from 
analysis, the concordance between ∆PVPI values and  ∆PaO2/FiO2 was substantial 
at 65-81%. The observed negative association between ∆PVPI values and 
∆PaO2/FiO2 was supported by with-in subject analysis (Table 5.20). 
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a) 
 
 
b) 
 
 
 
c) 
 
Figure 5.30.  Four quadrant plot of changes in PVPI against corresponding changes in 
PaO2/FiO2. 
 a) UNadj, unadjusted result, r=-0.30, p=0.03, concordance=76%. b) ANadj, ITBV/GEDV adjusted 
by ‘anatomical’ segment counting approach, r=-0.28, p=0.04, concordance=81%. c) SEGcorr, 
result corrected by no. of pulmonary segments remaining, r=-0.27, p=0.05, concordance=65%. 
Spearman’s rho. Quadrants of agreement defined as top left and bottom right. Data falling in 
dashed area (corresponding to ∆PVPI less than +/-17.7%) not included in the concordance 
analysis. N=8, n=54. 
Concordance between contemporaneous changes in PVPI and chest X-
ray score 
There were 11 paired sequential changes in PVPI score and post-operative CXR 
score available for analysis. There was no significant association observed 
between ∆PVPI and ∆CXR score for any PVPI parameter on pooled (Figures 5.31a-
c, Table 5.20); due to small numbers, with-in patient analysis could not be 
performed. All but two data points fell within the +/-17.7% exclusion zone 
meaning concordance analysis could not be performed (Figures 5.31a-c, Table 
5.24).  
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a) 
 
b) 
 
c) 
 
 
Figure 5.31. Four quadrant plot of changes in PVPI against corresponding changes in CXR 
score.  
a) UNadj, unadjusted result, r=-0.16, p=0.64. b) ANadj, GEDV/ITBV adjusted by ‘anatomical’ 
segment counting approach, r=-0.17, p=0.62. c) SEGcorr, result corrected by no. of pulmonary 
segments remaining, r=-0.30, p=0.38. Spearman’s rho. Data area corresponds to ∆EVLW less than 
+/-17.7% (LSC value for PVPI). No direction of change analysis performed. N=8, n=11. 
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Contemporaneous changes in PVPI and fluid balance 
There were 49 paired sequential changes in PVPI and post-operative fluid 
balance available for analysis. There was no significant association observed 
between ∆PVPI and ∆Fluid balance score for any PVPI parameter, either on 
pooled or within-subject analysis (Figures 5.32a-c, Table 5.20). No concordance 
analysis between ∆PVPI and ∆Fluid balance was performed in light of the 
hypothesis that PVPI would not be associated with fluid balance.  
a) 
 
b) 
 
c) 
 
 
Figure 5.32. Four quadrant plot of changes in PVPI against corresponding changes in fluid 
balance.  
a) UNadj, unadjusted result, r=-0.06, p=0.70. b) ANadj, ITBV/GEDV adjusted by ‘anatomical’ 
segment counting approach, r=-0.05, p=0.73. c) SEGcorr, result corrected by no. of pulmonary 
segments remaining, r=-0.03, p=0.82. Spearman’s rho. Data falling in dashed area corresponds to 
∆PVPI less than +/-17.7% (LSC value for PVPI). N=8, n=48. 
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Table 5.20 Longitudinal construct validity of PVPI following lung resection: Association and concordance between change in post-operative PVPI values 
and corresponding changes in oxygenation, CXR score and fluid balance. 
 
∆PVPIUNadj (%) ∆PVPIANadj(%) ∆PVPISEGcorr(%) n 
 
rmax v rmin
A 
Pairwise comparisons (p for difference)A 
rUNadj v rANadj rANadj v rSEGcorr rSEGcorr v rUNadj 
Pooled analysis (Spearman) 
∆PaO2/FiO2 
r 
p 
C 
-0.30 
0.03 
76% 
-0.28 
0.04 
81% 
-0.25 
0.07 
65% 
54 
z 
p 
 
0.956 
0.34 
 
- 
 
 
- 
 
 
- 
 
 
∆CXR score 
r 
p 
C 
-0.16 
0.64 
- 
-0.17 
0.62 
- 
-0.30 
0.38 
- 
11 
z 
p 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
∆Fluid balance 
r 
p 
C 
-0.06 
0.70 
- 
-0.05 
0.73 
- 
-0.03 
0.82 
- 
48 
z 
p 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
Within-subject analysis (ANCOVA) 
∆PaO2/FiO2 
r 
p 
-0.30 
0.04 
-0.25 
0.09 
-0.25 
0.08 
54 
z 
p 
1.54 
0.12 
- - - 
∆CXR score 
r 
p 
- - - 11B 
z 
p - - - - 
∆Fluid balance 
r 
p 
0.13 
0.40 
0.14 
0.37 
0.12 
0.46 
48 
z 
p - - - - 
UNadj, unadjusted result; ANadj, GEDV/ITBV adjusted by ‘anatomical approach’; SEGcorr, result corrected to reflect no. of pulmonary segments remaining. C, 
concordance (%). 
A
p-value by Steiger’s method following Fisher’s r-to-z transformation
529
. 
B
Within-patient analysis not possible due to small numbers. 
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5.9.5 Summary of results: Construct validity of ELWI and PVPI 
following lung resection 
In an attempt to provide a summary of the multiple comparisons between ELWI 
and PVPI and the constructs PaO2/FiO2, CXR score and fluid balance made both 
contemporaneously (cross-sectional analysis) and longitudinally, Table 5.21 was 
constructed. In this table which seeks to present a point of reference from which 
the presence or absence of construct validity can be determined, the results of 
the comparisons are graded according to what extent the results support the 
concept of construct validity: 
++ Consistent relationship (or lack of) demonstrated, consistent with 
hypotheses, within-patient analysis supports pooled. 
+ Relationship (or lack of) demonstrated, consistent with hypotheses, but is 
either inconsistent, or results of within-patient and pooled analyses are not 
consistent. 
‒ No relationship demonstrated (or relationship demonstrated where not 
hypothesised), against hypothesis. 
‒ ‒ Consistent relationship demonstrated, with-in patient analysis supports 
pooled, NOT consistent with hypotheses. 
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Table 5.21. Summary of results: Construct validity of ELWI and PVPI after lung resection. 
 
ELWIUNadj ELWIANadj ELWISEGcorr 
 Cross. Long. Cross. Long. Cross. Long. 
PaO2/FiO2 ++ ++ ++ ++ + ++ 
CXR score ++ ‒ ++ ‒ ++ ‒ 
Fluid balance ‒ ‒ ‒ ‒ ‒ ‒ 
 PVPIUNadj PVPIANadj PVPISEGcorr 
 Cross. Long. Cross. Long. Cross. Long. 
PaO2/FiO2 ++ ++ ‒ ‒ ++ ‒ ‒ ++ 
CXR score ‒ ‒ ‒ ‒ ‒ ‒ 
Fluid balance ++ ++ ++ ++ ++ ++ 
UNadj, unadjusted result; ANadj, GEDV/ITBV adjusted by ‘anatomical approach’; SEGcorr, result 
corrected to reflect no of pulmonary segments remaining. For explanation of symbols see text. 
Cross, cross-sectional construct validity; Long, longitudinal construct validity. 
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5.10 Discussion 
5.10.1 Changes in ELWI and PVPI following lung resection 
There were no significant immediate post-operative changes in ELWIUNadj or 
ELWIANadj. In contrast, ELWISEGcorr was significantly higher immediately post-
operatively than pre-operatively, a finding which ‘feels right’ intuitively in the 
context of the discussion of ‘what might be expected to occur following lung 
resection?’ provided in Section 5.7.3.1.  The observed ELWIUNadj values are in 
keeping with those reported by others, for a group primarily composed of 
patients undergoing lobectomy (Table 5.11)235, 245, 511. 
PVPIUNadj fell immediately post-operatively whilst PVPIANadj and PVPISEGcorr were 
increased. Again, the changes in adjusted values ‘feel right’; it is hard to 
conceive that undergoing lung resection with one lung ventilation would lead to 
reduced pulmonary vascular permeability. Such a finding would be in contrast 
with the observations of Waller et al, who used lung scintigraphy (as close to a 
‘gold standard’ permeability measure as exists), to demonstrate increased 
pulmonary vascular permeability in 9 of 10 patients undergoing pneumonectomy 
and 6 of 11 patients undergoing lobectomy125. It must be emphasised that the 
comparisons made pre- versus post- operatively were made in ventilated versus 
spontaneously breathing patients, compromising their reliability. Relative to 
observations made during mechanical ventilation, observations made during 
spontaneous breathing would be anticipated to underestimate ELWI (Section 
5.7.1.3), as such all values perhaps under represent the (hypothesised) post-
operative rise in ELWI per unit of lung tissue.  
All post-operative observations were made in spontaneously breathing patients. 
There were no significant changes in median ELWI (adjusted or unadjusted) 
compared to immediate post-operative baseline values throughout the 
monitored period. Similarly, besides a fall in PVPIUNadj 6 hours post-operatively 
there were no other significant changes in median PVPI (adjusted or 
unadjusted). Such observations are not however at odds with the suggestion that 
TPTD might be a useful monitor in this post-operative population. Arguably the 
purpose of the monitor should be to identify the individuals, in whom (clinically) 
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significant changes do occur. Inspection of Figure 5.18 suggests there were 
marked increases in ELWI and PVPI during the monitored period in two 
individuals patients within the 8 patient cohort. 
5.10.2 Feasibility 
In general TPTD monitoring was well tolerated by patients and appears feasible 
in the early post-operative period following lung resection. The femoral arterial 
catheters appeared not to cause any discomfort and did not impair mobilisation. 
Interruption of the power supply or disconnection of the EV1000 monitor unit 
from the arterial cannula unfortunately necessitates re-calibration by triplicate 
thermodilution injection as the monitor has no battery nor ‘hot-start’ function. 
One patient suffered a femoral haematoma following unsuccessful placement of 
the arterial cannula which was subsequently placed without event on the contra-
lateral side. The disconnection experienced in patient 9 was unfortunately the 
result of user error and a failure to check the security of the Luer-Lok 
connection. The author (B. Shelley) has since been informed by the 
manufactures that the ‘VolumeView thermistor manifold’ (which became 
disconnected from the central venous cannula) is available as a additional 
‘spare’ (person communication, Jane Wylie, Account Manager – Scotland and NE, 
Critical Care,  Edwards Lifesciences); had this not been the last monitoring set in 
the hospital then the disconnection would not have caused any problems. 
5.10.3 Methodology 
Before considering the results of the current study, it is important first to pay 
some attention to the methodology. In the opinion of the author (B. Shelley), 
‘construct validity’, is seldom discussed but often implied within the medical 
literature. All of the studies in Table 5.5, for example, make comparison 
between EVLW and some ‘construct’ perceived to be supportive of the 
supposition that EVLW is a measure of lung injury, but none explicitly describes 
construct validity in its methodology. It is arguable that to Sackett et al’s 
“conscious clinician” (Section 5.2.), who is mandated to make some assessment 
of the usefulness of the diagnostic criteria364, the observation of association with 
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such ‘constructs’ is a powerful driver in the process of establishing ‘face 
validity’. 
To offer some endorsement of the use of construct methodology to validate tests 
where no ‘gold standard’ exists, the example quoted in the text of Ely et al 
seeking to validate the Richmond Agitation-Sedation Scale (RASS)371, was 
published in the Journal of the American Medical Association (JAMA)’ in 2003 
and has since received 377 citations (Web of Science® ‘times cited’ at the time 
of writing (18th October 2014)). Seeking to compare diagnostic tests by 
comparing the strength of association between constructs is a further extension 
of the ‘construct validity’ methodology, but is not without precedent. The 
widespread acceptance that EVLW should be indexed to predicted rather than 
actual body weight stems from the observations of Craig et al and Philips et al, 
who observed that the predictive validity of EVLW measurement (for mortality) 
is improved when EVLW is indexed for predicted body weight (PBW)405, 429.  
Similarly, Berkowitz et al observed that indexing EVLW to PBW resulted in a 
stronger correlation with Lung Injury Score and PaO2:FiO2 ratio
433.  
The testing of statistical significance between the corresponding correlation 
coefficients (as performed in this study) is not generally pursued. To this end the 
author (B. Shelley) is grateful for the advice of Dr Malachy Coulomb, Consultant 
in Anaesthesia and Intensive Care Medicine at the University Hospital of South 
Manchester, and statistical advisor to the British Journal of Anaesthesia. Dr 
Coulomb was in agreement with the author’s conclusion ; that  the use of 
Fisher’s r-to-z transformation and comparison of the two correlation coefficients 
with greatest separation, followed by pairwise comparisons in the event of a 
significant result represented the most appropriate methodology in the absence 
of a suitable global test (analogous for example to one way analysis of variance 
across multiple groups before pairwise comparisons). It may have been equally 
valid however to make no statistical comparison “and allow the correlation 
coefficients to stand for themselves” (personal communication, Dr Malachy 
Coulomb, January 2013). It must be emphasised firstly, that no power analysis 
has been performed to the assess the discriminatory ability of the sample size 
presented in distinguishing between the different adjustments when compared 
in this way, and secondly, multiple pairwise comparisons conducted in this way 
carry high risk of type I error. 
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It is undoubtedly a strength of this study that within-patient analysis of co-
variance was performed to ‘confirm’ the results of the pooled analysis. In almost 
all occasions this analysis was supportive of the pooled analyses, though on 
occasion the results were different, more often than not with the within-patient 
result appeared to correct a biologically ‘implausible’ pooled result. In such 
circumstances the question of ‘which result to believe?’ is pertinent. Bland et al 
suggest that the within subject analysis yields the ‘true’ result, citing an 
example in their manuscript where “the correct analysis within-subjects reveals 
a relation which the incorrect [pooled] analysis misses”526. The grading devised 
to summarise overall construct validity in Table 5.21, attempts to address this 
issue by awarding greater significance to relationships where the results of the 
pooled and within-patient analyses are consistent. 
Finally (before discussion of the results), I shall discuss the methodology of the 
longitudinal analyses. Concordance analysis by the use of four-quadrant plots is 
classically described to compare cardiac output measurement between a novel 
monitor and a reference technique. In such a situation, it can be appreciated 
that the novel monitor, if valid, should provide identical results to the reference 
monitor and as such “a concordance rate of >90% to 95% indicates reliable 
trending ability”528. In the current investigation however, whilst it is desirable 
that changes in EVLW are mirrored (for example) by changes in oxygenation, 
concordance rates in excess of 90% are an unlikely finding, and should not be 
anticipated; there are of course many other causes of poor oxygenation 
following lung resection than pulmonary oedema. As such, concordance in excess 
of 50% (representing a 50:50 chance that the monitor mirrors the clinical 
change) are desirable, but it would require a more detailed study of the 
perceived clinical explanation for all changes in clinical parameters in order to 
identify a ‘target value’ representing ‘acceptable’ concordance. 
5.10.4 Reproducibility  
Holm et al describe that “according to usual practice”  a coefficient of variation 
(CV) of less than 10% may be considered ‘good’; between 10 and 15% considered 
‘acceptable’ and greater than 15% considered ‘poor’373. By this criteria, in the 
pooled analysis, the CV  of all variables in the current study could be described 
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as ‘good’, with the possible exception of PVPI where the 95% confidence interval 
for the mean just exceeds 15% (Table 5.15). Though clinically acceptable, the CV 
values appear larger than those previously reported by Tagami et al for TPTD 
measurement in critically ill post-cardiac arrest patients374. There are a number 
of reasons why this might be the case. Firstly, Tagami et al used the PiCCO® 
system (Pulsion Medical Systems, Munich, Germany) whilst the EV1000 palatform 
was used in this study. Bendjelid et al however have demonstrated equivalent 
reproducibility between the two devices in animals525. Secondly, all of the 
datasets subject to reproducibility analysis were obtained during conditions of 
spontaneous breathing; where the majority (if not all) of the measurements 
obtained in Tagami et al’s study group will have been made during positive 
pressure ventilation. Using an early model ‘lung water computer’, Laggner et al 
reported that the CV for EVLWTDD measurement was higher in patients 
spontaneously breathing compared to those mechanically ventilated (16.1 vs 
10.8%, p<0.05)532. These authors attribute the improved reproducibility seen in 
mechanically ventilated patients to greater “stability of the thoracic cage”532. It 
is the authors’ belief, that the increased CV seen in spontaneous breathing 
reflects the naturally varying respiratory pattern observable when spontaneously 
breathing, leading to variation in stroke volume between (and during) 
measurement sets. Furthermore, it is hypothesised that the effects of 
ventilation (spontaneous or mechanical) on stroke volume will be amplified 
following lung resection leading to further increases in variability between 
measurements. The results of the post-hoc analysis presented in Figure 5.20, 
appear to demonstrate that CV increases in proportion to the volume of lung 
resected. This is a novel and important finding. Whilst further research is 
required to provide a precise estimate of the CV in patients undergoing larger 
resections (bi-lobectomy and pneumonectomy), it must be appreciated that such 
increases in CV will lead to marked increases in the least significant change 
(LSC) value in these patients. 
The LSC values obtained are perhaps the most useful outcome of the 
reproducibility study, allowing interpretation of changes in TPTD derived values 
in the context of whether they are likely to represent ‘actual’ change rather 
than measurement artefact. In the current cohort, of the 54, 6-hourly interval 
changes in ELWI and PVPI available for analysis, just 46% of the ELWI (Figure 
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5.27) and 31% of the PVPI changes (Figure 5.30) were greater than the 
corresponding LSC value, and so can be interpreted as ‘true’ changes. 
5.10.5 Validity 
5.10.5.1 Extravascular lung water index 
Construct validity of unadjusted TPTD measurement of ELWI is suggested by the 
following observations: 
 Negative association between ELWI and PaO2/FiO2  
 Negative association between ∆ELWI and ∆PaO2/FiO2  
 Positive association between ELWI and CXR score values  
 
There was no association between ELWI and fluid balance, or between ELWI and 
longitudinal analysis of CXR scores. The lack of association with fluid balance is 
not surprising. Several authors have found no association between ELWI and fluid 
balance in critically ill patients many of whom had ALI/ARDS381, 428, 433. In 
comparison to critically ill patients with ALI/ARDS, it is plausible to suggest that 
the patients in the current cohort might be expected to have relatively 
preserved alveolar-capillary membrane function. Furthermore, as it is routine 
practice in our institution to restrict fluids following lung resection, it would 
seem unlikely that fluid balance would have strayed into the range that would 
be required to influence ELWI. The lack of association between ∆ELWI and ∆CXR 
score (and associated low concordance) seems more surprising, given the 
significant association between (ELWI and CXR score) though it must be 
appreciated that there were just 11 sequential ∆CXR results on which the 
analysis could be performed, and just four of these represented a change 
greater than the LSC value for ELWI (Figure 5.28). 
Validity of ‘anatomical adjustment’ and ‘segment correction’ of ELWI 
Adjustment of TPTD derived values by either manipulation of GEDV/ITBV 
(‘anatomical’ adjustment, ANadj) or indexing of the results to the number of 
pulmonary segments remaining (segment correction, SEGcorr) did not appear to 
improve the construct validity of ELWI. There were no significant differences 
seen in the level of association observed between unadjusted and adjusted ELWI 
and PaO2/FiO2 and CXR score.  
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There are a number of possible explanations for why adjustment of values did 
not improve construct validity: 
1. Type II error. Potential for type II error in the comparisons between 
correlation coefficients is discussed above. Though the differences between 
rmax and rmin (of within-subject comparisons) occasionally demonstrated 
trends towards significance, consistency in the associations observed was 
striking, suggesting any clinical significance (in the face of statistical 
significance) may be negligible. For example, ELWIUNadj and ELWIANadj were 
both significantly negatively associated with PaO2/FiO2, r=-0.42 and -0.40 
respectively, p<0.01 for both (Table 5.17). Following Fisher’s r-to-z 
transformation, the p value when testing the null hypothesis that there is no 
difference between the two r-values observed, was 0.10. Had this p-value 
been 0.04, it would have been difficult to conclude that ELWIUNadj had 
greater construct validity than ELWIANadj on the basis of a 0.02 change in r-
value. 
2. The volume of lung resected was inadequate to invalidate unadjusted ELWI 
and PVPI values. All of the animal work suggesting a reduction in PBV post-
operatively and a consequent alteration in the GEDV/ITBV ratio, was 
performed in pneumonectomy models (Table 5.10)147, 411, 509. As the current 
study cohort only included one patient undergoing pneumonectomy (and 
otherwise could be described as a lobectomy population), it is conceivable 
that post-operative changes in the GEDV/ITBV were insufficient to 
compromise the validity of unadjusted ELWI and PVPI measurement. 
Extrapolation of the results of this work to populations undergoing 
pneumonectomy should therefore be undertaken with caution.   
3. The GEDV/ITBV ratio does not change to the degree anticipated. The 
hypothesis that pulmonary blood volume falls in direct proportion to the 
volume of lung resected may be an overestimation. Firstly, recruitment of 
previously hypo-perfused pulmonary vasculature may increase the ‘capacity’ 
of the pulmonary vasculature and so result in relative maintenance of PBV. 
This hypothesis is supported by the results of animal studies observing that 
PBV (determined by TDD) falls by 22-30% following pneumonectomy rather 
than the ~50% anticipated in the calculation of the ‘anatomical 
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adjustment’411, 511.  In this context it must be appreciated that PBV 
determined by TDD is a ‘theoretical volume’ rather than an actual one, and 
may not therefore be solely determined (as might be expected) by the 
volume of blood in the pulmonary vasculature497. 
Secondly, whilst ‘true’ GEDV (GEDVACTUAL) might be expected to increase 
following lung resection (Page 377), ‘measured’ GEDV decreases following 
lung resection, maintaining GEDV/ITBV ratio in the face of reduced 
pulmonary blood volume. In the current study, there was a small but non-
significant reduction in median GEDVSTD following lung resection (1075 vs 
1041ml, p=0.12, Wilcoxon Signed Rank Test, data not shown), but this 
comparison is compromised by making comparison of invasively ventilated 
pre-operative values with spontaneously breathing post-operative estimates 
and the administration of intravenous fluids intra-operatively (both of which 
would be anticipated to increase GEDVACTUAL). In more controlled conditions, 
Schreiber et al observed a significant reduction in GEDVSTD on occlusion of 
branch pulmonary arteries in ventilated swine462. GEDVSTD was reduced 
despite the observation of increased right ventricular end-diastolic volume; 
both changes reverted to baseline on removing the occlusion. Schreiber et al 
hypothesised this artefactual underestimation of GEDVACTUAL resulted from 
errors in ITTV measurement due to increases in transit velocity (and hence 
reduction in mean transit time) through the reduced pulmonary vascular 
bed462.  
4. Changes in the GEDV/ITBV occurring secondary to a reduction in PBV may be 
to an extent ‘cancelled out’ by the opposing change in the intercept value in 
the ITBV=aGEDV+b regression equation. As reported in Table 5.10, both Kirov 
et al411 and Roch et al509 used TDD to determine what changes occur to the 
relationship between ITBV and GEDV following pneumonectomy, observing 
the ‘a’ coefficient to fall, and the ‘b’ intercept to rise. Calculating ITBV post 
operatively based on an unchanged ‘a’ coefficient and ignoring any intercept 
value (as will be the case when determining ELWIUNadj) will lead to 
inaccuracies that will in effect ‘cancel out’. 
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5.10.5.2 Pulmonary Vascular Permeability Index 
Construct validity of unadjusted TPTD measurement of PVPI is suggested by the 
following observations: 
 Negative association between PVPI and PaO2/FiO2  
 Negative association between ∆PVPI and ∆PaO2/FiO2  
 The absence of any association between PVPI and fluid balance 
There was however no association observed between PVPI and CXR score (both 
contemporaneously and longitudinally). Though the number of comparisons 
involved in the CXR analyses was low (19 CXRs, 11 ∆CXRs), and this result could 
be the product of type II error, visual inspection of the scatter plots (Figures 
5.25 and 5.31) does not reveal any ‘signal’. Chew et al have reported a positive 
association between PVPI and chest X-ray score in intensive care patients with 
systemic inflammatory response syndrome and ‘circulatory failure’423 whilst 
others have observed positive association between PVPIs and Lung Injury Score 
(of which chest x-ray scoring is a component)441, 496. As has been highlighted 
previously however, in comparison to these critically ill patients with ALI/ARDS, 
the current cohort might be expected to have relatively preserved alveolar-
capillary membrane function. 
It is striking that in the analyses of ∆PVPI verses ∆CXR score, only two patients 
demonstrated changes in PVPI greater than the ±17.7% least significant change 
value; all other changes in PVPI could simply reflect measurement artefact 
(Figure 5.31). It seems likely therefore that the degree of pulmonary vascular 
permeability observed in the current cohort was insufficient to influence chest 
X-ray appearances. Such a supposition is supported by the concept of an 
‘oedema threshold’. It is well established that the relationship between 
pulmonary capillary hydrostatic pressure and pulmonary oedema formation is 
non-linear, such that below a certain threshold value, no pulmonary oedema 
formation is observed533, 534. Furthermore, the position of such a threshold value 
is determined by pulmonary capillary membrane permeability, such that with 
increased permeability, pulmonary oedema will occur at a lower ‘threshold 
pressure’535. Though pulmonary permeability may be ‘sub clinically’ elevated in 
the current cohort, in the face of (what is hypothesised to be) normal pulmonary 
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capillary hydrostatic pressures, it can be appreciated that modest changes in 
permeability would not influence oedema formation (and therefore X-ray 
appearances). 
Validity of ‘anatomical adjustment’ and ‘segment correction’ of PVPI 
As per the study hypothesis, PVPIUNadj was negatively associated with PaO2/FiO2, 
an association which became stronger and gained clinical significance on within-
subject analysis (Table 5.18). Both PVPIANadj and PVPISEGcorr however were both 
significantly positively associated with PaO2/FiO2, with the difference in 
associations between PVPIANadj and PVPISEGcorr versus PVPIUNadj being highly 
statistically significant. Such changes are difficult to explain; it seems 
biologically implausible that oxygenation should improve as alveolar-capillary 
permeability deteriorates. This is all the more difficult to rationalise given the 
observed associations between both ∆PVPIANadj and ∆PVPISEGcorr versus ∆PaO2/FiO2 
are negative, in keeping with the hypothesis, supported by within-subject 
analysis and though statistically less significant, no different in strength from 
the negative association observed between ∆PVPIUNadj and ∆PaO2/FiO2. Whilst the 
observed changes are difficult to explain, it is not difficult to argue that they 
challenge the construct validity of adjusting PVPI values. 
5.10.6 Conclusion 
This study is not presented as the definitive work on the reproducibility and 
validity of TPTD measurement of ELWI and PVPI following lung resection. 
Nontheless, the study’s findings are supportive of the reproducibility and 
construct validity of unadjusted ELWI and (to a lesser extent) PVPI 
measurements after lung resection; within the realms of the least significant 
change values observed, and in acknowledgement of the small sample size in 
which the observations were made. The study was not supportive however of the 
construct validity of either ‘anatomical adjustment’ or per ‘segment correction’, 
of ELWI and PVPI values. Furthermore care should be taken in extrapolating the 
findings in this lobectomy cohort to patients undergoing greater volume 
resection. This is especially so given the reduction in reproducibility observed as 
the volume of lung resected is increased. 
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The ‘conscious clinician’ is challenged by the fact that the very population in 
which ELWI and PVPI measurement might be desirable, those following large 
lung resections and with lung injury, are the very population in which theoretical 
concerns regarding the methodology of the measurements are greatest, and the 
reproducibility and validity least well established.   
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6 Major findings and conclusions 
Framed by comprehensive, contemporary reviews of the current literature, this 
thesis presents the findings of a collection of investigations concerned with the 
prevention, incidence, mortality and detection and monitoring of post-lung 
resection lung injury. 
6.1 Investigation I 
The results of this survey of UK thoracic anaesthetic practice suggest that 
aspects of lung protective ventilation and fluid restriction are being widely 
incorporated into UK thoracic anaesthetic practice. From the current work there 
is no way of assessing what are the barriers to implementation of these 
techniques; it would be useful to explore these in order to develop strategies to 
improve engagement. 
6.2 Investigation II 
Despite what is perceived to be widespread adoption of lung protective 
strategies, there was no evidence from the meta-regression analyses presented 
to suggest that the incidence of ALI and/or ARDS following lung resection is 
falling. It must be emphasised that though conducted on the entirety of the 
available literature, meta-regression analysis is an imperfect tool and so the 
analysis of trends in incidence over time may still have been underpowered. It is 
plausible however that the finding of no association between ALI and/or ARDS 
incidence and time may reflect increasing baseline risk of lung injury due to 
increased patient co-morbidity and trends in favour of performing lung resection 
on patients with increasingly advanced disease. Unfortunately, in the current 
literature, baseline covariates were reported too infrequently to allow a 
multivariate meta-regression analysis to be conducted to address this 
hypothesis.  
It is encouraging to observe that meta-regression analysis of ALI and/or ARDS 
mortality against time does suggest some evidence for reducing mortality. Such 
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a finding may reflect a reduction in the severity of lung injury developed, or 
better intensive care management of patients suffering lung injury. 
The results of the meta-regression analyses, and the reports of individual 
institutions in which fluid restriction is aggressive and lung protective ventilation 
is uniformly practiced suggest that despite adoption of preventative strategies, 
post lung resection lung injury continues to occur. It is the author’s opinion (B. 
Shelley), that ventilator induced lung injury and over-hydration represent but 
two parts of the complex pathophysiology of PLR-ALI. It is likely that the role of 
pulmonary endothelial dysfunction in the pathogenesis of PLR-ALI is under-
appreciated. Recent revelations regarding the important role of the endothelial 
glycocalyx in the regulation of alveolar-capillary permeability may offer avenues 
for future investigation in addition to potential therapeutic targets.  
Where Investigations I and II serve to reinforce in the author’s mind the need for 
increased understanding of PLR-ALI, and further research into its pathogenesis 
and prevention; biomarker measurement and transpulmonary thermodilution 
(Investigations III and IV) are offered as potential aids in this quest. Both 
biomarker measurement and TPTD have potential to serve as bedside clinical 
monitors of lung injury development in order to guide clinical decision making, 
monitor patient progress and serve as a surrogate end point in future clinical 
studies.  
6.3 Investigation III 
Pentraxin 3 (PTX3) compared favourably with the properties of the ideal lung 
injury biomarker and appeared to identify a population of patients with elevated 
post-operative Lung Injury Score with high sensitivity. PTX3 may have a role in 
both prognostic and diagnostic prediction of lung injury development. 
Association was observed between PTX3 and indices of injury severity (PaO2/FiO2 
and chest X-ray score) in addition to clinically important outcomes (duration of 
hospital and HDU stay). The near universal demonstration of PTX3’s superiority 
over C-reactive protein in this investigation is encouraging, and suggests that 
PTX3 may have more potential than being just ‘another’ inflammatory marker. 
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Though encouraging, there remains however much further work to be done 
before PTX3 measurement could be routinely advocated. Firstly, the current 
study needs to be replicated in a larger cohort in order to confirm the predictive 
values observed. Secondly, the predictive value of PTX3 needs to be confirmed 
against the ‘hard’ end-points of ARDS diagnosis (as defined by the ‘Berlin’ 
definition), need for post-operative mechanical ventilation and mortality, rather 
than the surrogate endpoints of modified Lung Injury Score, oxygenation and 
chest X-ray score as studied in the current investigation. Thirdly, the post-
operative kinetics of PTX3 require further exploration in order to more 
accurately characterise the optimal timing of blood sampling.  
The negative findings of the multiple biomarker panel study serve to highlight 
the complexities of biomarker studies in this population. Firstly, the desire for 
pulmonary ‘specificity’ in separating the pulmonary inflammatory response from 
the systemic is complicated by a fall in pulmonary epithelial biomarker levels 
occurring secondarily to lung resection. Whilst correction of biomarker levels for 
the proportion of lung resected has been proposed (and appears appropriate in 
this investigation), this methodology requires further validation. Secondly, the 
transient nature of biomarker expression post-operatively makes choosing 
appropriate sample timing of paramount importance. Attempts to combine the 
results of multiple biomarkers are challenged by peak expression occurring at 
different time points post-operatively. As such, the post-operative kinetics of 
any candidate biomarker require to be explored in detail at an early stage of the 
investigative process. In addition, it is not known what degree of heterogeneity 
exists in the timing of post-operative biomarker expression. 
6.4 Investigation IV 
Transpulmonary thermodilution (TPTD) offers the potential to provide a 
relatively non-invasive method of monitoring the accumulation of extravascular 
lung water (EVLW) and pulmonary vascular permeability (PVPI) in the early post-
operative period following lung resection. TPTD appeared feasible post-
operatively in this population, and was well tolerated by patients. In general this 
study’s findings were largely supportive of the reproducibility and construct 
validity of both EVLW and PVPI measurement following lung resection. It must be 
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emphasized however, that both indices require to be interpreted in the context 
of the least significant change values observed and in acknowledgement of the 
small sample size in which the observations were made. In addition, care should 
be taken in extrapolating the findings in this lobectomy cohort to patients 
undergoing greater volume resection. 
Furthermore, it should be noted that the current study suggests that 
reproducibility was reduced in proportion to the volume of lung tissue resected. 
It appears that the very population in which TPTD monitoring may be most 
useful, that is in patients with or at high risk of lung injury undergoing greater 
volume resection, are the very population in which the reproducibility and 
validity are least well established, and in which theoretical concerns are 
greatest.  
Perhaps the major barrier to optimal use of TPTD in patients undergoing lung 
resection is our ignorance to the post-operative changes in pulmonary blood 
volume and regional perfusion occurring following lung resection. Without such 
knowledge, any attempt to modify the single thermodilution algorithm to 
account for loss of lung tissue appears speculative. This study was not supportive 
of either the ‘anatomical’ or ‘per segment’ based corrections described.  
6.5 Conclusion 
Though mortality from ALI/ARDS following lung resection appears to be falling, 
the incidence is stable, and this condition remains the major cause of early 
mortality in this patient population.  The UK thoracic anaesthetic community 
appears to be adopting lung protective practices, yet even when implemented 
consistently the effects of such practices appear modest. Biomarker 
measurement and TPTD are monitoring modalities which may be serve to inform 
clinical decision making in this challenging patient population and act as 
surrogate endpoints in future research aiming to better understand the complex 
pathogenesis of this condition. 
As advances in surgical techniques and adjuvant therapies confer survival 
benefits; more, older and sicker patients with more advanced disease are 
presenting for lung resection. It is incumbent therefore on all involved in the 
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care of such patients, to embrace this increasing demand, and strive to better 
understand and combat the causes of mortality and morbidity in this patient 
group.  
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7.3 Appendix Three – Power calculation for meta-
regression analyses 
Hedges and Pigott provide methodology for power analysis of meta-regression 
analyses285. By working through this method, the power of the meta-regression 
analyses performed in Investigation II could be retrospectively derived. 
7.3.1 Formulae and methodology 
In a meta-regression analysis, the relationship between moderator variables and 
effect size can be modelled by the relationship: 
                                
Equation 7.1 
Where it is supposed that the effect size parameter (    is linearly related to p 
moderator variables x1, x2,...,xp, where         are unknown regression 
coefficients. As under random effects, the moderator variables do not explain all 
of the variation in effect size, the relationship is governed by a study specific 
random effect,     
For any individual regression coefficient, the test of the (null) hypothesis that 
βj=0, where βj is the regression coefficient for the relationship between the 
effect size and the jth moderator variable, uses the test statistic: 
  
  
   
 
    
 
 
Equation 7.2 
Where,     is the variance of    ,  
   
  and     
 is given by the jth diagonal element of the matrix: 
 
∑* = [X’(V*)-1X]-1 
Equation 7.3 
 
Appendix 3  423 
Where,  X is a k by (p+1) design matrix, whose first column is a vector of  
  ones and whose other elements are xij, and 
  V* is the conditional covariance matrix of the effect size estimates 
under random effects: 
 
             
      
       
 ) 
Equation 7.4 
Where, vi = the variance of study i, and  
    = tau squared, the variance of the true effect size.   
 
Power for a two sided test of this relationship can be computed by: 
 
Power =           
  
    
 
           
  
    
 
  
Equation 7.5 
Where,      is the standard normal cumulative distribution function, and 
 cα is the 100(1-α) percent critical value of the standard normal 
distribution.  
 
7.3.2 Application to the present study 
7.3.2.1 Power to detect effect sizes reported by Licker et al 
Licker et al reported a 2.9% decrease in the incidence of ALI, from a baseline of 
3.8% over a study period of 5.3 years (OR 0.85)155. The regression coefficient for 
the relationship between logit event rate and year can be determined as the 
natural logarithm of the odds ratio, hence for the study of Licker at al: 
 β= loge(0.85) = -0.1628  
Thus, we wish to determine the power of the current analysis to test the 
hypothesis that β = -0.1628. 
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From the 15 studies included in the meta-regression analysis of ALI incidence 
verses year, the study variance (vi) and a pooled estimate of Tau squared can be 
estimated   (and are in fact provided in the data output of the Comprehensive 
Meta-analysis software). 
From vi and    , the covariance matrix V* can be constructed (Equation 7.4). 
Using this solution for V*, solution of Equation 7.3 is possible where the values of 
x in the design matrix X are the median years of study conduct of the 12 studies 
in the analysis. Solution of Equation 7.3, yields the second diagonal element of 
∑*, the variance of          . Solving Equation 7.3 in this way for the current 
analysis of ALI incidence yields: 
     = 0.003967 
With these known values of β and      , Equation 7.5 can be solved to yield the 
power of the current investigation to detect the effect size observed by licker et 
al: 
         
 
       
   
    
 
 
   
 
        
   
    
 
 
  
Hence: 
                
       
         
           
       
         
  
(cα = 100(1-α), which for α=0.05 equals 1.96) 
Hence: 
           
7.3.2.2 Power to detect effect sizes reported by Tang et al 
Tang et al reported a 1.6% reduction in the incidence of ARDS form a baseline of 
3.2% over a study period of 5.4 years (OR 0.94)110. 
Using the same methodology as above, 
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β= loge(0.94) = -0.066  
and      = 0.000861 as calculated from the variance and median year of study 
conduct values in the 15 studies included in the analysis of ARDS incidence. 
Hence: 
                
      
          
           
      
          
  
Hence: 
           
It can be appreciated from these analyses that the current study, based on the 
totality of available literature, lacks sufficient power to confidently test for the 
effect sizes reported by Licker and Tang and colleagues within the pooled 
incidence estimates. 
7.3.2.3 What was the power of the current analysis? 
Given the negative findings of the analyses examining the incidence of ALI 
and/or ARDS against time, rather than ‘what was the power of the current 
analysis?’ a more pertinent question is perhaps ‘what effect size (β or OR) was 
the current study powered to detect?’ 
Once the variance of            , is known (as calculated above), for the current 
analyses, it is relatively straightforward step to deduce the power from the 
relationship Equation 8.5. This step is simplified by utilising power analysis 
software (e.g. Minitab Ltd., Coventry, UK) where power is similarly deduced 
based on the cumulative distribution function of the standard normal 
distribution.  
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7.4 Appendix Four – Summary of published literature describing biomarkers of ALI/ARDS in 
patients undergoing lung resection 
Table 7.1. Summary of studies measuring lung injury biomarkers in exhaled breath condensate in patients undergoing lung resection 
Biomarker Effect of lung resection? Association with outcome? Comment 
pH ↓vs T0
164
 
↓during OLV
315
 
Not tested No association with duration of OLV
164
 
Leukotriene B4 
 
↑ vs T0
164
 Not tested No association with duration of OLV
164
 
Hydrogen peroxide ↑ vs T0
163, 164
 Not tested No association with duration of OLV
164
, ↑only 
after L not P
163
 
8-Isoprostane ↔ vsT0
164
 
 
Not tested  
Myeloperoxidase Not detectable pre-op
164
 
 
Not tested  
Interleukin-1β 
 
↑ vs T0 on POD 3 and 7
536
 Not tested   
L, lobectomy; P, pneumonectomy; T0, baseline (pre-operative) value; OLV, one-lung ventilation.  Arrows refer to biomarker level being increased 
(↑), decreased (↓) or unchanged (↔). 
 
Table 7.2. Summary of studies measuring lung injury biomarkers in urine in patients undergoing lung resection 
Biomarker Classification Effect of lung resection? Association with outcome? Comment 
Malondialdehyde 
 
Oxidative stress ↑iPO
163
 Not tested Greater ↑ L vs P
163
 
L, lobectomy; P, pneumonectomy; iPO, immediately post-operatively. Arrows refer to biomarker level being increased (↑), decreased (↓) or 
unchanged (↔). 
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Table 7.3. Summary of studies measuring lung injury biomarkers in plasma in patients undergoing lung resection 
Biomarker Classification 
Effect of lung 
resection? 
Association with outcome? Comment 
Krebs von den Lungen (KL)-6 Epithelial ↓iPO and POD1
315
 
↓ vs baseline on POD 2, 7, 
14 & 28
316
 
Not tested Fall in proportion to volume of resected 
lung
315, 316
 
No association with duration of OLV, 
Pplat, VT
315
 
     
Surfactant protein (SP)-D Epithelial Unchanged iPO vs T0
315
, 
significant fall POD1
315
 
Not tested Fall in proportion to volume of resected 
lung
315
 
No association with duration of OLV, 
Pplat, VT 
315
 
     
Receptor for advanced 
glycation end products (RAGE) 
Epithelial ↑iPO vsT0
315
 Not tested No association with duration of OLV, 
Pplat, VT 
315
 
     
von Willebrand factor (vWF) Endothelial ↑iPO and POD1
315
 Not tested No association with duration of OLV, 
Pplat, VT 
315
 
     
Vascular endothelial growth 
factor (VEGR) 
Endothelial No change
537
 Not tested No change 2h PO and POD3
537
 
     
Angiopoietin (Ang)-1 
 
Endothelial ↓POD1 and POD3
537
 Not tested  
     
Ang-2 
 
Endothelial ↑POD1 and POD3
537
 Not tested Greater ↑ after VATS vs open resection 
     
soluble-VEGF receptor 
(sVEGFR)-1 
Endothelial ↑POD1 and POD3
537
 Not tested  
     
sVEGFR-2 Endothelial ↓POD1 and POD3
537
 
 
Not tested  
     
Lactate dehydrogenase Pro-inflammatory ↑ vs T0 on POD 
,2,7,14,28
316
 
Not tested Greater ↑ in L vs SL
316
 
     
Tumour necrosis factor (TNF)-α Pro-inflammatory Not detected
315
 
No change
241
 
↑intra-op at 3h
538
 
Not tested Not detected at iPO and POD1
315
 
No change iPO
241
 
No difference low TV vs high TV
538
 
↓POD 1,2,3 w. β2-agonist vs. control
539
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Biomarker Classification 
Effect of lung 
resection? 
Association with outcome? Comment 
TNF-soluble receptor(sr)-1 
 
Plasma No change
540
 Not tested  
TNF-soluble receptor(sr)-2 
 
Plasma ↑POD1
540
 Not tested  
     
Myeloperoxidase Plasma ↑iPO, 24hPO (but NS) 
162
 Not tested  
     
PMN elastase Pro-inflammatory ↑iPO and 24hPO
541
 Not tested  ↑ iPO in P only not L
541
,  
↑ 24hPO in L only not P
541
 
     
C-reactive protein Pro-inflammatory ↑POD1
310
 
↑ vs baseline on POD 
1,2,7,14,28
316
 
↑ vs T0 4hPO and POD 
1,2,3,5
180
 
↑ peak on POD2
180, 311
 
↑ at baseline in patients with 
complications
v
 
310
 
Peak higher in pts with 
complications
w,542 
↑ in pts w. infection. AUROCC for 
predicting infection 0.66 (CI 0.58-
0.73)
311
 
AuROCC for baseline CRP vs pulmonary 
complications = 0.86 
310
 
Greater ↑ in L vs SL 
316
 
Greater ↑ in P or L vs VATS SL
536
 
Greater ↑ in open vs VATS 
180
 
     
Interleukin-1 
 
Pro-inflammatory ↑intra-op at 3h
538
 Not tested No difference low TV vs high TV
538
 
     
Interleukin(IL)-1β Pro-inflammatory No change
241, 361, 540
 Not tested No change iPO
241
 
↓POD 1,2,3 w. inhβ2-agonist vs. control
539
 
     
IL-6 Pro-inflammatory ↑ iPO and POD1
241, 310, 312, 
315
, POD3 & 7
312
 
↑ during OLV and during 
TLV
166
 
↑intra-op at 3h
538
  
↑ peak on POD1
180, 311, 536
 
↑ at baseline and greater ↑ POD1 
in patients with complications 
(p=0.1)
K
 
310
  
↑IL-6 on POD 7 in pts w. 
complications
L
;  
OR (univariate) = 1.06
312
 
Levels slower to fall in patients w. 
complications
542
 
Modest ↑ “barely clinically significant”
166
 
No assoc w. duration OLV, Pplat, VT
315
 
AuROCC for baseline IL-6 vs pulmonary 
complications = 0.79 
310
 
No difference low VT vs high VT 
538
 
No difference low TV vs high TV 
538
 
↓POD 1,2,3 w. inhβ2-agonist vs. control
539
 
Greater ↑ in open vs VATS 
180, 361
 
     
IL-12 
 
 
Pro-inflammatory No change
538
 Not tested No change intra-op
538
 
 
                                         
v
 Major complications occurred in 9/153 (5.9%); pneumonia (n = 4), ARDS (n=3), myocardial infarction (n=1), pulmonary embolism (n=1), and acute renal failure (n=1). 
w
 Described “such as infectious or cardiac complications” 
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Biomarker Classification 
Effect of lung 
resection? 
Association with outcome? Comment 
IL-8 Pro-inflammatory Not detected
315
  
↑during OLV and TLV
362
 
No change
241
 
↑intra-op at 3h
538
 
Peak at 4hPO 
361
 
Not tested Not detected at iPO and POD1
315
 
No change iPO
241
 
No difference low VT vs high VT 
538
 
     
Albumin Pro-inflammatory ↓during OLV and TLV
362
 Not tested Modest↓, ? significance 
AuROCC for baseline albumin  vs 
complications = 0.86
310
 
     
Procalcitonin Pro-inflammatory ↑ peak on POD2
542
 
↑ peak on POD1
311
 
Peak higher in pts w. 
complications
x542
 
↑ in pts w. infection. AUROCC for 
predicting infection 0.92 (CI 0.87-
0.96)
311
 
Appears to be ↑ on POD1, no stats 
provided
542
 
↑ in P vs L / VATS
311
 
No difference in pts with non-infective 
complications (data not provided)
311
 
     
IL-10 Anti-inflammatory No change
241, 538
 
↑iPO, 4,8h PO (no stats)
361
 
Not tested No change iPO
241
 
↓ POD 1,2,3 w. inhβ2-agonist vs. placebo
539
 
Greater ↑open vs VATS
361
 
     
Protein thiol Oxidative stress ↓iPO
162
 
 
Not tested Greater ↓P and BiL vs L
543
 
Protein carbonyl Oxidative stress ↑iPO
162
 Not tested Greater ↑ P vs L
162
 
     
Malondialdehyde Oxidative stress ↑iPO, 6hPO
157, 165
 
↑ during O/TLV
166
 
157, 165
 
↑assoc w. major complications
y165
 ↑ proportional to duration OLV
157, 165
 
     
Thrombomodulin (TM) Coagulation / 
endothelial 
↓POD1
314
 ? ↑ levels linked to poor 
oxygenation PO (see text)
314
 
↓ in proportion to volume of resected lung 
tissue
314
 
SL, sub-lobar resection; L, lobectomy; P, pneumonectomy; T0, baseline (pre-operative) value; OLV, one-lung ventilation; POD, post-operative day; iPO, immediately 
post-operatively; Ppeak, peak airway pressure;VT, tidal volume; AuROCC, area under the receiver operating characteristic curve; NS, not significant. Arrows refer to 
biomarker level being increased (↑), decreased (↓) or unchanged (↔).  
                                         
x
 Described “such as infectious or cardiac complications”.  
y
 “respiratory failure, cardiac arrthymias and pulmonary hypertension” 
Appendix 4  430 
Table 7.4. Summary of studies measuring lung injury biomarkers in bronch-alveolar lavage / epithelial lining fluid in patients undergoing lung resection 
Biomarker Classification Effect of lung resection? Association with 
outcome? 
Comment 
Albumin Permeability ↑during OLV and TLV
362
 
↑after OLV and 2hPO
148
 
Not tested  
     
Protein 
 
Permeability ↑after OLV and 2hPO 
148
 Not tested  
     
Soluble intracellular adhesion 
molecule-1 
Endothelial ↓ after OLV and 2hPO
148
 Not tested ↓ only in low tidal volume group 
148
 
     
PMN elastase 
 
Pro-
inflammatory 
↑after OLV and 2hPO 
148
 Not tested  
     
Interleukin(IL)-1β Pro-
inflammatory 
↑iPO
241
 Not tested ↑PO only with propofol vs volatile anaesthesia 
241
 
     
IL-6 
 
Pro-
inflammatory 
↑iPO
241
 Not tested ↓after 30mins OLV w. inhβ2-agonist vs. placebo
539
 
     
IL-8 Pro-
inflammatory 
↑after OLV
148
, iPO
241
 and 
2hPO
148
 
↑during OLV and TLV
362
 
Not tested Greater ↑ PO with propofol vs volatile 
anaesthesia
241
 
↑ proportional to duration OLV
362
 
↓after 30mins OLV w. inhβ2-agonist vs. placebo
539
 
IL-10 Anti-
inflammatory 
 ↓ after OLV
148
 
 ↑iPO(NS)
241
 
Not tested ↓in low tidal volume ventilation group only
148
 
↑iPO only with propofol vs volatile anaesthesia
241
 
↓after 30mins OLV w. inhβ2-agonist vs. placebo
539
 
     
     
     
IL-12 p70 
 
Pro-
inflammatory 
No change
241
 Not tested No change iPO
241
 
     
Tumour necrosis factor-α Pro-
inflammatory 
↑after OLV
148
, PO
241
 and 
2hPO
148
 
Not tested No ↑ after OLV in low tidal volume vent
148
 
↑iPO only with propofol vs volatile anaesthesia
241
 
↓after 30mins OLV w. inhβ2-agonist vs. placebo
539
 
     
SL, sub-lobar resection; L, lobectomy; P, pneumonectomy; T0, baseline (pre-operative) value; OLV, one-lung ventilation; POD, post-operative day; iPO, immediately 
post-operatively; Ppeak, peak airway pressure;VT, tidal volume; NS, not significant. Arrows refer to biomarker level being increased (↑), decreased (↓) or unchanged (↔). 
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7.5 Appendix Five - Derivation of adjusted values of ELWI 
and PVPI 
The Edwards EV1000 transpulmonary thermodilution (TPTD) monitor used in this 
study incorporates the facility to download the results of all individual 
thermodilution procedures. Results are provided in Microsoft Excel format and 
include the TPTD derived parameters cardiac output, stroke volume, global end-
diastolic volume (GEDV), intra-thoracic blood volume (ITBV), extravascular lung 
water (EVLW) (and their corresponding ‘index’ values indexed to predicted body 
weight) and pulmonary vascular permeability index (PVPI). 
In Bendjelid et al’s validation paper of the “new transpulmonary thermodilution 
system” (EV1000), the authors provide the following formulae describing the 
derivation of TPTD derived indices525: 
                                
Equation 7.6 
 
Where DSt is the exponential downslope time of the thermal indicator, derived 
from the thermodilution curve. Though DSt is not provided in the results 
downloaded from the EV1000 monitor, rearrangement of Equation 7.6 allows DSt 
to be derived from the results provided: 
     
                  
  
    
Equation 7.7 
 
By deconvolution of the result in this way, the raw variables required to 
compute values of ELWI, pulmonary blood volume (PBV) and PVPI are then 
available. 
7.5.1 Rationale for derivation of adjusted values 
The methodology for single indicator TPTD relies on the fundamental assumption 
of the linear and continuous relationship between ITBV and GEDV (observed by 
Sakka et al 396) such that: 
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Equation 7.8 
  
As ITBV is the sum of the PBV and GEDV, this relationship can be simplified as: 
                 
Equation 7.9 
  
[It can now be seen from Equations 6.1 and 6.4, that the EV1000 monitor derives 
EVLW by subtracting the calculated PBV form the pulmonary thermal volume 
(derived from the thermodilution curve as the product of CO and DSt)]. 
It seems unlikely that this relationship between PBV and GEDV would remain 
constant following lung resection, where a proportion of the pulmonary 
vasculature has been excised. The hypothesis being tested in this investigation 
therefore is that modification of the derived values of EVLW, PBV and therefore 
PVPI to account for the lung resected will make a better assessment of the post-
resection EVLW and PVPI and so improve validity of the indices. Such an 
adjustment could be made in two principal ways. Firstly the ‘0.25’ coefficient in 
Equation 7.6 could be adjusted to reflect a hypothesised new relationship, and 
EVLW calculated with this revised equation – resulting in the proposed 
‘anatomical’ adjustment (yielding ELWIANadj and PVPIANadj). Secondly, TPTD 
derived indices could be calculated using the original equations, but the ELWI 
and PVPI results corrected to reflect that they have been determined from less 
than a whole lung. Correcting the result based on the number of pulmonary 
segments remaining following resection is the basis of the proposed ‘segment 
corrected’ result (yielding ELWISEGcorr and PVPISEGcorr). 
7.5.2 Derivation of the ‘anatomical adjustment’ 
If the consequent reduction in PBV following resection is assumed to be 
proportional to the volume of lung tissue resected, then this relationship can be 
‘adjusted’ to account for the assumed reduction in PBV. Based on a 19 segment 
model of pulmonary anatomy, any pneumonectomy or lobar resection can be 
expressed in terms of the number of segments resected. If Equation 7.9 is then 
considered to represent the relationship between PBV and GEDV for 19 segments 
of lung, then the relationship for n/19 segments can be derived by: 
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Equation 7.10 
  
Where n is the number of pulmonary segments remaining after resection. 
Substitution of Equation 7.10 into Equation 7.6 allows EVLW to be derived based 
on the anatomically adjusted coefficient: 
                       
 
  
                 
Equation 7.11 
  
PVPIANadj can then be derived as the quotient of ELVWANadj and PBVANadj: 
 
 
          
         
        
   
Equation 7.12 
 
7.5.3 Derivation of the ‘segment correction’ 
If it is considered that the EVLW value yielded from Equation 7.6 describes the 
EVLW per unit of lung tissue, where ordinarily the unit of lung tissue is defined 
as both lungs (i.e. 19 segments), then following resection where the volume of 
residual lung tissue is less than 19 segments, this equation might be expected to 
overestimate EVLW by a factor proportional to the volume of lung tissue 
resected. 
Thus if ordinarily the measured value provides EVLW per 19 segments of lung, 
then division of the value by 19 yields the EVLW per segment. Similarly, if it 
assumed that the total EVLW measured by the monitor post-operatively 
represents the ‘true’ total value, but for n/19 remaining segments, then the 
EVLW per segment can be derived: 
                 
    
 
  
Equation 7.13 
  
To allow rationale comparison of this value per segment between patients 
undergoing lung resections of differing sizes, this per segment value is multiplied 
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by 19 yielding an ELVW ‘corrected’ according to the no. of pulmonary segments 
from which it is derived: 
             
    
 
      
Equation 7.14 
  
Similarly, but in fact reciprocally, the derived value of PBV is corrected to 
reflect that the measured value (calculated from GEDV on the assumption that 
the pulmonary circulation is complete) is likely to be an overestimate of PBV by 
a factor proportional to the volume of lung resected, thus: 
            
   
  
     
Equation 7.15 
  
7.5.4 Simulation study reflecting hypothesised effect of un-adjust 
EVLW and PVPI values 
In order to explore the hypothesised effect of adjusting EVLW and PVPI values as 
proposed above, a simulation study was performed. Using the baseline data (i.e. 
pre lung-resection) from the eight patients included in the reproducibility and 
construct validity study (Chapter 5), ‘anatomically adjusted’ and ‘segment 
corrected’ EVLW and PVPI values were derived as described above.  Values were 
derived from the baseline data, making adjustment for resection of 3, 4, 5, 9 
and 10 pulmonary segments (representing the volume of lung tissue resected at 
right upper lobectomy, left lower lobectomy, right lower lobectomy, left 
pneumonectomy and right pneumonectomy respectively). The resulting bias, 
representing the degree to which EVLW and PVPI would be overestimated by 
unadjusted values should the anatomically / segment corrected values represent 
the true situation, was then determined as the difference between unadjusted 
and adjusted values and is displayed in Figure 7.1. 
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Figure 7.1. Simulated bias resulting from non-adjustment of EVLW and PVPI, in comparison 
to anatomically adjusted and segment corrected values.  
ANadj, ITBV/GEDV adjusted by ‘anatomical approach’; SEGcorr, result corrected to reflect no of 
pulmonary segments remaining. 
It can be seen that anatomical adjustment of the parameters leads to a more 
conservative estimate of the degree of overestimation. Anticipated bias ranges 
from -7.8% for EVLWANadj to -406.1% for PVPISEGcorr. 
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